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Older horses now make up a significant proportion of the equine population, meaning that 
geriatric medicine is increasingly important. Pituitary pars intermedia dysfunction (PPID) is a 
progressive disease prevalent in older horses, however, studies investigating diagnosis, 
treatment and prognosis are limited. The evidence base needs to be built on to inform 
management and treatment approaches and improve quality of life (QoL) of horses with 
PPID. The aims of this thesis were to i) identify and prioritise key research questions 
regarding PPID; ii) investigate management, health care and treatment strategies 
undertaken by owners iii) understand owner perceptions of treatment and QoL. A four-
phase mixed methods approach was applied. Phase one used patient and public involvement 
(PPI), to prioritise the top 10 unanswered research questions for PPID. The questions 
focused on disease progression, diagnostic accuracy, treatment efficacy and additional 
management/treatment strategies.  Literature on PPID diagnosis and treatment was 
subsequently evaluated in two systematic reviews, which highlighted the lack of high-quality 
evidence regarding current protocols. Phase two comprised a cross-sectional questionnaire 
to evaluate management and treatment strategies undertaken by 374 participating owners 
of PPID cases. Most horses were treated with pergolide (86.9%), while 17.4% received an 
alternative/complementary treatment. Pergolide had a higher efficacy rating compared to 
alternative/complementary treatments (p<0.001). PPID cases were perceived to have a very 
good QoL (median rating 9/10). Pergolide treatment was associated with an improvement in 
QoL rating since diagnosis (p=0.002).  Phase three built on the cross-sectional data in a 
prospective cohort, using follow-up telephone questionnaires to describe changes over time. 
A subset of 72 horses were enrolled, contributing a total of 53.4 horse-years at risk (HYAR), 
with a median duration of follow-up of 330.7 days. For horses receiving pergolide (n=55), 
the dose remained the same throughout the follow-up period in 78.2%. QoL ratings 
remained unchanged in 43.5% of horses but decreased in 21.0%. Overall mortality rate was 
20.6 deaths per 100 horse-years at risk (HYAR), while estimated incidence of laminitis was 
15.7 new episodes per 100 HYAR and that of infection was 24.9 events per 100 HYAR.  
Finally, phase four used qualitative semi-structured interviews with ten purposively selected 
owners to understand key topics surrounding care and QoL for PPID cases. Six overarching 
themes were identified; disease tangibility, balancing management and treatment 
complexities, owners being experts in their own horse, having a horse centered approach, 
the vet-owner relationship and how health and happiness go ‘hand in hand’.  The themes 
demonstrated how owner decisions were influenced by the impact of PPID on the horse’s 
daily life and the visible changes observed. This perception was then framed by the owners’ 
understanding of the disease, their in-depth knowledge of what is normal for their horse and 
the nature of the vet-owner relationship. This thesis introduces the concept of PPI 
methodology in to equine veterinary research and provides novel information on the 
management, treatment and prognosis of PPID. It also highlights the lack of high-quality 
evidence on which clinical decisions are made. Pergolide treatment was associated with an 
increase in QoL but did not appear to influence morbidities or mortality. Owner experiences 
and perceptions play an important part in the treatment and management decisions made. 
The findings presented will help to develop effective management and treatment strategies 
to improve the QoL of horses with PPID. Owner perspectives and behaviours will also inform 
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The aims of this PhD thesis are three-fold: 
i) To identify and prioritise key research questions regarding the diagnosis, 
treatment and prognosis of pituitary pars intermedia dysfunction (PPID) 
ii) To explore management and treatment strategies undertaken by owners of 
horses with PPID  
iii) To gain an understanding of owner perspectives on treatment and quality of life 
(QoL) of horses with PPID.  
The work presented here represents a mixed-methods approach to studying PPID. The 
chapters report findings from four studies. The initial study used patient and public 
involvement (PPI) methodology to identify and prioritise the key research questions about 
PPID that veterinary surgeons and horse owners want answering. Following this, evidence 
regarding current diagnosis and treatment protocols for PPID was assessed in two 
systematic reviews. Subsequent studies were developed to answer some of the important 
research questions prioritised in the initial PPI study. First, a cross-sectional study was 
designed to describe the management and treatment practices undertaken by owners and 
to investigate associations with quality of life (QoL). A subset of this population was then 
followed in a prospective cohort study to describe changes in management, treatment and 
QoL observed over time. Finally, to build on this, a qualitative approach was taken to 
provide an in-depth understanding of the role of horse owners in the management and 


























Introduction and literature review 
The relationship between human and horse has changed in recent years. This shift is 
thought to be because the purpose of the horse has changed, and many are valued for their 
companionship (Hintz, 1995) through the development of feelings of mutual respect, 
affection and awareness of horses’ individual needs (Dashper, 2017). Owners frequently 
develop a strong bond with their aged horse (McGowan and Ireland, 2016) and want to 
maintain their good health through the latter years of their life (Brosnahan and Paradis, 
2003a). Surveys have demonstrated the willingness of owners to manage horses into their 
old age with 26-43% of aged horses kept as companions or retired while 62% are kept for 
leisure (Hintz, 1995; Ireland et al., 2011a; McGowan et al., 2010a). This means that, similar 
to the human population, horses are living longer. The median life expectancy of horses is 
estimated to be 22.7 years of age (Welsh et al., 2016) with an aged horse having been 
defined as ≥15 years (Mellor et al., 2001). This demographic now makes up a considerable 
proportion (25%-34%) of the equine population in western society (Mellor et al., 1999; 
McGowan et al., 2010a; Ireland et al., 2011a). However, increased longevity brings its own 
health implications (Cossio et al., 2012), such as the increased risk of disease.  
Pituitary pars intermedia dysfunction 
Pituitary pars intermedia dysfunction (PPID) is an age-associated progressive 
neurodegenerative disorder that results in a wide variety of clinical signs including 
hypertrichosis, muscle wastage and lethargy (McGowan et al., 2013a; Ireland and 
McGowan, 2018). It has also been associated with hyperinsulinemia and subsequently an 
increased risk of endocrinopathic laminitis (de Laat et al., 2019b). PPID has been diagnosed 
with increasing frequency in recent years (Rohrbach et al., 2012) and has an estimated 
prevalence of 21% among aged horses (McGowan et al., 2013a). It has also been reported 
to significantly affect risk of mortality (Welsh et al., 2016), making it important in geriatric 
medicine and equine practice.  
A presumptive diagnosis of PPID has previously been based on the presence of specific 
advanced clinical signs such as generalised hypertrichosis (Frank et al., 2006a) however, in 
the earlier stages of disease, when clinical signs are more variable or less apparent, 
laboratory confirmation of diagnosis is required (Couëtil et al., 1996; Miller et al., 2008; 
McFarlane, 2011). Diagnosis and appropriate treatment at an early stage may be beneficial 
to help slow the progression of the disease (Roarty, 1990; McFarlane, 2007). The 
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measurement of basal adrenocorticotrophic hormone (ACTH) is currently recommended due 
to its ease and adequate accuracy when used with seasonal reference intervals (McGowan 
et al., 2013b). The thyrotropin-releasing hormone (TRH) stimulation test can also be used 
where a more sensitive test is required (Beech et al., 2007), however TRH is not currently 
licensed for use in horses.  
Once diagnosed, the current licensed treatment is pergolide, an ergoline-based dopamine 
receptor agonist (Anon, 2011a). Medical treatment is often used in conjunction with various 
management changes to address the clinical signs present and overall health (Schott, 2002). 
The progressive nature of PPID means it requires long-term management often for a 
significant proportion of the horse’s life; life expectancy post-diagnosis has been reported to 
be nearly 10 years (Welsh et al., 2016; Horn et al., 2019). The vast majority of management 
throughout this time is undertaken by the owner in the horse’s home environment. This 
means that the part owners play in the in the management and treatment of the disease is 
vitally important and could have a significant impact on quality of life (QoL).    
Pathophysiology  
The exact pathophysiology of PPID is still unknown, however evidence suggests that 
oxidative stress contributes to neurodegeneration of the inhibitory dopaminergic 
hypothalamic neurons (McFarlane and Cribb 2005). Histological examination of the pituitary 
gland has provided evidence of increased oxidative stress markers in PPID cases compared 
to age-matched controls (McFarlane et al., 2005a). This leads to a loss of dopaminergic 
inhibitory output to the melanotrope cells within the pars intermedia of the pituitary gland. 
In turn, this results in increased plasma concentrations of multiple pro-opiomelanocortin 
(POMC) peptide derivatives including α-melanocyte stimulating hormone, corticotropin-like 
intermediate lobe peptide, β-endorphin and ACTH (Heinrichs et al., 1990; Dybdal et al., 
1994; McFarlane, 2007; McFarlane, 2011; Durham, 2016a). The precise consequences of 
this are not fully understood (Durham, 2016a), however there a number of clinical signs 
associated with the disease which are described in further detail below. 
Epidemiology 
Risk factors  
Increasing age is a significant risk factor for PPID, with one study reporting an odds ratio of 
1.18 (95% CI 1.11–1.25; p<0.001) for every year increase in age among horses aged ≥15 
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years (McGowan et al., 2013a). Several other studies have also reported a significant 
association between PPID and increasing age. Horses with clinical signs of PPID were 
reported to be significantly older than those not showing clinical signs (Ireland et al., 2013). 
Similarly, owners reported PPID more frequently in horses aged ≥20 years compared to 
younger horses (Brosnahan and Paradis, 2003a) and the prevalence of PPID increased with 
increasing horse age in a referral hospital population (Brosnahan and Paradis, 2003b). Breed 
has been investigated as a risk factor for PPID in one study which compared diagnosis 
based on basal ACTH test results, and no significant associations were found (McGowan et 
al., 2013a). However, ponies were more likely to exhibit clinical signs than horses (McGowan 
et al., 2013a). The same study also investigated sex as a risk factor and found no significant 
difference in odds ratios between males and females.  
Clinical signs  
The foremost clinical signs associated with PPID are hypertrichosis, and other hair coat 
abnormalities (often incorrectly referred to collectively as hirsutism), weight loss, muscle 
wastage and signs of lethargy/depression-like state, while laminitis is also often reported as 
a comorbidity of PPID (McFarlane, 2011; McGowan et al., 2013a: Ireland and McGowan, 
2018). However, the disease may manifest in different ways in individual cases (Hillyer et 
al., 1992; Schott, 2002). Clinical signs in the early stages of the condition can be subtle 
which then progress over time (Love, 1993). 
Laminitis   
Laminitis is a painful and debilitating disease (Bailey et al., 2006; Collins et al., 2010), which 
can have long term implications on the structures within the feet and subsequently athletic 
performance (Hood, 1999b; Hunt & Wharton, 2010). Endocrinopathic laminitis is associated 
with insulin dysregulation (Asplin et al., 2007; de Laat et al., 2010a; Meier et al., 2018) and 
has now been recognised as the most common form of laminitis (Karikoski et al., 2011). 
Studies have shown a significant link between laminitis and insulin dysregulation, including 
insulin resistance (IR) and hyperinsulinaemia (Treiber et al., 2006a; Bailey et al., 2008; 
Carter et al., 2009a; de Laat et al., 2010a; de Laat et al., 2010b). Insulin is a major 
regulatory hormone in glucose metabolism, and IR alters insulin signalling causing a 
reduction in glucose metabolism and subsequently hyperinsulinaemia (Bailey et al., 2006; 
Walsh et al., 2009; de Laat et al., 2010a). Studies have shown normal horses develop 
laminitis when hyperinsulinaemia is experimentally induced (Asplin et al., 2007; de Laat et 
11 
 
al., 2010b). Insulin resistance and hyperinsulinemia have been observed in horses affected 
by PPID (van der Kolk et al., 1995; McGowan et al., 2004; Treiber et al., 2006a; Klinkhamer 
et al., 2011) and they are thought to be at an increased likelihood of developing laminitis 
(Donaldson et al., 2004; Carter et al., 2009a; Karikoski et al., 2011). 
The reported prevalence of laminitis amongst PPID cases varies widely between studies; one 
early case series reported the prevalence to be as low as 24% (van der Kolk et al., 1993), 
while a cases series from a university hospital reported a prevalence of 82% (Hillyer et al. 
1992).  Similarly, 74% of horses presenting with PPID at an ambulatory practice were 
reported to have laminitis (Donaldson et al., 2002). A recent systematic review assessed the 
epidemiology of PPID and calculated the overall prevalence of laminitis to be 48.9% (Ireland 
and McGowan, 2018). 
Hypertrichosis and other hair coat abnormalities 
Hypertrichosis, a long curly coat which fails to shed, is a ‘classic’ sign of PPID (Schott, 2002) 
and is considered a specific indicator of the disease (Frank et al., 2006a; McGowan et al. 
2013a). One study has provided evidence this is caused by a greater percentage of hair 
follicles in the anagen stage of growth (Innerå et al., 2013). During the earlier stages of 
disease hair changes are more subtle, with regional changes often restricted to the lower 
jaw, base of the neck and palmar or plantar aspects of the limbs (Schott, 2002; Innerå et 
al., 2013). This can progress over time to the long curly coat characteristic of the advanced 
stages of PPID. The prevalence of veterinary observed hypertrichosis and/or hair coat 
abnormalities was reported to be 33% in a cross-sectional study of 69 aged horses and 
ponies with PPID (McGowan et al., 2013a). In the same study, coat changes were observed 
by 40.6% of owners, suggesting it could possibly be over-diagnosed by owners or that they 
are better placed to recognise changes over the year compared to a single veterinary exam. 
Conversely, veterinary-reported prevalence of coat changes as high as 94-100% have been 
reported in a clinical trial (McGowan and Neiger, 2003) and several case series (Hillyer et al., 
1992; van der Kolk et al., 1993; Couëtil et al., 1996; Spelta and Axon, 2012). This variation 
is likely due to differences in selection criteria, time of year the study was performed and 
types of animals included; for example, ponies are more likely to show hair coat 
abnormalities than horses (McGowan et al., 2010b; Ireland et al., 2012c). An overall 
prevalence of 69.9% for all hair coat abnormalities reported amongst PPID cases has 
recently been calculated based data from 14 published studies (Ireland and McGowan, 
2018).   
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Muscle atrophy  
Muscle atrophy associated with PPID is characterised by loss of epaxial and gluteal 
musculature (McFarlane, 2011) and has been shown to affect type II fibres more than type I 
fibres (Aleman et al., 2006; Narici and Maffulli, 2010). Muscle atrophy as a result of aging 
(sarcopenia) is observed in equids and humans without underlying disease.  It can therefore 
be mistaken as normal sign of aging (Hintz, 1995; Narici and Maffulli, 2010) and may not be 
recognised until its later stages (Schott, 2002). Muscle atrophy occurs when protein 
degradation rates exceed protein synthesis (Schiaffino et al., 2013). One study has 
suggested greater gene expression of m-calpain involved in proteolysis may be one of the 
mechanisms which plays a role in the development of muscle atrophy in PPID (Aleman and 
Nieto, 2010). Muscle atrophy or epaxial muscle wastage are reported to have a prevalence 
of 18-50% in PPID cases (Pongratz et al., 2010; Spelta and Axon, 2012; McGowan et al., 
2013a). 
Abnormal fat distribution  
Abnormal fat distribution typically comprises the development of regional adiposity including 
fat deposits above the eyes in the supraorbital fossa, along the crest of the neck and over 
the tail head. The process underlying tissue relocation to the upper parts of the body is not 
fully understood, however, there may be a relationship between the redistribution of fat and 
hyperinsulinemia seen in a proportion of PPID cases (Frank et al., 2006b; Carter et al., 
2009b; McFarlane, 2011). Redistribution of body mass is a commonly reported clinical sign 
(Donaldson et al., 2004). Bulging supraorbital fat is reported in 6-50% of cases (Hillyer et 
al., 1992; van der Kolk et al., 1993; Couëtil et al., 1996; Donaldson et al., 2002; Perkins et 
al., 2002; McGowan and Neiger, 2003; Donaldson et al., 2004; Spelta and Axon, 2012; 
McGowan et al., 2013a).  
Lethargy  
Lethargy, or a depression-like state, is a common sign of illness in horses (Hausberger et al., 
2016). It is characterised by prolonged times of immobility, withdrawn or “slumped” posture 
and a lack of response to environmental stimuli; however, there is no standardised measure 
(Burn et al., 2010; Fureix et al., 2012). Changes to circulating neurosteroids, similar to that 
seen in humans with Parkinson’s disease, have been observed in horses with PPID and it 
has been hypothesised that this may contribute the lethargic state observed (Schott et al., 
2020a). Owners reported lethargy/depression-like state in 14.5% of horses diagnosed with 
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PPID in a cross-sectional study (McGowan et al., 2013a). However, the prevalence reported 
during veterinary examination among other studies varies from 3-95% (Hillyer et al., 1992; 
Couëtil et al., 1996; Donaldson et al., 2002; Perkins et al., 2002; McGowan and Neiger, 
2003; Donaldson et al., 2004; Pongratz et al., 2010). Overall prevalence has been estimated 
to be 41% (Ireland and McGowan, 2018).  
Diagnosis of PPID 
Previously, a presumptive diagnosis based on age and evidence of hypertrichosis, associated 
with the more advanced stages of disease, was considered adequate (Frank et al. 2006a; 
Schott, 2002). However, acknowledgement that PPID is a progressive disease with varying 
clinical signs (McGowan et al. 2013a; McGowan et al., 2013b) and the suggestion that early 
intervention might have a protective effect (Gille et al., 2002) meant there was a need to 
identify the disease in the early stages. Clinical diagnosis can be challenging in the early 
stages of disease when signs of hypertrichosis may not be evident or in cases with less 
specific clinical signs (Miller et al., 2008). Therefore, a number of different endocrinologic 
assay tests have been developed and used in the diagnosis of PPID, including basal and 
dynamic tests (Frank et al. 2006a; McGowan et al. 2013b). Current diagnostic tests for PPID 
that are considered to possess adequate accuracy and availability for clinical use comprise 
basal plasma ACTH concentration, the overnight dexamethasone suppression test (ODST) 
and the thyrotropin-releasing hormone (TRH) stimulation test (measuring ACTH) (Durham et 
al., 2014). However, there is a lack of a ‘gold standard’ laboratory test (McGowan et al., 
2013b).  
Basal plasma ACTH concentration  
Production of ACTH in horses normally occurs in corticotrope cells in the pars distalis, which 
release the hormone in response to corticotropin, following cleavage from the peptide POMC 
(Wilson et al., 1982; García-Borrón et al., 2005; Getting, 2006; Yang, 2011). Horses with 
PPID have elevated levels of ACTH released into plasma from the pars intermedia 
melanotropes (Couëtil et al, 1996; Durham et al., 2014) which is thought to gradually 
increase as the disease progresses (McGowan et al., 2013b). The activity of the pars 
intermedia melanotropes is regulated by hypothalamic and systemic neurochemicals, 




Plasma ACTH concentration compared to seasonally adjusted reference intervals (RIs) offers 
a simple test requiring only a single sample to be collected (Rendle et al., 2015a) and has 
been evaluated in several small studies with varying accuracy reported. However, these 
studies are limited by small sample sizes and there is a lack of standardisation to protocols, 
meaning different assays and definitions of disease were used, making comparison 
challenging. The accuracy of the basal ACTH test for diagnosing PPID is examined in detail 
in Chapter 3. However, ACTH concentrations can be affected by several in vivo and in vitro 
factors. Stress brought on by transportation has been shown to significantly increase ACTH 
levels in stallions (Fazio et al., 2008). A small study of five horses described that ACTH levels 
were significantly affected for up to 30 minutes after treadmill exercise (Nagata et al., 1999) 
and a similar effect has also been observed in humans (Buono, 1986). Incorrect sample 
handling and storage can also affect plasma ACTH levels. If samples are not promptly chilled 
or frozen ACTH levels have been shown to progressively decrease in horses with PPID 
(Perkins et al., 2002; Durham and Copas, 2011), and significantly decrease after 4-8 hours 
(Rendle et al., 2015b). It has also been reported that pain leads to an activation of the 
hypothalamic-pituitary-adrenal axis, resulting in the release of ACTH and cortisol from the 
pars distalis, in both livestock species (Molony and Kent, 1997) and horses (Beech et al., 
2007). A recent small case control study examined 17 horses, aged ≤15 years of age and 
with no clinical signs of PPID, that were suffering from pain (Gehlen et al., 2020). Pain 
scores were established and blood samples were taken at initial examination and again 
when the horse was considered to be pain free. A correlation between higher pain score and 
increased ACTH level was reported however, this was not statistically significant, possibly 
due to the small sample size. 
Seasonality is also an important consideration. An autumn increase in ACTH was first 
described by Donaldson et al, (2005), who reported significantly higher levels in September 
compared to January and May. This circannual rhythm was further investigated by Copas 
and Durham (2012) who demonstrated that the autumn rise in ACTH was magnified in 
horses with PPID compared to controls. The same study proposed seasonal RIs to allow 
testing year-round. However, borderline results in the ‘grey zone’ (commonly reported as 
between 20 and 40pg/ml) close to the autumn or non-autumn cut-off should be interpreted 
with caution alongside clinical history and retesting at a later date or using a different 




Overnight dexamethasone suppression test (ODST) 
The ODST test measures cortisol concentrations 18–20 hours following dexamethasone 
administration (Dybdal et al., 1994). In horses with PPID, significant amounts of ACTH are 
produced by the pars intermedia, which means that cortisol secretion is maintained after 
administration of exogenous glucocorticoids. This test was previously considered the gold 
standard for the diagnosis of PPID with 100% sensitivity and specificity reported (Dybdal et 
al., 1994). However, this was later brought into question by Frank et al, (2006) who 
reported a sensitivity of 65% and specificity 76% (Frank et al., 2006a) and another small 
study which reported a lack of repeatability (Miesner et al., 2003). Furthermore, the ODST 
test has other limitations and is no longer recommended for use (EEG, 2019); the test 
requires two samples to be taken on two consecutive days, prior to and then following 
dexamethasone administration, incurring additional costs.  Moreover, there are concerns 
around the administration of corticosteroids in horses at an increased risk of laminitis (Potter 
et al., 2019).  
Thyrotropin-releasing hormone (TRH) stimulation test  
The TRH stimulation test was developed to try and improve the diagnosis of early or mild 
cases, which the basal ACTH may not be sensitive enough to identify. The presence of 
messenger ribonucleic acid (mRNA) for TRH Type 1 receptors has been reported in the pars 
intermedia melanotropes and pars distalis corticotropes in normal horses and horses with 
PPID (McFarlane et al., 2006). Administration of TRH has been shown to increase plasma 
concentrations of ACTH in horses with a significantly greater response in horse with PPID 
compared to normal horses (McFarlane et al., 2006; Beech et al., 2007; 2011a,b). Currently, 
two small studies have reported the TRH stimulation test to have a sensitivity of 95-100% 
(Beech et al., 2007, 2011b). As with the basal ACTH test, seasonal variation affects test 
results and seasonal reference intervals have been developed (Diez de Castro et al., 2014). 
The TRH stimulation test is generally considered a second-tier test which is used to confirm 
borderline basal ACTH test results or when other basal diagnostic test results are not in 
agreement with observed clinical signs. TRH is not currently licensed for use in horses and is 
therefore only permitted for use via the prescribing cascade (Anon, 2013).   
Treatment and management of PPID   
Pergolide, a long-acting dopaminergic agonist which is thought to reduce the secretion of 
precursors of ACTH, is currently the only PPID treatment licensed for use in horses (Muñoz 
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et al., 1996; Anon, 2011a). Other treatments such as cyproheptadine, a serotonin 
antagonist, and bromocriptine, another dopaminergic agonist, have also been considered as 
treatment options. However, less supportive evidence has been published for these 
medications (Roarty, 1990; Beech, 1994; Donaldson et al., 2002; Perkins et al., 2002) and 
there are no licenced products available.  
Pergolide has been described as effective at decreasing ACTH concentrations and improving 
clinical signs of disease in several studies. In particular, a large field study of 113 cases 
described improvement in clinical signs and/or endocrine test results in 76% of horses 
following treatment with 2-4μg/kg pergolide for 180 days (Anon, 2011a). The efficacy of 
pergolide for the treatment of PPID is examined in detail in Chapter 4. In brief, studies are 
predominantly limited to hospital-based populations and no studies have formally assessed 
the impact of management changes. Regardless of the level of evidence available, the 
treatment approaches taken for any disease are predominantly dictated by the owner 
(Christley and Perkins, 2010) and the treatment decisions made can be influenced by a 
multitude of factors such as their own experiences and perceptions (Scantlebury et al., 
2014). 
Due to the disease’s progressive nature and varying clinical signs (Heinrichs et al., 1990; 
Miller et al., 2008; McGowan et al., 2013a) it is likely that the effective dose of pergolide 
varies between individuals. Current recommendation is a starting dose of 0.002mg/kg 
(Peters et al., 1995; Schott et al., 2001; Donaldson et al., 2002; Durham et al., 2014). Side 
effects such as decreased appetite, weight loss, depression-like state, sweating and 
dyspnoea have been reported when horses are started on a higher dose (Anon, 2011a; 
Muñoz et al., 1996; Schott et al., 2001). Time until a detectable response to treatment is 
expected to be observed and when dosage should be increased has not been well 
documented. Current recommendations are for treatment to be reviewed monthly until the 
horse is considered to be stabilised and then review 2 – 4 times a year (Durham et al., 
2014). In one study, 22% of owners discontinued treatment due to lack of response 
(Rohrbach et al., 2012) therefore effective monitoring is likely to be a necessary part of 
treatment. If pergolide is discontinued, ACTH levels increase considerably after 2-10 days 
(McFarlane et al., 2017) suggesting life-long daily dosing is required.  
Treatment of PPID also includes consideration of general health care and management 
changes as this notably impacts health and quality of life (QoL).  This may include regular 
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dental care and in the latter stages, clipping to remove excess coat (Schott, 2002). Changes 
to diet and daily routine are also likely to be required to reduce the risk of laminitis in horses 
with concurrent insulin dysregulation and to maintain a healthy body condition. Management 
practices carried out by owners have been reported to change as horses age, with exercise 
intensity reported to decrease in the majority of cases (60.8%), an increase in the use of 
veteran and hay replacer feeds and less preventive health care administered (Ireland et al., 
2011a,b). It is therefore important to understand the treatment and management practices 
undertaken by owners of horses with PPID and the level of compliance with veterinary 
recommendations, as these factors are likely to impact treatment efficacy.  
There is little evidence available regarding long-term prognosis of horses with PPID. 
However, it seems horses can live for long periods of time following diagnosis. One study 
followed horses for 5.5 years and reported 40% of horses survived to last follow-up 
(Schott et al., 2014), while another small study reported 50% of horses survived 4.5 years 
after diagnosis (Rohrbach et al., 2012). However, a recent study reported that a diagnosis of 
PPID was associated with an increased risk of mortality, although median life expectancy 
after diagnosis was 9.8 years (Welsh et al., 2016). A recent retrospective study had a 
maximum follow-up period of 7 years; however, the median follow-up time was only 11 
months (Horn et al., 2019). This study was unique in also following non-treated horses and 
reported improvement (as per attending clinician) in 64.3% of horses treated with pergolide 
and 6.7% of non-treated horses. Both pergolide treatment and clinical improvement at re-
examination were positively associated with survival (p=0.01) (Horn et al., 2019). There 
remains a lack of long-term or prospective cohort studies. 
Quality of life  
As a chronic disease that can affect horses for a large proportion of their life, it is important 
that both veterinary surgeons and owners are able to ensure horses with PPID enjoy a good 
QoL. The World Health Organisation defines health as "A state of complete physical, mental, 
and social well-being not merely the absence of disease" and QoL is a measure that 
encompasses ‘wellbeing’ and not just changes in the frequency or severity of disease (WHO, 
1997), however a consistent definition is lacking (Rapley, 2011). Health status has been 
used a proxy for QoL, however health problems do not necessarily directly relate to lower 
QoL ratings (Carr and Higginson, 2001). In veterinary medicine, the term QoL is often used  
synonymously with the term “welfare”, however the consensus is that QoL goes beyond 
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welfare to encompass psychological health and general enjoyment of life (Broom, 2007). It 
has been proposed that QoL encompasses three main elements: 
1) Positive and negative feelings, ranging from severe pain to playfulness 
2) Physical fitness and health, encompassing elements such as how a disease affects 
their day to day life and physical ability to cope with its environment 
3) Naturalness, the ability to carry out natural behaviours and experience elements of 
natural environments (Fraser et al., 1997) 
The emphasis placed on the different aspects of QoL varies between social groups; for 
instance farmers put an emphasis on health, while welfare scientists think feelings are most 
important (Kling-Eveillard et al., 2007; Prickett et al., 2010). There has been little 
investigation into how veterinary surgeons or horse owners perceive QoL in horses. One 
study asked owners of geriatric horses to rate QoL and reported that the vast majority of 
owners perceived their horse to have a good QoL (Ireland et al., 2011c). It has been 
acknowledged that owners play an important role in assessing the day to day QoL of their 
horse (Parker and Yeates, 2012) and have more experience of their horse as an individual 
(McMillan, 2000, 2003). It is therefore important to understand more fully how owners 
perceive QoL in their horses, both when healthy and with disease or injury.  
In human medicine, QoL assessment has been long established and used to successfully 
measure the effect of chronic conditions and the implications of aging as well as the effect 
of various interventions (Schlenk et al., 1997; Skevington et al., 2001; Hyde et al., 2003, 
2015; Megari, 2013; Van Es et al., 2013). Similar forms of QoL measures have subsequently 
been established and validated for small animal veterinary medicine, becoming an important 
part of veterinary assessments. Questionnaires and QoL scales have been developed to 
measure the effect of diseases such as epilepsy in dogs (Wessmann et al., 2014), chronic 
pain in dogs (Wiseman-Orr et al., 2004), heart disease in cats (Reynolds et al., 2010) and 
cancer in both cats and dogs (Lynch et al., 2011). QoL has also been used to assess the 
effects of treatments such as chemotherapy and palliative care (Mellanby et al., 2003; 
Tzannes et al., 2008). Owner evaluation of QoL has also been shown to be an important and 
effective way of assessing management (Lavan, 2013; Tatlock et al., 2017). Various types of 
pain assessment tools have been described for different types of pain in horses including 
composite pain scores for colic (van Loon et al., 2015; Van Dierendonck and van Loon, 
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2016) and facial expression pain scores for laminitis (Dalla Costa et al., 2016) and 
orthopaedic pain (Dyson et al., 2017; Mullard et al., 2017; van Loon et al., 2019). However, 
currently there is no standardised means of measuring QoL in horses. The ability to properly 
assess individual QoL can help identify areas for improvement and have clear benefits 
(Pitkänen et al., 2009) and is clearly an area in which equine medicine needs to advance.  
Sociological research in equine veterinary medicine  
Although some advances in the diagnosis and treatment of PPID have been made in recent 
years, ultimately it is the owners who mediate the diagnosis, treatment and care of their 
horses (Christley and Perkins, 2010). It is therefore important that veterinary surgeons 
understand the lay beliefs behind the decisions that owners make and the practices they 
undertake. Qualitative interviews can be utilised to shed light on what influences owner 
decision making around approaches to the treatment and management of PPID (DiCicco-
Bloom and Crabtree, 2006).  Such methods are important in investigating PPID from a novel 
perspective. In human medicine, sociological research is well established and forms an 
integral part of a patient centred approach. Although there has been an increase in 
qualitative sociological studies within veterinary medicine, they remain relatively scarce in 
equine veterinary medicine. This suggests further understanding of qualitative techniques 
and how these can be practically applied to equine medicine is needed.  
Owner perspectives of health in the older equid  
How owners rate the importance of their horse’s health issues as they age can provide some 
insight into how they perceive various diseases. McGowan et al, (2010b) reported what 
owners perceived as the most important health issues among older horses, with loss of 
condition, arthritis/lameness and teeth/dental care of particular concern. QoL and 
management factors around caring for their horse were also frequently reported welfare 
concerns. Knowledge of owner health priorities among older horses can be useful in 
focusing messaging or increasing awareness of diseases; however, it does not provide any 
understanding or context around why the diseases were ranked as important.    
Diagnosis of a disease in the first place relies on owners recognising clinical signs in their 
animals. Two studies have investigated owner perception of clinical signs in geriatric horses. 
Ireland et al, (2012a) found that owners under-reported many clinical signs of disease and 
there was poor agreement between what owners reported and subsequent veterinary 
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assessment. Another study similarly reported that owners readily described clinical signs but 
reported the actual disease much less frequently (McGowan et al., 2010b). This suggests 
that owners under-recognise clinical signs in their horses and when they do recognise them, 
they do not necessarily attribute them to a disease. This could lead to significant delays in 
seeking veterinary attention.  
A further study investigated factors affecting treatment decisions made by owners of older 
horses, and Ireland et al, (2011d) reported that post-procedure prognosis, the seriousness 
of the disease, pain associated with procedures and veterinary advice were the biggest 
influencers (Ireland et al., 2011d). Although this provides some useful information regarding 
owner decision making and considerations veterinary surgeons should make when 
discussing options with owners, it does not provide the level of context or depth of 
information required to fully understand owner perspectives or what influences them.  
Lay beliefs and perceptions  
A qualitative, interview-based study investigated how horse owners perceived the health and 
performance of Pony Club horses (Buckley et al., 2004). The high value that owners placed 
on their horse looking visibly healthy with “bright eyes, shiny coat and good body condition” 
was highlighted. This study also gave some insight into how owners acquired information 
regarding their horse health. The advice of ‘knowledgeable friends’ was considered an 
important point of contact, compared to veterinary surgeons who were only consulted for 
what were perceived as serious conditions (Buckley et al., 2004). This demonstrates the 
important influence of the horse-owning community to which owners belong and highlights 
where education and advice need to be communicated. Another study utilised a unique 
Delphi methodology to score vignettes of scenarios based on the themes ‘essentials, 
physical insult and psychological injury’. Rounds of Delphi surveys with key opinion-formers 
were used to identify important welfare issues among horses in Ireland and how welfare 
standards could be raised (Collins et al., 2010). The study used the novel approach of 
scoring vignettes and identified broad areas of concern such as unregulated gatherings. 
However, more importantly, it highlighted the need to understand the motivators for and 
barriers against improving welfare standards among owners if interventions are to be 
successful. Another focus group based study investigated the perceptions of stakeholders in 
the racing industry (Butler et al., 2019). This study differed slightly as it included both 
professional and lay participants such as veterinary surgeons, trainers, staff and owners. 
Thematic analysis highlighted how stakeholders divided what was needed for a horse to ‘live 
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its best life’ and what was considered a ‘minimum welfare standard’. The importance of 
available veterinary care, correct feed and management and allowing the horse to exhibit 
natural behaviours were all identified alongside training and exercise.    
Owner management and treatment practices 
Owner management strategies and beliefs surrounding these can vary widely. This was 
highlighted by a telephone-questionnaire based study investigating management of horses 
with stereotypical behaviours on different types of yards (McBride and Long, 2001). The 
study found significant differences between the type of establishment and how owners 
perceived and managed horses with stereotypical behaviours, including use of preventative 
measures, effect on performance and the underlying cause of the behaviour. Differences in 
management between amateur and professional horse owners such as how horses are 
housed and fed have been described (Harris, 1999). This paper also described owners would 
forgo things, such a holiday, to ensure their horse got what they needed. This again 
highlights the need to further understand the motivators and decisions of horse owners 
when it comes to the management and treatment of their horses. An Australian study 
analysed qualitative questionnaire responses to examine the barriers to owners vaccinating 
against Hendra virus (Manyweathers et al., 2017). The low perceived Hendra virus risk, 
vaccine safety and cost of vaccination were reported to be important barriers. Interestingly 
most owners would not consider vaccination even when advised by their veterinary surgeon. 
This shows the influence of owner perceptions when it comes to veterinary treatment and 
the importance of a trusting owner-vet relationship when it comes to animal welfare.  
The management and treatment of horses has been reported to change as they age, with a 
reduction in preventive health care and routine veterinary treatment described (Ireland et 
al., 2011b). A recent cross-sectional study used Likert-scale questions to assess owner 
confidence in managing and recognising disease in older equids (Bushell and Murray, 2016). 
Although owners had a high level of confidence with regards to management regimes, 
confidence in disease recognition was lacking.  Reduction in veterinary interactions and 
difficulty recognising disorders is likely to have a detrimental effect on welfare and QoL.    
Evidence-based medicine  
The term ‘evidence-based medicine’ (EBM) was first introduced to scientific literature in the 
British Medical Journal by Guyatt et al., in the early 1990’s and is defined as ”the 
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conscientious, explicit and judicious use of current best evidence in making decisions about 
the care of individual patients” (Guyatt et al., 1992). Since then the principles have been 
rapidly adopted, having a significant effect on implementing and teaching medicine (Guyatt 
et al., 1992; Bernstein, 2004; Mellis, 2015), integrating clinical expertise with evidence from 
systematic research (Sackett and Rosenberg, 1995; Sackett, 1997; Heneghan and 
Badenoch, 2006).  
EMB is underpinned by a process of five steps (Heneghan and Badenoch, 2006): 
1. Ask an answerable clinical question (by defining the patient/problem, intervention, 
comparison/control and outcomes, known as the PICO format). 
2. Acquire the best evidence. 
3. Appraise the evidence critically. 
4. Implement the evidence into practice where appropriate. 
5. Access the impact. 
The EBM process can be directly applied to equine veterinary medicine. However, the 
concept of evidence-based veterinary medicine (EBVM) is still fairly new (Dean, 2014) and 
has been met with a number of challenges. These include concerns about the scarcity of 
high-quality evidence, a lack of time to search for the evidence, lack of training/skills to 
appraise it and that clinical experience and expertise may be overlooked (More, 2012; 
Vandeweerd et al., 2012; Dean, 2014; Turner and Royle, 2015).  
The first step in improving the evidence base is to identify the clinical questions veterinary 
surgeons and horse owners need answering. As discussed previously, PPID has become 
increasingly important in equine medicine, however the availability of high-quality evidence 
regarding its diagnosis, treatment and prognosis is limited. EBM assesses types of evidence 
according to the probability of bias, with systematic reviews and randomised clinical trials 
considered the most robust studies, while case series or expert opinions are the lowest level 
(Phillips et al., 2009). Until very recently systematic reviews were scarce in veterinary 
medicine however their importance is beginning to be recognised. One has recently 
examined the epidemiology of PPID (Ireland and McGowan, 2018) and systematic reviews 
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conducted as part of the research in this thesis evaluated the diagnosis (Chapter 3) and 
treatment (Chapter 4) of PPID. Prior to this, the evidence pertaining to PPID was 
predominantly based on less robust case reports/series and case control studies from 
predominantly small hospital-based populations, which are not necessarily generalisable to 
the general population. This thesis builds on the evidence base to better inform veterinary 
surgeons and ensure the QoL of horses with PPID.  
Patient and public involvement  
Patient and public involvement (PPI) has been defined as ”Healthcare professionals working 
together with patients and the public to improve the health communities they serve” 
(Cartwright and Crowe, 2011). It encompasses a broad range of methods to engage heath 
care end users in the process of determining what research is done, how it is conducted and 
how the findings are interpreted and used (Adamson et al., 2005). People living with health 
problems and those who use health services can make useful contributions to widen 
perspectives, bridging the gap between patients and researchers. This was first recognised 
in the 1990’s (Chalmers, 1995; Oliver, 1995; Entwistle et al., 1998) and the scope for 
patient involvement to aid identification of important questions for research was also 
recognised (Chalmers, 1995; Oliver, 1995; Entwistle et al., 1998). It has been acknowledged 
that researchers do not always investigate areas that are important to the end users. PPI 
encourages research agendas to be broadened and to encompass the ‘voice of the patients’, 
with the aim of improving the delivery of health care and ensuring the evidence base is 
representative of the consumer (Tallon et al., 2000; Oliver et al., 2001; Chalmers et al., 
2012). This has led to initiatives such as INVOLVE designed to support active public 
involvement in the National Health Service (NHS) by carrying out research ‘with’ the public 
rather than ‘about’ them (INVOLVE, 2017). In theory, PPI methodology could easily be 
adapted into an equine veterinary setting to ensure that future research is clinically relevant 
to the end users such as veterinary surgeons and owners.    
The James Lind Alliance framework 
The James Lind Alliance (JLA) framework is used in human medical research to provide a 
platform for an independent and integrated approach to PPI, involving patients, carers and 
clinicians in setting research priorities (Elwyn et al., 2010; Lophatananon et al., 2011; 
Cowan, 2013; JLA, 2016). The freely available framework provides guidance on establishing 
and managing Priority Setting Partnerships (PSPs), with the aim of raising the awareness 
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and funding of research questions which have a direct relevance and benefit to patients and 
the clinicians who treat them (JLA, 2016).  
The JLA methodology uses a mixture of quantitative and qualitative approaches to identify 
and prioritise gaps in the current available evidence known as ‘uncertainties’. Uncertainties  
occur when questions about diagnosis, treatment and prognosis cannot be answered by up 
to date information based on research evidence (JLA, 2016). The methodology includes 
surveys to identify uncertainties and an adapted Delphi method to undertake prioritisation 
(Pill, 1971; Gordon, 1994; Lophatananon et al., 2011). PSPs are structured using a nominal 
group technique to ensure equal contributions from patients and clinicians to efficiently 
prioritise the uncertainties identified (Jones and Hunter, 1995), resulting in a prioritised ‘top 
10’ of research questions that need answering. This technique is underpinned by principles 
of a clear audit trail, transparency and a commitment to using and contributing to the 
evidence base (JLA, 2016).  The first PSP in 2007 identified the top 10 research questions 
for asthma (Elwyn et al., 2010). Since then, the technique has been used in many further 
publications making it a tried and tested method (JLA, 2016). A PSP was previously utilised 
to identify and prioritise treatment uncertainties for chronic kidney disease in cats (Dean, 
2014). Otherwise, the JLA framework has rarely been used in veterinary medicine as a 
whole, and to date has not been used in equine veterinary medicine.  
The JLA framework has been used to identify priorities for Parkinson’s disease, which is 
thought to share pathologic similarities to PPID. Parkinson’s disease is also an age-
associated neurodegenerative disease. It occurs sporadically in the geriatric human 
population. Neurodegeneration of the nigrostrial dopaminergic neurons results in a loss of 
inhibitory neurotransmitter dopamine in the striatum. This leads to the motor dysfunction 
observed in Parkinson’s disease (McFarlane, 2007). The priorities identified included: 
• What is the best method of monitoring a person with Parkinson's response to 
treatments? 
• What drug treatments are best for the different stages of Parkinson's? 
• Can we develop accurate tests/techniques to determine medication timing and 
amount (dose)? (JLA 2016 online archive) 
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This example demonstrates several parallels to treatment and monitoring considerations for 
horses with PPID, thereby indicating that the JLA method could readily be adapted from 
human to equine medicine in order to prioritise research questions pertaining to PPID. 
Overall, current literature regarding the diagnosis, treatment and prognosis of PPID is 
limited in terms of the populations studied and outcome observed. The evidence base needs 
to be built on, and PPI methodology can be adapted to help prioritise and direct areas of 
research to fill evidence gaps and ensure future research is applicable to end users. Due to 
the long-term management horses with PPID require, it is important to understand the 
management and treatment practices made by the owners that care for them to help 
improve QoL. Sociological based research can contribute to a more evidence-based 
approach to management and treatment, by understanding owner perceptions of QoL and 















Ojectives of the thesis  
1. To adapt PPI methodology in order to identify and prioritise key research 
questions regarding the diagnosis, treatment and prognosis of pituitary pars 
intermedia dysfunction (PPID) 
2. To systematically collate and evaluate the evidence regarding diagnostic and 
treatment protocols for PPID 
3. To identify and evaluate management and treatment strategies undertaken by 
owners of horses with PPID and how these change over time  
4. To gain an understanding of owner perceptions of and decision making around 
treatment and QoL in horses with PPID 
 
In order to achieve these objectives, quantitative and qualitative studies were undertaken in 
a population of horses diagnosed with PPID: 
Chapter Two describes the adaptation of the JLA framework to identify research priorities for 
the diagnosis, treatment and prognosis of PPID.  
Chapter Three systematically collates and assess the evidence regarding measurement of 
basal ACTH for the diagnosis of PPID. 
Chapter Four systematically collates and assess the evidence regarding the use of pergolide 
for the treatment of PPID. 
Chapter Five describes the management and treatment practices undertaken by owners of 
horses diagnosed with PPID as well as perceptions of QoL, utilising a cross-sectional online 
questionnaire. 
Chapter Six prospectively follows a subset of horses from the cross-sectional study over a 12 
month period using follow-up telephone questionnaires. Rates of mortality and disease 
incidence are described as well as changes in owner management and treatment strategies 
and perceptions of QoL. 
Chapter Seven uses semi-structure interviews to gain an in-depth understanding of owner 
decision making around the treatment of PPID and perceptions of QoL. 
Chapter Eight summarises the information gained from these studies, discusses practical 
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Equine pituitary pars intermedia dysfunction: Identifying research 
priorities for diagnosis, treatment and prognosis through a priority setting 
partnership 
The following chapter comprises the James Lind alliance Priority Setting Partnership, and is 
presented as it was published in PLOS ONE. 
Reference: Tatum RC, McGowan CM, Dean RS, Ireland JL (2021) Equine pituitary pars 
intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis 
through a priority setting partnership. PLOS ONE 16(1) 
Summary  
Pituitary pars intermedia dysfunction (PPID) is the most prevalent endocrine disorder of 
older equids. To date, key research areas likely to have the greatest impact on equine 
health have not been identified. In human medicine, public and patient involvement is 
widely used to inform research agendas. This study aimed to engage with veterinary 
surgeons and horse owners to identify evidence gaps (‘uncertainties’) and prioritise these 
into a list of the 10 most important PPID research questions. The James Lind Alliance (JLA) 
Priority Setting Partnership (PSP) Framework was adapted. Questions about the diagnosis, 
treatment and prognosis of PPID were gathered via an online survey targeting veterinary 
surgeons and horse owners with experience of PPID. Thematic analysis was used to form a 
longlist of collated indicative research questions (CIRQs), defined by the JLA as true 
‘evidence uncertainties’ when not answered by a published, clinically relevant, up-to-date 
systematic review. In an interim prioritisation survey, questions were ranked by weighted 
scores creating a shortlist of 25 that were taken forward to the PSP workshop, where 
participants reached a consensus on the top 10. Useable responses containing ≥1 question 
were received from 524 respondents (92.6% owners, n=485; 7.4% veterinary surgeons, 
n=39). After screening for relevance, 1,260 individual questions were included in thematic 
analysis, resulting in 47 CIRQs. Interim prioritisation votes for the CIRQs were received from 
360 respondents. The top 10 questions prioritised at the PSP workshop focused on long-
term prognosis, diagnostic accuracy, efficacy of pergolide treatment, alternative 
treatment/management strategies and potential treatment options for poor responders to 
pergolide. The quantity of questions generated indicates an extensive number of 
uncertainties regarding the diagnosis, treatment and prognosis of PPID. The top 10 research 
questions will help to inform key areas for evidence synthesis and knowledge translation, 
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and to direct future research into areas most important to end users involved in caring for 
and treating animals with PPID.   
Introduction 
Pituitary pars intermedia dysfunction (PPID) is a common age-associated equine 
neurodegenerative disorder (McFarlane and Cribb, 2005; McGowan et al., 2013a). While the 
exact pathophysiology of the disease remains poorly understood (McFarlane, 2007; Miller et 
al., 2008), oxidative stress is thought to contribute towards progressive neurodegeneration 
of the inhibitory dopaminergic hypothalamic neurons (McFarlane and Cribb, 2005; McFarlane 
et al., 2005c). This leads to a loss of dopaminergic inhibition of the pars intermedia lobe of 
the pituitary gland and over production of pituitary-derived hormones. As a result, increased 
plasma concentrations of pro-opiomelanocortin (POMC) peptide and its derivatives, including 
α-melanocyte stimulating hormone, corticotropin-like intermediate lobe peptide, β-endorphin 
and adrenocorticotrophic hormone (ACTH), are observed (Heinrichs et al., 1990; McFarlane 
et al., 2005c; McFarlane, 2007). This proliferation of hormones is associated with a variety 
of clinical signs and comorbidities including hypertrichosis, laminitis, epaxial muscle wastage 
or muscle atrophy and lethargy (Schott, 2002; McFarlane, 2011; McGowan et al., 2013a; 
Ireland and McGowan, 2018). Current published evidence about diagnosing and managing 
PPID is limited, both in terms of the study populations included and the outcomes 
measured. Various different endocrinologic assay tests have been developed for the 
diagnosis of PPID. However, a ‘gold standard’ laboratory test is currently lacking  (Frank et 
al., 2006a; McGowan et al., 2013b). Once diagnosed, the dopamine agonist pergolide is 
currently the only licensed treatment for PPID (Muñoz et al., 1996; Anon, 2011a). However, 
evidence regarding its efficacy is largely based on a single uncontrolled trial (Anon, 2011a) 
and numerous descriptive reports (Peters et al., 1995; Muñoz et al., 1996; Sgorbini et al., 
2004; Aleman et al., 2006; Rohrbach et al., 2012; Spelta and Axon, 2012). Therefore, a 
more robust evidence base is required to inform veterinary surgeons and horse owners 
regarding optimal methods for diagnosis and medical treatment of PPID.   
Ensuring that research is relevant and applicable to those who can improve patient care is 
essential. However, researchers do not always investigate areas or answer questions 
important to the end users (Tallon et al., 2000; Oliver et al., 2001). Inclusive research 
methods in medicine have been developed to bridge the gap between patients, clinicians 
and researchers, encouraging widening of perspectives to identify gaps in the evidence and 
prioritise research agendas (Chalmers, 1995; Oliver, 1995; Entwistle et al., 1998). One of 
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these methods is the framework developed by the James Lind Alliance (JLA) Priority Setting 
Partnership (PSP). The JLA has been established as a platform for an independent 
integrated approach to setting research agendas (Petit-Zeman et al., 2010; JLA, 2017). It 
brings together patients, carers and clinicians on a “level playing field” to identify and 
prioritise unanswered research questions, known as ‘uncertainties’ (Elwyn et al., 2010; 
Lophatananon et al., 2011; Cowan, 2013; JLA, 2016, 2017). Despite successful public and 
patient involvement (PPI) being used in priority setting for human medical research for over 
a decade (Entwistle et al., 1998; Adamson et al., 2005), it has only recently been adapted 
for use in a veterinary setting. An adaptation of the JLA framework has previously been used 
to set priorities for research into the treatment of chronic kidney disease in cats (Dean, 
2014). However, to date such priority setting has not been applied to equine research.  
Veterinary surgeons and horse owners with experience of PPID are best placed to identify 
questions about the disease most in need of answering.  Therefore, the aim of this study 
was to engage these end users in order to identify their top 10 research priorities for the 
diagnosis, treatment and prognosis of PPID. 
Materials and methods  
Adaptation of the James Lind Alliance (JLA) Framework  
This study did not include animal participants, therefore international, national, or 
institutional guidelines for humane animal treatment are not applicable. This project 
received institutional ethical approval from the University of Liverpool and Animal Health 
Trust. Following institutional ethical approval, the six steps of the JLA framework (Petit-
Zeman et al., 2010) were adapted to identify research priorities for PPID: 
• Identification of, and contact with, collaborators to form a steering group. 
• Development and dissemination of surveys to the target audience to gather 
questions they have regarding PPID.  
• Collation, categorisation and refining of the questions submitted by participants into 
a longlist, and formatting these collated questions in PICO (population, intervention, 
comparison, outcome) format where possible. 
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• Searching the literature to identify if the questions are ‘uncertainties’. An uncertainty 
is defined by the JLA as “a question which cannot be answered by a relevant, up-to-
date systematic review” (Petit-Zeman et al., 2010). 
• If >30 uncertainties are identified, interim prioritisation is undertaken to form a short  
list of 25 questions taken forward to the PSP workshop.  
The organisation of a PSP workshop 
Establishing a Priority Setting Partnership  
A steering group was established to run and oversee the Priority Setting Partnership (PSP). 
The steering group consisted of veterinary surgeons, including specialists in evidence-based 
medicine and equine internal medicine, as well as horse owners with experience of PPID. A 
protocol detailing the specific objectives of the PSP was developed in accordance with the 
JLA guide lines (Crowe, 2009; JLA, 2016) (Appendix 1) and adapted for use in an equine 
veterinary setting. The target population was veterinary surgeons and horse owners with 
experience of PPID. Boehringer Ingelheim Animal Health UK Limited (BI) was identified as a 
collaborator, and their extensive database of relevant participants facilitated survey 
dissemination.  
Survey development and distribution 
A survey was developed to collect questions from respondents based on the JLA guidelines 
using the freely available online survey tool, KwikSurveys (KwikSurveys, 2017) (Appendix 2). 
The survey gathered questions regarding the diagnosis, treatment and prognosis of PPID 
from veterinary surgeons and horse owners with experience of the disease. Open questions 
with free text boxes were used to facilitate this, and respondents could enter as many or as 
few questions as desired. An invitation to participate in the survey was distributed via email 
to collaborator BI’s “Care and Connect” database (a service which enables owners and 
veterinary surgeons to monitor horses with PPID after diagnosis) (TAL, 2017) and BI’s 
veterinary practice contact list: a tailored introduction was included explaining the purpose 
of the research. A link to the survey was also promoted through BI’s Talk About Laminitis 
Facebook page, and the respective websites and/or social media pages of the University of 
Liverpool Equine Hospital, University of Nottingham Centre for Evidence Based Veterinary 
Medicine (CEBVM) and Animal Health Trust. The aim was to reach as many relevant 
participants as possible. Enrolment efforts were targeted within Great Britain (GB); however, 
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participation was not limited to respondents from GB. The survey was available online for 
eight weeks from 13th April 2017 to 9th June 2017.  
Processing the responses   
Responses were downloaded into a Microsoft Excel spreadsheet and anonymised. Each 
individual question was screened for relevance and to ensure the inclusion and exclusion 
detailed in the JLA PSP protocol (Appendix 1) were met. Questions outside the specific 
objectives of the PSP were excluded. Questions about diagnosis, treatment and prognosis of 
PPID were systematically categorised into themes. Duplicates and similar submissions were 
then interpreted and combined to create indicative questions to enable searching of the 
evidence base (Figure 1). For example, questions about the various possible side-effects of 
pergolide treatment were combined to form the CIRQ ‘In horses with PPID, what are the 
side-effects of pergolide treatment both long and short-term?’. This enabled the themes and 
issues raised by the survey to be captured and made accessible to a non-research audience.  
Verification of uncertainties 
The literature was searched for relevant, up-to-date systematic reviews using appropriate 
databases including MEDLINE, CABI, SCOPUS, Web of Science (WOS) and the online 
database of citations for systematic reviews of relevance to veterinary medicine and science 
VetSRev (Grindlay et al., 2016). Broad search terms were used to ensure all relevant 
evidence was located (Appendix 3).The literature regarding diagnosis, treatment and 
prognosis of PPID was identified and categorised into type of study: [i] systematic review, 
[ii] narrative review, [iii] clinical trial, [iv] case-control study, [iv] observational study 
[prospective/retrospective], [v] cross-sectional study, [vi] descriptive reports and [vii] 
“other” (which included all other types of study including conference abstracts or where 
study design could not be determined).  
Interim prioritisation  
From the initial survey, more than 30 uncertainties were identified; therefore, an interim 
survey was undertaken to prioritise which uncertainties should be included in the PSP 
workshop (Appendix 4). A link to the interim survey was sent via email to all original survey 
respondents. To encourage additional responses, especially from veterinary surgeons, a link 
was also shared via the University of Liverpool Equine Practice Facebook page and other 
relevant social media pages replicating the original survey dissemination. This interim stage 
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required participants to select their top 10 most important questions from the longlist, but 
not to rank them. The interim prioritisation survey was available online from 23 rd October 
2017 to 20th November 2017. Questions were ranked via weighted scores, depending on the 
number of votes received, to ensure equal weighting of veterinary surgeon and horse owner 
responses. Separate rankings were then combined to form a final ranked list of all 
questions. The top 25 questions were taken forward to final PSP workshop. 
 
Figure 1: Process by which survey responses were converted to a shortlist of questions for 
prioritisation at the priority setting partnership workshop. 
34 
 
Priority setting workshop 
Participants from both surveys who expressed an interest in participating further, and had 
provided contact details for this purpose, were invited to attend the final PSP workshop. The 
final priority setting was conducted in a face-to-face workshop using both small and whole 
group discussions, utilising an adapted nominal group technique (Potter et al., 2004; JLA, 
2016). This allowed horse owners and veterinary surgeons to contribute equally to the 
discussion. The workshop was chaired and facilitated by the authors. To ensure 
transparency, each participant had to disclose who they were, what they did and any 
competing interests they had, for example if they worked in the pharmaceutical industry. 
Three rounds of prioritisation were undertaken using visual cue cards to rank questions; two 
small group sessions and one final whole group session. To ensure an even distribution of 
participants, veterinary surgeons and owners were assigned an identification number and 
randomly allocated to a group using a random number generator prior to the workshop 
(Augustana, 2004). The groups were purposively changed after the first session to ensure 
diverse collaboration and opinion sharing. After each round of prioritisation, the rankings 
from each small group were combined to form an overall aggregate rank for each question. 
The final ranking was then discussed and amended in the final whole group session with 
particular attention being paid to the top 10 collated questions.  
Results 
Respondent demographic information 
A total of 524 usable responses, which contained at least one question about diagnosis, 
treatment and/or prognosis, were received from veterinary surgeons and/or horse owners 
with experience of PPID in the initial online survey. The majority of responses were from 
owners (92.6%; n=485), of which 438 currently owned a horse with PPID and 47 had 
previously owned a horse with PPID. The remaining 39 responses were from veterinary 
surgeons, of which 35 were currently in practice treating horses with PPID, and four were 
also current owners of a horse with PPID. The majority of respondents were from GB 
(92.4%; n=484), and 7.3% (n=38) were from other regions including North America 
(n=12), Europe (n=10), Ireland, the British Channel Islands and Isle of Man (n=9), 
Australasia (n=6) and Asia (n=1).  A further two respondents did not provide information 
regarding their country of residence.  
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Collation and rationalisation of questions 
The process of rationalising the list of questions is summarised in Figure 1. The 524 
participants submitted a total of 2,174 individual questions about PPID in horses/ponies. The 
responses were very variable: some contained one question and others contained multiple 
questions. Some respondents did not submit a question at all and simply described their 
experiences or asked about their own horse specifically. These were utilised where relevant 
statements were made but otherwise excluded. Each response was broken down into 
possible questions and themes for the next step of the process, in which 1,260 questions 
specific to diagnosis, treatment and prognosis that met pre-defined criteria (Appendix 1) 
were identified. After thematic analysis, 47 CIRQs were identified.  
Literature searches conducted on 06th December 2017 (Table 1 and Appendix 3) identified 
134 relevant publications (after removal of duplicates), however no relevant up-to-date 
systematic reviews were identified (Table 1). Therefore, all 47 CIRQs from the survey were 
classed as unanswered, and consequently uncertainties, as defined by the JLA, and were 
taken forward to the two stage prioritisation process. After interim prioritisation, the 25 
questions ranked highest overall were taken forward to the final PSP workshop (Table 2 and 
Appendix 5). Examples of the questions submitted by respondents, how they were 
categorised to form the CIRQs and their ranking following interim prioritisation are shown in 
Table 2.  
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Table 1: Study design and main topics of relevant publications regarding pituitary pars intermedia dysfunction identified via a literature search 




















0 12 0 20 9 3 26 14 
Treatment of 
PPID 
0 29 4 3 4 2 19 4 
Prognosis of 
PPID 
0 6 0 0 3 1 3 1 






Table 2: The interim prioritisation rankings of the final top 10 questions agreed as shared priorities at the pituitary pars intermedia dysfunction 
priority setting partnership workshop, including examples of the original questions submitted and how they were categorised to form collated 
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45 • What is the likely progression of the 
disease or is it very individual. 
• How will it develop and what are the 
signs that it is developing? 
• Is there any way of assessing likely rates 
of deterioration of PPID? 
In horses with PPID, what is the 
expected disease progression 
over a horse’s lifetime both with 
and without treatment? 
4 1 1 
20 • Should the dosage vary at different times 
of year/when horse shows different 
symptoms? 
• I realise there are seasonal variations in 
the ACTH levels. Can the Prescend [sic] 
be safely reduced during off peak times? 
• And should the amount of medicine 
change through the seasons? 
In horses with PPID, does the 
dose of pergolide need to vary 
with the season? 
3 9 2 
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13 • By treating with Prascend, and lowering 
ACTH levels to within the normal range, 
how much will the likelihood of symptoms 
reduce? E.g. reduce laminitis risk by 70%, 
skin infections by 60% 
• Are they still at the same risk of laminitis 
as they were before treatment was 
started? 
• Is it true that if you reduce the prascend 
that you may cause laminitis? 
In horses with PPID receiving 
treatment with pergolide, is the 
risk of laminitis reduced? 
2 10 3 
75 • Is there anything else that can be done to 
slow this disease apart from prascend? 
• If Prascend stops working what other 
treatments are available? 
• Can radiotherapy or surgery be used? 
In horses with PPID, are there 
any medical treatments, other 
than pergolide, that work? 
8 5 4 
31 • Can results be inaccurate if a horse is 
stressed? 
• Can results be inaccurate if a horse is in 
pain? 
• Can other conditions such as ir and ems 
cause a false positive? 
In horses with PPID, does stress, 
concurrent illness and/or pain 
affect the reliability and accuracy 
of diagnostic tests? 
1 13 5 
9 • Some cases refractory to treatment and 
difficult to explain why 
• What is the best way of treating apparent 
"non-responders" to pergolide? 
• What if treatment doesn't have the 
desired results? 
What is the best way of dealing 
with horses who do not respond 
to pergolide treatment? 
5 16 7 
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110 • What "lifestyle changes" should be made 
to help with the condition?  
• how can I keep my pony healthier while 
having PPID? 
• Are there any published studies of 
effective management and feed strategies 
for horses with PPID that can educate 
horse owners? 
In horses with PPID, what 
additional management strategies 
[i.e. feed & turnout] are best to 
use in conjunction with pergolide 
treatment? 
18 4 8 
91 • Long term side effects of Prascend? 
• What are the side effects of the tablets? 
• Have you documented dysphagia as a 
side effect to prascend? 
In horses with PPID, what are the 
side-effects of pergolide 
treatment [both long and short-
term]? 
17 7 9 
3 • What is the recommended 
treatment/course of action after the horse 
has reached the recommended maximum 
daily number of Prascend tablets [i.e. 3 
per day] and the ACTH levels are 
continuing to increase? 
• At what point in the progression of PPID 
is it advisable to discontinue increasing 
doses of pergolide? 
• What happens when you get to the 
maximum dose of prascend? 
In horses with PPID, what should 
be done when the maximum dose 
of pergolide has been reached 
but hormone levels are still 
elevated? 
16 12 11 
67 • Homeopathic remedy that is as effective? 
• Have any herbal remedies ever been 
tested to work? 
• Are herbal/alternative treatments really 
effective in any way? 
In horses with PPID, are any non-
prescription treatments [i.e. 
Agnus Castus, homeopathy, other 
herbal products] effective? 
37 2 16 
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11 • What is more important, clinical signs or 
bloods? What if the two don't match? 
• Should we diagnose an old horse without 
any clinical symptoms but a high ACTH in 
the blood, as having PPID? 
• What is the recommended plan for horses 
displaying symptoms of PPID but not 
testing positive? 
In horses with suspected PPID, 
what is the best way to deal with 
inconclusive or conflicting test 
results and/or clinical signs 
[symptoms]? 
10 35 21 
 *The raw questions are as they were entered by respondents, only spelling has been corrected. 
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The Priority Setting Partnership Workshop  
The PSP workshop was attended by a total of nine veterinary surgeons and 13 horse owners 
with experience of PPID (Figure 2). A list of the top 10 uncertainties for PPID was agreed by 
consensus.  
During the small group discussion rounds, each group decided on their shared list of 
priorities. Following the second round of small group discussions, there was little change 
overall in the order of the top eight questions. However, there was some change in the 
middle rankings. During the third whole group discussion, the final shared prioritised list of 
questions was agreed (Table 3). Overall, there was general consensus on the ranking for the 
majority of questions with the exception of question P (‘In horses with PPID, are any non -
prescription treatments (i.e. Agnus Castus, homeopathy, other herbal products) effective?’). 
There was much debate around this question and owners put forward a case for it to be 
moved into the top 10. However, agreement could not be reached on which question should 
be moved out of the top 10 in order to accommodate question P. Throughout the workshop 
discussions, participants considered that question P was closely related with question H (‘In 
horses with PPID, what additional management strategies (i.e. feed & turnout) are best to 
use in conjunction with pergolide treatment?’). Therefore, it was decided that the two 
questions could be encompassed under a single ranking and that question P would form a 
‘part b’ to question H (ranked fourth).  
Following the PSP workshop, participants were sent a feedback questionnaire. The feedback 
questionnaire was completed by 16 attendees (five veterinary surgeons and eight owners, 
three did not specify). Median participant ratings for their overall experience, usefulness, 













Table 3: Final shared top ten research priorities for the diagnosis, treatment and prognosis 
of pituitary pars intermedia dysfunction (PPID) ranked during the PPID Priority Setting 
Partnership workshop 
ID Question Final 
Order 
A In horses with PPID, what is the expected disease progression 
over a horse’s lifetime both with and without treatment? 
1 
E In horses with PPID, does stress, concurrent illness and/or pain 
affect the reliability and accuracy of diagnostic tests? 
2 
D In horses with PPID, are there any medical treatments, other 
than pergolide, that work? 
3 
H In horses with PPID, what additional management strategies 
[i.e. feed & turnout] are best to use in conjunction with 
pergolide treatment? 
4a 
P In horses with PPID, are any non-prescription treatments [i.e. 
Agnus Castus, homeopathy, other herbal products] effective? 
4b 
C In horses with PPID receiving treatment with pergolide, is the 
risk of laminitis reduced? 
5 
I In horses with PPID, what are the side-effects of pergolide 
treatment [both long and short-term]? 
6 
B In horses with PPID, does the dose of pergolide need to vary 
with the season? 
7 
U In horses with suspected PPID, what is the best way to deal 
with inconclusive or conflicting test results and/or clinical signs 
[symptoms]? 
8 
G What is the best way of dealing with horses who do not 
respond to pergolide treatment? 
9 
K In horses with PPID, what should be done when the maximum 






This PSP achieved engagement with horse owners and veterinary surgeons across two 
phases of prioritisation to identify research priorities for PPID. The JLA framework was 
successfully applied to an equine disease of complex pathophysiology, indicating this 
methodology could be effectively applied to other equine diseases. The research priorities, 
within the pre-defined topics of diagnosis, treatment and prognosis, included: [i] long-term 
prognosis, [ii] diagnostic accuracy, [iii] efficacy of pergolide, [iv] alternative 
treatment/management strategies and [v] potential treatment options for poor responders 
to treatment with pergolide. As the study was conducted in GB and respondents were 
primarily from GB, differences in horse populations, management and treatment practices 
around the world means the questions raised here may not be globally representative. 
The PSP followed a rigorous and transparent predefined process to create a top 10 list of 
shared research priorities. The process gathered a large number of responses, comparable 
with other JLA PSPs (Eleftheriadou et al., 2011; Gadsby et al., 2012). The JLA does not 
define a target sample size. Instead, a saturation point is reached where no new themes are 
emerging (JLA, 2016). Participants posed multiple questions resulting in numerous themes 
and a large but manageable number of questions. At the point the survey was closed, no 
new themes were emerging.  
Various methods were used to distribute the survey with some being more successful than 
others. Advertising via social media was effective for recruiting horse owners but not 
veterinary surgeons. A large number of veterinary surgeons were contacted via BI’s mailing 
list. However, the number of veterinary responses compared to horse owners was 
disappointing. This may have been for a number of reasons, such as they were not 
interested in engaging in this type of research, the open question design of the 
questionnaire discouraged them from participating or they felt there were no gaps in the 
evidence and therefore did not have a question to pose. A more targeted approach or a 
prior, formal collaboration with veterinary practices may have improved veterinary 
responses. However, a low response rate from veterinary surgeons and veterinary practices 
has been noted in other studies (Hotchkiss et al. 2007a,b; Ireland et al., 2011a). Exploring 




Despite the low number of responses, questions posed by participating veterinary surgeons 
did not markedly differ from those posed by owners. Around a quarter of questions raised 
by participants were not specific to diagnosis, treatment or prognosis and instead covered 
other PPID-related subjects. This is comparable the previous veterinary PSP conducted by 
Dean, (2014). The majority of these non-useable questions were regarding the disease’s 
pathophysiology which remains poorly understood (McFarlane, 2011). Many of the questions 
collated were un-structured and non-specific. Therefore, in order to form structured 
questions which enabled searching for evidence, questions were adapted and combined to 
form CIRQs. This stage was a qualitative process, with a set structure and technique set out 
by the JLA followed to ensure consistency (Crowe, 2009). This allowed questions to be 
combined and managed without losing context. A limitation of the process is that some of 
the research questions identified may represent a failure of communication, knowledge 
transfer or understanding, rather than actual evidence gaps. For example, submitted 
questions such as ‘what diagnostic tools are available?’ and ‘what is it you are actually 
testing the levels of in the blood sample?’ indicate that horse owners may not fully 
comprehend the diagnostic process. Therefore, the validity of each CIRQ was carefully 
considered by the steering group to ensure they were unanswered research questions, as 
defined by the JLA.  
The ‘Choose Ten’ interim prioritisation approach was chosen because it is an uncomplicated 
way of allowing participants to consider the whole list then make choices that involve 
genuine shortlisting (JLA, 2016). Despite additional promotion, the number of responses 
from veterinary surgeons for the second interim survey remained low. The scoring and 
ranking method ensured that votes from veterinary surgeons and owners were equally 
weighted. A difference in priorities between groups was observed; some questions ranked 
highly by veterinary surgeons were ranked considerably lower by horse owners and vice 
versa. For example; ‘In horses with PPID, does stress, concurrent illness and/or pain affect 
the reliability and accuracy of diagnostic tests?’ was ranked highest by veterinary surgeons 
but thirteenth by owners.  
During the adaptation of the JLA protocol, it was decided that the JLA definition of an 
‘uncertainty’ would be applied for the equine veterinary setting. There are few systematic 
reviews in equine medicine; at the time of writing only 23 were available on the VetSRev 
database. This meant it was likely all questions posed by participants would be defined as 
uncertainties. However, it was agreed by the steering group that the level of certainty could 
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not be lowered and the quality of evidence should remain the same across fields. Systematic 
reviews collate data from numerous studies and offer the highest level of evidence (Howick 
et al., 2009), and if the JLA definition was changed it may have mislead PSP participants 
regarding the level of evidence available (Dean, 2014). The evidence base found for the 
diagnosis, treatment and prognosis of PPID was of poor to moderate quality (Howick et al., 
2009).  While no published systematic reviews pertaining to PPID were available prior to this 
PSP, equine endocrinology has been identified as a fast‐moving field  (Marr and Mair, 2014) 
and a large number of studies published within the past two decades contribute some 
evidence towards the top 10 research questions reported here. Future knowledge synthesis, 
such as systematic reviews, focused on these questions could offer an opportunity to close 
some of these evidence gaps. Importantly, this PSP has also identified a requirement to 
raise awareness within the equine veterinary profession of the need for better dissemination 
of the findings from previous research.   
The final PSP workshop allowed an open and thoughtful exchange of views between horse 
owners and veterinary surgeons. This enabled consensus to be developed and facilitated the 
identification of the top 10 research questions. Both groups were represented by an 
appropriate number of participants (Crowe, 2009; JLA, 2016). All groups worked well 
together, with veterinary surgeons raising issues relating to owners and vice versa. As in 
other PSP workshops, changes in ranking after group discussions were noted (Finer et al., 
2017). For example, the question ‘In horses with PPID, how effective is pergolide at slowing 
the progression of the disease?’ was ranked seventh and third by veterinary surgeons and 
owners respectively during the interim prioritisation, but was not prioritised into the final top 
10. This is evidence of good group discussion and decision making, suggesting the ability to 
overcome biases (Finer et al., 2017). The number one prioritised question, ’In horses with 
PPID, what is the expected disease progression over a horse’s lifetime both with and without 
treatment?’ was ranked highly throughout the prioritisation process. Pituitary pars 
intermedia dysfunction is a chronic progressive disease associated with several comorbidities 
(McFarlane and Cribb, 2005; McFarlane, 2007; McGowan et al., 2013a; Bang and Frith, 
2017) it is therefore unsurprising this question was ranked highest. It is a broad question 
encompassing several elements and therefore in the process of answering this question, it is 
possible a number of the other top 10 questions may also be answered. Several studies 
have investigated the initial efficacy of pergolide (Beech, 1994; Muñoz et al., 1996; van der 
Kolk, 1997; Donaldson et al., 2002; Perkins et al., 2002; Anon, 2011a). However, there is 
very little evidence regarding long-term effectiveness of treatment for improving prognosis. 
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One small study investigated treatment response after 5.5 years and found owners of 
surviving horses were satisfied with clinical response (Schott et al., 2014), and a recent 
retrospective study reported increased odds of short-term survival (median 11 months) in 
PPID cases treated with pergolide (Horn et al., 2019).  
Two of the top 10 questions related to the accuracy and interpretation of diagnostic tests.  
In several studies, utilising a variety of different clinical reference standards, the commonly 
used basal ACTH test has been reported to have good sensitivity and specificity (Couëtil et 
al., 1996; Perkins et al., 2002; Horowitz et al., 2003; Frank et al., 2006a; Beech et al., 
2007). However, uncertainty remains regarding test accuracy for PPID diagnosis in the 
presence of factors that may affect ACTH levels (Table 3, question E), such as concurrent 
disease (particularly insulin dysregulation), stress (Fazio et al., 2008) and pain (Ayala et al., 
2012).  In referral hospital populations, a number of acute conditions have been reported to 
result in elevations of ACTH (Ayala et al., 2012; Stewart et al., 2019).  To date, these pre-
analytical factors have not been evaluated in a population of PPID cases. However, the high 
proportion of systemically ill horses with ACTH concentrations above the upper limit of the 
reference interval at hospital admission (Stewart et al., 2019) indicates that it is important to 
consider these factors when interpreting basal plasma ACTH concentration for the diagnosis 
of PPID in practice.  The second question encompassed respondents’ uncertainly regarding 
the relative importance of endocrine laboratory test results and observed clinical signs.  This 
included results that do not ‘fit the clinical picture’, such animals exhibiting clinical signs of 
PPID but with normal ACTH concentrations, as well as the interpretation of equivocal or 
‘borderline’ test results and the best way to manage these situations (Table 2).  
The majority of questions centred around treatment (Table 3), with questions focusing on 
additional management strategies, effective medical treatments other than pergolide [D], 
dosing of pergolide throughout the year [B], safety [I] and efficacy of pergolide treatment 
[C, G and K]. Several studies have reported that pergolide is effective at improving clinical 
signs and ACTH levels (Peters et al., 1995; Anon, 2011a; Schott et al., 2014), and this was 
generally the view point of participating veterinary surgeons at the beginning of the PSP. 
However, discussions with owners throughout the process highlighted that this is not always 
the case for individual animals. The process highlighted the need for a more robust evidence 




Priority questions identified in this PSP are potentially methodologically complex to answer in 
terms of study design, implementation, ethical concerns and financial limitations.  The JLA 
process is not concerned with how the questions raised will be answered: its function is to 
provide a platform for the involvement of end users (Elwyn et al., 2010; Petit-Zeman et al., 
2010; JLA, 2017). However, the breadth of each topic offers researchers the opportunity to 
develop future studies dependent on resources available. Although all questions are 
considered important, it may not be possible to fund or answer all of them. In addition to 
supporting the direction of future research, the top 10 questions identify specific issues that 
horse owners consider important within each topic, providing a valuable resource to inform 
targeted owner education.  
This study shows that horse owners and veterinary surgeons can be involved in identifying 
and prioritising uncertainties. The involvement of veterinary surgeons and owners at this 
stage of the research process has the ability to improve available evidence, ensure research 
is relevant to end users and aid decision making. During the PSP process horse owners 
acted as a proxy for the patient. The JLA has previously been utilised in this way for feline 
medicine (Dean, 2014). This adaptation is comparable to other JLA PSPs where patients 
cannot speak for themselves and carers or parents represent them, for example those 
involving children (Morris et al., 2015). The best interest of the patient remains the focus in 
each case.  
Conclusion  
The JLA methodology can be successfully adapted into an equine veterinary setting and 
applied to the diagnosis, treatment and prognosis of PPID in horses. The response and 
quantity of questions generated indicates an extensive number of uncertainties about the 
disease. However, as the research was undertaken in GB, it is possible that the research 
questions prioritised may differ from unanswered questions of veterinary surgeons and 
horse owners in other countries. Identifying the top 10 research questions for a disease or 
condition, especially those that require long-term management, will help to direct evidence 
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Appendices for Chapter 2 
Appendix 1: The Priority Setting Partnership Protocol  
 




Adapted from the James Lind Alliance protocol 
 
Purpose of the PSP and background 
The purpose of this protocol is to set out the aims, objectives and commitments of the Pituitary Pars 
Intermedia Dysfunction (PPID) Priority Setting Partnership (PSP) and the basic roles and 
responsibilities of the partners therein.   
The Pituitary Pars Intermedia Dysfunction PSP will be led and managed by the primary investigator 
Becky Tatum BSc (Hons).  
PSP lead and advisors (Steering Group) 
Advisors to the student investigator will comprise of equine veterinary surgeons Dr Jo Ireland and 
Prof Cathy McGowan of the University of Liverpool, as well as horse owning members of the Animal 
Health Trust Epidemiology department, two of whom are also veterinary surgeons. Methodological 
guidance will be provided by veterinary surgeon and Director of the Centre of Evidence-based 
Veterinary Medicine (CEVM) Dr Rachel Dean. These representatives of horse owners and veterinary 




Background to the Pituitary Pars Intermedia Dysfunction Priority Setting Partnership 
PPID is the most common endocrine disorder in older horses, affecting 21% of those aged 15 years 
or older and is therefore of significant importance in equine practice. It is a progressive endocrine 
disease which causes abnormal coat changes and fat distribution among other clinical signs, as well 
as comorbidities such as laminitis. The available evidence regarding the diagnosis, treatment and 
prognosis of PPID is limited both in terms of the study populations included and the outcomes 
measured.  An evidence base is needed to inform veterinary surgeons and owners, yet the quality of 
published evidence is fair to poor. Therefore, it is important that any research done in this area is 
applicable to practice and can be used directly by those that can improve patient care. The evidence 
gaps in the diagnosis, treatment and prognosis of PPID need to be identified and prioritised. 
Aims and objectives of the Pitu itary  Pars  Intermedia Dysfunction (PPID) PSP 
The aim of the PPID PSP is to identify the unanswered questions about PPID diagnosis, treatment 
and prognosis from horse owner and clinical perspectives, then prioritise those that horse owners 
and veterinary surgeons agree are the most important. A secondary aim is to ascertain if the JLA PSP 
framework can be applied to equine veterinary practice. 
The objectives of the PPID PSP are to: 
• Work with horse owners and veterinary surgeons to identify uncertainties about the accuracy, 
reliability and effectiveness of diagnosis techniques, including screening for PPID. 
• Work with horse owners and veterinary surgeons to identify uncertainties about the efficacy and 
effectiveness of PPID treatments, including monitoring and response to treatment.  
 
• Work with horse owners and veterinary surgeons to identify uncertainties about the prognosis 
of horses and ponies with PPID, both long and short term including quality of life and influencing 
factors.  
• To agree by consensus a prioritised list of those uncertainties, for research purposes 
• To publicise the results of the PSP and process 





Organisations and individuals will be invited to be involved with the PSP as partners.  Partners are 
groups or individuals who will commit to supporting the PSP by disseminating the PSP survey. 
Partners represent the following groups: 
• owner of horses with experience of PPID 
• veterinary surgeons with clinical experience of PPID 
It is important that organisations which can reach and advocate for these groups should be invited 
to become involved in the PSP. Boehringer Ingelheim Vetmedica Ltd (BI) has been engaged to 
collaborate with the project as they have contacts for both horse owners and veterinary surgeons 
with experience of PPID. To ensure wider coverage the Universities of Liverpool and Nottingham, 
Animal Health Trust and Veteran Horse Society were also engaged to collaborate.  
Some organisations may be judged as having conflicts of interest. These can be perceived to 
adversely affect those organisations’ views, causing unacceptable bias. This is likely to affect the 
ultimate findings of the PSP. As a pharmaceutical company BI is considered to have a conflict of 
interest. However, the Steering Group considers their partnership important to target a large 
number of relevant participants; therefore, BI will participate in a purely observational capacity once 
the survey has been disseminated.  
Methods  
This section describes a schedule of proposed stages through which the PSP aims to fulfil its 
objectives. The process is iterative and dependent on the active participation and contribution of 
different groups. The methods adopted in any stage will be agreed through consultation between 
the steering group members, guided by the PSP’s aims and objectives. More details can be found in 
the Guidebook section of the JLA website at www.jla.nihr.ac.uk where examples of the work of other 
JLA PSPs can also be seen.  
Step 1: Identification and invitation of potential partners and raising stakeholder awareness 
Potential partner organisations will be identified through a process of peer knowledge and 
consultation, through the Steering Group members’ networks. Potential partners will be contacted 
and informed of the establishment and aims of the PPID PSP.  
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Step 2: Identifying uncertainties 
An online survey will be developed to identify questions veterinary surgeons and horse owners  have 
about PPID. The survey will be based on the guidelines outlined in the JLA guidebook and adapted 
through consultation with the steering group. BI, the Animal Health Trust, Veteran Horse Society and 
the Universities of Liverpool and Nottingham will identify a method for distributing the initial survey 
to potential participants. This will enable questions and uncertainties of practical clinical importance 
relating to the diagnosis, treatment and prognosis of PPID to be identified. A period of 6 - 8 weeks 
will be given to complete this exercise or until no new themes are emerging from survey results.  
Step 3: Refining questions and uncertainties 
The consultation process (survey) will produce “raw” unanswered questions about diagnosis, 
treatments and prognosis. These raw questions will be assembled and categorised and refined by 
Becky Tatum into “collated indicative questions” which are clear, addressable by research and 
understandable to all.  
Questions will undergo two initial rounds of refinement, firstly to remove questions not relating to 
diagnosis, treatment or prognosis. Such as prevalence, prevention, risk factors, pathophysiology and 
associated diseases. 
Secondly out-of-scope submissions about diagnosis, treatment and prognosis which do not fall 
under the specific aims and objectives of the study will be removed. This will include, for example, 
questions relating to understanding diagnostic test results, availability of treatment options/how 
PPID is treated or whether there is a ‘cure’ for the disease.   
Relevant statements which can be formatted or merged into questions will be included where 
appropriate. 
Relevant submissions will be further refined by removing: 
• Questions submitted by only one participant 
• Incomplete submissions which do not define the respondent’s characteristics i.e. whether 
they are a veterinary surgeon or horse owner with experience of PPID (this information is 
needed to ensure the transparency of the refining process) 




Categorisation and thematic analysis will be used to identify similar or duplicate questions which will 
be combined where appropriate. Questions will then be reformatted and reworded where necessary 
to form research questions understandable to all.  
Existing sources of information about uncertainties for owners and clinicians will be searched. This 
will include research recommendations in systematic reviews and other evidence; clinical trials, 
narrative reviews and clinical guidelines. To identify sources of uncertainties  and research 
recommendations Medline, Web of Science, Vetsrev, Scopus, and CAB databases will be searched. 
The existing literature will be researched by Becky Tatum, with the assistance of Dr Jo Ireland and 
Prof Cathy McGowan, to see to what extent these refined questions have, or have not, been 
answered by previous research.  
If questions are expressed can be answered with reference to existing research evidence (systematic 
reviews that meet the JLA criteria of certainty) and are therefore "unknown knowns" and not 
uncertainties, this evidence will be highlighted by the PSP to their membership. This suggests that 
information is not being communicated effectively to those who need it. A separate record of these 
'answerable questions' will be kept. 
Uncertainties that are not adequately addressed by previous research will be collated for interim (if 
applicable) and final prioritisation. The checking undertaken to demonstrate that the uncertainties 
have not already been answered will be recorded.   
Steps 4 and 5: Prioritisation – interim and final stages  
The aim of the final stage of the priority setting process is to prioritise through consensus, the 
identified uncertainties relating to the diagnosis, treatment or prognosis of PPID. This will be carried 
out by members of the Steering Group and the wider partnership that represents horse owners and 
veterinary surgeons.  
The interim stage  
The refining process will result in a long list of indicative uncertainties, the number of which is hard 
to predict. If the long list of indicative uncertainties is >30 it will be reduced to a shortlist to be taken 
forward and discussed at the final PSP workshop. This will be achieved via a consultation process 
carried out over email to the steering group and participants who completed the survey and agreed 
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to partake in the next stages of the study. Participants in this ranking process will be invited to 
choose 10 uncertainties from the long (or interim) list. They will not be asked to prioritise them. The 
responses obtained will be used to rank the uncertainties by number of votes. The top 25 will be 
taken forward into the final PSP workshop. 
The final stage  
The process to reach 10 prioritised uncertainties will be conducted in a face-to-face workshop, using 
group discussions and plenary sessions. This will involve eligible members of the Steering Group and 
the wider partnership that represents horse owners and veterinary surgeons. The method used for 
this prioritisation process will be an adapted nominal group technique overseen by Becky Tatum and 
Dr Rachel Dean to ensure equal contribution from participants.  
The aim is to hold one workshop including questions about diagnosis, treatment and prognosis.  
However, if the number of questions regarding these individual areas is deemed by the Steering 
Group to warrant three separate PSP workshops, treatment uncertainties will be prioritised in the 
face-to-face workshop while uncertainties about diagnosis and prognosis will be prioritised online 
using adapted Delphi technique.   
Findings,  research and publicity   
Findings and research  
It is anticipated that the findings of the PPID PSP will be reported to the pharmaceutical industry and 
major research funding charities as well as other funding bodies for clinical veterinary research.  
Relevant Steering Group members and partners will publish the ‘top 10’ priorities on their websites 
and in various publications to horse owners and the veterinary profession. All partners will be 
encouraged to develop the prioritised uncertainties into research questions, and to work to establish 
the research needs of those unanswered questions to use when approaching potential funders, or 
when allocating funding for research themselves, if applicable.  
As well as alerting funders, partners and advisory group members the results will be published using 
both internal and external communication mechanisms. This will be done in an open access format 
that is easy to understand to all participants and potentially interested funders of research. The 
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findings will also be the topic of an MPhil thesis and peer reviewed papers. The production of an 
academic paper should not take precedence over publicising of the final results.  
Signed by the Primary Investigator  
The undersigned agree to follow the PPID Priority Setting Protocol.   
 
 
Becky Tatum 15/06/2017 
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Appendix 3: Search strategy  
Details of search terms used and databases searched when evaluating evidence for the 
diagnosis, treatment and prognosis of pituitary pars intermedia dysfunction  
Databases 
searched       
Medical Literature Analysis and Retrieval System 
Online (MEDLINE) 1966-2017  
Centre for Agriculture and Bioscience  
International (CABI) 1972-2017                     
Elsevier’s abstract and citation database (SCOPUS) 
1966-2017  
Web of Science (WOS) 1945-2017  
Via University of Liverpool library  
  
VetSRev    Via Centre for Evidence-Based  
Veterinary Medicine                       
Search 
terms:  
Horse* OR pony OR ponies OR equine* OR equid* AND Pituitary pars intermedia 
dysfunction OR PPID OR cushing* OR pituitary neoplasia OR hyperadrenocorticism  









































Appendix 5: The 25 questions ranked highest overall after the interim 
prioritisation and taken forwards to the priority setting partnership. 
 
Question ID  Question  
A  In horses with PPID, what is the expected disease progression over a horse’s 
lifetime both with and without treatment?  
B  In horses with PPID, does the dose of pergolide (Prascend) need to vary with 
the season?  
C  In horses with PPID receiving treatment with pergolide (Prascend), is the risk 
of laminitis reduced?  
D  In horses with PPID, are there any medical treatments, other than pergolide 
(Prascend), that work?  
E  In horses with PPID, does stress, concurrent illness and/or pain affect the 
reliability and accuracy of diagnostic tests?  
F  In horses with PPID, how effective is pergolide (Prascend) at slowing the 
progression of the disease?  
G  What is the best way of dealing with horses who do not respond to pergolide 
(Prascend) treatment?  
H  In horses with PPID, what additional management strategies (i.e. feed & 
turnout) are best to use in conjunction with pergolide (Prascend) treatment?  
I  In horses with PPID, what are the side effects of pergolide (Prascend) 
treatment (both long and short term)?  
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J  In horses with PPID, what is the best method of monitoring response to 
treatment so that dose alterations can be made?  
K  In horses with PPID, what should be done when the maximum dose of 
pergolide (Prascend) has been reached but hormone levels are still 
elevated?  
L  What is the prognosis for horses with PPID?  
M  In horses with PPID, what is the best way to manage asymptomatic cases (a 
horse diagnosed with PPID but with no symptoms)?  
N  In horses with PPID, do co-existing illnesses (such as equine metabolic 
syndrome, arthritis or laminitis) affect prognosis?  
O  In horses with PPID, what is the best way to manage side effects of pergolide 
(Prascend) treatment?  
P  In horses with PPID, are any non-prescription treatments (i.e. Agnus Castus, 
homeopathy, other herbal products) effective?  
Q  In horses with PPID, how do we improve prognosis?  
R  Could alternative preparations of pergolide (Prascend) be effective (i.e.  liquid 
preparation or injection) when treating PPID in horses?  
S  In horses with PPID, what is the best way to manage borderline cases?  
T  In horses with PPID, how effective is pergolide (Prascend) treatment at 
reducing/controlling clinical signs (symptoms) of PPID?  
U  In horses with suspected PPID, what is the best way to deal with 
inconclusive or conflicting test results and/or clinical signs (symptoms)?  
66 
 
V  In horses with PPID, do factors such as diet, management or time of day 
affect the reliability and accuracy of diagnostic tests?  
W  In horses with PPID, what is the most cost effective way of monitoring the 
disease?  
X  In horses with PPID, how long is pergolide (Prascend) treatment effective 
for?  
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Evaluation of the sensitivity and specificity of basal plasma 
adrenocorticotrophic hormone concentration for diagnosing pituitary pars 
intermedia dysfunction in horses: a systematic review 
The following chapter collates and reviews literature pertaining the diagnostic accuracy of 
the basal plasma adrenocorticotrophic hormone concentration test for diagnosis of PPID and 
is presented as it was published in the Veterinary Journal. 
Reference: Tatum RC, McGowan CM, Ireland JL (2021) Evaluation of the sensitivity and 
specificity of basal plasma adrenocorticotrophic hormone concentration for diagnosing 
pituitary pars intermedia dysfunction in horses: a systematic review. The Veterinary Journal 
275: 105695. 
Summary 
Measurement of basal adrenocorticotrophic hormone (ACTH) is currently considered to 
possess adequate accuracy for the diagnosis of pituitary pars intermedia dysfunction (PPID) 
in horses. However, there is a lack of a ‘gold standard’ diagnostic test and although 
recommendations have been published, a systematic review of the evidence for its use has 
not been undertaken. This study aimed to systematically review the current evidence 
regarding the sensitivity and specificity of the basal ACTH diagnostic test. Electronic 
databases were systematically searched in January 2019, September 2020 and updated in 
January 2021. English language publications published prior to these dates were included. 
Screening, data extraction and quality assessment of publications was undertaken 
individually by the authors using predefined criteria and subsequently cross-checked. Study 
design, methodology and information reported in included studies were assessed using 
STARD checklists. Risk of bias and applicability were appraised using the QUADAS-2 quality 
assessment tool for diagnostic accuracy studies. Due to identified biases and marked 
between-study variations, meta-analysis was not undertaken. 
After removal of duplicates, 415 publications were identified, of which 25 publications were 
evaluated in full, with 11 of these publications meeting inclusion criteria. In the majority of 
studies, the basal ACTH test was reported to have good sensitivity (overall median 75.5%; 
interquartile range (IQR) 64.0-86.5%; range 36.0-100%) and excellent specificity (overall 
median 95.2%; IQR 84.2-98.9%; range 63.3-100%). However, QUADAS-2 and STARD 
assessment highlighted that studies did not utilise optimal study design and/or study 
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populations for the evaluation of a diagnostic test and the majority were subject to bias or 
provided insufficient information to fully assess possible biases. The evidence base needs to 
be improved by utilising a representative sample of cases suspected of having PPID, a 
diagnostic cut-off value defined a priori and an appropriate reference standard, before any 
concrete recommendations can be made, or conclusions drawn.  Based on this review, basal 
ACTH performed better at ruling out PPID than detecting it.  
Introduction 
Pituitary pars intermedia dysfunction (PPID) is a progressive neurodegenerative disease, 
common in older equids (McGowan et al., 2013a). A loss of dopaminergic inhibitory output 
to the pars intermedia of the pituitary gland results in increased plasma concentrations of 
multiple pro-opiomelanocortin (POMC) derived peptides, including adrenocorticotrophic 
hormone (ACTH) (van der Kolk, 1997; McFarlane et al., 2005b). This leads to a spectrum of 
clinical signs including lethargy or depression-like state, coat abnormalities and muscle 
atrophy (Ireland and McGowan, 2018). Historically, diagnosis was predominantly based on 
age and evidence of hypertrichosis, which may be adequate for detection of advanced 
stages of disease (Schott, 2002; Frank et al., 2006a). However, clinical diagnosis is more 
challenging in the earlier stages of disease when classical signs may not be evident or in 
cases with less specific clinical signs (Miller et al., 2008). Therefore, a number of different 
endocrine laboratory tests have been developed, evaluated and used for the diagnosis of 
PPID.  These include basal tests such plasma ACTH and α-melanocyte stimulating hormone 
(α-MSH) concentrations (McFarlane et al., 2006; McGowan et al., 2013b), and dynamic tests 
including overnight dexamethasone suppression (ODST) and thyrotropin-releasing hormone 
(TRH) stimulation tests (Frank et al., 2006a; Beech et al., 2007). 
Anecdotally the diagnostic test of choice in the UK is basal ACTH concentration. This is due 
to the convenience of collecting a single blood sample, the wide availability of diagnostic 
assays and seasonal reference intervals that allow year round testing (Copas and Durham, 
2012; Rendle et al., 2015a; Durham et al., 2020). This blood test is currently considered to 
possess adequate accuracy for clinical use (Durham et al., 2014a). However, there is a lack 
of a ‘gold standard’ laboratory test (McGowan et al., 2013b) and although diagnostic 
recommendations have been published (EEG, 2019; Secombe et al., 2018), a systematic 
review of the current evidence has not been undertaken.  
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With aged horses making up a significant proportion of the equine population (Mellor et al., 
1999; Ireland et al., 2011a), PPID is being diagnosed with increasing frequency (Rohrbach 
et al., 2012). Further to this, engagement with veterinary surgeons and owners with 
experience of PPID identified that evaluation of diagnostic test accuracy and factors which 
may affect it should be high on the research agenda (Chapter 2). It is therefore important to 
further investigate the accuracy of basal ACTH as the most commonly used diagnostic test. 
The aim of this systematic review was to collate and evaluate the current evidence 
regarding the sensitivity and specificity of the basal ACTH diagnostic test for the diagnosis of 
PPID. 
Materials and methods 
Search methodology  
Based upon guidelines for electronic search strategies (McGowan et al., 2016), a systematic 
search of the veterinary literature was undertaken in January 2019, repeated in September 
2020 and updated in January 2021. The following electronic databases were searched to 
ensure appropriate coverage (Grindlay et al., 2012); NCBI PubMed, Clarivate Analytics Web 
of Science, CAB Direct, SciVerse Scopus, and the database of the International Veterinary 
Information Service (IVIS). The bibliographies of retrieved publications were also screened 
for additional relevant records. Searches were conducted using a range of free text search 
terms and MEDLINE MeSH terms, including (Equine Cushing’s syndrome), (pituitary pars 
intermedia dysfunction) and (Adrenocorticotrophic hormone [ACTH]). The full list of search 
terms and Boolean operators is detailed in Appendix 1. This review is specific to PPID in 
horses and ponies, therefore search terms relating to donkeys and other equids were not 
included. All retrieved records were imported and formatted into a pre-designed Microsoft 
Excel spreadsheet. 
Inclusion criteria  
Publication limitations on study design, publication date, setting or study population were 
not imposed.  Although not peer-reviewed, conference proceedings were also considered for 
inclusion, but other grey literature sources were not. Only English language studies were 
included. However, English language abstracts were assessed, where available, for foreign 
language studies. Initial title screening was undertaken for all identified studies, and at this 
stage, textbook chapters, letters, review articles, non-equine studies and those not 
pertaining to the diagnosis of PPID were excluded. The abstracts of remaining studies were 
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subsequently screened and those that reported on other basal or dynamic diagnostic tests 
or did not contain data relevant to the diagnostic accuracy of basal ACTH for the diagnosis 
of PPID were excluded. All studies that reported, or contained sufficient data to calculate, 
sensitivity and/or specificity of the basal ACTH diagnostic test were included. If abstracts 
reported findings from the same study as a full publication, to avoid duplication only the full 
publication was assessed. Eligibility assessment was carried out independently in a 
standardised, unblinded manner by the authors. 
Review methodology 
Standardised forms adapted from critically appraised topic (CAT) data collection forms were 
developed a priori and used to extract relevant data from included publications. Data 
extraction and appraisal of included studies were undertaken individually by the doctoral 
student and subsequently cross-checked by the other authors to ensure a consensus was 
reached. No attempt was made to obtain missing data and investigators were not contacted 
to confirm accuracy of included information.  Data and relevant results extracted from each 
included publication are presented in summary tables (Appendix 2). 
Formal quality assessment scoring was not undertaken and studies were not excluded on 
quality grounds. However, results from lower quality studies are presented with 
interpretation of their limitations. For each included study, risk of bias and applicability 
concerns were appraised using the quality assessment tool for diagnostic accuracy studies 
(QUADAS-2; Whiting et al., 2011; Appendix 3).  Due to the variations between included 
studies with respect to inclusion criteria and participant selection, which may alter the 
spectrum of disease and non‐disease in the population, the use of non-comparable 
diagnostic assays and the risk of bias highlighted when studies were evaluated using the 
QUADAS-2 checklist, meta-analysis was not undertaken (Campbell et al., 2020).  Performing 
meta‐analysis on studies with important differences and a high risk of bias may compound 
the errors and produce an erroneous result which could be inappropriately interpreted as 
having credibility (Macaskill et al., 2010). However, median sensitivity and specificity 
estimates for basal ACTH were calculated, and where 95% confidence intervals (CI) were 
not provided in the publication, these were calculated by the authors where published 
information permitted.  Mann-Whitney U tests were used to test the statistical significance of 
differences in median values of sensitivity and specificity between different ACTH assays and 
reference standards. Aspects of study design, methodology and information reported in 
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included studies are presented aligned with selected items included in the STARD (Bossuyt 
et al., 2015; Cohen et al., 2016), and STARD for abstracts (Cohen et al., 2017) checklists. 
Results 
A total of 795 records were identified via the combined electronic database searches, with 
an additional four records obtained from other sources. Following removal of duplicate 
records, 415 records were screened for relevance to the review question. Following title and 
abstract screening, a total of 25 publications were evaluated in full. Fourteen publications 
did not meet inclusion criteria and were subsequently excluded, resulting in 11 studies 
included in the review (Figure 1).  
Study design and populations 
Only five publications included reference to diagnosis of PPID within the title (van der Kolk 
et al., 1995; Horowitz et al., 2003; McGowan et al., 2013b; Rendle et al., 2015a; Horn et al., 
2020), while two studies did not refer to any measure of diagnostic test accuracy within the 
abstract (Sojka et al., 2006; Beech et al., 2011b). None of the included studies completely 
fulfilled reporting guidelines for items to be included within abstracts for diagnostic accuracy 
studies (Cohen et al., 2017), primarily due to insufficient details regarding eligibility criteria 
and sample selection, precluding assessment of risk of bias.   
While some publications utilised other designs for components of the study, for evaluating 
basal ACTH for the diagnosis of PPID, nine included publications represented case control 
selection cross-sectional studies (Mathes and Pieper, 2019), with a two-gate design using 
healthy controls (van der Kolk et al., 1995; Couëtil et al., 1996; Horowitz et al., 2003; Sojka 
et al., 2006; Beech et al 2011b; Rendle et al., 2015a), or a three-gate design, using healthy 
controls combined with suspected PPID cases (Perkins et al., 2002), or using healthy 
controls compared with separate groups of PPID and suspected PPID cases (Beech et al., 
2007, 2011a). One further study enrolled a cohort of horses that were followed over a 12 
month period, using case control selection with a two-gate design using healthy controls, 
and basal ACTH diagnostic accuracy was evaluated monthly in repeated cross-sectional 
studies (Horn et al., 2020). The remaining study used a cohort selection cross-sectional 




Figure 1: Flow diagram of the search strategy undertaken in a systematic review to identify 
and screen publications with information on the sensitivity and specificity of the basal 
plasma ACTH diagnostic test for identifying PPID in horses, resulting in the identification of 
10 included publications (adapted from Moher et al., 2009). 
No included studies enrolled a consecutive or random sample of horses/ponies presenting 
due to suspected PPID, and all included studies provided relatively limited description of how 
potentially eligible cases were identified and screened for inclusion. No studies reported 
information regarding previous test results as a component of their eligibility criteria, and 
only one study provided full details regarding the study location and the date range during 
which the study population was selected (Perkins et al., 2002). Four of the studies included 
referral hospital populations (van der Kolk et al., 1995; Couëtil et al., 1996; Perkins et al., 
2002; Rendle et al., 2015a), and one used a field-based population (McGowan et al., 
2013b). The remainder did not include sufficient information to determine study setting 
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(n=6), although it is probable that at least a proportion of their study populations were 
selected from referral hospitals (Table 1 and Appendix 2). Three studies reported that PPID 
cases were identified via hospital cases or clinical records, but provided limited information 
about the selection of controls (van der Kolk et al., 1995; Couëtil et al., 1996; Perkins et al., 
2002). Regardless of the choice of reference standard, the most common method for 
selecting PPID cases for inclusion was a presumptive diagnosis based on clinical signs (n=6), 
with half of these studies including hypertrichosis as an inclusion criterion in all cases (van 
der Kolk et al., 1995; Couëtil et al., 1996; Perkins et al., 2002).  
No studies stated an intended sample size, although one study aimed to sample at least 50 
horses (including both cases and controls) per month during the study period (Horn et al., 
2020), and all studies had small sample size of PPID cases (n<55), with the majority also 
having a small number of controls (n<50) (Table 1). Furthermore, in several studies, sample 
size was further reduced by performing subgroup analyses (van der Kolk et al., 1995; 
Couëtil et al., 1996; Beech et al., 2007, 2011a; McGowan et al., 2013b; Horn et al., 2020).   
Inclusion criteria for controls also varied between studies. The majority of studies defined 
controls by the absence of clinical signs.  However, in three studies (with some overlap 
between study populations), a subset of animals selected as controls on the basis of 
absence of clinical signs of PPID subsequently had post mortem examination where 46.5-
58.3% had histological evidence of pars intermedia hyperplasia or adenoma (Beech et al., 
2007, 2011a,b).  Another study selected controls on the basis of absence of clinical signs of 
PPID and a maximum of two ACTH results that were identified as outlying values during a 
12 month period, together with an absence of pituitary adenoma in a subset that had post 
mortem examination (Horn et al., 2020). One further study selected controls based on 
results of an ODST (Horowitz et al., 2003).    
Only two studies used age-matched controls (Horowitz et al., 2003; McGowan et al., 2013b).  
One study only provided age data overall, rather than by group (Rendle et al., 2015a) and 
for all other studies, while mean or median age of the control group was younger compared 
to the PPID groups, the control group included at least one animal aged ≥15 years. 
Descriptions of baseline demographic characteristics of the study population were limited in 
all included studies.  Where sufficient information was provided regarding the demographic 
composition of the control group, there were breed differences, particularly with respect to 
pony breeds being represented among PPID cases, but not the control group (van der Kolk 
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et al., 1995; Beech et al., 2007; 2011a,b), while one study’s eligibility criteria specifically 
excluded ponies (Horn et al., 2020). There were also differences in sex distribution with a 
greater proportion of mares in the PPID group compared to controls (Beech et al., 2007; 
2011a,b). Only one study provided details regarding clinical signs exhibited by PPID cases 
beyond the description of case inclusion criteria (Couëtil et al., 1996), meaning that the 
distribution of disease severity in PPID cases could not be ascertained in other included 
studies.  The prevalence of clinical signs was reported for the entire study population in one 
publication, but not for the PPID and control groups used for assessment of diagnostic test 
accuracy (McGowan et al., 2013b). 
Test methods: index test 
Only three studies solely evaluated ACTH (Couëtil et al., 1996; Perkins et al., 2002; Rendle 
et al., 2015a) with all other studies including assessment of at least one other basal and/or 
dynamic test for PPID diagnosis. Basal ACTH was the index test (or one of the index tests) 
under evaluation in seven included studies. Of these, six stated the intended use of ACTH to 
be for diagnosis of PPID (van der Kolk et al., 1995; Couëtil et al., 1996; Horowitz et al., 
2003; McGowan et al., 2013b; Rendle et al., 2015a; Horn et al., 2020) and one reported the 
intended use to be monitoring response to treatment (Perkins et al., 2002), with no 
publications defining the intended clinical role of basal ACTH.  Other included studies were 
designed to evaluate various dynamic diagnostic tests for PPID, but reported data pertaining 
to basal ACTH and its diagnostic accuracy (Sojka et al., 2006; Beech et al., 2007; Beech et 
al., 2011a,b).  
The diagnostic (positivity) cut-off value for ACTH used to identify PPID also varied between 
studies (Table 1). Five studies determined the ACTH diagnostic cut-off value a priori based 
on laboratory reference intervals (Perkins et al., 2002; Sojka et al., 2006; Beech et al., 2007; 
Beech et al., 2011a,b).  Five studies derived single (van der Kolk et al., 1995; Horowitz et 
al., 2003), breed-adjusted (separate values for horses and ponies; Couëtil et al., 1996) or 
seasonal (separate values for autumn and non-autumn; McGowan et al., 2013b) or monthly 
(Horn et al., 2020) cut-off values as part of the study. In the latter study, monthly reference 
intervals based on basal ACTH concentrations for 40-50 control horses were also calculated 
(Horn et al., 2020). The final study derived different diagnostic cut-off values for both single 
and paired ACTH measurements (from two samples collected 5-15 minutes apart) (Rendle et 
al., 2015a). This study also presented agreement between ACTH and histopathology, which 
was assumed to utilise seasonally adjusted cut-off values (>47 pg/ml for autumn (August-
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October) and >29 pg/ml for non-autumn (November–July); however, the cut-off values 
used for these analyses were not stated (Rendle et al., 2015a).  
Pre-analytical factors such as sample handling varied between studies. Only five studies 
reported obtaining blood samples where horses were in familiar surroundings or kept quiet 
in stalls (Couëtil et al., 1996; Beech et al., 2007; 2011b; McGowan et al., 2013b; Horn et al., 
2020), and only one study reported the diet offered around the time of sampling (Couëtil et 
al., 1996), with one further publication reporting that ad libitum food was available prior to 
sampling, although diet varied between included horses (Horn et al., 2020).  Three studies 
reported use of glass ethylenediaminetetraacetic acid (EDTA) tubes for sample collection 
(Couëtil et al., 1996; Beech et al., 2011a; McGowan et al., 2013b), while three reported 
using plastic EDTA tubes (Beech et al., 2007; 2011b; Horn et al., 2020) and the remaining 
five studies did not report the type of tube used.  Samples were centrifuged to separate 
plasma at time points ranging from immediately after collection to within 2 hours afterwards 
(Appendix 2). Plasma samples were frequently frozen prior to analysis, at between -20°C to 
-80°C, for periods of between 1 week and 2 years (Appendix 2). Additionally, included 
studies used two different diagnostic assays to determine ACTH concentrations; the 
chemiluminescent immunoassay (CIA; n=8) and the radioimmunoassay (RIA; n=3) (Table 
1).  
Test methods: reference standards 
The reference standards utilised to confirm presence of PPID included histological evidence 
of pituitary adenoma (n=2; van der Kolk 1995; Sojka et al., 2006), pituitary hyperplasia or 
adenoma (n=3; Beech et al., 2011a,b; Rendle et al., 2015a), or pituitary hyperplasia (n=1; 
Beech et al., 2007); clinical signs of PPID (including hypertrichosis) (n=3; Couëtil et al., 
1996; Perkins et al., 2002; McGowan et al., 2013b), and overnight dexamethasone 
suppression test (ODST; n=1; Horowitz et al., 2003) (Table 1). One study utilised the 
eligibility criteria used for identifying PPID cases as the reference standard, where horses 
had to meet at least two of three criteria, including; exhibiting clinical signs consistent with 
PPID, post mortem examination findings that confirmed or excluded pituitary adenoma or 
hyperplasia, or having ≥6 of the monthly ACTH results obtained that were statistical outliers 
within the 12 month study (Horn et al., 2020). Histopathological grade was not reported in 
any study using pituitary hyperplasia for the reference standard.  
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No studies included a flowchart or other graphical representation of flow and timing of 
recruitment, index and reference standard tests.  Studies utilising histopathology as the 
reference standard, necessarily conducted all index tests (ACTH measurements) prior to the 
reference test, although only one of these studies provided information regarding the time 
interval between ACTH measurement and post mortem examination (Beech et al., 2007).  
The study utilising the ODST as the reference standard did not report the time interval 
between this and ACTH measurement (Horowitz et al., 2003). For studies using clinical 
sign(s) as the reference test, the time between observation of clinical signs and 
measurement of basal ACTH was not reported, with the exception of one study, where 
ACTH measurement was performed at the time of veterinary examination, although the 
reference standard comprised a combination of examination findings and owner-reported 
clinical signs observed within the preceding 12 months (McGowan et al., 2013b). 
Sensitivity and specificity of basal ACTH measurement for the diagnosis of PPID 
Only five studies included all enrolled cases and controls in the evaluation of the diagnostic 
accuracy of basal ACTH (Couëtil et al., 1996; Perkins et al., 2002; Horowitz et al., 2003; 
Sojka et al., 2006; Beech et al., 2011b).  Overall in all included papers there were a total of 
234 cases and 558 controls that contributed data towards analysis of diagnostic accuracy. 
The median sensitivity was 75.5% (IQR 64.0-86.5%; range 36.0-100%; based on 22 
estimates provided in all 11 included studies) and median specificity was 95.2% (IQR 84.2-
98.9%; range 63.3%-100%; based on 21 estimates provided in ten included studies) (Table 
1). The lowest sensitivity reported across all studies was calculated where a diagnostic cut-
off of >35 pg/ml was applied for the diagnosis of histological evidence of pituitary 
hyperplasia in clinically normal horses exhibiting no signs of PPID (Beech et al., 2007; Table 
1).   
When studies were grouped by the type of assay used, reported sensitivity was significantly 
higher in studies using the RIA assay (p=0.04), whereas reported specificity did not differ 
significantly between assay types (p=0.19). For those using the CIA assay the median 
sensitivity was 71.0% (IQR 60.6-84.4%; range 36.0-100%) and median specificity was 
94.6% (IQR 82.1-96.5%; range 63.3-100%), while those using the RIA assay had a median 
sensitivity of 87.5% (IQR 82.4-97.7%; range 81.8-100%) and a median specificity of 100% 
(IQR 89.5-100%; range 89.5-100%). When studies were grouped by reference standard 
(excluding the single study using ODST (Horowitz et al., 2003) and the study where the 
composite reference standard varied between horses (Horn et al., 2020), reported sensitivity 
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was significantly higher in studies using a clinical reference standard (p=0.04), whereas 
reported specificity did not differ significantly between reference standards (p=0.71). For 
studies that used histology as the reference standard, the median sensitivity was 65.0% 
(IQR 56.8-71.0%; range 36.0-100%) and the specificity was 95.6% (IQR 86.0-100%; range 
80.9-100%), while for those using clinical signs of PPID, the median sensitivity was 82.9% 
(IQR 74.8-93.2%; range 59.0-100%) and the median specificity was 94.6% (IQR 81.4-
100%; range 78.0-100%). 
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Table 1: Summary of sensitivity and specificity of the basal plasma adrenocorticotrophic hormone concentration for diagnosing pituitary pars 












Number of controls 































PPID   
Beech et 
al., 2007# 
CIA Histological PH on 
PM 
6 10 (clinically normal with no 
evidence of PH) 
No USA 
Not stated  
71.0% 100% >35 pg/ml 
Clinically normal 
but PH on PM 
14 10 (clinically normal with no 





CIA Histological PH or 
PA on PM (in 
horses with ≥2 




23 (clinically normal with no 
evidence of PH) 
No USA 

















Histological PH or 
PA on PM (in 
horses with ≥2 
clinical s igns of 
PPID, plus horses 
with ≥1 clinical s ign 
of PPID which did 
not include hair 
coat abnormalities) 
35 23 (clinically normal with no 
evidence of PH) 










Histological PH or 
PA on PM (in 
horses with ≥2 




53 (all clinically normal animals 
including those with no PM 
examination, or no evidence of 






Histological PH or 
PA on PM (in 
horses with ≥2 
clinical s igns of 
PPID, plus horses 
with ≥1 clinical s ign 
of PPID which did 
not include hair 
coat abnormalities) 
35 53 (all clinically normal animals 
including those with no PM 
examination, or no evidence of 





CIA ≥2 clinical s igns of 
PPID (n=10) or 
equivocal clinical 
s igns (n=3) (of 
these, n=8 had 
confirmed PH or PA 
on PM) 
13 19 (all clinically normal animals, 
n=14 had PM of which n=7 had 
















excessive long hair 
growth, delayed or 
incomplete 
shedding) plus ≥1 
additional clinical 
s ign (n=18)  
histological PA on 
PM (n=4) 















Horn et al., 
2020# 
CIA 2 out of 3 of: i) 




and epaxial muscle 
wastage, abnormal 
fat distribution or 
abnormal 
sweating); ii) PM 
findings confirming 
or excluding PA or 
PH; iii) outlying 
basal or post-TRH 
ACTH values for ≥6 
tests (out of 
maximum 12 
monthly tests) 
7 44 (clinically normal; unreported 
number did not have PA on PM) 
No 
Australia 










10 41 (clinically normal; unreported 











46 (clinically normal; unreported 
number did not have PA on PM) 
88.9%                 
(CI 56.5-
99.4%) 






7 50 (clinically normal; unreported 
number did not have PA on PM) 




























excessive long hair 
growth, and/or 
delayed shedding 
and/or failure to 
shed coat normally) 
plus ≥3 additional 
clinical s igns 











>29.7 pg/ml  

















19 49 (healthy controls combined 
with possible PPID cases; 
hypertrichosis not present) 















CIA Histological PH or 
PA on PM 
44 23 (normal PI on PM) No Australia, 









69.4% 80.9% >21.3 pg/ml 





















CIA Histological PA on 
PM 









al., 1995  
RIA Histological PA on 
PM 









N/R >55 pg/ml 
Overall   #Total 
number of 
cases n=234 
#Total number of controls  
n=558 













PH= pituitary hyperplasia; PA= pituitary adenoma; ACTH= adrenocorticotrophic hormone; RIA=radioimmunoassay; ODST= overnight 
dexamethasone suppression test; CIA = Chemiluminescent immunoassay; PM = post mortem; N/R Not reported or insufficient data available; 
*Sensitivity and/or specificity calculated from data provided 
 
#Subgroup analyses presented in separate rows: for Beech et al., 2007, maximum sample size included in diagnostic accuracy data analysis 
was n=20 PPID cases (6 confirmed cases plus 14 clinically normal animals with histological evidence of PH) and n=10 controls (clinically 
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normal horses without histological evidence of PH); for Beech et al., 2011a, maximum sample size included in diagnostic accuracy data analysis 
was n=35 PPID cases (suspected and confirmed cases) and n=53 controls (clinically normal horses with or without histological evidence of PH, 
and those without PM examination); for Horn et al., 2020, only the data from months with the highest and lowest reported values for 
sensitivity (identical sensitivity reported for both November and December, with November included in table due to slightly larger sample size) 
and specificity are presented, and maximum sample size included in diagnostic accuracy data analysis was n=11 PPID cases (sampled during 




This is the first study to systematically review published evidence regarding the sensitivity 
and specificity of measurement of basal ACTH for the diagnosis of PPID in horses and 
ponies.  Overall, the basal ACTH test was reported to have good sensitivity and excellent 
specificity in the majority of studies with overall medians of 75.5% and 95.2%, respectively. 
However, sensitivity varied more widely among studies with it reported to be <60% in two 
studies, which both used ungraded histopathology as the reference standard (Sojka et al., 
2006; Beech et al., 2011b).  
QUADAS-2 and STARD assessment highlighted that all included studies were at risk of 
significant biases, which can lead to inappropriate recommendations about testing protocols 
(Whiting et al., 2011; Cohen et al., 2016, 2017). In many cases, studies provided limited 
information regarding eligibility criteria and sample selection meaning full assessment of 
related biases was not possible. It was therefore considered that combination of numerical 
data was not appropriate and meta-analysis was not undertaken. Meta-analysis of biased 
results can result in misleading results and is likely to compound errors, producing an 
erroneous result that is incorrectly interpreted as having credibility (Macaskill et al., 2010).  
Additionally, the studies included here varied considerably in their design, using different 
reference standards, assays and diagnostic cut-off values. In instances such as this, meta-
analysis has been described a ‘combining apples with oranges’ (Macaskill et al., 2010) and 
analysis of such varied studies would produce a meaningless result or obscure differences in 
measures of diagnostic accuracy where clinical and/or methodological characteristics vary 
between studies (Macaskill et al., 2010). Therefore, undertaking meta-analysis would likely 
have led to inappropriate recommendations and could ultimately negatively affect case 
outcomes. However, effective data synthesis can still be undertaken without meta-analysis 
by following synthesis of results guidelines (McInnes et al., 2018; Salameh et al., 2020), 
evaluation check lists and calculating summary statistics (Campbell et al., 2020) as 
presented here.  
Overall, none of the studies identified utilised optimal study designs for the assessment of 
diagnostic tests. Ideally a diagnostic test should be assessed using a prospective cohort of 
patients representative of the population to which it will be applied (Drobatz, 2009; Linnet et 
al., 2012), however none of the included studies enrolled a consecutive or random sample 
of horses/ponies presenting due to suspected PPID. How the study population is selected 
greatly influences the results of the diagnostic test being assessed and how applicable any 
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findings are to the target population (Vetter et al., 2018).  Although no included studies 
enrolled a cohort of horses suspected of having PPID, the field-based study by McGowan et 
al., (2013b) enrolled a population of horses/ponies aged ≥15 years. Age is a risk factor for 
PPID (Ireland and McGowan, 2018), which is predominantly diagnosed in horses aged ≥15 
years (Welsh et al., 2016). Therefore, the age range of included animals would define them 
as at risk of PPID (McGowan et al., 2013b), providing an indication to perform a diagnostic 
test (Mathes and Pieper, 2019). The other ten included studies utilised a case control design 
to select the study population, enrolling suspected cases of PPID based on presentation of 
clinical signs and a healthy control group defined by a lack of clinical signs. This method of 
using highly selected animals is likely to increase the risk of various biases that exaggerate 
diagnostic accuracy (Whiting et al., 2004, 2013; Hall et al., 2019) and to increase the 
likelihood of reporting clinically unrepresentative estimates (Linnet et al., 2012).  
PPID is a progressive disease and therefore, like many diseases, has a spectrum of clinical 
signs that should be represented in the sample population in which the test characteristics 
were developed (Drobatz, 2009). The sensitivity and specificity of a test varies with the 
prevalence or distribution of a disease in the population or sample (Irwig et al., 2002; 
Leeflang et al., 2009). Therefore, when studies include a narrow range of individuals, such 
as described here, spectrum bias is observed and both sensitivity and specificity are falsely 
increased (Usher-Smith et al., 2016; Hall et al., 2019; Kea et al., 2019). One study in 
particular excluded horses based on some clinical signs, effectively selecting the ‘sickest and 
wellest’ animals (McGowan et al., 2013b) meaning a small spectrum of more advanced 
disease was represented. The fact that the median sensitivity for studies using clinical signs 
as the reference standard was greater than the overall median sensitivity, and significantly 
higher than when histology was used, supports the potential for exaggerated diagnostic 
accuracy due to spectrum bias. Additionally, none of the included studies reported a 
predefined sample size that they attempted to reach and enrolled small number of cases 
and controls, resulting in sample sizes below those recommended for evaluating sensitivity 
and specificity (Bujang and Adnan, 2016). This may be due in part to ethical considerations, 
such as performing unnecessary invasive procedures in healthy controls or clearly diseased 
animals.  
All included studies met the definition of a diagnostic accuracy study, and were therefore 
described as cross-sectional studies (Mathes and Pieper, 2019). However, only one study 
that utilised histopathology as the reference standard and provided sufficiently detailed 
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information to accurately determine the time interval between the conduct of index and 
reference tests (Beech et al., 2007). If a substantial time period elapsed between ACTH 
measurement and subsequent post mortem examination in other studies using 
histopathology, these studies may more correctly be described as longitudinal studies and 
may reflect predictive accuracy of elevated ACTH for the future development of pars 
intermedia hyperplasia or adenoma (Mathes and Pieper, 2019). Since PPID is largely 
considered to be slowly progressive in the majority of cases, the likelihood of delayed 
verification bias may be small.  
Five of the included studies used pituitary pars intermedia histopathology as the reference 
standard. Descriptions of pituitary histological findings in PPID demonstrate a range of 
pathology from hyperplasia and enlargement of the pars intermedia, through to micro and 
macroadenomatous changes (Boujon et al., 1993; Yoshikawa et al., 2001).  However, poor 
agreement between pathologists has been reported, with some participating pathologists 
reporting normal histologic findings in eight out of ten suspected PPID cases where other 
pathologists reported pars intermedia hyperplasia and/or adenomatous hyperplasia or 
adenoma (McFarlane et al., 2005a). Other reports have indicated discrepancies between 
clinical findings and histopathology, with pars intermedia lesions evident in up to 46% of 
apparently clinical normal horses (van der Kolk et al., 2004; Miller et al., 2008); with 28% of 
geldings, 55% of lactating and 84% of pregnant mares showing pars intermedia 
hyperplasia, microadenoma or macroadenoma (van der Kolk et al., 2004). Pituitary glands, 
obtained at post mortem examination from clinically normal horses, had significantly higher 
histologic grades, with 12 of 34 (35%) glands classified as grade 3 (pars intermedia 
adenomatous hyperplasia) and 7 of 34 (21%) as grade 4 (pars intermedia microadenomas) 
during the autumn months, compared to 27% and 5%, respectively, in non-autumn months 
(Cordero et al., 2012).  The same study also reported that pituitary size and pars intermedia 
area were significantly higher in the autumn compared to non-autumn months (Cordero et 
al., 2012). These studies indicate that pituitary intermedia histopathology is influenced by 
both reproductive status and season, and may have poor specificity for the diagnosis of 
PPID. Collectively, these findings do not support pituitary histopathology as the gold 
standard for diagnosis of diagnosis of PPID.   
Four studies used clinical signs of PPID including (including hypertrichosis) as the reference 
standard for some (Couëtil et al., 1996; Beech et al., 2011b) or all PPID cases (Perkins et 
al., 2002; McGowan et al., 2013b). Hypertrichosis has been reported to be a specific 
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indicator of PPID (Schott, 2002), with a significant difference between PPID cases and 
controls when hypertrichosis was graded on a scale of 0-3 (Schott et al., 2017) and was 
reported to have high specificity (95%) for the diagnosis of PPID in one study (Frank et al., 
2006a) when compared to histological evidence of pars intermedia adenoma. However, 
overt generalised hypertrichosis is now considered an advanced clinical sign of PPID (EEG, 
2019), and therefore is unlikely to be representative of the earlier stages of disease. Only 
one study used owner-reported delayed shedding and hair coat changes over the previous 
12 months as well as overt hypertrichosis identified on clinical examination (McGowan et al., 
2013b). Compared to veterinary clinical examination findings, owner observations over a 
longer time period are likely to be more sensitive for detecting regional hypertrichosis and 
other subtle hair coat changes, and owner-reported history of hypertrichosis was the only 
clinical sign found to be predictive for PPID in a large cross-section of geriatric horses 
(McGowan et al., 2013a). One study used the ODST as the reference standard (Horowitz et 
al., 2003). The ODST was once thought of as the ‘gold standard’ diagnostic test for PPID 
reportedly having 100% sensitivity and specificity of 100% (Dybdal et al., 1994). However, 
this has subsequently been brought into question by a small study that reported only one of 
seven PPID cases had positive ODST results when repeated on three occasions at monthly 
intervals (Miesner et al., 2003) and concerns around the unnecessary administration of 
steroid means it is now seldom used in the UK. Given the lack of a true gold standard 
reference test for the diagnosis of PPID, future evaluation of diagnostic test accuracy could 
be improved by utilising methods to assess diagnostic test accuracy in the absence of an 
ideal reference standard (Umemneku Cikere et al., 2019), a composite reference standard 
(Naaktgeboren et al., 2013), or expert panel diagnosis (Bertens et al., 2013). 
ACTH is not the major pituitary peptide normally produced from the equine pituitary pars 
intermedia, with its typical site of production and regulation being the pars distalis. 
However, it was shown to be increased (along with other POMC-derived peptides) in high 
amounts from diseased pars intermedia, and much of that was shown to be biologically 
inactive, which is why it remains a useful diagnostic test for PPID (Orth et al., 1982; Okada 
et al., 1997; Cordero et al., 2011). However, pars distalis produced ACTH as part of the 
hypothalamic-adreno-cortical axis may still provide false elevations of ACTH.  ACTH levels 
have been shown to elevate as a result of factors such as stress (Fazio et al., 2008), 
exercise (Nagata et al., 1999), diet (Diez de Castro et al., 2014; Jacob et al., 2017), 
discomfort (Gehlen et al., 2020) and hospitalisation, even in mildly ill horses (Towns et al, 
2010). These changes are often short lived but are still an important consideration when 
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interpreting ACTH concentration. There was a lack of information regarding the 
management of horses/ponies around the time samples were collected or where and how 
samples were taken, with six studies providing no information at all. If sampling took place 
in an environment that was not properly controlled to prevent the influence of external 
factors, ACTH levels may have been inadvertently affected, resulting in biased results. 
However, two of the studies also measured α-MSH, which is not affected by external 
influences like ACTH, and reported broadly comparable measures of diagnostic accuracy 
(Horowitz et al., 2003; McGowan et al., 2013b), and a strong positive correlation between α -
MSH and ACTH (McGowan et al., 2013b). The description of demographic characteristics, 
and presence of differential or alternative diagnosis or comorbidities amongst study 
populations included in most reviewed publications was also poor, meaning the assessment 
of applicability to the target population was not able to be assessed fully (Drobatz, 2009; 
Linnet et al., 2012). However, the high proportion of hospitalised populations suggest the 
results may not be entirely generalisable in practice, and reported measures of diagnostic 
accuracy might be affected by referral filter bias. 
Other pre-analytical factors also varied between studies. Once samples had been collected, 
there was variability in sample handling, which can affect ACTH concentrations (Hegstad et 
al., 1990; Teahan et al., 2006; Hirayama et al., 2015; Rendle et al., 2015c). Additionally, 
one study (McGowan et al., 2013b) stored samples for a prolonged period of time, meaning 
samples may have degraded by the time of analysis, potentially affecting ACTH measures 
and producing inaccurate results (Banse et al., 2020).  
The CIA assay was most commonly used among studies with three studies using the RIA 
assay. Two method comparison studies have shown significant differences in results using 
different assays when measuring ACTH levels in equids (Knowles et al., 2018; McGilvray et 
al., 2020). A cohort of 85 ponies had samples collected in the autumn and spring months 
with ACTH levels measured using both CIA and immunofluorescent (IF) assays, which 
yielded significantly different results in both seasons (p<0.001), with the IF assay results 
proportionally lower (Knowles et al., 2018). In healthy adult horses, ACTH values from both 
CIA and IF assays were positively correlated, but differed in both November and May with 
significantly higher values from the CIA (McGilvray et al., 2020). Here, the median sensitivity 
and specificity of the CIA assay was lower than the RIA assay, suggesting similar differences 
between these assays may be observed. However, this finding may also be subject to 
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confounding due to differences in reference standards, case selection and definition, or 
other variables. 
No studies reported any blinding of observers with respect to test results, though this 
unlikely to be source of introduced bias for ACTH where the index test is an objective 
measure, compared to a diagnostic test that requires clinical interpretation (Whiting et al., 
2011). The diagnostic cut-off values for ACTH varied between studies which can result in an 
increase or decrease in sensitivity and specificity, depending on the cut-offs used (Sharma 
and Jain, 2014). Moreover, selecting the diagnostic cut-off value to maximise test 
performance, as performed in half of the studies reviewed here, increases the risk of 
overestimating measures of diagnostic test accuracy (Cohen et al., 2016). Due to this 
between study variation, estimating overall sensitivity and specificity was challenging. A 
correlation between sensitivity and specificity can be calculated to assess heterogeneity in 
thresholds, however, this is unreliable where studies have small sample sizes (Moses et al., 
1993; Leeflang et al., 2013) and was therefore not undertaken. The overall median 
sensitivity and specificity reported in this systematic review should simply be treated as a 
summary of reported results and interpreted with appropriate caution, based on the 
limitations of included studies. Seasonally adjusted reference intervals have been developed 
for ACTH in equids to account for the higher plasma ACTH observed in autumn months 
(Copas and Durham, 2012) and two included studies derived monthly (Horn et al., 2020) or 
seasonal cut-off values for autumn and non-autumn periods (McGowan et al., 2013b). 
However, subsequently an Australian review has recommended a third interval between the 
autumn and non-autumn cut-offs (Secombe et al., 2018), and more recently a large field-
based study proposed weekly thresholds for ACTH to account for continuous circannual 
variation (Durham et al., 2020). Most studies selected the diagnostic cut-off value based on 
the upper limit of laboratory reference intervals (Perkins et al., 2002; Sojka et al., 2006; 
Beech et al., 2007, 2011a; 2011b) or derived single cut-off values (van der Kolk et al., 1995; 
Horowitz et al., 2003) and made no allowance for circannual variation, suggesting they may 
have been insufficient for accurate differentiation between disease and non-diseased 
animals.  
Overall, the available evidence demonstrates that measurement of basal ACTH is highly 
specific and has good sensitivity for the diagnosis of PPID in horses and ponies exhibiting 
clinical signs consistent with the disease. However, the evidence base is limited, with 
selection of study populations and study designs used in the included studies likely to over-
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estimate measures of diagnostic accuracy.  Ideally, a cohort selection cross-sectional study, 
enrolling a consecutive sample of horses presenting due to suspicion of PPID, using a 
diagnostic cut-off value that is defined a priori, would be performed to appropriately 
evaluate the diagnostic accuracy of basal ACTH. However, it is essential that all horses 
would be correctly classified as diseased or non-diseased, and the lack of a gold standard 
reference test for PPID makes this particularly challenging.  
Conclusion 
None of the included studies utilised an optimal study design or study population for the 
evaluation of a diagnostic test and the majority were subject to bias. Furthermore, the 
amount of inter-study variations precluded direct comparison and meta-analysis. Despite 
this, basal ACTH was consistently reported to have good-excellent specificity, and while 
sensitivity estimates were more varied, overall medial sensitivity for the diagnosis of PPID 
was good in selected populations of horses and ponies. Basal ACTH performed better at 
ruling out PPID than detecting it, meaning a risk of missing some cases of PPID.  
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Appendices for Chapter 3 
Appendix 1: Search strategy and results 
 
 
Databases searched and 
dates covered 
NCBI PubMed (1950 – Present)  
Clarivate Analytics Web of Science (1898 – Present)  
CAB Direct (1960 – Present) 
Scopus (1823 – Present) 
International Veterinary Information Service (IVIS) database (1997 – 
Present)  
Further relevant records were identified by the authors via the 
bibliographies and reference lists of retrieved publications and freely 
available or published conference proceedings. 
Search terms (Equine Cushing* OR Pituitary pars intermedia dysfunction OR PPID 
OR Hyperadrenocorticism OR Pituitary adenoma) AND (horse* OR 
pony OR ponies OR equine OR equid*) AND (ACTH OR 
adrenocorticotropic hormone OR adrenocorticotrophic hormone OR 
adrenocorticotropin OR corticotropin)  
Dates searches 
performed 















Excluded –             
non-systematic 
review article, review 
in conference 
proceedings or letter 




Excluded – did not 
report data 
required to answer 




NCBI PubMed 134 0 0 16 84 25 9 
Clarivate Analytics Web of Science 145 1 0 21 89 25 9  
CAB Direct 170 1 0 53 89 18 9 
Scopus 174 0 0 56 90 19 9 
International Veterinary Information 
Service (IVIS) database 
172# 0 0 102 61 4 1 
Other sources 4 0 1 0  3 0 
Total relevant papers when duplicates removed, following title and abstract screening 11 




Appendix 2: Summary tables and data of included studies 
A summary of extracted data for each included study, main limitations of the studies and 
conclusions are presented in the tables below.  
 
ACTH = Adrenocorticotrophic hormone 
α-MSH = Alpha-Melanocyte-stimulating hormone 
CIA = Chemiluminescence assay 
CI = Confidence interval  
EDTA = Ethylenediaminetetraacetic acid 
ODST = Overnight dexamethasone suppression test 
PPID = Pituitary pars intermedia dysfunction  
RIA = Radioimmunoassay 
ROC = Receiver operating characteristic  





Beech et al., 2007  
Journal publication 
Study Design: Case control selection cross-sectional study; multiple-gate design 
using healthy controls 
Aim/Objective of 
the Study: 
To compare the effect of TRH administration on ACTH 
concentrations in healthy horses and those with PPID and to 
compare the TRH stimulation test with the ODST. 
Setting: Not stated. 
n=4 horses at university referral hospital in Canada; all others mid-
Atlantic region of the United States (presumed to have been cases 
attending a university referral hospital). 
Study Population:  No information provided regarding study population selection. 
n=48: 
Controls: n=29 clinically normal horses (breeds not reported, no 
ponies) 
• no clinical signs of PPID 
• n=16 aged ≤10 years; n=9 aged >10 - <15 years; n=4 
aged >15 - 20 years 
• 20 geldings, 1 stallion and 8 mares   
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• within this group, 1 horse developed clinical signs of PPID 
after the first TRH test and further tests were performed 
when the horse was clinically abnormal 
PPID cases: n=15 
• 11 horses and 4 ponies with ≥2 clinical signs of PPID  
• n=1 aged ≤10 years; n=3 aged >10 - <15 years; n=3 aged 
>15 - 20 years; n=8 aged >20 years 
• 4 geldings and 11 mares  
Horses with equivocal signs of PPID: n=4 
• appearance was suspicious but not classical or only had 1 
sign suggestive of PPID; none had hypertrichosis  
• n=1 aged >10 - <15 years; n=1 aged >15 - 20 years; n=2 
aged >20 years 
• 3 geldings and 1 mare  
Post mortem examination was undertaken within 22 days of a TRH 
stimulation test for n=24 animals without signs of PPID, n=4 
animals with equivocal signs of PPID, and n=5 animals with signs 
of PPID. For one further PPID case, post mortem was undertaken 




All except 4 TRH stimulation tests were performed by the same 
technicians, and horses were maintained in familiar surroundings. 
Animals were catheterised 30 minutes prior to basal sample 
collection, and 2 baseline samples were obtained 5 minutes apart. 
Blood samples were collected in plastic potassium EDTA tubes and 
centrifuged to separate plasma within 45 minutes of collection. 
Plasma was stored at -20°C in plastic tubes, then placed on ice 
packs, and sent by overnight post to the Animal Health Diagnostic 
Center at Cornell University for analysis. 
ACTH measured by immunometric chemiluminescence assay (CIA).  
Cut-off value of >35 pg/ml used for plasma ACTH concentration at 
baseline and both time points following TRH administration. 
Outcome 
Measures:  
Baseline ACTH concentrations in PPID and normal horses.  
Secondary outcome was to compare baseline ACTH in PPID and 
non-PPID horses to post mortem results.   
Main Findings: 
All 6 PPID cases and all 4 cases with equivocal clinical signs that 
had post mortem examination had histologic evidence of pars 
intermedia hyperplasia. Of the 24 clinically normal animals that had 
post mortem examinations, 14 had histologic evidence of pars 
intermedia hyperplasia. 
Baseline ACTH measured for 2 samples obtained 5 minutes apart 
varied minimally for clinically normal horses but were more variable 
in the PPID cases. 
Normal basal plasma ACTH concentrations (≤ 35 pg/ml): 
• Clinically normal horses: 
 6/7 tests from 5 controls that did not have post mortem 
examination  




 9/14 controls with pituitary hyperplasia at post mortem  
• Equivocal clinical signs horses: 
 3/8 tests from 4 cases with pituitary hyperplasia at post 
mortem  
• PPID cases: 
 6/16 tests from 9 PPID cases that did not have post 
mortem examination  
 2 PPID cases with pituitary hyperplasia at post mortem  
 
Using histopathology as the reference standard, and a cut-off of 
>35 pg/ml, basal ACTH had a sensitivity of 71% and specificity of 
100%, based on 10 clinically normal animals with no pituitary 
hyperplasia and 6 PPID cases with pituitary hyperplasia. 
In clinically normal animals, basal ACTH had a sensitivity of 36% 
and specificity of 100%, based on 10 controls with no pituitary 
hyperplasia and 14 controls with pituitary hyperplasia. 
For histological diagnosis of PPID (regardless of clinical signs, 
combining 6 PPID cases with pituitary hyperplasia and 14 clinically 
normal horses with pituitary hyperplasia) using an ACTH cut off of 
>35 pg/ml: sensitivity 100%, positive predictive value 72%, and 
diagnostic accuracy 72%. No animals without pituitary hyperplasia 





Small sample size and splitting to subgroups for analysis reduces 
study power further. Different subgroups used for classifying 
animals based solely on clinical presentation, and for classification 
based on both clinical presentation and pituitary histopathology.  
Likely that at least a proportion of the study population were from 
a referral hospital population but information on sample selection 
limited therefore unable to assess selection bias and ability to 
generalise to other equine populations. Using control population 
selected based on absence of clinical signs of PPID (i.e. not 
suspected PPID cases) may introduce bias to estimates of 
diagnostic accuracy. Study uses histopathology as reference 
standard for diagnosis of PPID. Baseline ACTH showed variability 
between samples collected 5 minutes apart, especially in PPID 
cases. Seasonal effect on ACTH observed, but study did not use 
seasonally adjusted reference intervals. All horses with 
histologically normal pituitary glands had low baseline ACTH 
concentrations (≤ 35 pg/ml), but normal basal ACTH 
concentrations were detected in some horses with histological 
evidence of PPID.  Basal ACTH was shown to have good sensitivity 









Study Design: Case control selection cross-sectional study (for component of 
study evaluating measures of ACTH diagnostic test accuracy); 
multiple-gate design using healthy controls 
Aim/Objective of 
the Study: 
To compare ACTH and α-MSH after administration of TRH, and to 
compare ACTH concentrations after TRH administration with those 
following domperidone administration, in healthy horses and horses 
with PPID. 
Setting: Not stated 
Study Population: No information provided regarding study population selection. 
Substantial proportion of study population (n=48) also included in 
authors’ previous study (Beech et al., 2007). 
n=88  
Controls: n=69 clinically normal horses (mixed breeds, n=3 ponies) 
• no clinical signs of PPID  
• of these animals, ACTH was evaluated for: 
 10 animals with no post mortem 
▪ 5 geldings, 1 stallion, 4 mares; mean age (± 
standard deviation) 8±2 years (range 4-11 years) 
 23 with no histologic pituitary changes 
▪ 17 geldings, 6 mares; mean age 8±4 years (range 
5-18 years) 
 20 with histologic pituitary hyperplasia or adenoma 
▪ 11 geldings, 9 mares; mean age 16±7 years (range 
5-29 years) 
PPID cases: n=47 
• animals with ≥2 clinical signs of PPID or suspected to have 
PPID (based on ≥1 clinical sign, other than hypertrichosis or 
abnormal coat shedding, plus pituitary adenoma at post 
mortem) 
• post mortem examination performed on 34 PPID cases, all 
of which had histologic evidence of pituitary adenoma 
• of these animals, ACTH was evaluated for:  
 25 PPID cases  
▪ 9 geldings, 16 mares; mean age 21±7 years (range 
8-30 years); 4 of the 7 ponies/pony crosses in the 
study population were in the PPID group 
 10 suspected PPID cases 





Animals were catheterised 30 minutes prior to basal sample 
collection, and 2 baseline samples were obtained 5 minutes apart 
(except one horse with single baseline sample), and mean of the 2 
samples was used as baseline value (except one horse with single 
sample). Blood samples were collected in glass EDTA tubes and 
centrifuged to separate plasma within 2 hours of collection. Plasma 
was stored at -70°C in plastic tubes, then placed on ice packs, and 
sent by overnight post to the Animal Health Diagnostic Center at 
Cornell University for analysis.  
ACTH measured with CIA.  





ACTH concentrations at baseline and following TRH or 
domperidone in normal and PPID horses. A secondary outcome 
was basal ACTH measurements taken as part of the stimulation 
tests compared between PPID and non-PPID horses. 
Main Findings: Baseline ACTH concentrations were significantly higher when values 
for suspected and confirmed PPID cases were combined (median 
52.4 pg/ml), compared to clinically normal horses (median 21.2 
pg/ml) (p<0.05). Median basal ACTH for confirmed PPID cases 
(71.6 pg/ml) was higher than that of suspected PPID cases (24.2 
pg/ml); however a statistical comparison of these data was not 
presented.  
 
Using at cut-off value of >36 pg/ml, baseline ACTH was reported to 
have: 
• sensitivity of 71%; specificity of 96%; diagnostic odds ratio 
(DOR) = 54 and diagnostic accuracy of 80% when 
confirmed PPID cases (n=25) were compared to clinically 
normal horses with normal histopathology (n=23)  
• sensitivity of 65%; specificity of 96%; DOR = 40 and 
diagnostic accuracy of 75% when confirmed and suspected 
PPID cases combined (n=35) were compared to clinically 
normal horses with normal histopathology (n=23)  
• sensitivity of 71%; specificity of 86%; DOR = 15 and 
diagnostic accuracy of 80% when confirmed PPID cases 
(n=25) were compared to all clinically normal horses 
(including those with normal histopathology, those with no 
post mortem and those with histologic pituitary changes; 
n=53)  
• sensitivity of 65%; specificity of 86%; DOR = 11 and 
diagnostic accuracy of 77% when confirmed and suspected 
PPID cases combined (n=35) were compared to all clinically 
normal horses (including those with normal histopathology, 
those with no post mortem and those with histologic 




Small sample size and splitting to subgroups for analysis reduces 
study power further. Different subgroups used for classifying 
animals based solely on clinical presentation, and for classification 
based on both clinical presentation and pituitary histopathology.  
Subgroup presentation of results is difficult to follow. Likely that at 
least a proportion of the study population were from a referral 
hospital population but information on sample selection limited 
therefore unable to assess selection bias and ability to generalise to 
other equine populations. Not all animals in study population 
included in ACTH element of study, and no details of case selection 
or reasons for exclusion are provided. Using control population 
selected based on absence of clinical signs of PPID (i.e. not 
suspected PPID cases) may introduce bias to estimates of 
diagnostic accuracy. Study uses histopathology, or a combination of 
histopathology and clinical diagnosis of PPID, as reference standard 
for diagnosis of PPID against various control subgroups. Seasonal 
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effect on ACTH observed, but study did not use seasonally adjusted 
reference intervals.  Basal ACTH was shown to have good 
sensitivity and specificity for diagnosis of PPID, when comparing 





Beech et al., 2011b  
Journal publication 




To compare ACTH and cortisol responses to TRH administration in 
normal horses and in horses with PPID. 
Setting: Not stated 
Study Population: No information provided regarding study population selection. 
Substantial proportion of study population (ACTH data from 15 
normal horses and 10 tests in 9 PPID horses) also included in 
authors’ previous study (Beech et al., 2007). 
n=32  
Controls: n=19 clinically normal horses (mixed breeds, no ponies) 
• no clinical signs of PPID  
 of these animals, 7 had no histologic pituitary changes 
at post mortem, 7 had histologic pituitary hyperplasia, 
and 5 did not have a post mortem examination  
▪ 11 geldings, 1 stallion, 7 mares; mean age 10.5±5.5 
years (range 2-25 years) 
PPID cases: n=13 
• 1 case receiving pergolide treatment 
• 8 horses and 2 ponies had ≥2 clinical signs of PPID  
 of these animals, 3 had pituitary macroadenomas and 2 
had microadenomas at post mortem, and 5 did not have 
a post mortem examination  
• 3 horses had mild signs of PPID  
 of these animals, 1 had pituitary macroadenomas and 2 
had microadenomas at post mortem  





All TRH stimulation tests were performed by the same technician, 
and horses were maintained in familiar surroundings. Animals were 
catheterised 30 minutes prior to basal sample collection. Blood 
samples were collected in plastic EDTA tubes and centrifuged to 
separate plasma within 45 minutes of collection. Plasma was stored 
at -20°C in plastic tubes, then placed on ice packs, and sent by 
overnight post to the Animal Health Diagnostic Center at Cornell 
University for analysis.  
ACTH measured with CIA.  
Reference value for basal ACTH was <35 pg/ml. 
 
Control horses:  
• all controls had a single TRH stimulation test  
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• 16 tested December-March, 1 in April, 1 in July, and 1 in 
August 
 
PPID cases:  
• 2 of the 13 cases had 3 TRH stimulation tests and all others 
had single test  
• 12 tests performed December-March, 2 in May, 1 in August, 
1 in October and 1 in November 
Outcome 
Measures:  
Baseline ACTH concentrations, and ACTH and cortisol responses to 
TRH administration in normal and PPID horses. 
Main Findings: Elevated basal ACTH (>36 pg/ml): 
• PPID group: 10/17 tests from 13 horses  
• Control group: 1/19 horses  
Mean basal ACTH for PPID cases (78.0 pg/ml) significantly higher 
than that of clinically normal controls (21.0 pg/ml).  
 
Using at cut-off value of >36 pg/ml, baseline ACTH was reported to 
have: 




Small sample size. Likely that at least a proportion of the study 
population were from a referral hospital population but information 
on sample selection limited therefore unable to assess selection 
bias and ability to generalise to other equine populations. Using 
control population selected based on absence of clinical signs of 
PPID (i.e. not suspected PPID cases) may introduce bias to 
estimates of diagnostic accuracy. Reference standard used for 
calculation of sensitivity and specificity of basal ACTH not clearly 
stated. Tests undertaken in different months but study did not use 
seasonally adjusted reference intervals.  Interpretation of results 
challenging as some horses had multiple tests included in analysis 
and one PPID horse was receiving treatment with pergolide, 
although its ACTH levels were reported not be significantly different 
from the other PPID horses. Basal ACTH was shown to have had 
good specificity but moderate sensitivity for diagnosis of PPID, 





Couëtil et al., 1996 
Journal publication 




To compare basal ACTH concentrations between normal horses and 
horses with PPID. Secondary objectives were to determine whether 
ACTH concentrations differed between normal horses and ponies, 
and whether ACTH quantification in plasma was affected by blood 
sample handling techniques. 
Setting: University referral hospital  
Study Population: Study population comprised horses/ponies presented to a single 




Controls: n=27 clinically normal animals (18 horses and 9 ponies) 
• determined to be normal on clinical examination, 
haematology and biochemistry  
• no recent history of corticosteroid or exogenous ACTH 
administration 
 horses: 9 geldings/stallions, 9 mares; n=6 aged <10 
years, n=5 aged 11-15 years, n=4 aged 16-20 years 
and n=3 aged >20 years; mean age 13.7 years 
 ponies: 1 gelding/stallion, 8 mares; n=7 aged <10 years 
and n=2 aged 11-15 years; mean age 6.7 years 
PPID cases: n=22 (11 horses and 11 ponies) 
• n=18 clinically diagnosed based on hypertrichosis or 
abnormal hair coat shedding, plus ≥1 other clinical sign of 
PPID 
• n=4 with post mortem histological evidence of pituitary 
adenoma (including 1 horse with no clinical signs) 
 horses: 6 geldings/stallions, 5 mares; n=1 aged <10 
years, n=2 aged 11-15 years, n=1 aged 16-20 years 
and n=7 aged >20 years; mean age 21.5 years 
 ponies: 5 geldings/stallions, 6 mares; n=1 aged 11-15 
years, n=1 aged 16-20 years and n=9 aged >20 years; 




Blood sample collection performed between 9-12am, and 
horses/ponies stabled with access to water and hay during the 
sampling period. Blood samples were collected in EDTA glass tubes, 
kept chilled in iced water, then centrifuged at 1500g at room 
temperature for 10 minutes, within 15 minutes of sample collection. 
EDTA plasma then transferred into plastic tubes and stored frozen 
at -20°C and analysed within a week of sample collection.  
ACTH measured with a commercial human ACTH 
radioimmunoassay (RIA). Intra-assay and inter-assay variations, as 
were determined during the RIA validation. 
Outcome 
Measures:  
Baseline ACTH concentrations in healthy controls and PPID cases, 
and following different sample handling protocols. 
Main Findings: Mean basal ACTH concentrations: 
• Control group:  
 horses 18.68 ± 6.79 pg/ml 
 ponies 8.35 ± 2.92 pg/ml 
 no statistically significant difference between age groups 
• PPID group:  
 significantly higher than control animals (p<0.001) 
 horses 199.18 ± 182.82 pg/ml 
 ponies 206.21 ± 319.56 pg/ml  
 no statistically significant difference between age groups 
 
Diagnostic cut-off points chosen arbitrarily as halfway between 
logarithmic mean ACTH concentration for PPID and control groups: 
horses 50 pg/ml and ponies 26.96 pg/ml. 
Using these cut-off values, basal ACTH was reported to have: 
• sensitivity of 90.9% and specificity of 100% in horses 
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Small sample size. Limited information regarding selection of cases 
and controls, although sample selection likely to introduce bias. 
Inclusion criteria for PPID group likely to have selected for cases 
with advanced disease. Using control population selected based on 
absence of clinical signs of PPID (i.e. not suspected PPID cases) 
may introduce bias to estimates of diagnostic accuracy. Clinical 
signs (hypertrichosis or abnormal hair coat shedding, plus ≥1 other 
clinical sign of PPID) used as reference standard for calculation of 
sensitivity and specificity of basal ACTH, with the exception of one 
case without hypertrichosis that had post mortem confirmation of 
pars intermedia adenoma. Sensitivity and specificity calculated 
based on the markedly different diagnostic cut-off points derived 
for horses and ponies, and no overall measures of diagnostic test 
accuracy are presented. Study conducted over a 1-year period but 
did not use seasonally adjusted reference intervals.  Basal ACTH 
was shown to have had good sensitivity and excellent specificity for 






Horn et al., 2020 
Journal publication 
Study Design: Case control selection with repeated cross-sectional studies; two-
gate design using healthy controls 
Aim/Objective of 
the Study: 
To compare measures of diagnostic accuracy of baseline and post-
TRH stimulation plasma ACTH concentrations in horses using 
diagnostic cut-off values and reference intervals 
Setting: Not stated  
Study Population: No information provided regarding study population selection. 
Study population were enrolled over a 24 month period, and each 
horse was followed for up to 12 months. 
n=106 horses (aged ≥10 years; ponies were excluded); all 
considered to be healthy other than clinical signs of PPID amongst 
cases. Enrolled horses had not received pergolide treatment in the 
12 months prior to the study, and had not travelled within the 24 
hours prior to sampling. 
• 53 geldings, 4 stallions and 49 mares 
• breeds included were: Australian Stock Horse (n=35), 
Standardbred (n=24), Warmblood (n=18), Thoroughbred 
(n=12), Arab (n=7), Quarter Horse (n=4), and mixed 
breeds (n=6) 
 
Controls: n=72 clinically normal horses  
• no clinical signs of PPID during the study  
• outlying values for basal or 30 minute post-TRH ACTH 
concentration returned from ≤2 monthly samples in the 12 
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month period (not stated, but presumably this criterion 
applied solely to high outlying values) 
• in subset where post mortem examination was undertaken, 
findings not consistent with pituitary adenoma (number of 
controls with post mortem not reported) 
 median age 16 years (range 10 – 27 years)  
PPID cases: n=34 horses, with ≥2 of the following 3 criteria:  
• clinical signs consistent with PPID (hypertrichosis or delayed 
shedding and epaxial muscle wastage, abnormal fat 
distribution or abnormal sweating) 
• post mortem findings confirming or excluding pituitary 
adenoma or hyperplasia  
• outlying values for basal or 30 minute post-TRH ACTH 
concentration returned from ≥6 monthly samples in the 12 
month period  
 median age 22 years (range 11 – 31 years); significantly 




Horses were sampled once monthly (during the second week of 
each month) for up to 12 months. Samples were collected with 
horses in familiar surroundings (either home premises or in 
paddocks at the institution where the study was undertaken), with 
ad libitum access to food and water prior to and following 
sampling. Samples were collected by venipuncture (horses were 
not catheterised) at baseline and at 30 minutes following TRH 
administration. Blood was collected into plastic EDTA vacutainer 
tubes, then kept on ice, centrifuged and separated within 2 hours 
of collection. ACTH measured using CIA (Immulite 1000 assay) 
within 8 hours of collection. 
Outcome 
Measures:  
Sensitivity, specificity, positive likelihood ratios and diagnostic 
accuracy (area under the ROC curve) of ACTH compared to 
reference standard comprising the eligibility criteria used to define 
PPID cases.  
Youden’s index used to derive monthly ACTH cut-off values that 
optimise differentiating ability (between diseased and non-diseased 
animals) when equal weight is given to sensitivity and specificity. 
Monthly reference intervals for ACTH were derived from the control 
population using Box-Cox transformation and bootstrapping.  
Main Findings: Youden’s index derived monthly ACTH diagnostic cut-off values 
ranged from a minimum of 24.0pg/ml in June (winter in Southern 
hemisphere) to a maximum of 79.1pg/ml in April (autumn in 
Southern hemisphere). 
The upper limit of derived monthly reference intervals ranged from 
a minimum of 28.6pg/ml in October, based on 42 control horses, to 
a maximum of 138.0pg/ml in March, based on 50 control horses. 
Using derived the upper limit of derived reference intervals resulted 
in lower sensitivity and higher specificity for basal ACTH compared 





Greatest sensitivity identified in April (autumn), using cut-off value 
of 79.1pg/ml. Using this cut-off value, basal ACTH was reported to 
have: 
• sensitivity of 100% (95% CI 64.6-100%) and specificity of 
95.4% (95% CI 84.5-99.2%), positive likelihood ratio = 
21.5 (95% CI 4.98-56.0) and area under ROC curve 0.99 
(n=7 PPID cases and n=44 controls) 
Greatest specificity identified in May (autumn), using cut-off value 
of 41.6pg/ml. Using this cut-off value, basal ACTH was reported to 
have: 
• sensitivity of 88.9% (95% CI 56.5-99.4%) and specificity of 
97.8% (95% CI 88.7-99.9%), positive likelihood ratio = 
40.9 (95% CI 5.8-281.0) and area under ROC curve 0.93 
(n=9 PPID cases and n=46 controls) 
Lowest sensitivity identified in November (spring) and December 
(summer). Only November data extracted here due to slighter 
larger sample size included. Using the November cut-off value of 
25.7pg/ml, basal ACTH was reported to have: 
• sensitivity of 80.0% (95% CI 49.0-96.5%) and specificity of 
72.5% (95% CI 57.2-83.9%), positive likelihood ratio = 2.9 
(95% CI 1.62-5.20) and area under ROC curve 0.84 (n=10 
PPID cases and n=41 controls) 
Lowest specificity identified in March (autumn), using cut-off value 
of 58.3pg/ml. Using this cut-off value, basal ACTH was reported to 
have: 
• sensitivity of 85.7% (95% CI 48.7-99.3%) and specificity of 
63.3% (95% CI 49.3-75.3%), positive likelihood ratio = 2.3 
(95% CI 1.45-3.75) and area under ROC curve 0.82 (n=7 




ACTH cut-off values and reference intervals derived and these 
values were then used to assess diagnostic test accuracy. Variable 
sample size per month (between 49 and 57 horses in total per 
month) included in data analyses. Seasonal variations seen may not 
be directly comparable to the climate in the northern hemisphere.  
Eligibility criteria for defining PPID cases used as reference 
standard for calculation of sensitivity and specificity of basal ACTH, 
effectively forming a composite reference standard. However, not 
all PPID cases had each of the 3 eligibility criteria, and no details 
regarding the frequency of clinical signs, post mortem pituitary 
abnormalities or recurrent outlying ACTH values are reported.   
Using control population selected based on absence of clinical signs 
of PPID (i.e. not suspected PPID cases) may introduce bias to 
estimates of diagnostic accuracy. Horses with outlying ACTH results 
occurring on 3-5 occasions during the 12 month study period were 
excluded. Results reported separately for each month, and no 
overall measures of diagnostic test accuracy are presented. Basal 
ACTH was shown to have had good sensitivity and specificity for 
diagnosis of PPID, when comparing PPID cases horses without 
clinical signs of PPID. Sensitivity for basal ACTH was greater where 
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derived diagnostic cut-off values were used to define a positive 
result, whereas the higher ACTH values derived as the upper limit 





Horowitz et al., 2003 
Conference abstract 




To compare basal α-MSH, β-endorphin and ACTH concentrations 
between normal horses and horses with PPID, and to determine 
sensitivity and specificity of these values for diagnosis of PPID 
when compared to the ODST.  
Setting: Not stated  
Study Population: No information provided regarding study population selection. 
n=63, classified as PPID cases or normal controls based on the 
results of ODST 
Controls: n=38 age-matched controls; mean age 22.5±2.9 years 




Blood was collected in EDTA tubes and stored at -80°C prior to 
analysis. ACTH measured at the Michigan State Endocrinology 
Laboratory using RIA.  
Outcome 
Measures:  
ACTH tests results compared to ODST diagnosis. ROC curve used 
to derive ACTH cut-off value that optimised sensitivity and 
specificity. 
Main Findings: Mean basal ACTH concentrations: 
• Control group:  
 8.0 ± 9.1 pmol/l (equivalent to 36.3 ± 41.3 pg/ml) 
• PPID group:  
 significantly higher than control animals (p<0.001) 
 33.7 ± 23.5 pmol/l (equivalent to 153.0 ± 106.7 pg/ml) 
Using a diagnostic cut-off point of 11 pmol/l (equivalent to 49.95 
pg/ml), derived from ROC curve analysis, basal ACTH was reported 
to have: 
• sensitivity of 84% and specificity of 89.5%  
α-MSH and β-endorphin significantly higher in PPID group 
compared to controls (both p<0.001).  Both α-MSH and β-




Conference abstract with limited information provided. Small 
sample size. No description of sample selection, nor clinical signs 
exhibited by included animals therefore unable to determine if 
study population is appropriate for a diagnostic test accuracy study. 
Unable to determine whether results are generalisable to other 
populations.  ODST used as reference standard for calculation of 
sensitivity and specificity of basal ACTH.  Basal ACTH was shown to 
have had good sensitivity and specificity for diagnosis of PPID, 









McGowan et al., 2013b 
Journal publication 
Study Design: Cohort selection cross-sectional study; single gate  
Aim/Objective of 
the Study: 
To evaluate basal α-MSH and ACTH concentrations for the 
diagnosis of PPID in a population of horses aged ≥15 years 
Setting: Field based  
Study Population: Study population were selected from a subset of animals in a 
preceding cross-sectional study of geriatric horses. 
n=974 horses (aged ≥15 years) recruited via a questionnaire from 
members of an equestrian organisation, from which n=340 
subgroup selected by geographic location for veterinary clinical 
examination and endocrine tests (n=339). 
Of this subgroup, n=325 had ACTH assay performed, of which 304 
included in final analysis for ACTH 
n=21 with owner-reported history of hypertrichosis with ≤2 other 
clinical signs of PPID excluded from analysis 
 
Controls: n=281 had no clinical evidence of PPID, of which 280 
included in final analysis for ACTH  
PPID cases: n=27 had hypertrichosis plus ≥3 other current and/or 
historical clinical signs of PPID (based on both veterinary clinical 
examination findings and owner-reported questionnaire data), of 




Blood samples collected prior to moving the horse and clinical 
examination, to minimise stress or excitement. Blood was collected 
into glass EDTA vacutainer tubes, then immediately centrifuged at 
1000g for 10 minutes using a portable centrifuge. EDTA plasma 
was then placed on ice packs before storage at -80°C (within 6 
hours) until being shipped frozen to the laboratory for analysis (1-
24 months after sample collection). ACTH measured using CIA 
(Immulite 1000 assay). 
Outcome 
Measures:  
Sensitivity, specificity, positive and negative predictive values, and 
positive and negative likelihood ratios of ACTH compared to 
reference standard of hypertrichosis plus ≥3 other clinical signs of 
PPID (based upon results of one-way ANOVA comparing α-MSH 
and ACTH concentrations in horses with owner-reported 
hypertrichosis and 0-12 other clinical signs). 
Youden’s index used to derive ACTH cut-off value that optimises 
differentiating ability (between diseased and non-diseased animals) 
when equal weight is given to sensitivity and specificity. 
PPID prevalence estimate of 13%, based owner-reported 
hypertrichosis, used for calculation of ACTH sensitivity, specificity, 
predictive values and likelihood ratios. 
Main Findings: ACTH showed a moderate positive correlation (r=0.69; p<0.001) 
with total number of clinical and historical indicators of PPID, in 
animals with owner-reported hypertrichosis.  
 
Youden’s index derived diagnostic ACTH cut-off values:                      
Non-autumn seasons: 29.7pg/ml                 
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Autumn: 77.4pg/ml  
 
Using these cut-off values, basal ACTH was reported to have: 
• sensitivity of 80.0% and specificity of 82.5% in non-autumn 
seasons (June-February) (n=20 PPID cases and n=217 
controls) 
• sensitivity of 100% and specificity of 95.2% in autumn 




ACTH cut-off values derived in a field-based population and these 
values were then used to assess diagnostic test accuracy. Samples 
were collected in field conditions but confined to a geographically 
convenient area.  Small sample size of animals samples during 
autumn. Seasonal variations seen may not be directly comparable 
to the climate in the northern hemisphere.  Clinical signs 
(hypertrichosis plus ≥3 other clinical signs of PPID) used as 
reference standard for calculation of sensitivity and specificity of 
basal ACTH. Inclusion criteria for PPID group likely to have selected 
for cases with advanced disease. Using control population selected 
based on absence of clinical signs of PPID (i.e. not suspected PPID 
cases) may introduce bias to estimates of diagnostic accuracy. 
Animals with hypertrichosis plus ≤2 other clinical signs of PPID 
were excluded. Results reported separately for autumn and non-
autumn period, and no overall measures of diagnostic test accuracy 
are presented. Basal ACTH was shown to have had good sensitivity 
and specificity for diagnosis of PPID, when comparing PPID cases 
with geriatric horses/ponies without clinical signs of PPID. Measures 
of diagnostic test accuracy for basal ACTH were greater during the 





Perkins et al., 2002  
Journal publication 
Study Design: Case control selection cross-sectional study (for component of 
study evaluating measures of ACTH diagnostic test accuracy); two-




To validate the CIA for ACTH and to calculate the sensitivity and 
specificity of plasma ACTH levels for detecting PPID. 
Setting: New York State Diagnostic Laboratory 
Population for evaluating ACTH sensitivity and specificity from 
university referral hospital. 
Study Population:  Retrospective review of referral hospital clinical records from April 
1997 to December 1998, to collate clinical data for animals that 
had ACTH samples within that period. Data collected included age, 
month of sampling, ACTH concentration, hypertrichosis, laminitis, 
lethargy and other signs of PPID, plus any other diagnosis.  
Histologic evidence of pituitary hyperplasia was recorded for cases 
undergoing post mortem examination (n=6). 
n=68  
Controls: n=29  
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• no clinical signs consistent with PPID or had alternative 
definitive diagnosis that explained clinical signs  
 age and sex data only reported combined with possible 
PPID group; overall median age 16 years (range 2-21 
years) 
PPID cases: n=19  
• based on hypertrichosis  
 9 mares, 2 stallions and 8 geldings; median age 21 
years (range 13-32 years) 
 breed data appear to be reported erroneously: text 
results state 2 of 5 ponies had hypertrichosis, yet table 
displays 0% for pony breed in PPID group  
Possible PPID cases: n=20  
• clinical signs consistent with PPID (listed as recurrent 
laminitis, lethargy, obesity, secondary infections, 
polyuria/polydipsia and muscle wastage), but not 
hypertrichosis  
 age and sex data only reported combined with control 




No information regarding blood sampling or sample handling 
reported. ACTH assumed to be measured with CIA (Immulite), 
since it was the assay validated in another phase of this study. 
Laboratory’s previously derived diagnostic cut-off value for PPID 
was used (>35 pg/ml; based on data from young-mature horses 
and ponies). The intra-assay coefficient of variation was 
determined on samples for each of 4 equine plasma samples 
(mean 9.3%).  Inter-assay precision on 2 equine plasma samples 
assayed for 25 consecutive runs over a month (9.1% for low 
control and 7.0% for high control). 
Outcome 
Measures:  
Basal ACTH concentration  
Main Findings: Elevated ACTH significantly associated with PPID group (defined 
based on hypertrichosis; p<0.01).  ‘Winter onset’, defined as 
samples obtained between October-April, was not associated with 
elevated ACTH (p=0.88). Of the 6 animals that had post mortem 
examination, 4 cases had no gross evidence of pituitary 
enlargement and all had normal ACTH level, while the remaining 2 
had histological evidence of pituitary adenomatous hyperplasia, of 
which one had normal ACTH (on several occasions) but did have 
hypertrichosis and severe hyperhidrosis. Which group these 6 
animals were in is not reported.  
Using a diagnostic cut-off point of >35 pg/ml, basal ACTH was 
reported to have: 
• sensitivity of 84% (95% CI 60-97%) and specificity of 78% 




First phase of the study demonstrated the ACTH was valid for use 
in horses. Insufficient information provided to assess methods used 
by laboratory to derive cut-off value for ACTH. Small sample size. 
Subject to inherent biases affecting retrospective studies, including 
potential for missing data or data not accurately recorded in clinical 
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records. Hypertrichosis used as sole criterion used for clinical 
reference standard. An alternative definitive diagnosis to explain 
clinical signs may not have been sufficient to exclude PPID cases 
from the non-PPID control group. Using control population selected 
based on absence of clinical signs of PPID (i.e. not suspected PPID 
cases) may introduce bias to estimates of diagnostic accuracy.  
Study conducted over a 21-month period but did not use 
seasonally adjusted reference intervals.  Basal ACTH had good 
sensitivity and specificity for diagnosis of PPID. Sensitivity and 
specificity presumed to be against non-PPID control and possible 
PPID groups combined, however this is not stated and no raw data 





Rendle et al., 2015a 
Journal publication 




To determine whether the mean of two paired measurements of 
ACTH concentration is more reliable in assessing PPID than a single 
measurement. 
Setting: Two university referral hospitals (USA and Australia) and one 
private referral hospital (UK). 
Study Population:  Retrospective data collection from review of referral hospital clinical 
records and prospective data collection from research herds.   
n=250; median age 16 years (range 3-33 years) 
Controls: n=50 horses (n=63 paired samples) 
• no clinical suspicion of PPID 
PPID cases: n=76 horses (n=90 paired samples)  
• receiving treatment with pergolide 
Possible PPID cases: n=124 horses (n=148 paired samples)  
• being investigated for PPID  
Histological examination was performed for n=67 untreated horses, 
by board-certified pathologists at a single institution, and PPID was 
diagnosed where there was par intermedia adenomatous 
hyperplasia, microadenoma or macroadenoma.  
• n=44 horses had histological changes 
• n=23 horses considered to have normal pars intermedia  
Histology used as reference standard for evaluation of ACTH 




Paired blood samples collected 5-15 minutes apart, then chilled and 
centrifuged. Plasma was then refrigerated and analysed within 24 
hours or frozen at -20°C or -80°C for up to 4 weeks prior to 
analysis. Results of analysis of the first sample were used as the 
single sample result. 
Used seasonally adjusted reference intervals of <29pg/ml for non-
autumn (November-July) and <47pg/ml for autumn (August-
October). It is not reported, but presumably autumn months were 
altered accordingly for samples obtained in Australia. 
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ACTH measured with CIA (Immulite).  The coefficient of variation 
was determined over a range of concentrations as 6%, and for 
values between 20 and 39 pg/ml, the median coefficient of 
variation was 9.0%. 
Outcome 
Measures:  
Agreement between single and paired ACTH samples for diagnosis 
of PPID, based on seasonally adjusted reference intervals.  ROC 
curve used to derive ACTH cut-off values for single and paired 
samples that optimised overall diagnostic accuracy (% correctly 
classified).  Sensitivity and specificity for ACTH calculated for both 
single and paired measurements. 
Main Findings: Of the 211 samples from untreated horses (both PPID positive and 
negative), single and paired tests were in agreement in 205 cases 
(97.2%). All 6 cases in which results were not in agreement were 
tested in the non-autumn period, and close to the cut-off point 
(median 29.2pg/ml). 
 
Single ACTH measurements did not agree with histopathology 
results in 31.3% of cases (n=21/67; 19 false negatives and 2 false 
positives): ACTH for these cases n=1 >39pg/ml; n=9 20-39pg/ml 
and n=11 <20pg/ml. 
Not reported, but calculated from these data, basal ACTH would 
have: 
• sensitivity of 56.8% (95% CI 41.0-71.7%) and specificity of 
91.3% (95% CI 72.0-98.9%) 
For single samples: 
Using a diagnostic cut-off point of >21.3 pg/ml (selected to give 
greatest diagnostic accuracy), basal ACTH was reported to have: 
• sensitivity of 69.4% and specificity of 80.9% 
Using a diagnostic cut-off point of >23.6 pg/ml, basal ACTH was 
reported to have: 
• sensitivity of 61.1% and specificity of 95.2%  
 
Mean of paired ACTH measurements did not agree with 
histopathology results in 32.8% of cases (n=22/67; 20 false 
negatives and 2 false positives): mean ACTH for these cases n=1 
>39pg/ml; n=10 20-39pg/ml and n=11 <20pg/ml. 
Not reported, but calculated from these data, mean paired ACTH 
would have: 
• sensitivity of 54.6% (95% CI 38.9-69.6%) and specificity of 
91.3% (95% CI 72.0-98.9%) 
For paired samples: 
Using a diagnostic cut-off point of >21.9 pg/ml (selected to give 
greatest diagnostic accuracy), mean ACTH was reported to have: 
• sensitivity of 72.2% and specificity of 76.2% 
Using a diagnostic cut-off point of >23 pg/ml, mean ACTH was 
reported to have: 




Histopathology was only available for subset of cases. Limited 
information provided on selection of study sample and no details of 
clinical signs, therefore it is not possible to determine whether the 
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control group (no histologic evidence of PPID) presented with 
clinical signs. Subject to inherent biases affecting retrospective 
studies, including potential for missing data or data not accurately 
recorded in clinical records. No information is provided regarding 
which of the 2 groups (being investigated for PPID or no clinical 
suspicion of PPID) that the 67 horses with post mortem histology 
were in. Details of time interval between ACTH measurement and 
post mortem examination for histopathology not reported. Study 
uses histopathology as reference standard for diagnosis of PPID. 
Cut-off values used for initial comparison with histopathology not 
clearly stated, but presumed to be based on the seasonally 
adjusted reference intervals provided in the methods section. The 
season(s) in which the 67 cases were sampled is not reported. 
Sensitivity and specificity of single and paired samples using the 
cut-off points based on the seasonally adjusted reference intervals 
are not reported (however these were calculated from raw data 
presented). The vast majority of cases with histologic evidence of 
PPID incorrectly classed as negative on single ACTH measurement 
had equivocal results close to the non-autumn cut-off value (29 
pg/ml). Rationale for selecting a cut-off value ~23 pg/ml for both 
single and paired samples not reported. Using the mean value of 
paired ACTH tests did not have a diagnostic benefit over a single 
basal sample. Basal ACTH had relatively low sensitivity and 
moderate-good specificity for diagnosis of PPID at cut-off points 
selected to optimise overall diagnostic accuracy, which are 





Sojka et al., 2006 
Conference abstract 




To investigate the effect of domperidone on ACTH concentrations 
in horses with and without histologically-confirmed tumours of the 
pars intermedia. 
Setting: Not stated  
Study Population: No information provided regarding study population selection. 
n=7 
Controls: n=2  
• average age 14.5 years (12 and 17 years) 
PPID cases: n=5  




Blood samples were collected into silicone-coated EDTA tubes and 
plasma was separated within 15 minutes of collection and frozen 
prior to analysis. Further blood samples were obtained 4 and 8 
hours following oral administration of 1.5g domperidone.  
ACTH measured using CIA.  
Outcome 
Measures:  
ACTH response following administration of domperidone. 
Secondary outcome was comparison of basal ACTH concentrations 
with gross and/or histologic evidence of pars intermedia adenoma. 
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Main Findings: Basal ACTH concentrations: 
• Control group:  
 20.5 and 37.1 pg/ml (mean 28.8 pg/ml) 
• PPID group:  
 37.8, 25.8, 30.8, 271.0, and 77.0 pg/ml (mean 77.5 ± 
104.0 pg/ml) 
 3/5 PPID cases had baseline ACTH values within 
reference interval (10-59 pg/ml) therefore would not 
have been diagnosed with PPID 
Not reported, but calculated from these data, using a cut-off value 
of >59 pg/ml basal ACTH would have: 
• sensitivity of 40.0% (95% CI 5.3-85.3%) and specificity of 
100% (95% CI 15.8-100%) 
Using a cut-off value of >29 pg/ml (upper limit of non-autumn 
reference interval determined by Copas & Durham, 2012), 4/5 
cases with histologic changes and 1/2 controls would have been 
diagnosed with PPID, and basal ACTH would have: 
• sensitivity of 80.0% (95% CI 28.4- 99.5%) and specificity 




Conference abstract with limited information provided. Very small 
sample size with no details of case selection or clinical signs 
provided, therefore it is not possible to determine whether the 
control group (no histologic evidence of PPID) presented with 
clinical signs. Unable to determine whether results are 
generalisable to other populations.  Details of time interval between 
ACTH measurement and post mortem examination for 
histopathology not reported. Study uses histopathology as 
reference standard for diagnosis of PPID. Time of year samples 
taken not reported and single cut-off value of >59 pg/ml used for 
ACTH diagnosis of PPID. Sensitivity and specificity are not reported 
(however these were calculated from raw data presented). Two of 
the five cases with histologic evidence of PPID classed as negative 
on basal ACTH measurement had equivocal results.  Using a cut-off 
value of >59 pg/ml, basal ACTH had low sensitivity and 100% 
specificity, when comparing PPID cases to two control animals 





van der Kolk et al., 1995 
Journal publication 




To determine the sensitivity of measuring basal plasma ACTH 
concentration for the detection of pars intermedia adenoma 
(plasma glucose, cortisol and insulin, as well as urinary 
concentration of corticoids and urinary corticoid:creatinine ratio 
were also evaluated, but are not reported here as not relevant to 
systematic review). 
Setting: University referral hospital 
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Study Population:  PPID cases examined between February 1990 and November 1993 
identified from review of referral hospital clinical records.   
Controls: n=7  
• clinically healthy Dutch Warmbloods  
 4 geldings, 3 mares; mean age 10 ± 1.5 years (range 7-
17 years) 
PPID cases: n=24  
• 11 Dutch Warmbloods and 13 ponies 
 12 geldings, 12 mares; mean age 20 ± 1.2 years (range 
12-30 years) 
• presented for investigation of suspected PPID due to 
presence of hypertrichosis  
• all had histologically confirmed pituitary pars intermedia 
adenomas 




Blood samples collected in EDTA tubes at 9am, then centrifuged at 
1500g for 10 minutes at 4°C. Plasma was separated and stored as 
2ml samples at -20°C prior to analysis.  ACTH measured with RIA.  
Intra-assay and inter-assay coefficients of variation ACTH were 8% 
and 12%, respectively. Mean ACTH plus 2 x standard deviation 
from control horses used to diagnostic determine cut-off value. 
Outcome 
Measures:  
Basal ACTH concentrations in healthy controls and cases presenting 
with hypertrichosis and being investigated for PPID. Sensitivity of 
ACTH for detecting pars intermedia adenoma.  
Main Findings: Basal ACTH concentrations: 
• Control group:  
 30 ± (standard error) 5.0 pg/ml (range 10-50 pg/ml) 
 cut-off value of 55 pg/ml calculated  
• PPID group (n=16/24):  
 489 ± 84.8 pg/ml (range 104-1000 pg/ml) 
Using a diagnostic cut-off point of >55 pg/ml, and 16 PPID cases, 
basal ACTH was reported to have: 




Small sample size and no explanation provided as to why basal 
ACTH measurements were not available for 8 of the 24 PPID cases. 
PPID cases all from referral hospital population, and no details 
provided regarding selection of control population. Details of t ime 
interval between ACTH measurement and post mortem 
examination for histopathology not reported. Using control 
population selected based on absence of clinical signs of PPID (i.e. 
not suspected PPID cases) may introduce bias to estimates of 
diagnostic accuracy.  Study uses histopathology as reference 
standard for diagnosis of PPID. Diagnostic cut-off determined by 
mean plus 2 x standard deviation from small sample of clinically 
normal animals; however data are presented as means ± standard 
error. Time of year samples taken not reported and single cut-off 
value used for ACTH diagnosis of PPID. Study design meant only 
sensitivity could be calculated for ACTH. Using a cut-off value of 
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Efficacy of pergolide for the management of equine pituitary pars 
intermedia dysfunction: A systematic review 
The following chapter collates and reviews literature pertaining to the treatment of PPID 
with pergolide, and is presented as it was published in The Veterinary Journal. 
Reference: Tatum RC, McGowan CM, Ireland JL (2020). Efficacy of pergolide for the 
management of equine pituitary pars intermedia dysfunction: A systematic review. The 
Veterinary Journal 266: 105562. 
Summary  
Pergolide, a dopamine agonist, is commonly administered to manage pituitary pars 
intermedia dysfunction (PPID), a progressive neurodegenerative disease prevalent in aged 
horses. However, available evidence regarding pergolide’s efficacy in improving clinical and 
endocrine parameters is limited. The aim of this systematic review was to assess published 
literature and evaluate evidence regarding whether pergolide treatment results in 
improvement of clinical signs and/or adrenocorticotrophic hormone (ACTH) concentration 
compared to no treatment or other unlicensed treatments. Systematic searches of electronic 
databases were undertaken in April 2019, repeated in August and October 2019, and 
updated in July 2020. English language publications published prior to these dates were 
included. Screening, data extraction and quality assessment of publications was undertaken 
individually by the authors using predefined criteria and subsequently cross-checked. 
Modified critically appraised topic data collection forms were used to extract data. Due to 
marked between-study variations, meta-analysis was not undertaken. 
After removal of duplicate records; 612 publications were identified, of which 129 abstracts 
were screened for eligibility and 28 publications met criteria for inclusion in the review. Most 
studies were descriptive case series, cohort studies or non-randomised, uncontrolled field 
trials. Despite marked variation in study populations, case selection, diagnostic protocols, 
pergolide dose, follow-up period and outcome measures, in the vast majority of the included 
studies, pergolide was reported to provide overall clinical improvement in >75% of cases. 
However, reported improvements in individual clinical signs varied widely. A reduction in 
plasma ACTH concentrations was reported in 44-74% of cases, while normalisation to within 




Pituitary pars intermedia dysfunction (PPID) is the most prevalent endocrine disorder of 
older horses (aged ≥15 years; McGowan et al., 2013a). This demographic now represents a 
significant proportion of the equine population (Mellor et al., 2001; Brosnahan and Paradis, 
2003b; Ireland et al., 2011a). Consequently, PPID is diagnosed with increasing frequency 
(Rohrbach et al., 2012) and is therefore important in equine practice. PPID is a progressive 
neurodegenerative disease, possibly caused by oxidative stress, which affects the inhibitory 
dopaminergic hypothalamic neurones, leading to a loss of dopaminergic control (McFarlane 
and Cribb 2005; McFarlane et al., 2005c; McFarlane, 2007). Consequently, a lack of 
regulation within the melanotrope cells of the pituitary pars intermedia results in over 
production of multiple pro-opiomelanocortin (POMC)-derived peptides and their derivatives, 
including adrenocorticotrophic hormone (ACTH; Heinrichs et al., 1990). The precise 
consequences of this are not fully understood (Durham, 2016a). However, once present, 
PPID is a progressive lifelong condition with varying clinical signs (Schott, 2002; McGowan, 
et al., 2013a; Ireland and McGowan, 2018). Currently, measurement of basal plasma ACTH 
concentration is widely used for diagnosing and monitoring PPID and is considered sufficient 
when seasonal reference intervals are utilised (McGowan et al., 2013b; Durham et al., 
2014). 
Pergolide mesylate, an ergot-derived, long-acting dopamine D2 receptor agonist, is used 
extensively to manage the disease (Anon, 2011a; Durham et al., 2014). It was previously 
used as an adjunctive treatment for Parkinson’s disease (Van Camp et al., 2004), an age-
associated neurodegenerative condition in humans, which has been compared to PPID 
(McFarlane, 2007). Horses with PPID have been found to have significantly less dopamine 
and dopamine metabolites compared to normal controls (Millington et al., 1988) and 
systemic supplementation of dopamine or a dopamine agonist was shown to decrease 
plasma concentration of POMC peptides (Orth et al., 1982).  Pergolide is reportedly well 
tolerated, rapidly absorbed and reaches high plasma concentrations in horses (Gehring et 
al., 2010; Rendle et al., 2019). Therefore, the rationale for the use of the dopamine agonist 
pergolide for the management of PPID is strong. However, systematic evaluation of 
treatment options for PPID has not been undertaken and treatment recommendations have 
evolved primarily from clinical experience. 
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Systematic reviews are an established reproducible method of collating and assessing 
available evidence to answer a specific research question. They provide a high level of 
evidence and can be used to assess interventions (Anon 2011b; Higgins et al., 2019), 
helping to inform decisions about the provision of healthcare (Rodgers et al., 2009). The aim 
of this paper was to perform the first systematic review of published literature about the 
efficacy of pergolide for the treatment of PPID in horses and ponies. Unless otherwise 
stated, all results presented in this paper pertain to horses and/or ponies and may not be 
applicable to other equids. The question addressed by this review was: ‘in horses/ponies 
diagnosed with PPID, is treatment with pergolide effective in improving clinical signs and/or 
plasma ACTH concentrations compared to no treatment or other unauthorised treatments?’. 
Published literature regarding the use of pergolide to treat PPID was systematically reviewed 
and included studies are presented with assessment of their design and validity (Moher et 
al., 2009). 
Materials and methods 
Search methodology  
The search strategy was based on current guidelines (McGowan et al., 2016). A systematic 
search of electronic databases was undertaken in April 2019, repeated in August and 
October 2019 and updated in July 2020. In order to obtain the best coverage of the 
veterinary literature, databases searched were; NCBI PubMed, Clarivate Analytics Web of 
Science, CAB Direct, SciVerse Scopus, and the database of the International Veterinary 
Information Service (IVIS; Grindlay et al., 2012). Additional relevant records were identified 
via the bibliographies of retrieved publications. Searches were conducted using a range of 
free text search terms and MEDLINE MeSH terms, including (Equine Cushing’s syndrome), 
(pituitary pars intermedia dysfunction) and (treatment). The full list of search terms and 
Boolean operators is detailed in Appendix 1. This review focused on PPID in horses and 
ponies, therefore search terms relating to donkeys and other equids were not included. All 





Figure 1: Flow diagram of the search strategy undertaken in a systematic review to identify 
and screen publications with information on the effect of pergolide treatment on clinical 
signs and plasma adrenocorticotrophic hormone (ACTH) concentrations in horses and ponies 
with pituitary par intermedia dysfunction (PPID), resulting in the identification of 28 included 
publications (adapted from Moher et al., 2009). 
Inclusion criteria  
Due to a lack of randomised controlled trials, studies of Level 4 evidence and above were 
included (Anon, 2011b). Descriptive individual case reports with no comparison group were 
excluded. Limitations on publication date, setting or study population were not imposed. 
Although not peer-reviewed, conference proceedings and government documents were also 
considered for inclusion, but other grey literature sources were not. Only English language 
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studies were accessed. However, English language abstracts were assessed, where 
available, for foreign language publications. Initial screening of all identified studies was 
undertaken and textbook chapters, letters, review articles, non-equine studies and those not 
pertaining to PPID were excluded at this stage. The abstracts of remaining studies were 
then screened. Studies where PPID pathophysiology, pergolide pharmacology, diagnostic 
test accuracy or other endocrinological parameters were the outcome measure, as well as 
those which did not contain information relevant to the review question were excluded. If 
abstracts reported findings from the same study as a full publication, only the full publication 
was assessed to avoid duplication. Eligibility assessment was carried out independently in a 
standardised, unblinded manner by the authors. 
Review methodology 
Study design, methodology and information reported in each included study was evaluated 
using appropriate STROBE checklists (checklists for cohort, case-control and cross-sectional 
studies combined or conference abstracts (Anon, 2007a) (Appendices 2 and 3). Quality 
assessment scoring was not undertaken. Studies were not excluded on quality grounds; 
however, results of lower quality studies are presented with interpretation of their 
limitations. 
Standardised forms adapted from critically appraised topic (CAT) data collection forms were 
used to extract relevant data from included publications. Data extraction was undertaken 
individually by the authors and subsequently cross-checked by the other authors to ensure 
agreement was reached. No attempt was made to obtain missing data and investigators 
were not contacted to confirm accuracy of included information. 
Data and relevant results extracted from each included publication are presented in 
summary tables (Appendices 4 and 5). Due to variations in study design, study populations 
and outcome measures between included studies, meta-analysis was not undertaken. 
Therefore, the results of qualitative evidence synthesis are presented in this review. 
However, overall prevalence estimates were calculated for clinical and endocrinological 
improvement in pergolide treated PPID cases, where numerator and denominator data were 
reported in included studies.  Where 95% confidence intervals (CI) were not provided in the 
publication, these were calculated by the authors where published information permitted.
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Table 1: Summary of clinical and endocrinological response to treatment with pergolide in horses diagnosed with PPID, in a systematic review 
of published literature. 
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Results    
A total of 833 records were identified via the combined electronic database searches, with 
an additional three records obtained from other sources. Following removal of duplicate 
records, 612 records were screened for relevance to the review question. Following title and 
abstract screening, a total of 41 publications that investigated treatment with pergolide were 
evaluated in full. Thirteen publications did not meet inclusion criteria and were subsequently 
excluded, resulting in 28 studies included in the review (Figure 1). The included publications 
comprised descriptive case series (n=10), cohort studies (n=7), uncontrolled non-
randomised trials (n=5), case control studies (n=4), a randomised placebo-controlled trial 
(n=1) and a non-randomised controlled trial (n=1).   
Study populations included were predominantly from university referral hospitals, university 
research herds or other referral hospitals (n=12). Five studies had field-based populations 
selected from first opinion practice and several had mixed populations including referral 
hospitals, research herds and/or private practice (n=5).  One study was based at an equine 
retirement sanctuary and five studies did not provide sufficient details to ascertain the 
population setting (Appendices 4 and 5).  
Case inclusion criteria varied between studies; the majority of PPID cases were diagnosed 
via a combination of clinical signs and various diagnostic tests including basal ACTH 
concentration and/or other diagnostic tests such as the overnight dexamethasone 
suppression test (ODST) and thyrotropin-releasing hormone (TRH) stimulation test (n=21). 
Other case inclusion criteria were elevated basal ACTH concentration alone (n=3), clinical 
signs alone (n=1), ODST alone (n=1), and TRH stimulation test alone (n=1). Diagnostic 
criteria were not reported in one study (Appendix 5). A total of 15 studies utilised basal 
ACTH concentration for PPID diagnosis in all or some of the included cases. One of these 
studies reported utilising contemporaneous seasonally adjusted reference intervals (Rendle 
et al., 2013) and a case series used values above seasonally adjusted reference intervals in 
three of the four PPID cases diagnosed using basal ACTH (Dunkel et al., 2014), while a 
further study (Rendle et al., 2018) utilised clinical decision limits recommended by the 
Equine Endocrinology Group (EEG, 2019). One further study utilised seasonally adjusted 
reference intervals that varied dependent on geographical location; however, these 
reference intervals were not contemporaneous for a considerable proportion of the study 
period (Horn et al., 2019). Two studies completed case enrolment and follow-up testing 
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avoiding the autumn seasonal rise in ACTH (July – October in the Northern hemisphere; 
Aleman et al., 2006; Anon, 2011a).  
Across all included publications, a total of 2,740 horses and ponies were treated with 
pergolide with 2,649 of these cases including some form of follow-up observation. The most 
frequently reported median starting dose of pergolide was 0.002 mg/kg/day (range 0.001 –
0.0125 mg/kg/day; Table 1). The majority of studies assessed treatment with pergolide 
alone (n=15), with no comparison group or control group (Peters et al., 1995; Froin et al., 
1998; Watson et al., 1998; Sgorbini et al., 2004; Aleman et al., 2006; Walsh et al., 2009; 
Pongratz et al., 2010; Anon, 2011a; Pease et al., 2011; Innerå et al., 2013; Rendle et al., 
2013; Dunkel et al., 2014; Schott et al., 2014; McFarlane et al., 2017; Rendle et al., 2018). 
The remainder assessed pergolide treatment in comparison with no treatment (n=4; Beech 
et al., 2009; Spelta and Axon, 2012; Gehlen et al., 2014; Horn et al., 2019), a placebo 
treatment (n=1; Christen et al., 2018) or in comparison to an active control group receiving 
an alternative unauthorised treatment including cyproheptidine (n=6; Love, 1993; Williams, 
1995; Schott et al., 2001; Donaldson et al., 2002; Perkins et al., 2002; Rohrbach et al., 
2012; ) bromocriptine (n=1; Orth et al., 1982) or Vitex agnus castus (n=1; Beech et al., 
2002). Three of these studies also included an untreated control group (Love, 1993; 
Williams, 1995; Schott et al., 2001; Table 1).  
Clinical response 
Reported improvement in at least one clinical sign following commencement of pergolide 
treatment ranged from 40-100% (Table 1), with a high proportion of cases (≥76%) showing 
clinical improvement in the majority of studies (Peters et al., 1995; Froin et al., 1998; 
Watson et al., 1998; Beech et al., 2002; Donaldson et al., 2002; Perkins et al., 2002; 
Aleman et al., 2006; Anon, 2011a; Spelta and Axon, 2012; Innerå et al., 2013; Dunkel et al., 
2014; Schott  et al., 2014). Evaluation of clinical response varied between studies with no 
standardised method used. Evaluation was most frequently based on subjective 
improvement in clinical signs, which was predominantly assessed via veterinary clinical 
examination (Williams, 1995; Schott et al., 2001; Beech et al., 2002; Perkins et al., 2002; 
Anon, 2011a; Pease et al., 2011; Innerå et al., 2013; Schott et al., 2014; Rendle et al., 
2018; Horn et al., 2019), however owner assessment was also utilised (Peters et al., 1995; 
Donaldson et al., 2002; Pongratz et al., 2010; Rohrbach et al., 2012).  A case series included 
both veterinary and owner-reported assessment of clinical improvement (Spelta and Axon, 
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2012), while the method of evaluation was either not reported or was unclear in five further 
studies that provided information on clinical response to pergolide treatment (Love, 1993; 
Froin et al., 1998; Watson et al., 1998; Sgorbini et al., 2004; Dunkel et al., 2014).  
Two clinical trials used objective measures (Anon, 2011a; Innerå et al., 2013) providing 
some of the highest quality evidence regarding clinical improvement. One study was 
associated with licensing of pergolide tablets for use in horses (Prascend, Boehringer 
Ingelheim), where 76.1% of 113 enrolled horses assessed over a 6-month study period 
were considered treatment successes based on objective clinical assessment scores and/or 
endocrinological improvement (defined as either normalisation of ODST results or a post-
treatment reduction in basal ACTH of ≥50% from pre-treatment values) (Anon, 2011a). The 
other study showed objective improvement in coat quality with a reduction in anagen phase 
hair follicles following 6 months of treatment with pergolide (Innerå et al., 2013). 
Relative improvement in specific clinical signs following pergolide treatment could be 
determined in five studies. Improvement in hypertrichosis ranged from 30-100%, abnormal 
fat distribution 0-33%, hyperhidrosis 15-45%, lethargy/poor performance 20-47%, muscle 
wastage 21-46% and laminitis 32-75%, of cases treated with pergolide (Beech et al., 2002; 
Donaldson et al., 2002; Perkins et al., 2002; Pongratz et al., 2010; Anon, 2011a). High 
proportions of pergolide treated animals showing improvement in clinical signs were 
reported in both referral/hospital and field-based studies although more variation was seen 
within the referral/hospital populations (Figure 2). Clinical improvement was also observed 
over prolonged time periods, with eleven studies including follow-up periods of ≥12 months 
(Peters et al., 1995; Williams, 1995; Froin et al., 1998; Watson et al., 1998; Schott et al., 
2001; Perkins et al., 2002; Walsh et al., 2009; Pongratz et al., 2010; Horn et al., 2019), 
including some horses followed for up to 5.5 years (Schott et al., 2014) and one horse was 
followed for 7 years (Spelta and Axon, 2012). 
Only a small number of studies compared pergolide to other unauthorised medical 
treatments. When compared to the serotonin agonist cyproheptadine, pergolide was 
reported to be superior at alleviating clinical signs in all studies, with the majority reporting 
only 25-29% of cases improved clinically when treated with cyproheptadine (Love, 1993; 
Schott et al., 2001; Donaldson et al., 2002; Rohrbach et al., 2012). The exception was one 
study which reported that 81% of cases treated with cyproheptadine showed improvement 
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in at least one clinical sign, however this was still inferior to the proportion reported in 
pergolide treated cases (90%; Perkins et al., 2002). The herbal supplement Vitex agnus 
castus was also investigated in a single uncontrolled field study (Beech et al., 2002). Clinical 
deterioration was observed in all but one of 14 PPID cases treated with Vitex agnus castus 
and nine of these animals were subsequently treated with pergolide (Beech et al., 2002).  
Plasma ACTH concentrations  
The proportion of PPID cases demonstrating improvement in plasma ACTH concentrations 
following pergolide treatment ranged from 20-74% (Table 1). Laboratory reference intervals 
used for the measurement of ACTH varied between studies. The majority of included studies 
used either ≤35 pg/mL or ≤50 pg/mL as the upper limit of the reference interval when 
reporting response to treatment, dependent on the type of assay used (Table 1). 
Normalisation of plasma ACTH concentrations to within these non-seasonally adjusted 
reference intervals occurred in 58-71% of cases (Donaldson et al., 2002; Anon, 2011a; 
Schott et al., 2014), while a decrease in plasma ACTH concentrations was reported in 20-
54.8% of cases (Froin et al., 1998; Beech et al., 2002; Rendle et al., 2013; Dunkel et al., 
2014).  
One retrospective study reportedly used seasonally adjusted reference intervals when 
measuring improvement in ACTH concentration following pergolide treatment, in which 28% 
of cases returned to within these intervals (Rendle et al., 2013). The same study reported a 
≥75% reduction in basal plasma ACTH concentrations in 54.8% of 2,122 cases, and those 
with a higher initial plasma ACTH concentration were more likely to improve. Another 
retrospective study using seasonally and geographically adjusted cut-off values reported 
normalisation of plasma ACTH concentrations in 44.4% of cases overall, across multiple 
repeat tests over a prolonged period (Horn et al., 2019). One study reported that ACTH 
concentration returned to within reference intervals for 74% of cases following pergolide 
treatment; however only seasonally adjusted clinical decision limits for initial diagnosis and 
not reference intervals used for follow-up testing were reported (Rendle et al., 2018).  
Two studies reported that ACTH concentration did not significantly decrease in pergolide 
treated cases compared to non-treated PPID controls (Gehlen et al., 2014) or pre-treatment 
values (McFarlane et al., 2017) over ≥3 months. Conversely, one placebo-controlled trial did 
report significantly lower plasma ACTH concentrations in pergolide treated cases over a 
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similar time period (Christen et al., 2018). There was some evidence to suggest that a 
prolonged time period or requirement for an increase in dose (from the median starting 
dose of 0.002 mg/kg/day) may be needed to achieve a satisfactory endocrine response 
(Williams, 1995; Spelta and Axon, 2012; Rendle et al., 2013; Schott et al., 2014; McFarlane 
et al., 2017). 
 
Figure 2: Reported proportion(s) of pituitary par intermedia dysfunction (PPID) cases 
treated with pergolide that showed improvement in clinical signs and/or endocrine levels in a 
systematic review of published literature. Error bars represent 95% confidence intervals, 
calculated by the authors where published information permitted. *Clinical improvement and 
adrenocorticotrophic hormone (ACTH) plasma concentrations could not be determined 
separately from the data provided. #In Horn et al., 2019, sample size differs for clinical 
(n=143) and ACTH concentration (n=117) improvement. Additionally, the study population 




Side effects and adverse events 
Side effects attributed to pergolide administration were recorded in seven studies with 
transient inappetence most frequently reported (Love, 1993; Muñoz et al., 1996; Schott et 
al., 2001; Pongratz et al., 2010; Dunkel et al., 2014; Schott et al., 2014; Rendle et al., 2018; 
Table 1).  The most robust study reporting the prevalence of side-effects found 33% of 
horses developed transient inappetence, which responded well to a short-term dose 
reduction (Anon, 2011a). Another study reported that 29% of pergolide treated cases 
developed mild side-effects including anorexia, lethargy and diarrhoea, which were generally 
self-limiting (Pongratz et al., 2010). Less than 10% of horses showed adverse events such 
as colic, lameness and laminitis (Anon, 2011a). Adverse events were reported whether 
related to the treatment under investigation or not, therefore it is not possible to determine 
whether these were directly associated with pergolide treatment (Anon, 2011a). 
Discussion  
This is the first paper to systematically review published evidence regarding the use of 
pergolide for the management of clinical signs and endocrine parameters associated with 
PPID.   
A large proportion of the available evidence regarding the treatment of PPID with pergolide 
has come from descriptive case series or small hospital-based populations. These studies 
had varying case selection criteria, diagnostic protocols, pergolide doses, treatment 
durations and outcome measures. It is also likely that the product used was inconsistent. 
Early studies conducted before the current authorised equine formulation of pergolide 
mesylate used pergolide products authorised for human use, while others may have used 
compounded pergolide, which has been reported to differ in potency (Davis et al., 2009; 
Shank, 2009; Stanley and Knych, 2010). Additionally, one recent study evaluated an 
unauthorised pergolide paste formulation (Rendle et al., 2018).  Despite these noted 
variations between studies, pergolide was consistently reported to provide overall 
improvement in clinical parameters in over 75% of reported cases. This high proportion of 
cases showing overall clinical improvement was observed in a large multicentre study 
performed as part of the licensing requirement for equine use (Prascend, Boehringer 
Ingelheim; Anon, 2011a), and in both field and hospital-based studies (Figure 2), with the 
exception of two retrospective cohort studies that had a high level of loss to follow-up 
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(Rohrbach et al., 2012; Horn et al., 2019).  Improvement in individual clinical signs was 
more varied; this is likely to be due to the differences in treatment duration and selection 
criteria. Determining the efficacy of pergolide for treating specific clinical signs with any 
degree of certainty was not possible due to variability in reporting. Clinical signs of PPID are 
diverse (Schott, 2002) and the interrelationship between them is unclear (McFarlane et al., 
2006; McFarlane, 2011). Further evidence is required regarding the effect of pergolide 
treatment on specific clinical signs, particularly laminitis due to its high prevalence and 
welfare impact (Herthel and Hood, 1999; Mellor et al., 2001; Karikoski et al., 2011).  
Due to the number of confounding factors and lack of control groups, it is difficult to 
attribute the side effects or adverse events observed to pergolide treatment specifically. 
However, transient inappetence was reported in a relatively high proportion of cases, which 
resolved after a reduction in the dose administered (Anon, 2011a). It may, therefore, be 
beneficial to introduce pergolide gradually, especially when a higher dose is required. There 
is insufficient evidence regarding possible long-term side-effects of pergolide, however the 
studies where cases were followed for a prolonged period (>5 years) did not report any 
adverse effects (Spelta and Axon, 2012; Dunkel et al., 2014; Schott et al., 2014; Horn et al., 
2019).  
The life expectancy of horses in the UK is increasing (Ireland et al., 2011a; Welsh et al., 
2016) and with efficient diagnostic testing readily available, cases of PPID are likely to be 
diagnosed and treated earlier. Median life expectancy following PPID diagnosis has been 
reported to be 9.8 years (Welsh et al., 2016), therefore in practice, pergolide treatment is 
likely to be undertaken for a number of years.  There is some evidence to suggest this may 
have a protective effect against further neurodegeneration caused by oxidative stress (Gille 
et al., 2002). Pergolide treatment has been associated with increased odds of survival, 
supporting its use to improve prognosis in PPID cases (Horn et al., 2019).  However, further 
evidence is needed regarding the benefits of early treatment and the efficacy of pergolide in 
the long term. 
Plasma ACTH concentrations offer an objective measure of improvement in response to 
treatment, however, variation in the diagnostic assays, laboratory and sampling protocols as 
well as reference intervals used, made comparison between studies challenging. In the UK, 
measurement of basal ACTH using seasonally adjusted reference intervals is the primary 
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endocrine test used to diagnose PPID and monitor response to treatment. This test is 
reported to provide a high level of sensitivity and specificity, accounting for seasonal 
variations in basal plasma ACTH concentrations (McGowan et al., 2013b).  As seasonally 
adjusted reference intervals were established fairly recently (Copas and Durham, 2012), the 
majority of included studies used non-seasonally adjusted reference intervals when 
measuring response to treatment. Therefore, the likelihood of non-differential 
misclassification bias is increased (Jurek et al., 2005), and this could lead to cases being 
falsely classified as having ‘abnormal’ plasma ACTH concentrations during the autumn 
seasonal rise or ‘normal’ concentrations in non-autumn months. However, despite this, such 
studies are still useful for determining improvement in plasma ACTH concentrations. One 
clinical trial reported significantly lower ACTH values in pergolide treated cases compared to 
placebo treated controls (Christen et al., 2018). However, in general, reduction in plasma 
ACTH concentrations was much more varied than overall improvement in clinical signs, and 
the two did not always correspond (Froin et al., 1998; Donaldson et al., 2002; Anon 2011a; 
Dunkel et al., 2014; Schott et al., 2014). This is not unexpected; the clinical signs of PPID 
are multifactorial and ACTH is one of many POMC-derived peptides which increase as a 
result of PPID (Heinrichs et al., 1990; McFarlane, 2011). ACTH is utilised as a biomarker 
because assays to measure it are widely available (Wilson et al., 1982) and sampling is 
convenient (Rendle et al., 2015a). However, plasma ACTH concentrations have been 
reported to be affected by external factors such as stress and pain (Fazio et al., 2008; 
Towns et al., 2010) as well as exercise (Alexander et al., 1991; Nagata et al., 1999) and 
ingestion of feed (Diez de Castro et al., 2014). Further evidence is required to fully interpret 
the clinical picture as a whole and the relationship between endocrine parameters and 
clinical signs. 
Where study population was able to be adequately determined, all included studies had 
potential biases (Appendices 4 and 5). Small convenience samples recruited via hospital or 
referral practices are likely to be biased towards cases in the advanced stages of disease or 
with concurrent disease(s), so results are not likely to be generalisable to the general 
population. Samples from first opinion practice have the potential to be more representative 
of the target population, however, the number of treated cases in many studies was small 
(n≤30), reducing study power, and convenience sampling was still used. Two field-based 
studies had larger study populations (Pongratz et al., 2010; Anon, 2011a), however due to 
non-random selection and the necessity for voluntary recruitment of cases, there is the 
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possibility of selection bias; systematic differences between owners and cases which 
participated compared to those that did not. Rendle et al. (2013a) had the largest study 
population, however this study used data from a retrospective review of laboratory data, 
which has inherent limitations, such as the possibility of incomplete or incorrect records. 
Additionally, it is likely that the accuracy of signalment and clinical data provided on 
laboratory submission forms could not be verified (Rendle et al., 2013). Furthermore, many 
studies did not use an objective measure for clinical signs or a control group (Peters et al., 
1995; Froin et al., 1998; Watson et al., 1998; Beech et al., 2002; Donaldson et al., 2002; 
Perkins et al., 2002; Pongratz et al., 2010; Rohrbach et al., 2012; Dunkel et al., 2014; 
Schott et al., 2014; Rendle et al., 2018), meaning assessment bias is probable. Veterinary 
surgeons and owners may expect to see improvement as a result of treatment and 
overestimate efficacy, thus resulting in bias towards a positive effect. However, the results 
from these studies were comparable to studies that did use objective assessment (Aleman 
et al., 2006; Anon, 2011a; Innerå et al., 2013) or a control group (Love, 1993; Williams, 
1995; Schott et al., 2001; Spelta and Axon, 2012).   
The lack of adequate control groups also means other potentially confounding factors, such 
as changes in management post-diagnosis cannot be controlled for.  In their small case 
series, Spelta and Axon (2012) detailed the standardised management advice that was 
provided to owners, including dietary and preventive health care recommendations.  Since 
many of these management changes could have an impact on clinical signs associated with 
PPID, and therefore the outcome of clinical response to treatment, they may be considered 
as co-interventions. Where co-interventions are not balanced across the study population, 
there is potential for performance bias, and none of the studies reviewed reported making 
any considerations for co-interventions in the evaluation of response to treatment. It is 
therefore possible that some clinical improvements attributed to a positive response to 
pergolide treatment could actually reflect a response to improved husbandry and general 
health care.  
While studies including client-owned animals are likely to be more representative of the 
general population of PPID cases, compared to experimental studies, or those undertaken 
within research herds, there is a necessary reliance on owners correctly and successfully 
administering the prescribed dose of pergolide. None of the publications where the study 
population included client-owned animals reported making any attempts to evaluate owner 
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compliance with pergolide treatment recommendations.  Non-adherence to, or departures 
from, the intended pergolide treatment represent another important potential source of bias. 
Overall, the available evidence demonstrates improvement in clinical and endocrine 
parameters in response to pergolide treatment. However, the evidence base is limited with 
outcomes observed frequently being poorly defined.  Ideally, a randomised, placebo 
controlled clinical trial would be conducted to appropriately evaluate pergolide as an 
effective treatment for PPID. However, it may not be considered ethical to withhold an 
authorised treatment which has been shown to improve animal welfare (Fenwick et al., 
2009). Instead, further research should concentrate on the interrelationship between 
endocrine parameters and clinical signs to improve interpretation of the clinical signs, the 
effect of early intervention and long-term administration as well as the efficacy of pergolide 
for treating specific clinical signs such as laminitis. 
Conclusion 
Although the evidence available regarding the efficacy of pergolide treatment is varied and 
with potential biases, the current evidence indicates that treatment with pergolide is 
effective at improving clinical signs of PPID in the majority of cases. However, the reported 
efficacy for improving plasma ACTH concentrations was more varied. Further evidence is 
required to better inform clinical decision making.     
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Appendices for Chapter 4 





Databases searched and dates 
covered 
NCBI PubMed (1950 – Present)  
Clarivate Analytics Web of Science (1898 – Present)  
CAB Direct (1960 – Present) 
Scopus (1823 – Present) 
International Veterinary Information Service (IVIS) database (1997 – Present)  
Further relevant records were identified by the authors via the bibliographies and reference lists of 
retrieved publications and published conference proceedings. 
Search terms (Equine Cushing* OR Pituitary pars intermedia dysfunction OR PPID OR Hyperadrenocorticism OR 
Pituitary adenoma) AND (horse* OR pony OR ponies OR equine OR equid*) AND (treatment* OR 
therapy OR therapeutic* OR medication* OR management)  





























NCBI PubMed 156 2 30 5 87 32 
Clarivate Analytics Web of 
Science 
154 2 41 6 65 40 
CAB Direct 245 12 122 3 88 20 
Scopus 249 7 64 4 132 42 
International Veterinary 
Information Service (IVIS) 
database 
29 4 7 1 13 4 
Other sources 3      




Appendix 2: Study design, methodology and information reported in included studies based on STROBE checklist for cohort, 




Appendix 3: Study design, methodology and information reported in included studies based on STROBE checklist 
for conference abstracts 
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Appendix 4: Summary tables and data of included studies 
 
A summary of extracted data for each included study, main limitations of the studies and 
conclusions are presented in the tables below.  
ACTH = Adrenocorticotrophic hormone 
ODST = Overnight dexamethasone suppression test 





Aleman et al., 2006  
Journal publication 
Study Design: Case control study 
Aim/Objective of 
the Study: 
To compare muscle characteristics and haematological and serum 
biochemical parameters between PPID cases and normal horses. 
Setting: University referral hospital 
Study Population:  Non-random selection –PPID cases from university research herd or 
presented to a university hospital; details on recruitment of horse 
owners/selection of horses not reported. 
Controls: n=16 normal horses 
• normal ODST or ACTH tested during winter and spring  
PPID cases: n=15 
• Quarter Horse (n=5), Thoroughbred (n=4), Standardbred 
(n=2), Arab (n=2), Appaloosa (n=1) and Mustang (n=1) 
• diagnosed based on clinical signs and positive ODST or 
basal ACTH 
• 11 female, 4 male 
• age range 15 – 28 years (median 21 years)  




Control Group: n=12 PPID cases not treated with pergolide due to 
financial constraints. 
Treatment Group: n=3 PPID cases treated with 1mg pergolide 
mesylate (Permax®) once daily for 3 months. 
Outcome 
Measures:  
Clinicopathological findings, clinical signs, electromyography, 
muscle biopsy 
Main Findings: Haematology and biochemistry: 
• no abnormalities of haematological and biochemical 
parameters in control group   
• mild leucocytosis with neutrophilia and lymphopenia in 1 
PPID horse; hyperglycaemia in 3 PPID horses; increased 
sorbitol dehydrogenase and gamma glutamyl transferase in 




• EMG studies were not performed after treatment with 
pergolide mesylate 
Muscle biopsy: 
• PPID cases had mild non-specific myopathic alterations 
including myofibre size variation (n = 15), internal nuclei (n 
= 11), perimysial, endomysial, and sarcoplasmic fat 
accumulation (n = 7) 
• muscle wasting in PPID horses was the result of atrophy of 
types 2A and 2B muscle fibres and loss of type 2B myofibres 
Pergolide treatment (n=3): 
• treatment with pergolide improved body condition score and 
physical activity 
• no statistical differences in myopathic alterations of horses 
with PPID before and after pergolide treatment 
• muscle fibre type composition was significantly different 
following pergolide treatment: type 1 myofibres decreased 
and  types 2A and 2B increased  





Sample selection likely to introduce bias. Baseline details of treated 
and untreated PPID cases unspecified. Some laboratory tests poorly 
described. 
Neutrophilia, lymphopenia, hyperglycaemia and increased liver 
enzymes occasionally seen in PPID cases. 
Muscle atrophy in PPID cases is caused by Type II muscle fibre 
myopathy – change in muscle fibre composition identified in all 
cases; however not clear if all PPID cases showed the same degree 
of myopathic changes. 
Very small sample size treated with pergolide. Treatment for PPID 
with pergolide resulted in clinical improvement (improved body 
condition score and physical activity) and showed beneficial effect 





Anon 2011a  
Freedom of Information Summary – NADA 141-331 
Study Design: Uncontrolled, non-randomised field trial 
Aim/Objective of 
the Study: 
To evaluate the effectiveness of pergolide mesylate in controlling 
the clinical signs associated with PPID in horses under field 
conditions. 
Setting: University referral hospital, research herds and private practice 
Study Population: 122 equids diagnosed with PPID (age range 10 – 35 years; 59 
male, 63 female, bodyweight 137-621 kg, and 16 breeds) at eight 
sites. 
 
Animals were scored (0-3) for hypertrichosis, hyperhidrosis, 
polyuria-polydipsia, abnormal fat distribution, and muscle wasting. 
Inclusion criteria were a hypertrichosis score >1 and either a 
plasma ACTH concentration >50 pg/ml or failure of endogenous 
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cortisol concentration to suppress (<1.0 μg/dl) 19 hours after 
intramuscular dexamethasone administration (40 μg/kg), autumn 
seasonal rise was avoided 
Intervention 
Investigated: 
Control Group: Not applicable 
Treatment Group: n=122 treated with oral pergolide mesylate (2 
μg/kg, once daily) 
Treatment with oral pergolide mesylate (2 μg/kg once daily per os) 
was started within 7 days of initial evaluation. Animals were re-
evaluated (physical exam and endocrine testing) after 90 (n=113) 
and 180 days (n=111) of treatment. When endocrine test results 
remained abnormal at 90 days (n=47), the pergolide dose was 
increased to 4 μg/kg orally once daily. 
Outcome 
Measures:  
Clinical signs and endocrine testing. 
Treatment success after 180 days was defined as either 
normalisation of ODST results (<1.0 ug/dl) or a decrease in plasma 
ACTH concentration by 50% (or to <50 pg/ml but with a reduction 
of at least 5 pg/ml) and improvement by a score of >1 in at least 
one clinical sign. Treatment was also considered successful when 
the sum of clinical scores decreased by >3, regardless of endocrine 
test results. 
Main Findings: 76% (86/113) equids were treatment successes (two horses 
withdrawn by their owners between 90 and 180 days were 
categorised as treatment failures). The remaining nine animals died 
(n=8) or were euthanized (n=1) due to worsening of pre-existing 
conditions (laminitis and dental disorders) or colic. After 90 days of 
treatment, 58% (66/113) had normal endocrine test results and 
clinical improvement. Both median scores of clinical signs and mean 
concentrations of ACTH and cortisol (following dexamethasone 
administration) decreased during the study period. Transient 
inappetance was the most common adverse event observed in 
40/122 (33%) equids, mostly during the initial 30 days of 
treatment. Other adverse events reported included lethargy, colic, 
diarrhoea, lameness, and weight loss in less than 10% of cases and 
it was unclear whether or not these events were related to use of 
the drug. There were ten reports of laminitis during the study: 
seven were recurrent episodes in animals with a previous history of 




Limited information regarding selection of study population, 
therefore not possible to assess risk of bias.  Enrolment of all PPID 
cases during winter period however follow-up examinations and 
endocrine tests conducted January – March and April – June 
avoiding seasonal increases in reference intervals.  
This open label field efficacy study demonstrated that pergolide is 
effective in improving endocrine parameters and clinical signs of 
PPID in the majority of treated horses; however, not all clinical 
problems may be fully corrected (e.g. laminitis).   
All disease events occurring during trial reported as adverse 
reactions. Of the adverse events reported, only transient 
inappetance was noticeably higher than previous reports of disease 







Beech et al., 2002  
Conference abstract 
Study Design: Uncontrolled, non-randomised field trial 
Aim/Objective of 
the Study: 
To evaluate the effects of Vitex agnus castus extract for the 
treatment of PPID. 
Setting: Unclear (all horses were maintained and medicated by their 
owners) 
Study Population:  14 horses selected based on clinical signs of PPID and increased 
plasma ACTH (n=12) and/or ODST (n=4).  Aged ≥20 years (n=11) 
and ≤19 years (n=3); 8 geldings and 6 mares.  
Intervention 
Investigated:  
Control Group: Not applicable 
Treatment Group: n=14 PPID cases treated with Vitex agnus 
castus extract for 2 – 6 months. Study design intended treatment 
duration to be 6 months, but due to deterioration in clinical signs, 
treatment was discontinued after 2 months (4 horses) or 4 months 
(4 horses), while 6 remained on treatment for the 6 month 
duration. 
 
Due to worsening of their clinical condition, 9 of the Vitex treated 
horses were subsequently treated with pergolide (0.002 – 0.006 
mg/kg once daily per os) for 2 – 9 months (7 horses received 
pergolide for 3 months and 2 horses for > 4 months). 
Outcome 
Measures:  
Clinical signs and endocrine testing 
Main Findings: Only 1 of 14 horses remained stable and did not show clinical 
deterioration while treated with Vitex agnus castus extract.   
8/9 horses subsequently treated with pergolide showed 
improvement in clinical signs. ACTH decreased in pergolide-treated 
horses: after 1 month of pergolide, ACTH was unchanged in 2/6 
horses and reduced by ≥50% in 4/6 horses.  After 3 months of 
pergolide, ACTH was within normal reference interval for 1/5, >35 
but <60 pg/ml for 3/5 and remained elevated for 1/5 (between 
240–363 pg/ml, but >50% reduction from pre-treatment values).   
Of the 4 PPID cases diagnosed based on abnormal ODST, 3 
showed normal suppression after commencing pergolide treatment.  
One horse had pergolide treatment discontinued due to lethargy 





No description of case selection precluding assessment of selection 
bias. Very small sample size treated with pergolide. Did not use 
seasonally adjusted reference intervals for ACTH for diagnosis or 
monitoring response to treatment. 
Results demonstrate lack of efficacy of Vitex agnus castus in the 
treatment of PPID, and that pergolide is effective in improving 
endocrine parameters and clinical signs of PPID in the majority of 







Beech et al., 2009  
Journal publication 
Study Design: Non-randomised controlled trial 
Aim/Objective of 
the Study: 
To measure plasma ACTH, α-MSH and insulin concentrations during 
various photoperiods between February and October in horses and 
ponies with and without PPID. 
Setting: Not stated – 36 privately owner pleasure horses/ponies; 6 PPID 
horses from research herd at University 
Study Population:  No information provided regarding study population selection.  
PPID cases: n=15 with at least 2 “classical clinical signs” of PPID; 7 
ponies (mean age 21.3 ± 4.3 years), 8 horses (mean age 24.5 ± 
5.2 years); 5 geldings; 10 females. 
Controls: n=27 with no clinical signs of PPID; 13 ponies (mean age 
7.1 ± 2.5 years), 14 horses (mean age 6.6 ± 1.6 years); 12 
geldings, 14 females, 1 entire male.  
Intervention 
Investigated: 
Control Group: n=7 untreated PPID cases 
Treatment Group: n=8 (4/7 PPID ponies and 4/8 PPID horses) 
were being treated with oral pergolide. Pergolide dose ranged from 
0.5mg daily in ponies to 3mg daily in horses. 
Outcome 
Measures:  
ACTH, α-MSH and insulin concentrations in different photoperiods 
in normal and PPID horses and ponies. 
Jugular blood samples collected during 8 photoperiods: 1) February 
13th – March 2nd; 2) April 4th – 6th; 3) June 19th – 22nd; 4) August 
6th – 7th; 5) August 14th – 17th; 6) September 4th – 6th; 7) 
September 26th – 28th and 8) October 16th – 18th.  All plasma 
samples were assayed for ACTH and α-MSH. Insulin concentration 
was measured on plasma samples from 8 PPID group horses, 4 
PPID group ponies, 6 control group horses and 6 control group 
ponies. Laboratory reference intervals were 9 – 35 pg/mL for ACTH 
and 10 – 40 μIU/mL for insulin. Reference concentration for α-MSH 
<90 pmol/L. 
Main Findings: Control group: 
Plasma ACTH significantly higher August – October than February – 
June.  
Plasma α-MSH concentrations significantly higher with increasing 
daylight. There were no significant seasonal changes in plasma 
insulin concentration except that log insulin concentration was 
lower in photoperiod 3 than in photoperiod 1. 
 
PPID group:  
Plasma ACTH and α-MSH concentrations were significantly higher 
in autumn photoperiods. 
 
Horses and ponies receiving pergolide, compared with those not 
receiving pergolide, had significantly less of an increase in plasma 
log α-MSH concentration in photoperiods 7 and 8, and significantly 






Response to treatment with pergolide was not a study objective. 
Information on sample selection limited therefore unable to assess 
selection bias. Small sample size. 
Seasonally adjusted reference intervals indicated when using basal 
ACTH or α-MSH as diagnostic test for PPID.  
PPID cases treated with pergolide had lower ACTH compared to 





Christen et al., 2018  
Journal publication 
Study Design: Randomised placebo-controlled trial  
Aim/Objective of 
the Study: 
To evaluate faecal worm egg counts (FWEC) in horses with pre-
clinical PPID before and after treatment with pergolide. 
Setting: Sanctuary for retired horses 
Study Population:  n=48 horses; mean age 24.8 years (standard deviation 3.6 years; 
range 14–32 years); 22 geldings and 26 mares; divided in to pre-
clinical PPID or healthy control groups based on basal ACTH: 
Pre-clinical PPID cases (n=24) with no obvious clinical signs of 
PPID but ACTH concentrations >35 pg/mL in July. Horses in pre-
clinical PPID group randomly allocated to pergolide or placebo 
treatment group using simple randomisation from freely available 
online software.  
Controls (n=24) – healthy horses with ACTH concentrations below 
upper limit of reference interval.  
Intervention 
Investigated: 
Control Group: n=9 placebo-treated subclinical PPID cases 
(received same tablet as pergolide (Prascend, Boehringer 
Ingelheim) without the active ingredient for 3 months) 
Treatment Group: n=10 treated with pergolide (0.002 mg/kg once 
daily per os) for 3 months (1st October 2014 to 31st January 2015) 
Outcome 
Measures:  
Primary outcome measure was faecal worm egg count, measured 
at baseline, one month prior to treatment and after 3 month 
treatment period.  
ACTH measured before treatment (July) and after 3 months of 
pergolide or placebo treatment (January; n=19 horses as 5 animals 
in PPID group died of unrelated causes before second blood sample 
collected).  
Main Findings: Difference in FWEC after treatment in pergolide group compared 
with placebo-treated animals did not reach statistical significance.  
FWEC significantly lower after treatment in pergolide-treated 
animals compared to baseline (p=0.03) but not significantly 
different from baseline in placebo group. 
ACTH significantly lower following treatment with pergolide 
(p<0.01): median ACTH 75.2 pg/mL (range 39.1–195) at baseline 
and 25.9 pg/mL (7.4–50.1) following 3 months of pergolide 
treatment. No significant difference in baseline and post-treatment 
ACTH in placebo group: median 80.7 pg/mL (range 39.3–127) at 






Small sample size made smaller by high loss to follow-up for a 
short study. Methods do not state whether study was blinded. 
Treatment with pergolide resulted in significant reduction in ACTH 





Donaldson et al., 2002  
Journal publication 
Study Design: Case series 
Aim/Objective of 
the Study: 
To evaluate the response of horses with PPID to treatment with 
pergolide or cyproheptadine by evaluating clinical signs and plasma 
ACTH, insulin, and glucose concentrations before and after 
treatment. 
Setting: University referral hospital ambulatory service  
Study Population: n=27 PPID cases  
Records of horses evaluated for PPID at University of Pennsylvania 
Ambulatory service between June 1996 and November 2001. 
Criteria included plasma ACTH >50 pg/mL, at least 1 clinical sign, 
and evaluation before and after treatment.  Horses were evaluated 
for 1-10 months (median 2 months). 
Intervention 
Investigated:  
Control Group: n=7 cases treated with oral cyproheptadine: 
0.25 mg/kg as a total dose every 24 hours. 
Treatment Group: n=20 cases treated with oral pergolide: median 
oral dose was 3 μg/kg (0.003 mg/kg) once daily with a range of 
1.7 to 5.5 μg/kg. 
Outcome 
Measures:  
Clinical signs and ACTH 
Main Findings: With pergolide treatment, there was a significant decrease in 
plasma ACTH, but not insulin or glucose concentration; 60% of 
horses reached a plasma ACTH within the normal reference 
interval. There was no significant change in any of the 3 
parameters with cyproheptadine treatment.   
There was a direct correlation between pergolide dose and ACTH 
concentration after treatment, as well as between duration of 
treatment and ACTH concentration.  
Improvement in clinical signs was reported by 85% of owners of 
horses treated with pergolide and 28% of owners of horses treated 
with cyproheptadine. 
There was a significant decrease in the prevalence of laminitis 




No details provided regarding selection of study population, nor 
treatment allocation, which was not randomised. Selection criteria 
for treatment not reported.  Long study period yet short duration of 
follow-up.  Subject to inherent biases affecting studies that rely on 
retrospective review of clinical records. Pergolide was clearly shown 
to be more effective than cyproheptadine in improving both clinical 
signs and ACTH, with 60% of pergolide-treated horses having 
normal ACTH concentration after treatment and 85% reported to 







Dunkel et al., 2014  
Journal publication 
Study Design: Case series 
Aim/Objective of 
the Study: 
To describe historical and clinicopathological findings, progression 
and outcome in horses and ponies with severe 
hypertriglyceridaemia secondary to an endocrine disorder. 
Setting: Cases presented to or treated by various University referral 
hospitals in the UK and USA.   
Study Population: n=6 PPID cases  
Age range 17 – 28 years; 2 mares, 3 geldings and one case where 
sex was not reported. PPID diagnosed on clinical signs and ACTH 
concentrations (n=4) or overnight dexamethasone suppression test 
(n=2).   
Intervention 
Investigated:  
Control Group: Not applicable 
Treatment Group: n=5 cases treated with oral pergolide; doses 
ranged from 0.7 – 8 μg/kg daily per os (median starting dose 3.8 
μg/kg once daily per os) 
Outcome 
Measures:  
Clinical signs and ACTH 
Main Findings: Clinical improvement was observed in the majority of treated 
horses (4/5), short term improvement in ACTH was reported in 2/3 
horses. Adverse effects (depression, anorexia, and heart murmur) 
observed in 1 horse treated with compounded pergolide (3.8 μg/kg 





Small descriptive case series treated at/by teaching/referral 
hospitals, and all cases also had concurrent hypertriglyceridaemia 
so results are not likely to be generalisable all PPID cases. Variable 
follow-up duration and in terms of clinical examination findings and 
laboratory analyses reported. Subject to inherent biases affecting 
studies that rely on retrospective review of clinical records.  Severe 
hypertriglyceridaemia can develop secondary to PPID, and 
successful treatment of PPID with pergolide may resolve this 





Froin et al., 1998  
Conference abstract 
Study Design: Case series 
 To study the influence of pergolide treatment on plasma ACTH and 
cortisol values of horses with an adenoma of the pars intermedia 
and control horses. 
Setting: Private referral practice 
Study Population: ACTH and cortisol measured in 42 PPID cases and 55 healthy 
controls.  






Control Group: Not applicable 
Treatment Group: n=5 treated with pergolide (1.7 µg/kg once daily 
per os)  
Outcome 
Measures:  
Treatment response based on clinical signs, ACTH and cortisol 
Main Findings: All treated horses showed clinical improvements, after a minimum 
period of 3 months of pergolide treatment. All horses returned to 
their pre-illness activity level after 3-12 months of treatment. ODST 
results returned to normal in 3, basal cortisol reduced in 1 and 
ACTH reduced in another.  
Interpretation of 
Results: 
Small study, incompletely reported as an abstract, with variable 
laboratory analyses reported for assessing response to treatment.  
No information on case selection reported therefore unable to 
assess selection bias. A further 37 PPID cases identified via 
elevated basal ACTH but no details provided regarding why these 
cases were not treated/followed-up. Overall positive response to 





Gehlen et al., 2014  
Journal publication 
Study Design: Case control study  
Aim/Objective of 
the Study: 
To examine insulin and glucose metabolism in horses with PPID, to 
investigate the effect of pergolide treatment on insulin and glucose 
metabolism and to determine whether pergolide has an effect on 
laminitis by lowering hyperinsulinaemia. 
Setting: Not reported  
Study Population: n=38 PPID cases, diagnosed based on basal ACTH ≥50 pg/mL 
measured in January plus advanced clinical signs of PPID. 
Study population included 17 ponies, 16 Warmbloods, 4 
Thoroughbreds, and 1 draught horse; 22 mares and 16 geldings; 
mean age 24 years (range 16 – 38 years).   
Intervention 
Investigated:  
Control Group: n=25 untreated PPID cases 
Treatment Group: n=13 cases treated with oral pergolide for at 
least 3 months; doses ranged from 0.5-2 mg/day per os  
Outcome 
Measures:  
Insulin, insulin resistance (IR) and ACTH were measured along with 
triglyceride, fructosamine and glucose levels, and number of 
animals with historical laminitis episodes. 
Main Findings: Difference in ACTH levels between pergolide-treated and non-
treated horses not shown but reported as not statistically 
significant, however levels tended to be lower in treated animals. 
Overall, 39.5% (n=15/38) showed alterations of glucose and 
insulin metabolism.  There were no significant differences between 
groups for insulin, glucose, triglyceride, fructosamine or IR and 
these were not different between treated and untreated animals. 
No correlation between glucose metabolism and ACTH levels or 






Stated study aim of determining whether pergolide affects insulin 
and therefore laminitis incidence is not addressed.  Similarly, 
without having assessed insulin and glucose parameters before and 
after pergolide treatment, the study aim of investigate the effect of 
pergolide treatment on insulin and glucose metabolism has not 
been achieved.  
No description of the sampling frame or case selection, precluding 
assessment of selection bias. Selection criteria for pergolide 
treatment not reported. Possible bias towards more severe cases 
receiving pergolide which may have influenced findings. Variable 
doses without bodyweight information also make comparison or 
extrapolation of findings difficult. Provides very limited information 
regarding the effect of pergolide treatment on insulin and glucose 





Horn et al., 2019  
Journal publication 
Study Design: Retrospective cohort study 
Aim/Objective of 
the Study: 
To describe clinical features of PPID at lower southern latitudes in 
Australia and to investigate factors associated with survival, 
laminitis and insulin dysregulation (ID) in equids diagnosed with 
PPID. 
Setting: Eight veterinary institutions in five regions of Australia; 57% of 
PPID cases were first opinion and 43% were referral hospital cases, 
diagnosed between 2002 – 2018  
Study Population: n=274 PPID cases, diagnosed between 2002 and 2018, based on 
basal ACTH (n=263), ODST (n=9), TRH stimulation test (n=12) or 
post mortem examination (n=2).  Reported data indicate a small 
number of cases were diagnosed using >1 of the tests above, but 
no further details provided. ACTH cut-off values adjusted by season 
and location: 
northern Queensland: autumn 101 pg/mL; non-autumn 67 pg/mL 
southern Western Australia: autumn 94 pg/mL; non-autumn 43 
pg/mL 
Tasmania: autumn 75 pg/mL; non-autumn 46 pg/mL 
southern South Australia, Victoria and southern Queensland: 
autumn 77.4 pg/mL; non-autumn 29.7 pg/mL 
Season of diagnosis was spring for 22.3%, summer for 19.0%, 
autumn for 38.5% and winter for 20.1% of cases. 
 
Study population included 48.1% ponies, 12.6% Thoroughbreds, 
10.7% Warmbloods, 9.5% Arabs, and 50 other horse breeds 
(19.1%) (based on 262 cases with breed recorded); 42.0% mares, 
53.3% geldings and 4.7% stallions (based on 255 cases with sex 




71.9% of cases had follow-up information, with duration of follow-
up ranging from 0 – 85 months (median 11 months). Proportion of 
pergolide-treated cases with follow-up data not reported.  
Intervention 
Investigated:  
Control Group: n=29 PPID cases, presumed to be untreated but 
not reported in publication and not clear how many of these cases 
had follow-up  
Treatment Group: n=218 cases treated with oral pergolide; doses 
ranged from 0.5 – 12.5 μg/kg daily per os (median starting dose 2 
μg/kg once daily per os). Where reported (n=119/218 cases), 
45.6% were treated with a liquid formulation of pergolide and 
54.6% were treated with a tablet form. Pergolide dose was 
increased for 61 cases, with final pergolide dose ranging from 0.5 – 
16 μg/kg daily per os (median final dose 2 μg/kg daily per os). The 
proportion of cases treated with a tablet form of pergolide 
increased by the final re-examination (78.1%; n=57/73) compared 
to 21.9% of cases treated with liquid pergolide.  
Outcome 
Measures:  
Laminitis (diagnosed by radiography or histology), insulin 
dysregulation clinical signs, ACTH concentrations and survival. 
Main Findings: 92 pergolide-treated cases (64.3%; denominator not reported but 
calculated as 143 and presumed to represent total number of 
pergolide-treated horses with follow-up data) had veterinary-
reported clinical improvement at re-examination.  Only 1 untreated 
case (6.7%) was reported to have clinical improvement observed 
at re-examination.  
ACTH concentrations were first retested for 62.9% of cases at a 
median of 4 months (range 1 – 6 months), with up to 3 further re-
tests reported for a small proportion of cases, performed at 
decreasing frequency (median 12.5 months between 1st and 2nd 
tests up to median of 25 months between the 3 rd and 4th tests).  Of 
117 pergolide-treated cases, 44.4% had ACTH concentrations 
within reference intervals at repeat testing, compared to 0% of 
untreated cases. However, data presented indicates that not all 
pergolide-treated cases had normal ACTH concentrations at the 
first re-examination, nor across all repeat tests.  
Pergolide treatment was associated with increased odds of survival 




Provides some comparison between pergolide-treated and 
untreated cases. Subject to inherent biases affecting studies that 
rely on retrospective review of clinical records. 28% loss to follow-
up which may introduce bias if not occurring at random. Several 
variables evaluated had moderate-high amount of missing data, 
with only 71 cases included in the final multivariable logistic 
regression model for prediction of survival. Seasonally adjusted 
ACTH cut-off values utilised for PPID case definition were not 
available for the first 10 years of the study period, and may 
therefore differ from diagnostic cut-off values utilised by treating 
veterinary surgeons at the time of case presentation.  Selection 
criteria for pergolide treatment not reported. Possible bias towards 
more severe cases receiving pergolide which may have influenced 
findings. Conversely, more severe cases may have been more likely 
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to be euthanased at the time of, or within short time period 
following, diagnosis. Variable follow-up duration and intervals at 
which laboratory analyses performed.  Duration of pergolide 
treatment prior to veterinary re-examination not reported, 
therefore unable to determine time period over which clinical 
improvement was observed.  Pergolide treatment resulted in 
clinical improvement in in 64% horses, normalisation of ACTH 
concentration in ~44% following treatment and was positively 





Innerå et al., 2013 
Journal publication 
Study Design: Uncontrolled, non-randomised field trial 
Aim/Objective of 
the Study: 
To compare hair follicle stages in PPID-affected horses with 
hypertrichosis with normal aged horses (controls) and to compare 
hair follicle stages in PPID-affected horses after 6 months of 
treatment with pergolide mesylate with those of control horses. 
Setting: University referral hospital and 5 client-owned PPID cases kept at 
home premises 
Study Population:  n=8 PPID-affected horses (5 mares and 3 geldings; mean age 24 
years; range 20-29 years) and n=4 normal, age-matched control 
horses (3 mares and 1 gelding; mean age 25 years; range 21-29 
years).  
PPID cases diagnosed based on hypertrichosis and ODST, and were 
included in study population for pergolide field trial (Anon 2011). 
Control horses had no history of abnormal hair coat or delayed 
shedding and had normal ODST results.  
Intervention 
Investigated:  
Control Group: Not applicable 
Treatment Group: n=8 treated with oral pergolide (2 µg/kg once 
daily per os), and increased to 4 µg/kg once daily for all 8 cases as 
ODST test results remained abnormal after 3 months of treatment. 
Outcome 
Measures:  
Skin biopsy results – the number of hair follicles in anagen (A) or 
telogen (T) was counted using transverse sections, and mean 
percentages of A and T stages of hair follicles in PPID cases post-
treatment with pergolide were calculated. Clinical scoring of 
hypertrichosis (0 = normal, no unusual hair growth; 1 = regional 
hair coat changes, long hair growth restricted to discrete areas; 2 
= generalised hair coat changes (slightly to moderately long hair 
coat that fails to shed out as in previous years); 3 = severe hair 
coat changes (severely long and/or curly hair coat over the entire 
body that fails to shed)). 
Main Findings: Pre-treatment biopsies had a greater percentage of A follicles (neck 
96%, rump 95%) and a lower percentage of T follicles (neck 4%, 
rump 5%) in PPID-affected horses than in control horses (A, neck 
15%, rump 25%; and T, neck 85%, rump 75%).  After 3 months 
of pergolide treatment, PPID cases showed improved attitude, 
decreased sweating, and decreased polyuria and polydipsia, and a 
decreased in median hair coat score from 3 pre-treatment to 2.5.  
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After 6 months treatment with pergolide, 50% of PPID cases had 
normal ODST results, all PPID-affected horses had improved 
shedding, median hair coat score had decreased to 1, and the 
percentages of A follicles (neck 69%, rump 70%) and T follicles 
(neck 31%, rump 30%) were not different from untreated control 




Information on sample selection limited therefore unable to assess 
selection bias. Small sample size. Study gives an objective indicator 
of treatment success un-reliant on owner opinion.  Findings 
indicate excessively long hair coat in horses with advanced PPID is 
a consequence of persistence of hair follicles in the anagen stage.  
Treatment with pergolide improved hair coat shedding and reduced 
the percentage of anagen follicles in PPID-affected horses, and 






Love 1993  
Journal publication 
Study Design: Case series  
Aim/Objective of 
the Study: 
To describe clinical presentation and outcome following treatment 
in 5 PPID cases.   
Setting: University referral hospital 
Study Population: n=5 PPID cases; age range 13 – 34 years; all British native breed 
ponies referred to Glasgow University during a 2 year period 
starting in January 1990. PPID diagnosed based on TRH stimulation 
test measuring cortisol.  
Intervention 
Investigated:  
Control Group: n=1 untreated; n=4 treated with oral 
cyproheptadine (incremental increased dose from 0.6 mg/kg0.75 to 
1.2 mg/kg0.75) 
Treatment Group: n=1 treated with oral pergolide; following poor 
results with cyproheptadine treatment and 2 ponies being 
euthanased, 1 of the remaining 2 treated ponies was subsequently 
treated with oral pergolide (3mg daily for 6 weeks, 1mg daily for 6 




Main Findings: Five ponies were diagnosed with PPID.  Four of the 5 ponies were 
treated with cyproheptadine with a satisfactory response in only 
one pony.  One pony was treated with pergolide after unsuccessful 
treatment with cyproheptadine and showed marked clinical 
improvement after 3 weeks, which was sustained during 6 months 
of follow-up. Temporary anorexia (10 day duration) was noted 
after initiation of pergolide treatment in this animal, but improved 




No information on case selection reported therefore unable to 
assess selection bias. Small sample size from referral hospital 
population. Single pony treated successfully with pergolide after 
treatment failure with cyproheptadine.  Temporary anorexia in one 







McFarlane et al., 2017 
Journal publication 
Study Design: Uncontrolled, non-randomised clinical trial 
Aim/Objective of 
the Study: 
To evaluate the pharmacokinetic and pharmacodynamic properties 
of pergolide in horses with PPID after long-term oral 
administration. 
Setting: University referral hospital research herd 
Study Population:  n=6 PPID cases (mean age 24.3 years; range 18 – 28 years; 3 
geldings and 3 mares; 3 Quarter Horses, 2 Tennessee Walking 
Horses and 1 Standardbred cross). 




Control Group: Not applicable 
Treatment Group: n=6 treated with oral pergolide once daily: 1 
mg/day per horse (~0.002 mg/kg/day) for 2 months and then 2 
mg/day per horse (~ 0.004 mg/kg/day) for an additional 4 months. 




Steady-state pharmacokinetic properties of pergolide in PPID cases 
and duration of ACTH regulation and duration of quantifiable drug 
in the plasma of horses after discontinuation of pergolide following 
long-term administration. 
Main Findings: After discontinuing treatment, pergolide could be quantified in 
plasma for 2-7 days and ACTH levels significantly increased in all 
horses after 14 days following cessation of treatment. Basal (but 
not TRH stimulated) ACTH concentration was significantly lower at 
weeks 16, 20, and 24 after initiation of pergolide treatment 
compared to pre-treatment values. After 2 months of the initial 
dose, ACTH levels in all horses were above the reference interval 
and ACTH concentration remained above the seasonal reference 
interval (>100 pg/mL) in all horses after a subsequent increase in 




Information on sample selection limited therefore unable to assess 
selection bias. Small sample size with no comparison group. 
Pergolide effectively decreased ACTH concentration in all horses, 
though not to within seasonally adjusted reference intervals. After 
discontinuing pergolide treatment, ACTH concentration increased 
by 50% in 3/6 horses by 2 days and 6/6 horses by 10 days. 
Pergolide was detectable in all horses at 2 days and in none at 10 
days after the last dose. Results support once daily dosing with 





Orth et al., 1982  
Journal publication 





To study plasma concentrations of pro-OLMC peptides in 10 normal 
horses under basal conditions and in 2 PPID cases under basal 
conditions, during various tests of pituitary-adrenal function, and 
after the administration of dopamine and dopaminergic agonists. 
Setting: Not stated 
Study Population:  n=10 normal control horses  
n= 2 PPID cases 
Case 1: 7-year-old mare with clinical signs consistent with 
advanced PPID. Blood tests were performed, and the horse was 
then euthanased because no effective treatment was available.  
Post mortem revealed a pars intermedia adenoma and hyperplastic 
adrenal glands. 
Case 2: 12-year-old mixed breed pony mare with clinical signs of 
PPID, including laminitis. Blood tests were performed, and the pony 
was successfully treated (therapy not specified).  
Laboratory tests performed in PPID cases included cortisol, ACTH, 
and other pro-OLMC peptides including αMSH, βMSH, 
corticotrophin-like intermediate lobe peptide [CLIP], β-lipotropin [β-
LPH], and β-endorphin), low and high dose dexamethasone 
suppression tests, ACTH stimulation, glucose tolerance, and insulin 
tolerance. Additional tests performed in Case 2 included the 
response of plasma cortisol and pituitary peptides to insulin, 
vasopressin, dopamine-HCL, bromocriptine, or pergolide mesylate. 
Normal horses:  a single blood sample was taken between 8 and 10 






Control Group: Not applicable  
Treatment Group: n=1 PPID case 
• Intravenous dopamine hydrochloride, 4 μg/kg/min for 150 
minutes 
• Oral and subcutaneous bromocriptine, 100 mg total dose 
(dissolved in 2ml 40% ethanol) 
• Oral pergolide mesylate, 5 mg total dose alone and in 
combination with dexamethasone (capsule form of pergolide 
provided by Eli Lilly) 
Outcome 
Measures:  
Pro-OLMC peptides basally and in response to standard tests of 
pituitary-adrenal function. 
Main Findings: Both PPID cases had elevated basal and pro-OLMC peptides were 
disproportionately increased.  Both PPID cases were glucose 
intolerant. Agents that affect secretion from the pars distalis 
(glucocorticoids, vasopressin and hypoglycaemia) had little or no 
effect on pro-OLMC secretion. Dopamine and dopamine agonists 
(bromocriptine, pergolide) inhibited pro-OLMC secretion from the 
pars intermedia in a single PPID case.  Dopamine caused a rapid 
fall in hormone levels. Bromocriptine and pergolide caused rapid 




Only included 2 PPID cases with very advanced disease and 
concurrent insulin resistance.  Pharmacological intervention study 
on a single case of PPID provided details of the endocrinological 
effect and duration of action of pergolide. Pergolide mesylate (5 
mg, 0.014 mg/kg) was compared to dopamine and bromocriptine 
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and was found superior due to prolonged duration of action and 
ease of administration. There were clear and marked reductions in 
ACTH, α-MSH, β-endorphin and CLIP for 48 hours following a single 





Pease et al., 2011  
Journal publication 
Study Design: Case control study  
Aim/Objective of 
the Study: 
To determine whether pituitary glands of PPID-affected horses are 
larger than those of aged horses without signs of PPID, whether 
the size difference can be detected using computed tomography 
(CT) imaging and whether pituitary gland size decreased in subset 
PPID cases after treatment with pergolide. 
Setting: University referral hospital research herd 
Study Population:  n=8 PPID cases (mean age 24 ± 4 years; range 18-28 years).  
PPID diagnosed based on hypertrichosis and ODST.  
n=3 aged control (PPID negative) horses (mean 24 ± 5 years; 
range 20-29 years). Computed tomography (CT) imaging twice 6 




Control Group: n=2 untreated PPID cases  
Treatment Group: n=6 PPID cases treated with oral pergolide: 1 
mg/day per os for 6 months (~ 2.3 µg/kg/day based on mean 
weight of 435kg); increased to 2 mg/day for 3 horses after 3 
months due to ODST results remaining abnormal.  
Outcome 
Measures:  
Pituitary gland height, width, length, weight, response to treatment 
with pergolide. 
Main Findings: On initial examination, pituitary glands of PPID horses were larger 
in height (p<0.002) and width (p<0.01) than controls, but the 
difference in length was not significant (p=0.06).  
After 6 months of pergolide treatment of PPID horses, pituitary 
gland length increased (p<0.03), but height and width were not 
different from pre-treatment values. All 6 pergolide-treated horses 
showed clinical improvement (less lethargy, improved hair coat 
shedding and weight gain) after 3 months, and ODST results were 
normal in 3/6 horses.  
After 6 months of pergolide treatment, improved shedding of hair 
coat was observed in all treated horses, although 1 horse with a 
history of chronic laminitis had an exacerbation of laminitis when 
spring pasture became available.  ODST results were normal in 3 
horses after 6 months, including 2 horses that had not been normal 
at 3 months. One of the non-treated PPID horses remained fairly 
healthy (with persistent hypertrichosis) during the 6-month study 
period, whereas the other horse had exacerbations of chronic 
laminitis and developed fungal keratitis prompting unilateral 





Sample selection likely to introduce bias, and small sample size. 
Selection criteria for pergolide treatment not reported. ODST 
follow-up at 6 months was in August-September and likely to be 
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affected by season. Relevance of CT findings to clinical practice 
limited, but study showed CT may be a useful imaging modality to 
determine pituitary gland size of PPID-affected horses if facilities 
for contrast enhancement and general anaesthesia are available.  
Treatment with pergolide does not affect pituitary gland size, but 
resulted in improvement in ≥1 clinical sign in all cases and 5/6 





Perkins et al., 2002  
Journal publication 
Study Design: Retrospective cohort study 
Aim/Objective of 
the Study: 
To determine the value of monitoring plasma ACTH levels during 
treatment of PPID with either cyproheptadine or pergolide. 
Setting: New York State Diagnostic Laboratory 
Study Population:  Questionnaire survey sent to submitting veterinary surgeon where 
horses had ACTH >35 pg/mL.  Duration of follow-up: median time 
was 2 months (1-15 month range) between baseline and first 
recheck, and between first recheck and second recheck. 
Intervention 
Investigated:  
Control Group: n=32 PPID cases treated with cyproheptadine (23 
horses and 9 ponies): n=5 on 225-250 mg/day (either 0.5 mg/kg 
once daily or 0.25 mg/kg every 12 hours) and n=27 on 450-500 
mg/day  
Treatment Group: n= 10 PPID cases treated with pergolide (7 
horses and 3 ponies): 
n=7 on 0.75-1.0 mg/day (~0.0017 mg/kg/day once daily per os); 
n=1 on 1.5-2mg/day and n=2 on 0.38-0.5mg/day.  
Outcome 
Measures:  
ACTH and clinical improvement based on survey of veterinary 
surgeons 
Main Findings: Overall including both treatment group, ACTH decreased 
significantly from baseline to first recheck in all PPID cases, but not 
between first and second rechecks. 90% of pergolide and 81% of 
cyproheptadine treated horses had an improvement in ≥1 clinical 
sign. 90% of pergolide-treated horses presented with 
hypertrichosis, and of these 44% (n=4/9) showed an improvement 
after treatment.  Decreases in ACTH were associated with 
improvements in hypertrichosis.  Pergolide-treated horses showed 
normalisation to within reference interval for ACTH at first recheck 
in 10% of horses and 40% at second recheck.  Improvement (but 
not normalisation) in ACTH was seen in 60% of horses at first and 




Major limitation is that study is based on laboratory sample data 
and the authors did not examine the horses, but relied on 
veterinary-reported questionnaire data. Subject to inherent biases 
affecting retrospective studies and where data not accurately 
recorded in clinical records, there may be recall bias.  No indication 
of vet response rate is provided. 
Results are presented as percentage of horses with decreases in 
ACTH and so limit the ability to interpret the statistics.  Seasonality 
is not taken into consideration and will have affected the results.  
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Pergolide treatment resulted in improvement in at least one clinical 






Peters et al., 1995  
Journal publication  
Study Design: Case series 
Setting: Private practice 
Aim/Objective of 
the Study: 
To assess the efficacy of low-dose pergolide therapy in horses and 
ponies with adenomas of the pituitary gland. 
Study Population: n=9 PPID cases; 5 horses (age range 18 – 32 years) and 4 ponies 
(age range 16 – 30 years). Cases presented between May 1993 
and April 1995 for evaluation of clinical signs indicative of PPID. 
PPID diagnosed based on ODST. 
Intervention 
Investigated:  
Control Group: Not applicable 
Treatment Group: n=9 PPID cases treated with oral pergolide 
(Permax® tablets) at 0.0017 mg/kg a day (1.7 μg/kg), divided to 
be administered twice daily.  Average duration of treatment 13.6 
months (range 1 – 23 months). 
Outcome 
Measures:  
Clinical signs and ODST  
Main Findings: Eight of nine horses (88.9%) showed clinical improvement within 
14 to 35 days (average 22.75 days), and seven of those had 
ongoing improvement for 5 to 52 weeks (average 21 weeks; after 
which response to treatment appeared to stabilise). 
ODST showed improvement in 5 of 7 horses (71.5%) in 1.75-4.5 
months (average 3.05 months); normalisation in ODST in 2 of 7 
horses (28.6%). Hyperglycemia resolved in all 5 horses/ponies that 
presented with elevated glucose at baseline. 
Two of three horses presenting with laminitis were reported to be 
markedly improved within 2 weeks after pergolide treatment 
started.  One horse showed no clinical improvement but did show 





No information regarding case selection therefore unable to assess 
selection bias. Small sample size with no comparison group. 
Monitoring was by owners and not by veterinary surgeons, for an 
average time of 13.6 months (range 1 – 23 months); therefore 
potential for introduced biases/errors from owner-reported data.  
Clinical signs improved in 8/9 (89%) and 5/7 horses showed 
improvement of the ODST.  Several other clinicopathological or 
endocrinological variables improved in the majority of cases. 
Improvements occurred in a time frame of 2 – 5 weeks.  The 
authors report favourable clinical results and lack of side effects at 









Study Design: Retrospective cohort study  
Aim/Objective of 
the Study: 
To evaluate the long-term effects of pergolide therapy in PPID 
cases by surveying owners using a questionnaire.  
Setting: 19 PPID cases from University referral hospitals and 19 from first 
opinion vets in Switzerland 
Study Population: n=38 PPID cases, diagnosed between 1999 – 2009. PPID 
diagnosed by ODST (n=13/38), elevated plasma ACTH (n=20/38) 
or both tests (n=4/38). One horse was diagnosed solely on the 
basis of clinical signs. Mean age 22 years (range 13-36 years); 22 




Control Group: Not applicable 
Treatment Group: n=38 treated with oral pergolide; 0.001 – 0.002 
mg/kg per os once daily (n=23 on 0.001mg/kg and n=11 on 0.002 
mg/kg; dose not reported for other 4 cases). 
Outcome 
Measures:  
Owner-reported questionnaire data on clinical signs 
Main Findings: Clinical improvement reported for 88.6% of cases (n=31/35). 
Improvement in clinical signs noted by owners after starting 
pergolide treatment within 1-2 weeks (18.4%; n=7/38); within 2-4 
weeks (47.4%; n=18/38) or after 8 weeks (21.1%; n=8/38).  
Following pergolide treatment, prevalence was significantly lower 
(all p<0.05) for hypertrichosis (before 86.5%, n=33/38; after 
23.7%, n=9/38), hyperhidrosis (before 63.2%, n=24/38; after 
18.4%, n=7/38), poor performance (before 55.3%, n=21/38; after 
79%, n=3/38), lethargy (before 57.9%, n=22/38; after 7.9%, 
n=3/38), polyuria/polydipsia (before 39.5%, n=15/38; after 
13.2%, n=5/38), muscular atrophy/lordosis (before 50.0%, 
n=19/38; after 28.9%, n=11/38), weight loss (before 34.2%, 
n=13/38; after 10.5%, n=4/38), fat redistribution (before 36.8%, 
n=14/38; after 7.9%, n=3/38), ataxia (before 28.9%, n=11/38; 
after 7.9%, n=3/38), skin infections (before 26.3%, n=10/38; after 
10.5%, n=4/38) and laminitis (before 39.5%, n=15/38; after 
7.9%, n=3/38; 12/15 cases with previous history of laminitis had 
no further reported episodes following commencement of pergolide 
treatment).   
Average duration of treatment was 13.8 months (range 1 – 38 
months).  
90% of owners (n=34/38) were extremely satisfied with pergolide 
treatment. 
Adverse effects were reported in 28.9% of cases (n=11/38); most 
frequently anorexia (15.8%, n=6/38), lethargy (10.5%, n=4/38), 
and diarrhoea (5.3%, n=2/38), and 73.3% of affected horses 
(n=8/11) showed adverse effects within the first 4 weeks of 
treatment. All adverse effects were self-limiting with a constant 
daily dosage, with the exception of 1 case where pergolide dose 




Relied on owner-reported health data.  May be subject to selection, 
response and recall biases (variable and long time period between 
diagnosis and data collection, e.g. 5/38 cases diagnosed >6 years 
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previous to completion of questionnaire).  Moderate owner 
response rate – no comparison with non-responders, and very low 
veterinary response rate (8%), though unclear which data were 
veterinary-reported.  The vast majority of owners were satisfied 
with pergolide treatment, and clinical improvement was observed 





Rendle et al., 2013  
Conference abstract  
Study Design: Retrospective cohort study 
Aim/Objective of 
the Study: 
To evaluate ACTH response in horses treated with pergolide and to 
investigate factors that may influence response to treatment. 
Setting: Records of submissions to a single private practice diagnostic 
laboratory (The Liphook Equine Hospital Laboratory) 
Study Population:  n=2,122 PPID cases 
Laboratory records reviewed for cases in which ACTH concentration 
was measured before and after instigation of pergolide treatment 
between January 2007 and December 2012. 
Intervention 
Investigated: 
Control Group: Not applicable 
Treatment Group: all PPID cases where pergolide was commenced 
after PPID diagnosis; no details of dose presented.  
Outcome 
Measures:  
Reduction of ACTH concentration of ≥75%, or a return of ACTH 
concentration to within seasonally adjusted reference intervals. 
Main Findings: At the first follow-up, improvement in ACTH was identified in 
54.8% of cases and return of ACTH concentration to within 
seasonal adjusted reference intervals was identified in 28% of 
cases. Equids with a higher ACTH concentration pre-treatment with 
pergolide were more likely to improve (odds ratio [OR] 1.01, 95% 
CI 1.00-1.02; p=0.03), but less likely to return to within the 
reference interval (OR 0.97; 95% CI 0.96–0.98; p<0.001).  Older 
equids were less likely to improve (OR 0.56, 95% CI 0.46-0.67; 
p<0.001). Improvement was more likely after a cumulative 
pergolide dose of 50 mg (OR 1.59, 95% CI 1.10-2.29; p=0.01) and 
duration of treatment was positively associated with treatment 
response (p=0.04).  A daily dose of >0.5 μg/kg was less likely to 
be associated with a reduction in ACTH concentration (OR 0.86, 




Major limitation is that study is based on laboratory sample data 
and the authors did not examine the horses, but relied on clinical 
data recorded on laboratory submission forms. Subject to inherent 
biases affecting retrospective studies.  Unclear as to how 
cumulative and estimated daily pergolide dose were calculated.  
Results show pergolide treatment is effective in reducing ACTH in 
the majority of PPID cases, although degree of improvement may 





Rendle et al., 2018  
Conference abstract  
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Study Design: Retrospective cohort study 
Aim/Objective of 
the Study: 
To assess the efficacy of a palatable pergolide paste in PPID cases 
considered to be refractory to treatment with a licensed pergolide 
tablet formulation. 
Setting: Not reported 
Study Population:  n=19 PPID cases 
PPID cases selected for inclusion based on history of being 
refractory to treat with a licensed pergolide tablet formulation.   
Retrospective review of clinical records of 19 ponies with clinical 
signs of PPID and ACTH concentration >50 pg/mL in July (10 
ponies) or >100 pg/mL from August to October (9 ponies). All 
ponies were re-examined after 1 month of treatment, in October, 
November and after 6 months of treatment. 
Intervention 
Investigated: 
Control Group: Not applicable  
Treatment Group: n=19 administered palatable pergolide paste; 
dose not reported 
Outcome 
Measures:  
Clinical signs, ACTH and insulin concentrations 
Main Findings: Median ACTH decreased significantly following treatment with the 
pergolide paste (from 206 pg/mL to 25 pg/mL in autumn cases, 
and from 110 pg/mL to 37 pg/mL in non-autumn cases). ACTH 
concentrations returned to within seasonally adjusted reference 
intervals for 74% of cases (n=14/19). No significant difference in 
insulin concentration observed following treatment. Not possible to 
interpret improvement in clinical signs following treatment: abstract 
states “clinical signs improved markedly, mildly, did not improve or 
deteriorated in 31%, 12%, 43%, 4% and 10%, respectively” – the 
number of categories does not correspond to the number of 
proportions reported, therefore unable to determine which 
proportion relates to which category. Inappetence was reported in 




Limited information provided in conference abstract. Limited 
information regarding case selection, therefore unable to assess 
selection bias: ponies appear to have been recruited from private 
practice(s) although this is not stated.  Small sample size. Subject 
to inherent biases affecting studies that rely on retrospective 
review of clinical records. Reasonable duration of follow-up, 
however information on dosing not reported. ACTH concentration 
improved significantly to within reference ranges in the majority of 
ponies. It is not possible to determine improvement in clinical signs 





Rohrbach et al., 2012  
Journal publication 
Study Design: Retrospective cohort study 
Aim/Objective of 
the Study: 
To identify trends in the diagnosis of PPID in horses presented to 
veterinary teaching hospitals and to identify clinical and laboratory 
factors associated with long-term prognosis, client perception of 
treatment, and quality of life in a subset of PPID cases. 
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Setting: Veterinary teaching hospitals  
Study Population:  Recorded diagnoses of PPID or synonym retrieved from database 
for 15 veterinary teaching hospitals from 1st January 1993 to 30th 
June 2004: 217 PPID cases identified, plus further 14 cases from 
clinical records at another University veterinary referral hospital. 
n=44 PPID cases meeting inclusion criteria, of which 34 cases had 
follow-up. Mean age of PPID cases at diagnosis 21.6 ± 6.6 years 
(n=36), 28 geldings and 16 mares; 35 horses and 9 ponies. Most 
frequent method of PPID diagnosis was by presence of 
hypertrichosis only in 15 (34%), and by hypertrichosis and ODST 
test results in 10 (23%) of cases. 
Intervention 
Investigated:  
Control Group: Not applicable 
Treatment Group: Treatments administered after diagnosis were 
available for 34/44 (77%) of study horses. Pergolide was given to 
16/34 (47%), cyproheptadine to 12/34 (35%), and both pergolide 
and cyproheptadine to 6/34 (18%). 
Outcome 
Measures:  
Owner based telephone follow-up over 6 month period from July to 
December 2004. For owner-reported clinical response, a positive 
response to treatment was defined as improvement in ≥ 1clinical 
sign at 2 months post-treatment without an increase in severity for 
any other signs exhibited at presentation. 
Main Findings: Across all participating veterinary teaching hospitals, proportional 
diagnoses of PPID increased from 0.25/1,000 hospital records in 
1993 to 3.7/1,000 in 2002. 
For the majority of horses, clinical signs did not change over the 
first 2 months post-treatment. Owners providing information on 
type of treatment and response to treatment at 2 months (n=22) 
reported positive response rates of 40% for pergolide (n=4/10) 
and 29% for cyproheptadine (n=2/7), whereas 3/5 (60%) of 
horses treated with both drugs had a positive response. Clinical 
signs and clinicopathological data were not associated with 




Significant loss to follow-up, even though study used a small 
convenience sample – likely to have introduced bias.  Majority of 
results presented relied on owner-reported health data.  Case 
selection for follow-up poorly described. May be subject to 
selection, response and recall biases (variable and long time period 
(6 months – 12 years) between diagnosis and data collection).  
PPID cases presented to veterinary teaching hospitals may not 
represent cases in the field.  Small sample size of animals treated 
solely with pergolide.  Pergolide had a better owner-reported 
outcome after 2 months of treatment than cyproheptadine, and the 
proportion of treated cases with clinical improvement was even 
greater when pergolide used in combination with cyproheptadine, 
but very small numbers and no direct comparison between 
treatment groups presented (though discussion section mentions 
difference between groups not statistically significant).   
 






Study Design: Uncontrolled, non-randomised field trial 
Aim/Objective of 
the Study: 
To compare clinical and/or endocrine responses in horses with PPID 
that are treated with cyproheptadine, pergolide, or not treated. 
Setting: Collaboration between a University referral hospital and local 
veterinarians 
Study Population:  Horses with naturally occurring PPID presented to Michigan 
veterinary surgeons and enrolled in this field study administered by 
Michigan State University from 1997 to 1999. Enrollment criteria 
included clinical signs and diagnostic low-dose ODST or TRH 
stimulation test (measuring cortisol). 
n=77 PPID cases enrolled; mean age 22.8 years (range 12–34 
years); most numerous breeds were Crossbreds (n=16), ponies 
(n=15), Morgan (n=14), Quarter Horse (n=8), Arab (n=7), and 
Thoroughbred (n=4); 37 (48%) mares, 38 (49%) geldings, and 2 
(3%) stallions.  Follow-up evaluations undertaken at 6 to 12 




Control Group: n=5 PPID cases receiving no treatment  
Treatment Group:  
Treatment group 1: n=20 PPID cases administered oral pergolide, 
2 μg/kg once daily  
Treatment group 2: n=7 PPID cases administered oral 
cyproheptadine, 1.2 mg/kg once daily 
Outcome 
Measures:  
Clinical signs and endocrine testing 
Main Findings: Clinical improvement was reported more often with pergolide 
treatment compared with cyproheptadine.  Normal ODST and TRH 
stimulation results were found in more horses treated with 
pergolide (35%; n=7/20) than in horses treated with 
cyproheptadine (14%; n=1/7) or no treatment (20%; n=1/5) 
(p<0.05).  Mean concentrations for ACTH and insulin decreased 
significantly after 6-12 months of pergolide treatment (p<0.05) in 
contrast to a lack of significant changes for cyproheptadine and no 
treatment groups. There was no significant difference between 
cyproheptadine-treated and untreated horses in proportion of cases 
with normalisation of ODST and TRH.  Decreased appetite was 
seen in some pergolide-treated horses during the first week of 




No information on case selection reported therefore unable to 
assess selection bias. No information provided regarding case 
selection for treatment, and allocation to treatment group was not 
randomised. There was substantial drop-out from the trial (58% of 
enrolled animals failed to complete the trial), which was 
unaccounted for and may bias the results towards positive 
outcomes. Results show that pergolide, at a dose rate of 0.002 
mg/kg/day, was superior to cyproheptadine in alleviating clinical 
signs and improving endocrine test results and that side-effects 







Schott et al., 2014  
Conference abstract 
Study Design: Retrospective cohort study 
Aim/Objective of 
the Study: 
To document long-term (>5 year) treatment response to pergolide 
in PPID cases. 
Setting: University referral hospital 
Study Population: n=30 PPID cases; diagnosed based on ODST or elevated ACTH 
(>50 pg/mL) during 2008-2009. Follow-up evaluations undertaken 




Control Group: Not applicable  
Treatment Group: n=30 PPID cases administered oral pergolide, 2 
μg/kg once daily. Pergolide dose was increased to 4 μg/kg/day 
when endocrine test results remained abnormal.  
Outcome 
Measures:  
Clinical signs and endocrine testing 
Main Findings: 40% of cases survived >5 years (47% were euthanased, of which 
3/14 due to chronic laminitis and 13% died during the study).  All 
owners of surviving cases (n=12) remained satisfied with clinical 
improvement, and 4/12 cases (33%) remained on the starting 
pergolide dose (2 μg/kg once daily).  At last follow-up, ACTH 
concentration was normal (<50 pg/mL) in 71% of cases and ODST 




No information on case selection reported therefore unable to 
assess selection bias.  Small sample size, and based on referral 
hospital population. Did not appear to use seasonally adjusted 
reference interval for ACTH. Long-term treatment with pergolide 
resulted in clinical improvement, normalisation of endocrine test 





Sgorbini et al., 2004  
Journal publication 
Study Design: Case series 
Aim/Objective of 
the Study: 
To describe clinical presentation and outcome following treatment 
in 2 PPID cases.   
Setting: University hospital (assumed not stated) 
Study Population: n=2 PPID cases; diagnosed based on elevated basal ACTH, plus 




Control Group: Not applicable 
Treatment Group: n=2 
Oral pergolide mesylate (Nopar® tablets), initial dose of 0.5 mg 
total dose every twenty-four hours, gradually increased by 0.5 mg 
every three days to a final total dosage of 3 mg once daily. Dose 
increased to 4 mg/day after 1 month in case 2 due to lack of 





Clinical signs and ACTH 
Main Findings: • Case 1: 18 year old Italian saddle horse mare. History of chronic 
recurrent laminitis, infertility, progressive hypertrichosis, 
hyperhidrosis, pendulous abdomen, lethargy, polyuria, polydipsia, 
and anorexia. Presented with a fever and increased respiratory 
rate. Blood work showed hyperglycemia, hyposthenuria, 
hyperinsulinemia, and elevated plasma ACTH.  Clinical signs 
resolved and ovarian activity resumed with 6 to 7 weeks of 
pergolide treatment. ACTH dropped from 155 pg/mL to 26.8 pg/mL 
after 45 days and 27.7 pg/mL after 14 months of treatment. 
 
• Case 2: 25 year old French saddle horse mare with recurrent 
laminitis, hypertrichosis, pendulous abdomen, bulging supraorbital 
fat pads, severe polyuria and polydipsia, and a plasma ACTH of 370 
pg/mL.  There was no response to 3 mg of pergolide daily for one 
month. The dose was increased to 4 mg total dose per day and 
clinical signs were resolved with 6 weeks. ACTH dropped to 91.9 
pg/mL at 2 months and to 59.1 pg/mL after 4 months of treatment. 





No information on case selection reported therefore unable to 
assess selection bias. Small sample size from unknown population, 
with both showing advanced clinical signs of PPID. Pergolide doses 
were 3 and 4 mg for each case respectively. Improvement in 
clinical signs, including a return of cyclic activity in one mare where 
this had been a problem, and ACTH (normalisation for one case 
and improvement by >50% in the other) within 6-8 weeks of 
pergolide treatment.  No adverse events observed after 14 months 





Spelta and Axon 2012  
Journal publication 
Study Design: Case series 
Aim/Objective of 
the Study: 
To describe clinical signs exhibited by PPID cases in the hot, humid 
conditions of a tropical climate and their response to treatment. 
Setting: First opinion practice 
Study Population: n=11 PPID cases (23 diagnosed with PPID from 2002-2010; 
however 12 cases were not available for follow-up).  Cases 
comprised 4 light horse breeds and 7 ponies, age range 9 – 30 
years; 5 mares and 6 geldings. 
PPID diagnosed based on ODST and clinical signs in 8 cases; 




Control Group: No treatment (n=4) 
Treatment Group: n=7 PPID cases treated with oral pergolide 
mesylate (Permax®) at an initial dosage of 0.001 mg/kg/day with 
incremental increases of 0.001 mg/kg/day every 3-8 weeks until 





Improvement of clinical signs and ODST (if treated). Clinical 
stabilisation defined as resolution of all clinical signs and included 
an improvement of lameness to an Obel laminitis grade 0–1, with 
no requirement for non-steroidal anti-inflammatory drugs; and 
active hair coat shedding in spring or appropriate hair coat growth 
in the winter while on treatment. 
Main Findings: Improvement of clinical signs in all pergolide-treated horses within 
8 – 43 weeks (however results table indicates clinical resolution in 
2 – 27 weeks, excluding the relapsing case). Resolution of clinical 
signs, including hair coat shedding, was longer (20-30 weeks) 
when treatment was started in autumn and winter (4 cases) than 
when treatment started in spring or summer (2-8 weeks; 3 cases).  
All 5 cases presenting with anhidrosis, heat stress and/or secondary 
exercise intolerance that were treated with pergolide had resolution 
of these clinical signs.  One PPID case maintained on 0.014 
mg/kg/day of pergolide failed to shed winter coat and had a 
recurrence of sinusitis after 14 months; therefore dose of pergolide 
was increased to 0.0023 mg/kg/day, which resulted in clinical 
resolution. One pony had a normal ODST result when treated with 
pergolide at 0.0015 mg/kg/day, but did not shed its coat, although 
hair coat shedding was achieved when the dose was increased to 
0.0022 mg/kg/day. Unable to determine improvement in ODST 
results following pergolide treatment as text description of case 
numbers that had repeat ODSTs does not reconcile with data 
presented in results table.  
Four cases were managed with improved husbandry alone 
(untreated control group), which only resulted in weight 
stabilisation. There was no improvement in dorsum muscle atrophy, 
fat pad deposition, anhidrosis or heat stress with secondary 
exercise intolerance. Two untreated horses were euthanased 
because of severe heat stress and associated secondary exercise 




No information on case selection reported therefore unable to 
assess selection bias. Small sample size. No information provided 
regarding nature and duration of follow-up period (presumed to be 
based on clinical records). 3 of 11 cases lost to follow-up after 2-5 
years, and outcome for other cases reported from 1-7 years after 
diagnosis. Systematic bias in that 3 of the 4 untreated horses did 
not have a diagnostic test and had presumptive diagnosis based on 
overt hypertrichosis. No adverse events observed with pergolide 






Walsh et al., 2009  
Journal publication 
Study Design: Case series 
Aim/Objective of 
the Study: 
To determine whether insulin concentration is correlated with 
severity of clinical laminitis in horses with EMS or PPID and to 
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determine how rapidly pergolide treatment reduces circulating 
ACTH in horses with PPID. 
Setting: First opinion practice 
Study Population:  25 horses were included from December 2004 to May 2007 and 
assigned to one of three groups:  
n=6 PPID; diagnosed based on basal plasma ACTH >70 pg/mL 
(laboratory reference interval 9-35 pg/mL); mean age 28.5 ± 8.14 
years 
n=10 EMS; diagnosed based on normal ACTH and plasma insulin 
>70 mIU/mL (laboratory reference interval 10-30 mlU/mL); mean 
age 15.5 ± 5.11 years 
n=9 controls; with no history of laminitis and plasma ACTH and 
insulin within normal reference intervals; mean age 12 ± 7.6 years  
Blood samples were collected at an initial visit, and then at regular 
intervals for the next 12 months. Plasma values for ACTH, cortisol 
and insulin and serum values for glucose and total thyroxine (T4) 
were obtained. 
Follow-up 2.5 years 
Intervention 
Investigated:  
Control Group: Not applicable 
Treatment Group: n=6 PPID cases (4 horses; 2 ponies); oral 
pergolide, 1 mg orally daily 
The 2 ponies in the PPID group died after 2 months, and a 
complete dataset was available for only 3 pergolide-treated horses. 
Outcome 
Measures:  
Clinical signs and ACTH concentration 
Main Findings: After treatment with pergolide, mean ACTH concentration of the 
PPID group decreased within one week from >120 pg/mL to ~ 70 
pg/mL where it remained for the rest of the study, except the 
autumn where a seasonal peak was observed. Mean baseline 
plasma insulin concentration was not different between EMS (53.0 
± 16.3 mlU/mL) and PPID cases (52.0 ± 21.6 mlU/mL). Including 
both EMS and PPID cases, there was a significant correlation 





Small sample size. Data regarding number of cases meeting 
inclusion criteria but not enrolled in study are not reported, 
therefore unable to assess selection bias. Results of this field-based 
study showed improvement in PPID cases treated with pergolide (1 
mg orally daily), with ACTH decreasing within 1 week of 
commencing treatment; however, complete data were available for 
only 3 pergolide-treated horses. Limited data available on 
improvement of clinical signs other than laminitis. Statistical 
significance for decrease in ACTH was unlikely to be achieved due 
to the low power of the study (due to lack of numbers and high 
variation of plasma ACTH concentration), but the raw data 









Study Design: Case series  
Aim/Objective of 
the Study: 
To evaluate the effect of long-term treatment with oral pergolide in 
PPID cases. 
Setting: University referral hospital 
Study Population: n=6 PPID cases; diagnosed based on ODST was used to evaluate 
PPID and treatment efficacy.   
Intervention 
Investigated:  
Control Group: Not applicable 
Treatment Group: n=6 PPID cases treated with oral pergolide 
mesylate at 1.8 to 2.8 µg/kg/day for 6 to 26 months 
Outcome 
Measures:  
Clinical signs and ODST. 
Pituitary gland mass was evaluated in two horses: one by magnetic 
resonance imaging and one at post mortem. 
Main Findings: All 6 horses responded to pergolide treatment, as measured by 
improvement in clinical signs and ODST, without a need to increase 
the dose of pergolide over the follow-up period.  Improvements in 
clinical signs were seen before improvement in ODST in 2 of the 6 




Very limited information provided in conference abstract. No 
information on case selection reported therefore unable to assess 
selection bias. Small sample size. Reported that pergolide can be 
effective for extended periods (>2 years) at these doses without a 
need to increase the dose. No side effects reported.  Clinical signs 





Williams 1995  
Conference abstract 
Study Design: Case control study 
Aim/Objective of 
the Study: 
To describe clinical presentation and outcome following treatment 
in 14 PPID cases.   
Setting: Private practice (first opinion and referral hospital; however not 
stated as to whether cases recruited from first opinion, referral or 
both) 
Study Population:  n=23 PPID cases (24 in title); diagnosis of PPID by TRH stimulation 
and clinical signs.  
Treated for up to 3.5 years 
Intervention 
Investigated:  
Control Group: n=9 untreated PPID cases 
Treatment Group: n=14 treated with one or more of: 
Cyproheptadine (Periactin), dose not specified  
Low dose oral pergolide (Celance® tablets) maximum of 1 to 2 mg 
total dose per day 
High dose oral pergolide (Celance® tablets) maximum of 4 to 5 mg 
total dose per day   
Outcome 
Measures:  
Treatment response was evaluated by resolution of clinical signs 
and return to normal serum glucose concentration.  In horses 
treated for a significant period of time, TRH stimulation tests and 
cortisol levels were monitored. 
174 
 
Main Findings: Four of the 9 untreated animals were euthanased due to clinical 
signs of PPID within 6 months.  Cyproheptadine caused little 
improvement in clinical signs and the cyproheptadine-treated cases 
that survived were changed to pergolide treatment.  High-dose 
pergolide caused immediate clinical improvement, but the cost of 
this regimen was prohibitive.  The clinical response to low-dose 




Very limited information provided in conference abstract for poster 
presentation. No information on case selection reported therefore 
unable to assess selection bias. Small sample size. Selection criteria 
for the 3 treatment options not reported, and treatment allocation 
was not randomised.  Results of this study show a lack of efficacy 
of cyproheptadine, with no horses in this group responding, but all 
animals treated on the high dose pergolide showed an excellent 
and repeatable response. The author concludes positively about the 
low dose regimen as an alternative.  
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Appendix 5: Summary of studies presenting data regarding the efficacy of pergolide to improve clinical signs of 









































15 – 28 
years) 
Non-random selection – 
university research 
herd and university 
hospital cases; details 
on recruitment of horse 
owners/selection of 
horses not reported 





for ACTH for 
inclusion as PPID 
case not reported 
although reference 
interval of 2 – 10 
pmol/L (4.5-45.5 
pg/ml) reported 






muscle biopsy  
▪ Sample selection likely 
to introduce bias 
▪ Laboratory tests poorly 
described  
▪ Small sample treated 
with pergolide 
▪ Selection criteria and 
baseline details for 
treatment unknown (12 
of 15 PPID cases not 
treated due to financial 
constraints)  
▪ Unable to determine if 
seasonality accounted 














of hospital or client 
owned horses – details 
on recruitment of horse 
owners not reported. 
PPID cases enrolled 
November – January to 
avoid baseline 
A hypertrichosis 
score >1/3 and 
either a plasma 
ACTH 
concentration >50 








• Unable to determine if 





endocrine tests during 
autumn months  
Beech et 

















Non-random selection – 
details on recruitment 
of horse owners not 
reported  
Clinical signs and 
plasma ACTH 
(n=12) (diagnostic 
cut-off for ACTH 
for inclusion as 
PPID case not 
reported) and/or 






• Unable to determine if 
sample selection could 
introduce bias 
• Small sample treated 
with pergolide 
• Study design 
complicated by prior 
treatment with Vitex 
agnus castus 
• Unable to determine if 
seasonality accounted 

























At least 2 “classical 





• Unable to determine if 
sample selection could 
introduce bias 
• Small sample size 
• Diagnostic criteria main 
outcome versus 





















14 – 32 
years) 
Non-random selection – 
cases identified by 
screening of horses at a 
foundation for retired 
equids.  
ACTH >35pg/mL in 
July. No obvious 






• Sample selection likely 
to introduce bias 
• Small number of treated 
cases and high loss to 

















• Does not state whether 



















at one university’s 
ambulatory service 
between June 1996 and 
November 2001. 
Plasma ACTH >50 
pg/mL, at least 1 
clinical sign of 
PPID, and 
evaluation before 






• Single practice 
population 
• Inherent biases due to 
retrospective study 
design - potential for 
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Kingdom: Demographics, management practices 




A cross-sectional study of horses diagnosed with pituitary pars intermedia 
dysfunction in the United Kingdom: Demographics, management practices 
and factors associated with quality of life 
Summary 
Little information is currently available regarding management of horses with pituitary pars 
intermedia dysfunction (PPID) following diagnosis. This study aimed to evaluate the current 
management and treatment practices undertaken by owners and how these impact owner-
perceived quality of life (QoL). Owners of horses diagnosed with PPID were recruited via a 
single equine veterinary practice and online to participate in a cross-sectional questionnaire 
study. The questionnaire included questions pertaining to management practices, preventive 
health care and general health as well as clinical signs of, and treatment for, PPID. Visual 
analogue scale questions were used to gather owner-perceived ratings of QoL on a scale of 
1 (could not be worst) – 10 (could not be better).  
A total of 377 useable questionnaires were returned. Horses were most frequently kept at 
livery yards (36.4%); the majority received pasture turnout (81.6%), daily forage (95.2%) 
and bucket/concentrate feeds (94.6%). Owner decisions regarding diet were predominantly 
based on personal experience (67.2%). Most owners reported restricting their horse’s access 
to grazing for at least some period during the year (75.7%) and those with a history of 
laminitis spent fewer hours turned out year-round (p=0.003). Owners reported a median of 
2 routine veterinary visits within the previous year and 56.8% of horses were reported to 
have ≥1 concurrent health condition. Median current QoL was 9/10; significantly higher than 
QoL at the time of diagnosis (median = 6/10; IQR 4.75-8) (p<0.001). Most horses were 
currently treated with pergolide (86.9%) which had a higher efficacy rating (median = 8/10; 
IQR 7-10) compared to complementary or alternative treatments (median = 5/10; IQR 2.5-
7) (p<0.001). Pergolide treatment was associated with an improvement in QoL rating since 
the time of diagnosis (p=0.002) and pergolide treatment alone was associated with a higher 
QoL rating compared to treatment combinations or no treatment (p=0.008). Clinical signs 
associated with lower QoL ratings were laminitis (p<0.001), a curly/over-grown coat 
(p=0.007), lethargy/poor performance and patchy/excessive sweating (both p=0.002). 
Owners perceived their horses to have a very good QoL, with significant improvement 
reported since PPID diagnosis and pergolide treatment was positively associated with QoL 
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rating. Evaluation of QoL may be beneficial as a component of routine monitoring of PPID 
cases, and the impact of PPID on daily management should be considered alongside clinical 
factors to maximise QoL in horses diagnosed with PPID.  
Introduction 
Over a quarter (25%) of the equine population in the United Kingdom now consists of aged 
horses (≥15 years) (Mellor et al., 1999, 2001; Ireland et al., 2011a). Pituitary pars 
intermedia dysfunction (PPID) is a progressive neurodegenerative endocrine disorder of 
older equids (van der Kolk, 1997; McFarlane and Cribb, 2005; McFarlane et al., 2005b) 
which is prevalent and frequently diagnosed in older horses (McGowan et al., 2013a; Ireland 
and McGowan 2018). Clinical signs are varied and include hypertrichosis, muscle wastage 
and lethargy, and associated comorbidities such as laminitis (Schott, 2002; McFarlane, 
2014). PPID can affect horses for a significant proportion of their life-time, with the median 
life expectancy following diagnosis reported to be nearly 10 years (Welsh et al., 2016). 
Effective management of the disease is vital to maximise quality of life (QoL) following 
diagnosis. 
There is currently little information available regarding how horses with PPID are managed 
by their owners including the routine health care and treatment they receive. Previous 
studies have focused on the management and care of the general equine geriatric 
population as a whole with significant changes in diet, exercise and veterinary care reported 
as horses age (McGowan et al., 2010a; Ireland et al., 2011a, 2011b). Pergolide is the 
treatment of choice for PPID and has been shown to be effective at managing clinical signs 
(Anon, 2011a; Chapter 4). However, although veterinary surgeons recommend treatment, 
owners are responsible for the day to day decisions regarding management and treatment 
(Ireland et al., 2011a,b) which are central to controlling PPID. Little is currently known 
about owner compliance with veterinary recommended treatment or owner perception of 
response to PPID treatment. In human medicine, interventions such as structured self-
assessments can improve patient management of chronic conditions producing posit ive 
outcomes including better monitoring, increased uptake of treatment and fewer clinical signs 
allowing patients to enjoy a good QoL (Skevington et al., 2001; Lorig et al., 2013; Reynolds 
et al., 2018).  
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The term QoL is defined by the World Health Organisation (WHO) as a ‘state of complete 
physical, mental and social well-being, and not merely the absence of disease and infirmity’ 
(WHO, 1997). In veterinary medicine, definitions of QoL vary. QOL is generally considered to 
be closely linked to welfare but encompasses the broader concepts of physical and mental 
health, positive and negative feelings and the ability to exhibit natural behaviours (Clark, 
1997; McMillan, 2003; Wojciechowska and Hewson, 2005; Broom, 2007). Owners of aged 
horses perceive QoL to be an important health issue (McGowan et al., 2010b) and are likely 
to be the ones best placed to determine the QoL of their animal (McMillan, 2000; 
Wojciechowska and Hewson, 2005; Ireland et al., 2011c). In small animal medicine, tools 
have been developed to evaluate QoL generally (Yeates and Main, 2009; Lavan, 2013; 
Mullan, 2015) and in animals with chronic conditions (Wiseman-Orr et al., 2004; Freeman et 
al., 2012). In equine medicine, owner-perceived QoL in geriatric horses has previously been 
investigated, with owners reporting that horses enjoyed a good QoL (McGowan et al., 
2010b; Ireland et al., 2011c) however, there is currently no information specifically 
regarding QoL in horses with a chronic condition such as PPID. As the most common 
endocrine disorder of older equids (McGowan et al., 2013a), PPID is becoming increasingly 
important in equine practice. An understanding of QoL in horses with PPID and factors that 
influence it could be used to facilitate a more individual animal approach to care, improve 
disease monitoring and aid clinical decision making (Bradley, 2001; Yeates and Main, 2009; 
Mullan, 2015).  
This study aimed to evaluate the current management practices owners undertake when 
caring for horses with PPID, including health care and treatment, and how these impact 
owner-perceived QoL.  
Materials and methods 
Selection of study sample  
A cross-sectional questionnaire was distributed to owners of horses and ponies diagnosed 
with PPID. Two routes were used to recruit eligible owners; firstly, a review of the University 
of Liverpool Equine Practice (UoLEP) database was undertaken to identify PPID cases and 
secondly appropriate social media platforms were also used to recruit eligible owners. For 
PPID cases recruited through the UoLEP, diagnosis was confirmed by clinical record of a 
basal plasma ACTH concentration above the upper limit of seasonally adjusted reference 
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intervals (>29.7 pg/ml November-July or >47 pg/ml August-October). For those recruited 
online, PPID diagnosis was determined by owner confirmation of a positive diagnostic test 
result along with the reported reason for carrying out diagnostic testing, which included one 
or more of the following: age, veterinary surgeon suspected PPID, active laminitis, previous 
history of laminitis, abnormal fat distribution, pot-bellied appearance, muscle wastage, fat 
pads around the eyes, excessive/patchy sweating, increased drinking and urination, 
lethargy, recurrent infections, abnormal coat shedding, curly coat/overgrown coat and 
changes to coat colour/texture. Horses diagnosed prior to 1st January 2014 were excluded to 
reduce the risk of owner recall bias. All owners recruited via the UoLEP received a letter and 
information sheet (Appendices 1 and 2) informing them about the study, and to optimise 
recruitment they were contacted by the author via telephone to complete the questionnaire. 
For participants recruited online, the study information and a link to the questionnaire were 
made available through the UoLEP and Talk About Laminitis1 Facebook pages (Appendix 3). 
The questionnaire link remained open for four weeks. This study was awarded institutional 
ethical approval on the 18th May 2018, reference number VREC667. 
Questionnaire design  
Effective management and treatment strategies have been identified as important areas for 
further investigation (Chapter 2). The questionnaire was therefore designed to gather data 
on current management factors such as feed, exercise, hoof care, general health, medical 
treatment, alternative treatments and owner-perceived QoL (Appendix 4). Additionally, 
information regarding management practices, such as stabling/turnout routine, throughout 
the year and any changes since PPID diagnosis in clinical signs, medical 
treatment/alternative treatments and QoL. The questionnaire was designed to facilitate 
completion over the phone or online using data capture software (KwikSurveys). The 
majority of the questions were closed-ended with predefined options provided for 
participants to indicate their response. Where “Other” was provided as an option, additional 
space was provided for respondents to provide further information or criteria. A number of 
open-ended questions were also used with boxes provided for free written text.  
 
1 Talk about laminitis (TAL) is an online forum and educational service established by Boehringer 
Ingelheim for owners of horses diagnosed with PPID. It aims to raise awareness of the link between 
laminitis and endocrine disease.  
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Questions around QoL were developed from visual analogue scales (VAS) utilised in human 
medicine (Katsura et al., 2003) and small animal practice (Belshaw et al., 2015). For these 
VAS questions, a number of statements and factors/measures were provided with Likert-
style descriptors at the two extremes of the scale. The factors/measures were chosen to 
encompass activities of daily living (Ireland et al., 2011c) and the five freedoms (Mellor, 
2016). Owners were asked to rate their horse’s appetite, demeanour, overall QoL and QoL 
at time of PPID diagnosis on a scale of 1 (could not be worse) to 10 (could not better). 
Additionally, they were also asked to rate the level of discomfort they perceived they horse 
to be in from 1 (no discomfort) to 10 (severe discomfort). Owner-perceived efficacy of 
pergolide and alternative treatments, where applicable, were also assessed using a rating 
scale of 1 (not at all effective) to 10 (extremely effective). Owner-reported body condition 
score (BCS) was adapted from Carroll and Huntington (1988), with descriptions provided for 
each score (Appendix 4). Owners were requested to provide separate BCS ratings for their 
horse’s neck (1-5 scale), ribs and pelvis (0-5 scale). Owners of more than one horse with 
PPID were asked to complete individual questionnaires for each horse.  
Data Analysis  
All data were exported into a Microsoft Excel spreadsheet, using the KwikSurveys software, 
and each horse was allocated a unique identification number. Statistical analyses were 
performed using commercial statistical software (IBM SPSS Statistics Version 25). For BCS, 
the mean of the three owner-reported scores (neck, ribs, and pelvis) was calculated to 
provide an overall BCS. Continuous data from the questionnaire responses were not 
normally distributed and are therefore described as medians with interquartile ranges (IQR) 
and categorical data are described as proportions. Kruskal-Wallis, Mann-Whitney U and 
Wilcoxon signed-rank tests were used to test differences in median values of continuous 
variables between categories of categorical variables. Where appropriate, Pearson Chi-
squared or Fisher’s exact tests were used to assess associations between categorical 
variables. Current overall QoL was assessed using raw interval data from the responses to 
the question ‘how would you rate your horses current overall QoL?’ where respondents 
provided a rating on a scale of 1-10, as well as using these data to derive a categorical 
outcome, where a rating of ≤4/10 was defined as a poor QoL, 5-7/10 as average and ≥8/10 
as a good QoL. Statistical significance was set at p<0.05. For a number of questions there 
was a low level of item omission and some questions were only answerable conditionally on 
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other responses, therefore the denominators for the results vary, and are reported 
throughout. 
Results 
Case demographics  
In total, 377 questionnaires met inclusion criteria with a median of one horse per owner 
(IQR 1-2). Questionnaires were completed between July 2018 and February 2019 with the 
majority being completed online in March and April 2019 (80.6%; n=304/377). The 
response rate of owners registered with the UoLEP was 70.2% (n=73/104). Horses had 
been diagnosed with PPID between 1st January 2014 and 31st March 2019. The median age 
of the study population was 23 years (IQR 19-26 years; range 7-40 years) and the median 
duration of ownership was 12 years (IQR 7-18 years; range 0.3-35 years). The population 
comprised 54.5% (n=205/376) geldings, 44.9% (n=169/376) mares and 0.5% (n=2/376) 
stallions. Ponies (≤147.3 cm in height) made up 52.1% (n=195/374) of the study 
population, and the most numerous breeds were UK and Irish Native/native-cross breeds 
(46.9%; n=176/375), followed by Thoroughbred/Thoroughbred-cross (11.7%; n=44/375) 
and Irish Draught/Irish Draught-cross (10.4%; n=39/375).  
Management  
Horses were mainly kept at livery yards (36.4%; n=137/376) or at the owner’s private 
premises (30.3%; n=114/376). Most owners reported that their horse spent at least some 
time in an outside turnout area: median turnout time throughout the year is shown in Figure 
1. Turnout was generally at pasture (81.6%; n=271/332) and most commonly in a paddock 
<1 acre in size (43.4%; n=145/334) with at least one equine companion (75.0%; 
n=252/336). Horses spent a median of 20 hours (IQR 12-24) turned out on pasture in the 
summer and 8 hours (IQR 6-8) in the winter. Compared to horses without a history of 
laminitis, horses with a history of laminitis spent fewer hours turned out throughout the year 
overall (p=0.003) (median hours turned out 15 and 9.5, respectively). Furthermore, the 
duration of daily turnout for animals with a history of laminitis was significantly shorter 
throughout each season compared to horses without a history of laminitis; during the spring 
(p=0.009), summer (p=0.004), autumn (p=0.005) and winter months (p=0.02) (Figure 1). 
The majority of owners restricted their horse’s access to pasture for a period of time 
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throughout the year (75.7%; n=253/334), and the most frequently used methods were strip 
grazing (25.4%; n=85/334), time restricted grazing (17.1%; n=57/334) and use of a 
bare/dirt paddock 13.5%; n=45/334). Only 24.0% (n=79/328) of horses were turned out at 
pasture for 24 hours per day all year round. Most of the study population received daily 
supplementary forage (95.2%; n=318/334), which was most frequently fed on an ad-lib 
basis (34.3%; n=109/318). The majority also received some form of bucket/concentrate 
feed (94.6%; n=306/325). Owner feeding practices are shown in Table 1.  
 
Figure 1: Box and whisker plot of owner-reported hours spent turned out during different 
seasons and throughout the year overall (median represented by horizontal lines within each 
box, which represents IQR) in a cross-section of horses diagnosed with PPID in the UK, 
including differences between horses reported to have a history of laminitis, horses with no 






Table 1: Current owner-reported feeding practices for a cross-section of horses diagnosed 
with PPID in the UK  
Feed type N  % 
Forage (n=318) 
Dry hay 158 49.7 
Soaked hay 101 31.8 
Haylage 81 25.5 
Steamed hay 15 4.7 
Hay replacer 11 3.5 
Straw 8 2.5 
Bucket/concentrate feed (n=306) 
Chaff/chop 197 64.4 
Sugar/fibre beet 103 33.6 
Balancer 103 33.6 
Fibre/grass cubes 85 27.8 
Mash feeds 44 14.4 
Veteran mix/cubes 41 13.4 
PPID/laminitis specific feeds 40 13.1 
Coarse mix 17 5.6 
Conditioning mix/cubes 14 4.6 
Bran 8 2.6 
Cereals 5 1.6 
  
Owners generally designed their horse’s diet to maintain their horse’s current weight 
(70.6%; n=233/330). Decisions regarding diet were predominantly based on their own 
personal experience (67.2%; n=227/338) with only 25.7% of owners reporting that 
veterinary advice influenced their feeding practices (n=87/338). Horses were most 
frequently reported to be in average body condition, with an overall owner-reported BCS 
calculated as 2/5 (60.0%; n=201/335). The most frequently reported individual scores 
were; neck 1/5 (56.1%; n=188/335), ribs 3/5 (34.9%; n=117/335) and hind quarters 3/5 
(58.8%; n=197/335). Basing decisions regarding diet on personal experience was 
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associated with overall BCS (p=0.02), however making decisions based on veterinary advice 
was not significantly associated with overall BCS (p=0.27). Most owners reported monitoring 
their horse’s weight on a regular basis (74.3%; n=248/334), most frequently ‘by eye’ 
without any formal measure (43.7%; n=145/332) or by using a weigh tape (38.9%; 
n=129/332).  
Half of respondents reported that their horse received some form of regular exercise 
(50.8%; n=169/333), which was mainly low intensity hacking/pleasure riding (91.7%; 
n=155/169). The age of horses reported to be currently in work (median 21 years) was 
significantly lower compared to horses not currently in work (median 25 years) (p<0.001). 
Preventive health care and concurrent health problems  
Over half of the study population were unshod (53.5%; n=175/327). Of the horses reported 
to be shod (46.5%; n=152/327), 24.3% (n=37/152) received some form of remedial 
shoeing. There was a significant association between laminitis and remedial shoeing: 35.3% 
of horses with current active laminitis had remedial shoes (n=6/17) compared to 10.0% of 
horses without laminitis at the time of questionnaire completion (n=31/310) (p=0.001).  
Within the preceding 12 months, horses were reported to have received a median of 2 (IQR 
1-3) routine veterinary visits and a median of 1 (IQR 0-2) non-routine veterinary visits. For 
those that received non-routine veterinary visits (48.5%; n=183/377), the most frequently 
reported reasons were non-specific disorders (such as viruses or weight loss) (31.1%; 
n=57/183), lameness (excluding laminitis) and laminitis (both 26.8%; n=49/183). 
The majority of horses were currently vaccinated against tetanus (75.9%; n=286/377) and 
equine influenza (67.1%; n=253/377). Most owners also reported their horse had regular 
dental examinations with around half receiving yearly checks (54.8%; n=182/332) and 
36.1% receiving six monthly checks (n=120/332). Dental care was provided by equine 
dental technicians (59.2%; n=199/336) or veterinary surgeons (40.8%; n=137/336). The 
vast majority of owners (96.2%; n=326/339) described following an anthelmintic 
administration regimen, which was most frequently based on the results of faecal worm egg 




Over half of horses were reported to currently have at least one concurrent health condition 
(56.8%; n=214/377), of which the most frequently reported were osteoarthritis (38.3%; 
n=82/214), equine metabolic syndrome (EMS) (24.8%; n=53/214) and respiratory disorders 
such as severe equine asthma (7.0%; n=15/214). 
Diagnosis of PPID and clinical signs  
The median time between diagnosis of PPID and completion of the questionnaire was 2 
years (IQR 1-3.5 years; range 0.1-5 years). Median horse age at time of diagnosis was 20 
years (IQR 17-24 years). The majority of horses were reportedly diagnosed using basal 
ACTH concentration (98.9%; n=370/374). Where owners reported ACTH test results at time 
of diagnosis, 44.2% (n=91/206) were ≤100 pg/ml, 40.8% (n=84/206) were between 101 -
500 pg/ml and 15% (n=31/206) were >500 pg/ml. As only 32.4% (n=122/377) of owners 
provided an exact date of PPID diagnosis, analysis of owner-reported ACTH concentrations 
for different seasons was not undertaken.  
Owners reported a variety of reasons for suspecting their horse had PPID, prior to diagnostic 
testing, and several of these reasons were significantly associated with age at the time of 
diagnosis (Table 2). Prior to diagnosis, 62.3% n=235/377 of horses were reported to have 
no previous history of laminitis. A small proportion of horses (9.0%; n=34/377) were not 
reported by their owners to be showing any specific clinical signs prior to diagnosis, with age 
being the sole reason for suspecting PPID. At the time of questionnaire completion, owners 
reported currently observing at least one clinical sign of PPID in 73.9% (n=252/341) of 
horses, of which the most frequently reported were muscle wastage (26.7%; n=91/341), 









Table 2: Owner-reported reasons for suspecting PPID and associations with age at the time 
of diagnosis in a cross-section of horses subsequently diagnosed with PPID in the UK 
(n=377; with age at diagnosis reported for n=376) 
Reported reason for 
suspecting PPID 











Active laminitis 108 28.6 19.0 (14.5-21.9) 21.0 (18.0-24.0) <0.001 
Veterinary suggested 97 25.7 20.5 (17.0-24.0) 20.0 (17.0-24.0) 0.58 
Overgrown coat 88 23.3 21.3 (18.1-24.4) 20.0 (17.0-23.9) 0.03 
Abnormal coat shedding 86 22.8 20.6 (18.0-25.0) 20.0 (17.0-24.0) 0.14 
Horse age 85 22.5 22.0 (22.0-26.0) 20.0 (16.1-23.0) <0.001 
Lethargy/poor performance 85 22.5 20.0 (15.0-22.0) 20.5 (17.0-24.0) 0.04 
Muscle wastage 82 21.8 21.0 (16.8-24.0) 20.0 (17.0-24.0) 0.62 
Fat pads around the eyes 67 17.8 19.0 (15.0-21.0) 20.5 (17.0-24.0) 0.005 
Increased drinking/urination 67 17.8 19.0 (15.0-22.0) 20.5 (17.0-24.0) 0.01 
Abnormal fat distribution 66 17.5 19.0 (15.0-22.0) 20.5 (17.0-24.0) 0.008 
Pot-bellied appearance  62 16.4 20.0 (15.0-24.0) 20.0 (17.0-24.0) 0.34 
Recurrent infections 60 15.9 20.5 (16.5-23.5) 20.0 (17.0-24.0) 0.67 
History of laminitis 55 14.6 18.0 (13.0-23.0) 20.5 (17.0-24.0) 0.006 
Excessive/patchy sweating 49 13.0 19.5 (16.8-21.0) 20.0 (17.0-24.0) 0.04 
Abnormal coat texture/colour 44 11.7 20.0 (17.0-26.0) 20.0 (17.0-24.0) 0.78 
Curly coat  38 10.1 21.5 (17.0-26.3) 20.0 (17.0-24.0) 0.04 
1Mann-Whitney U Test p values for the difference in age at time of diagnosis for each reason 
reported. 
Treatment  
The majority of horses had received pergolide treatment at some point after PPID diagnosis 
(94.1%; n=352/374), while 86.9% (n=325/374) were currently receiving pergolide 
treatment. Seventeen percent (n=65/374) currently received some form of complementary 
or alternative treatment and of these, 70.8% (n=46/65) also received pergolide. The most 
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frequently reported complementary or alternative treatments used were magnesium 
(43.1%; n=28/65), herbal supplements/feeds marketed for horses with PPID (41.5%; 
n=27/65) and Vitex agnus castus (Chaste berry) (26.2%; n=17/65). When asked to report 
what influenced their decision regarding treatment for PPID, owners most frequently stated 
advice from their usual vet (81.4%; n=307/377), their horse’s QoL (59.7%; n=225/377) and 
ACTH test results (52.0%; n=196/377). 
The median current dose of pergolide received per horse was 1mg per day (range 0.25-
6mg) and this was given once a day by the majority of owners (93.0%; n=305/328), where 
daily dose alternated the median daily dose was calculated. Unsurprisingly, dose was 
associated with height (p<0.001) with 42.3% (n=71/168) of ponies receiving <1mg and 
88.1% (n=128/158) of horses receiving ≥1mg. Owners reported that pergolide dose had 
not changed within the preceding 12 months for 65.8% (n=219/333) of horses, had 
increased for 24.0% (n=80/333) and decreased for 10.2% (n=34/333). Where modifications 
to the dose of pergolide administered had been made, the majority of owners reported 
consulting their vet before making changes (78.1%; n=89/114).  
When owners were asked to rate treatment efficacy, pergolide had a higher efficacy rating 
(median = 8/10; IQR 7-10) compared to complementary or alternative treatments (median 
= 5/10; IQR 2.5-7) (p<0.001). Of those who provided a reason for the pergolide efficacy 
rating given, the most frequently reported were; an improvement in demeanour/behaviour 
(26.7%; n=94/352), improvement in ACTH levels (17.0%; n=60/352) and laminitis 
perceived to be more controllable (12.8%; n=45/352).   
Only 8.0% (n=30/374) of horses currently received no PPID treatment of any kind. The 
median age of this subset of horses was not significantly different from those receiving any 
kind of treatment (p=0.98). The majority (76.7%; n=23/30) were reported to be currently 
showing at least one clinical sign of PPID, the most frequently reported of which were 
muscle loss (26.7%; n=8/30), curly/overgrown coat (23.3%; n=7/30) and fat pads around 
the eyes (20.0%; n=6/30). This subset had a median current QoL rating of 8 (IQR 7.75-10), 
and this was reported to have remained the same (n=11) or improved (n=17) since 
diagnosis in all but two cases.  
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Side effects of pergolide treatment  
Of those owners who stopped pergolide treatment, the most frequent reason provided for 
not currently treating their horse with pergolide was observed side effects (95.5%; 
n=21/22). Just over half of owners who treated their horse with pergolide reported 
observing side effects during the first two weeks of treatment (56.5%; n=199/352). The 
most frequently reported side effects during this period were loss of appetite (31.5%; 
n=111/352), lethargy/poor performance (21.0%; n=74/352) and diarrhoea/loose faeces 
(6.0%; n=21/352). These side effects were reported to continue after two weeks in 50.8% 
(n=101/199) of cases. Some owners (14.5%; n=51/352) reported observing new side 
effects after two weeks of treatment, 76.5% (n=39/51) of which were reportedly observed 
in horses that had no side effects during the first two weeks of treatment. The most 
frequently reported side effects after two weeks of treatment were loss of appetite (28.1%; 
n=99/352), lethargy/poor performance (18.2%; n=64/352) and erratic/unpredictable 
behaviour (7.4%; n=26/352). Pergolide dose was not significantly associated with side 
effects observed during the first two weeks of treatment (p=0.41).  
Quality of life  
Overall horses with PPID were perceived to have a very good current QoL (median rating = 
9/10; IQR 8-10). This was significantly higher compared to overall QoL rating at time of 
diagnosis (median = 6/10; IQR 4.75-8) (p<0.001). Quality of life was reported to have 
improved since diagnosis in the majority of horses (73.7%; n=258/377), no change was 
reported in 16.6% (n=58/377) and only 9.0% (n=34/377) were reported to have a worse 
QoL. Median ratings for other current QoL measures were; appetite 10/10 (IQR 8-10), level 
of discomfort 2/10 (IQR 1-4) and demeanour 9/10 (IQR 8-10). The factors most frequently 
reported by owners to influence overall QoL rating positively were pergolide treatment 
(22.3%; n=84/377) and access to grazing (16.2%; n=61/377), while laminitis was most 
frequently reported to have a negative impact on QoL (13.5%; n=51/377). 
Treatment with pergolide was associated with a higher current overall QoL rating compared 
other treatment groups (Table 3). Horses receiving alternative treatments, whether in 
combination with pergolide or not, had a significantly lower QoL rating compared to those 
not receiving alternative treatments (Table 3). Pergolide treatment was also associated with 
an improvement in QoL rating since the time of diagnosis (p=0.002), with 75.9% 
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(n=203/303) of owners reporting an improvement in horses treated with pergolide 
compared to 59.6% (n=28/47) of those that did not receive pergolide. Several clinical signs 
and concurrent conditions were associated with a lower overall QoL rating, which are 
reported in Table 3. Discomfort ratings were significantly higher in horses currently reported 
to be suffering from laminitis (median = 4/10; IQR 2-7) or lethargy/poor performance 
(median = 5.5/10; IQR 2-5.25) compared to horses without laminitis (median = 2/10; IQR 
1-3) and without lethargy/poor performance (median = 2/10; IQR 1-4) (p<0.001 and 0.02, 
respectively). Management factors associated with owner rating of overall QoL included type 
of turnout, the method used to restrict grazing and overall BCS (Table 4). Neither ACTH 
concentration nor age were significantly associated with QoL rating. 
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Table 3: Owner-reported current treatment and currently observed clinical factors associated with owner-perceived quality of life in a cross-
section of horses diagnosed with PPID in the UK 







Current treatment (n=374) Pergolide only 
Alternatives3 
Pergolide & alternatives 
None 
279 74.6 9 8-10 0.008 
19 5.1 8 7.75-9.25 
46 12.3 8 7-9 
30 8 8 7.75-10 























































Patchy/excessive sweating (n=341) Yes  25 7.3 8 6-9 0.002 
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No 316 92.7 9 8-10 






















1Kruskal Wallis and Mann-Whitney U Test p values for the difference in owner-perceived quality of life median ratings. 
2Overall current owner-perceived quality of life rating on a scale of 1 (could not be worse) – 10 (could not be better). 













Table 4: Owner-reported management factors associated with owner-perceived quality of life in a cross-section of horses diagnosed with PPID 
in the UK 
Factor associated with QoL Grouping Variable N % % with 






poor QoL rating 
(≤4/10) 
P value1 











































































Overall body condition score 
(scale of 0-5, however no owners 


























1Chi-squared test p value used to assess associations between categorical variables.  
2Overall owner-perceived quality of life rating comprised the owner response to the question ‘How would you rate your horse’s current overall quality of life?’ 




The results of this study provide a detailed description of owner practices regarding 
management, healthcare and treatment in horses diagnosed with PPID. The study has also 
provided important novel information regarding owner-perceived QoL and factors associated 
with that QoL rating in their horses. 
The sample used in this study comprised horses diagnosed with PPID over a five-year 
period. Owners were recruited via a review the UoLEP database and online through 
appropriate social media channels. This was a convenient, efficient and cost-effective way of 
reaching a wide range of potential participants. As with all questionnaire-based research 
there is the risk of response bias and this method meant it was not possible to calculate an 
overall response rate to the questionnaire. However, the response rate from owners 
registered with the UoLEP was high. In this study, horse owners may have been more likely 
to respond if they had higher standards of care or were veterinary registered and following 
veterinary treatment recommendations. Comparison with the general target population is 
also not possible because there is currently no way of quantifying non-veterinary registered 
PPID cases. However, the field-based sample presented here is likely to be more 
representative of the veterinary diagnosed PPID population compared to studies including 
solely referral hospital or research herd populations. Furthermore, the sample size is 
comparatively large compared to previous studies investigating treatment and management 
of PPID. 
In questionnaire-based research, even a small change in question order can have an impact 
on the answers given by respondents (Lasorsa, 2003; Huang and Cornell, 2016; Lee et al., 
2016). This is because each question is not considered in isolation by the participant but in 
context with those around it (Bowman and Schuldt, 2014; Dillman et al., 2014). Questions 
measuring subjective concepts such as QoL or well-being have been reported to be 
particularly affected (Garbarski et al., 2015). This is because participants are unlikely to 
have pre-defined answers for these types of questions and therefore consult the previous 
information for context (Tourangeau and Rasinski, 1988; Sudman et al., 1996; Tourangeau 
et al., 2000). This was demonstrated in a study by Bowling and Windsor (2008), where 
patients rated their QoL status as significantly better if health based questions were asked 
beforehand. Therefore, to minimise the influence of question order on over-estimation of 
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QoL ratings, questions relating to QoL were located close to the beginning of the 
questionnaire before sections regarding management, health care and concurrent disease.  
The horse-owner relationship is unique, as horses are neither a pet in the conventional 
sense or a livestock animal. In recent years the horse has been considered more of a 
companion animal, with surveys reporting that some owners value their horse for their 
companionship and consider them to be like a member of the family (Anon, 2007b; Visser et 
al., 2012). Furthermore, horses are being cared for into their old age with a significant 
proportion reportedly kept as kept as companions or retired (McGowan et al., 2010a; Ireland 
et al., 2011a). This increasing duration of ownership means owners are more likely to 
develop a strong bond with their aged horse (Ireland et al., 2011a; McGowan and Ireland, 
2016). The horse-owner relationship, developed over a prolonged period, is likely to 
influence decisions made around both routine management and treatment of diseases 
including PPID. It has been reported that owners are interested in maintaining the health 
and QoL of their horses into their old age (McGowan et al., 2010b). The results presented 
here may represent the population of owners who are more likely to seek and finance 
veterinary treatment for their older animal.  
The age and gender demographics described here are comparable with the survey of 
geriatric horses conducted by Ireland et al. (2011a), which reported the median age of the 
population was 20 years and 55.1% were geldings. However, breed demographics differ 
from previous surveys of the general equine population, with UK native/native cross breeds 
making up a much larger proportion than previously reported (Mellor et al., 1999; Hotchkiss 
et al., 2007a), and ponies comprising a large proportion of the population. Ponies are 
reportedly more like to show clinical signs such as laminitis and hypertrichosis (McGowan et 
al., 2010b) and are over-represented with increasing age (Ireland et al., 2011a), therefore 
the high proportion of pony breeds in this study is not unexpected.  
The proportion of the population kept at livery yards (36.4%) was over double that reported 
in a survey of British horse owners which reported only 16.2% of horses were kept at livery 
(Hotchkiss et al., 2007a), but was more comparable to the 27.3% reported by Ireland et al. 
(2011a) in a survey of geriatric horses and a recent UK equine health survey which reported 
that nearly half of horses (including animals of all ages) were kept in livery (Slater and 
Taylor, 2018). This might be due to changes in how people keep horses over the last 
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decade, with fewer people having access to their own facilities, or because owners who 
keep their horse on a livery yard are more likely to seek veterinary attention due to the 
influence of others around them. In human medicine, social networks have been reported to 
influence help-seeking behaviour. When patients consulted their social network, they were 
encouraged to seek help and peers pointed out changes that the patients themselves had 
not noticed (Walter et al., 2014). Being housed at a livery yard may also affect 
management, as owners might be restricted by yard rules around factors such as turnout 
and have less freedom to make their own decisions regarding their horse’s management. 
This may influence the management practices described here. However, the grazing and 
stable management practices for PPID horses were not dissimilar to that of equine 
populations described in other studies (Mellor et al., 2001; Hotchkiss et al., 2007a; Ireland 
et al., 2011a). 
Overall turnout hours reported here were very similar to the time spent at pasture described 
by Hotchkiss et al. (2007a). The majority of horses had access to grass/grazing (81.6%), a 
slightly smaller proportion compared to the 90.4% of geriatric horses reported by Ireland et 
al. (2011a). This may be due to the perceived increased risk of endocrinopathic laminitis 
associated with PPID (McGowan, 2010) and the proportion of horses in the current study 
population reported to have a history of laminitis. Although horses with a history of laminitis 
spent significantly less time at pasture, the majority of horses still spent a large proportion 
of time turned out throughout the year. This perhaps demonstrates the effectiveness of the 
restricted grazing management practices used by 77% of participants, allowing horses to be 
turned out while also restricting their grass intake (Geor and Harris, 2009).  
Diet is considered by owners of older horses to be an important contributor to QoL (Ireland 
et al., 2011c) and the feeding practices of owners change as their horse ages (Brosnahan 
and Paradis, 2003a; Ireland et al., 2011a). As the majority of questionnaires were 
completed during winter and early spring months, and owners were requested to provide 
information regarding their horse’s current diet, the feeding practices reported in th is study 
may not reflect dietary management of PPID cases over the whole year. However, feeding 
practices reported here were similar to those for the geriatric population reported by Ireland 
et al. (2011a). The vast majority of horses received some form of bucket/concentrate feed 
and the most frequently reported feeds were chaff/chop and sugar/fibre beet products in 
both populations. However, only 13.4% horses in this study were fed veteran/senior feeds 
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compared to 27.7% reported by Ireland et al. (2011a) and 51% of horses aged ≥20 years 
in an American study (Brosnahan and Paradis, 2003a). The types of forage fed also differed, 
with geriatric horses being most frequently fed haylage (52.1%) and only 11.5% receiving 
soaked hay (Ireland et al., 2011a). In the current study horses were most frequently fed dry 
hay (49.7%) or soaked hay (31.8%) with only 25.5% being fed haylage. This difference is 
likely to be linked to owner perception of laminitis risk. Endocrinopathic laminitis is a 
reported comorbidity of PPID, where concurrent insulin dysregulation and/or 
hyperinsulinaemia are observed in PPID cases (McGowan et al., 2004; Treiber et al., 2006a; 
Klinkhamer et al., 2011; de Laat et al., 2019a). In the current population, 28.6% of owners 
reported laminitis as a reason for suspecting PPID and 16.7% reported their horse had a 
history of previous laminitis. Feeding practices aimed at reducing calorie intake have been 
shown to improve insulin sensitivity (Morgan et al., 2016) and are recommended to help 
prevent endocrinopathic laminitis. The fact owners are choosing to feed less nutritious 
forage perhaps demonstrates owner awareness of the importance of restricting calorie 
intake to minimise the risk of laminitis. However, veterinary advice seems to have minimal 
influence on owner decision making regarding diet, with only a quarter of owners reporting 
that feeding practices were based on advice from their veterinary surgeon. The majority of 
owners (67.2%) based decisions regarding diet on their own personal experience. This could 
be a result of the high amount of value owners place on their own experience and 
understanding of their individual horse (Scantlebury et al., 2014) meaning owners believe 
they are best placed to make day to day management decisions.  
In a survey of owner-reported BCS in the general equine population, the majority of horses 
were reported to have a BCS of 4/6 on a 1-6 scale (Robin et al., 2013), whereas the 
majority of horses in this study had a mean BCS of 2/5 using the same scoring system but a 
0-5 scale. This suggests that horses with PPID are likely to have a lower owner-reported 
BCS compared to the general equine population. This is despite the fact a significant 
proportion of the population comprised Welsh and other UK native breeds, which are 
reported to have significantly increased odds of obesity (Robin et al., 2013) and contrary to 
a previous cross-sectional study which described increasing risk of obesity with increasing 
horse age (Thatcher et al., 2012). However, the majority of horses aged ≥15 years were 
reported by their owners to be in good body condition, although BCS decreased significantly 
with increasing horse age (Ireland et al, 2011a). The lower BCS reported here might be due 
to several factors. Owners have been reported to underestimate BCS in horses (Wyse et al., 
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2008; Ireland et al., 2012a) and clinical signs such as muscle wastage and changes in fat 
distribution often observed in PPID cases are likely to influence owners’ perception of body 
condition. Determining BCS is likely to be more difficult and less accurate when also 
accounting for these clinical signs of PPID. To try and combat this, detailed descriptions 
were provided for each BCS (Carroll and Huntington, 1988) and owners were asked to 
provide three individual scores, one for each region of the body, which were used to 
calculate overall mean BCS. Free access to grass has been reported as a risk factor for 
obesity (Thatcher et al., 2012) and the majority of animals in this study had their access to 
grass restricted for a least some period during the year. Despite the majority of horses 
reportedly being in ‘average’ rather than ‘good’ body condition, most owners (70.6%) 
designed their horse’s diet to maintain their current weight, suggesting owners were happy 
with their horse’s current weight. 
Geriatric horses have been reported to still have a useful working life, with as many as 74% 
still in ridden work (Ireland et al., 2011a). Similar to several other studies (Mellor et al., 
2001; Brosnahan and Paradis, 2003a; McGowan et al., 2010a; Ireland et al., 2011a) the 
main use of horses reported here was low intensity pleasure riding/hacking. However, the 
proportion of horses reported to be ‘in work’ was much lower, with just over half receiving 
regular exercise. In the general equine population, only 18% were described as being a 
companion or retired (Mellor et al., 2001). However, this difference is not unexpected, since 
increasing age has been associated with lower intensity exercise and retirement in various 
studies (Brosnahan and Paradis, 2003a; McGowan et al., 2010a; Ireland et al., 2011a) and 
the same association was reported in the current study. This perhaps highlights the 
continuing shift towards the role of the horse a companion animal and the willingness of 
owners to care for their horses beyond their ‘useful’ working life. 
Horses had received a median of two routine veterinary visits in the previous 12 months, 
considerably more the median of 0.5 per year received by the general population (Mellor et 
al., 2001). Ireland et al (2011b) reported that 68.7% of geriatric horses received a routine 
veterinary visit within the preceding year and that increasing age and retirement were 
associated with a reduced likelihood of routine veterinary visits. The results presented here 
suggest that horses with PPID receive more routine veterinary care than the general 
geriatric equine population. Clinical examination is required to renew prescriptions and twice 
yearly ACTH monitoring is currently recommended to assess disease progression and 
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response to treatment (Durham et al., 2014). As the majority of horses had received 
pergolide treatment, this recommended monitoring is likely to be one of the reasons for the 
increased veterinary care reported here. It is likely that veterinary registered horses are 
over-represented in the study population, therefore it is possible that the results presented 
here over-estimate the level of veterinary attention provided for the entire population of 
horses with PPID.  
The majority of horses were currently vaccinated against tetanus (75.9%) and equine 
influenza (67.1%), which although reduced compared to the general population (Hotchkiss 
et al., 2007b) is broadly comparable to the geriatric population (Ireland et al., 2011b). The 
likelihood of regular vaccination is reported to decrease with age (Mellor et al., 2001; Ireland 
et al., 2011b). This could pose a significant health risk as both geriatric horses (Muirhead et 
al., 2008) and PPID cases (Adams et al., 2014) have been shown to have a reduced immune 
response to vaccination. Immunosuppression has also been documented as a consequence 
of PPID (Schott et al., 2001; McFarlane, 2014). This is thought to be a result of high 
concentrations α-melanocyte stimulating hormone (α-MSH) and insulin. The mechanisms are 
poorly understood, however, neutrophil activity in horses with PPID has been reported to be 
reduced compared to healthy adult and aged controls (McFarlane et al., 2015). In light of 
the increased number of UK equine influenza outbreaks reported during 2019 (Animal 
Health Trust, 2019) increased emphasis should be put on the importance of vaccinating 
horses with PPID.  
Preventive health care undertaken was comparable with previous studies (Brosnahan and 
Paradis, 2003a; Ireland et al., 2011b): the majority of owners followed a worming regimen 
and provided regular dental care. The worming practices described here demonstrate the 
increasing utilisation of targeted selective worming programmes, with half of owners 
reportedly worming based on the results of FWECs. This is a marked increase from the 
10.9% and 1.8% described in previous studies (Hotchkiss et al., 2007b; Ireland et al., 
2011b). A relatively high proportion of horses in this study were reported to receive six 
monthly dental checks, which is in keeping with studies that have reported an association 
between the prevalence of dental disorders and increasing age (Ireland et al., 2011b; 
Ireland et al., 2012b). The importance of regular dental care in horses with PPID has been 
highlighted (McFarlane, 2011), however any association between dental problems and PPID 
is not well documented. The sampling method and questionnaire design employed in this 
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study could mean that horses from large establishments, such as riding schools, are possibly 
under-represented. This may bias the estimates of frequencies of preventive health care.  
A recent systematic review collated data on the most prevalent veterinary-diagnosed clinical 
signs of PPID, and reported an overall prevalence of hypertrichosis (69.9%; based on data 
from 14 studies), laminitis (48.9%; based on data from 13 studies) and muscle wastage 
(48.9%; based on data from four studies) (Ireland and McGowan, 2018). Compared to the 
current study, the higher prevalence of these clinical signs is most likely because many of 
the previous studies were case series with study populations often including horses with 
advanced disease (Ireland and McGowan, 2018). It is also possible that clinical signs in this 
study were under-reported or unrecognised by owners. This has previously been reported 
for factors such as coat abnormalities (Ireland et al., 2012a). One Australian survey 
described owner-reported clinical signs in 69 PPID cases aged ≥15 years: hypertrichosis was 
reported in 41%, lethargy in 14% and laminitis in 13% of horses (McGowan et al., 2013a). 
These also differed from the owner-reported reasons for suspecting PPID in the current 
study, where hypertrichosis was less prevalent and the prevalence of lethargy and laminitis 
was higher. This could be due to the younger median age of the study population presented 
here. In this study, horses reported to have an overgrown coat prior to diagnosis were 
significantly older, while horses with laminitis or lethargy/poor performance were 
significantly younger than those not displaying these signs. Younger horses are more likely 
to be in work, therefore owners may be more likely to notice signs of lethargy/poor 
performance and laminitis is more likely to occur in horses with concurrent EMS (McGowan, 
2010c) or hyperinsulinaemia (Karikoski et al., 2016). Additionally, PPID has been diagnosed 
with increasing frequency in recent years (Rohrbach, et al., 2012) due to increased 
awareness of the disease. This is likely to lead to a greater proportion of cases being 
diagnosed in the earlier stages of disease before overt generalised hypertrichosis develops. 
Since owners were asked to report reasons for suspecting PPID at the time of diagnosis, 
which was up to five years prior to the questionnaire, some of the differences in clinical 
signs reported may also be due to recall bias. Owners are more likely to recall significant 
events (Casey et al., 1967; Erk et al., 2003) which have a high impact and a laminitis 
episode or lethargy is likely to have a much greater impact on aspects such as daily routine 
than hypertrichosis.     
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Pergolide is the treatment of choice for PPID and has been shown by various studies to be 
effective at improving clinical signs and ACTH concentration in horses with the disease 
(Chapter 4). It is therefore unsurprising that the majority of the population described here 
were reported to currently receive pergolide treatment. However, this is in contrast to 
treatment compliance for chronic conditions in humans which has been reported to be as 
low as 50% (Miller, 1997). Owners following veterinary advice may have been more likely to 
respond to the questionnaire, therefore the frequency of pergolide treatment reported in 
this study might be over-estimated. One of the main reasons for non-compliance in human 
patients was because medications were considered to be ineffective (Miller, 1997). This is 
the first study to assess owner perception of treatment efficacy in a relatively large sample 
of PPID cases. Pergolide treatment was perceived by owners to be highly effective, with a 
median rating of 8/10. This is in keeping with a previous small retrospective cohort study, 
which reported that 90% of owners were satisfied with pergolide treatment (Pongratz et al., 
2010). Similarly, ten years after commencing treatment, 96% of owners agreed or strongly 
agreed that pergolide improved their horse’s QoL (Schott et al., 2020b). This seems to 
demonstrate that owners are observing the efficacy described in clinical research and 
perhaps contributes to the high compliance reported in this study population. Nearly all 
owners who reported stopping pergolide treatment did so because of observed side effects. 
Just over half of owners reported observing side effects during the first two weeks of 
treatment, which is a higher portion than previously described (Anon, 2011a). This could be 
a consequence of owners perceiving unrelated issues or events as side effects of treatment 
or because owners are perhaps more likely to notice side effects such as lethargy or 
changes in behaviour, compared to findings from veterinary examination.  
Assessing QoL is a useful tool to help veterinary surgeons make treatment recommendat ions 
and monitor longitudinal changes as well as providing an opportunity to assess owner 
perceptions of disease (Yeates & Main, 2009). Quality of life is considered one of the most 
important factors affecting owner decision making regarding disease treatment in older 
horses (Ireland et al., 2011c). The ability to assess individual QoL and factors affecting it is 
important when managing a chronic disease such as PPID. The importance of individualised 
QoL assessment has been recognised in small animal medicine (Budke et al., 2008) with 
several owner assessment tools already developed for dogs and cats (Wiseman-Orr et al., 
2004; Tzannes et al., 2008; Freeman et al., 2012; Lavan, 2013; Tatlock et al., 2017). It has 
been reported that owners’ perceptions of QoL and factors influencing it could be affected 
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by anthropomorphism or anthropocentrism (Bradshaw and Casey, 2007). However, 
compared to veterinary surgeons, owners have more experience of the individual animal and 
its normal daily activities, making them better positioned to assess QoL (McMillan, 2003; 
Wojciechowska and Hewson, 2005). The use of owner ratings in animal welfare research 
has been reported to be a legitimate and useful tool for assessing QoL (Meagher, 2009). 
Currently there is no validated way of measuring QoL in horses. Most currently available 
equine welfare assessment tools (reviewed by Hockenhull and Whay, 2014) focus on 
assessment of health indicators and clinical parameters, with none specifically designed for 
completion by horse owners. Therefore, no specific welfare assessment tool was deemed 
suitable for integration into an owner-completed questionnaire to gather information on 
owner perceived QoL. Instead, currently available assessment tools informed the QoL 
domains evaluated in the current study. Questions around QoL were developed from VAS 
utilised in human medicine (Katsura et al., 2003) and small animal assessment tools 
(Belshaw et al., 2015) to encompass a range of QoL domains (WHO, 2020). These included, 
activities of daily living, which have previously been considered to influence QoL in older 
horses (Ireland et al., 2011c), and the five freedoms (Mellor, 2016).  
Horses in this study were considered by their owners to have a very good overall QoL and to 
be experiencing minimal discomfort. This is similar to the good-excellent QoL rating reported 
for the general geriatric population (Ireland et al., 2011c). The high QoL rating given, 
despite the presence of a chronic condition, may be because PPID is perceived to be 
manageable, similar to diabetes in humans which may have minimal impact QoL if managed 
correctly (Hänninen et al., 2001). It has been suggested that owners may not be as adept at 
recognising pain in older horses because they misinterpret clinical signs as being signs of 
aging (McGowan et al., 2010b) and pain is an important influencer on QoL rating (Ireland et 
al., 2011c). Additionally, owners of horses with PPID recognise aspects of QoL that are good 
despite the condition. This has been described in human medicine where patients who have 
significant health and functional problems do not necessarily have QoL scores that seem to 
correspond with their health (Carr and Higginson, 2001) because they are able to adapt to 
overcome the illness (Hyde et al., 2003). 
Quality of life rating improved significantly from the time of diagnosis and treatment with 
pergolide was associated with a higher QoL rating. Although this might infer that pergolide 
treatment improved QoL ratings, owners were asked to retrospectively rate their horses QoL 
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at time of diagnosis, which may have introduced a degree of recall bias. Additionally, owners 
may have expected to see a difference after commencing treatment and therefore the 
difference in QoL rating may be over-estimated. Several management factors were 
associated with QoL rating. An average or good BCS was associated with a higher QoL 
rating, compared to animals reported to be underweight. Weight or BCS is considered and 
important health issue (Buckley et al., 2004), weight loss is a concern among owners of 
geriatric horses (McGowan et al., 2010b) and obesity is associated with metabolic health 
issues (Treiber et al., 2006b). Therefore, the association between BCS and QoL reported 
here is not surprising. Restricted grazing, particularly non-grass turnout, was negatively 
associated with QoL rating. For all methods of restricting grazing evaluated in the current 
study, the proportion of horses considered to have a good QoL (owner rating of overall QoL 
≥8/10) was smaller than that for horses with no restrictions to their access to grazing, with 
the greatest negative effect on QoL for use of a bare/dirt paddock, whereas use of a track 
system was not significantly different from no restriction. Further investigation is required to 
indicate if this effect on QoL varies dependent on whether restricted grazing practices are 
used for all or part of the year. Field turnout and good grazing were reported by owners as 
factors which positively influenced QoL of geriatric horses (Ireland et al., 2011c). Horses 
with access to grazing may be perceived by owners to have the freedom to express normal 
behaviours such as foraging and socialising resulting in a higher QoL rating. Stabling for 
extended periods of time has been associated with stereotypical and unwanted behaviours 
(McGreevey et al., 1995a,b). Also, horses with restricted access to grazing are more likely to 
have had or currently have laminitis, which was significantly association with a reduced QoL. 
Painful and recurrent conditions, such as laminitis, have previously been reported to 
influence owner perception of QoL (Ireland et al., 2011c). Several other clinical signs were 
also associated with a lower QoL rating including a curly/over-grown coat, muscle wastage, 
lethargy/poor performance and patchy/excessive sweating. It is doubtful that these clinical 
signs cause pain therefore, their association with QoL is likely to be due to their impact on 
daily management and owner perception of QoL.  
Conclusion  
Overall horses with PPID were perceived to have a very good QoL and pergolide treatment 
appeared to have a positive influence on QoL rating. The majority of horses received 
veterinary recommended treatment as well as a high level of routine and preventive health 
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care. Feeding and management practices undertaken was similar to those previously 
reported for geriatric horses, with the exception of carefully controlled access to grazing. 
Evaluation of QoL may be beneficial as a component of routine prescription checks or when 
considering changes in pergolide dose, but there remains the need for a practical tool that 
allows both owners and veterinary surgeons to easily assess QoL in horses. In the 
meantime, the impact of PPID on daily routine should be considered alongside clinical 





Appendices for Chapter 5 
Appendix 1 – Invitation letter sent to eligible owners registered with the 






Dear [client’s name], 
 
Further to our initial phone conversation we could like to give you details of a research study being 
carried out by the University of Liverpool. We are conducting a survey of owners of horses and ponies 
diagnosed with pituitary pars intermedia dysfunction (PPID; also known as Cushing’s syndrome).  
 
In our previous research, consultation with vets and owners with experience of PPID has identified 
important research questions, which you as carers want answered. One of top ten most important 
research priorities was to investigate the most effective management and treatment strategies for 
horses and ponies with PPID. We are writing to invite you to participate in a research study we hope 
will go some way to addressing this important area of research.   
 
The purpose of this study is to improve our knowledge and understanding of current management 
and treatment approaches undertaken and to develop healthcare plans to improve the quality of life 
of horses and ponies with PPID. However, this research could not be done without your help.  The 
answers you provide about your horse or pony can help make a real difference to the health of 
horses and ponies with PPID. 
 
It is important for you to understand why the research is being done and what it will involve.  Please 
take time to read the enclosed study information sheet carefully and feel free to ask us if you would 
like more information or if there is anything that you do not understand (using the contact details 




The initial survey will be conducted by telephone and consists of questions about your horse’s 
routine, feed, general health and, where applicable, treatment for PPID.  We will also ask you to 
complete three short follow-up questionnaires to document any changes over time. Your privacy is, of 
course, of the utmost importance to us and if you decide to take part, all responses are completely 
confidential and will only be used for the purposes of this survey.   
 
We hope you will be able to participate, however your involvement is entirely voluntary.  If you no 
longer wish to take part please email rebecca.tatum@liverpool.ac.uk or telephone Becky on 01638 
751000 extension 1241, we will not contact you further and the contact details you provided will be 
removed from our dataset. If we do not hear from you the University of Liverpool researcher, Becky 
Tatum, will contact you by telephone at your specified convenient time. 
 





Becky Tatum, PhD Student, University of Liverpool 
Dr Joanne Ireland, PhD Supervisor, University of Liverpool 





Appendix 2 - Information sheet sent alongside invitation letter to eligible 
owners registered with the University of Liverpool Equine practice 
 
Information Sheet  
Optimising Care for Cushing’s (PPID) Horses and Ponies   
You are being invited to participate in a research study. Before you decide whether to participate, it is 
important for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and feel free to ask us if you would like more 
information or if there is anything that you do not understand. Please also feel free to discuss this 
with your friends, relatives or veterinary surgeon if you wish. We would like to stress that are free to 
opt out of participation and should only agree to take part if you want to.  
What is the purpose of the study?  
The purpose of this study is to investigate which management and treatment factors are most likely 
to improve quality of life for horses and ponies with pituitary pars intermedia dysfunction (PPID; also 
known as Equine Cushing’s Syndrome). Quality of life is a way of measuring your horse/pony’s overall 
health, wellbeing and happiness.   
Why have I been chosen to take part?  
You have been chosen to take part in this study because your horse/pony has been diagnosed with 
PPID (based on a laboratory test result where the hormone ACTH was above the normal reference 
range for the time of year the sample was taken). If this information is no longer correct, please 
inform us of any change in circumstances using the contact details below.  All owners registered with 
the University of Liverpool Leahurst Equine Practice whose horse/pony has been diagnosed with PPID 
in the past three years are being invited to participate in this study. All horses/ponies diagnosed with 
PPID are eligible to be included in this study, whether or not they are currently receiving any medical 





About the study  
If you agree to take part in the study, we will ask you to take part in a telephone questionnaire, 
which will take around 20 minutes to complete. You will be asked questions about your horse/pony’s 
routine, daily care, exercise, health, any medication or other treatments they receive and how you 
perceive their quality of life. This will be followed by three shorter follow-up questionnaires at 
approximately three month intervals to document any changes over time. Your responsibility as a 
participant of this study will be to answer all questions honestly and with your own opinion. We will 
also use your horse/pony’s clinical records from the Leahurst Equine Practice in order to help us 
understand the associations between PPID laboratory test results (measuring ACTH) and health and 
quality of life of horses/ponies with PPID.   
Participating in this study will not interfere with your horse/pony’s management, routine preventive 
healthcare, treatment for PPID or treatment of any other conditions. However, if you chose to make 
any changes to your horse/pony’s management throughout the study, such as feeding, exercise 
regime, field turnout or stabling and any healthcare you provide such as worming or vaccinations, we 
would ask you to record these changes and let us know, either directly using the contact details 
provided, or during a follow-up telephone questionnaire.  
The data we collect will be anonymised with no information that could identify you or your horse. It 
will be kept confidential and stored securely on University password protected computers, it will be 
used for this specific study only and only the study research team at the University of Liverpool will 
have access to the data. You or your horse/pony will not be identifiable from the results.   
Why is this study important?  
Pituitary pars intermedia dysfunction is the most common hormonal disorder of older horses/ponies. 
Previously we have engaged with vets and owners (with experience of PPID) to prioritise areas of 
research they consider to be important. Establishing which management (including aspects such as 
dietary and turnout) and treatment strategies are most effective were areas ranked in the top 10 
research priorities. The information provided in this study will help us to better understand current 
management and treatment approaches undertaken for horses/ponies with PPID. The aim is to have 
more information about management and treatment options for veterinary surgeons and owners in 
order to improve the quality of life of horses and ponies with PPID.  
Are there any risks to myself or my horse/pony?  
As we are only using telephone questionnaires to collect data we do not anticipate any disadvantages 
or risks associated with your or your horse/pony’s participation.   
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What happens if I want to stop taking part?  
We would like to stress that your participation is voluntary. As a participant if you wish to end your 
participation at any point during the phone call or duration of the study you are free to do so. If you 
decide to withdraw your responses during or at the end of the interview, and if you request it, we will 
destroy any data regarding yourself or your horse from the study.   
Contact details  
If you have any questions or for further information please contact:  
Becky Tatum   
Email: rebecca.tatum@liverpool.ac.uk  
Telephone: 01638 751000 Ext. 1241  
  
If you are unhappy, or if there is a problem, please feel free to let us know by contacting Becky 
Tatum or Jo Ireland and we will try to help. If you remain unhappy or have a complaint which you 
feel you cannot come to us with then you should contact the Research Governance Officer on 0151 
794 8290 (ethics@liv.ac.uk). When contacting the Research Governance Officer, please provide 
details of the name or description of the study (so that it can be identified), the researcher(s) 
involved, and the details of the complaint you wish to make.  
  
Thank you for taking the time to read this.  
  
Becky Tatum   
  
The contact details of lead Researcher (Principal Investigator) are: [Contact: Dr Joanne Ireland, 
Leahurst Equine Practice, Leahurst Campus, University of Liverpool, Neston, Wirral, CH64 7TE, email: 







Appendix 3 - The image and text used to promote the survey on the UoLEP 
and Talk About Laminitis Facebook pages 
 
Can you help improve the care of horses and ponies with PPID (Equine Cushing's 
Syndrome) 
If your horse or pony has been diagnoses with PPID within the last 4 years please help us 
by completing our questionnaire by following this link: https://kwiksurveys.com/s/xRjV8Vdm 
Pituitary Pars Intermedia Dysfunction (PPID also known as Cushing’s) is the most common 
hormonal disorder in older horses and ponies in the UK. Here at the University of 
Liverpool we are conducting an important new research study called; Optimising Care 
for PPID Horses and Ponies.  
The purpose of this study is to improve our knowledge and understanding of current 
management and treatment approaches undertaken by owners and carers. This will help to 
develop healthcare plans to improve the quality of life of horses and ponies with 
PPID.  
For more information and to take part follow this link: https://kwiksurveys.com/s/xRjV8Vdm  
Picture to accompany post: 
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Appendix 4 - The questionnaire used to gather information regarding 






















































A prospective cohort study of horses diagnosed 




A prospective cohort study of horses diagnosed with pituitary pars 
intermedia dysfunction in the United Kingdom 
Summary  
The expected disease progression of PPID, both with and without treatment, has been 
identified as the most important research priority for owners and veterinary surgeons with 
experience of PPID. However, information regarding disease progression, management and 
prognosis is currently limited. Owners of horses diagnosed with PPID were identified 
through University of Liverpool Equine Practice (UoLEP) database and invited to participate. 
84.8% of owners (n=67/79) completed a baseline questionnaire, providing data for 72 PPID 
cases that were enrolled in the prospective cohort. At least one complete follow-up 
questionnaire was available for 62 cases that contributed a total of 53.4 horse-years at risk 
(HYAR), with a median duration of follow-up of 330.7 days (IQR 247.1-388.9 days). 
Throughout the follow-up period, pergolide dose remained the same for 78.2% (n=43/55) 
of cases. Quality of life rating remained unchanged in 43.5% (n=27/62) of horses, 
decreased in 21.0% (n=13/62), increased in 8.1% (n=5/62) and fluctuated in 27.4% 
(n=17/62). The most frequently reported clinical signs reported throughout follow-up were 
recurrent/persisting infection (19.4% n=12/62), abnormal coat shedding (16.1% n=10/62) 
and laminitis (12.9% n=8/62). During the follow-up period 17.7% (n=11/62) of horses died 
representing an overall mortality rate of 20.6 deaths per 100 HYAR (95% CI: 10.3-36.9 per 
100 HYAR). Based on the first new episode during the follow-up period, incidence of 
laminitis was estimated to be 15.7 episodes per 100 HYAR (95% CI 6.8-30.9 per 100 HYAR) 
and the incidence of infection was estimated to be 24.9 events of infection per 100 HYAR 
(95% CI 12.8-43.4 per 100 HYAR). The prospective changes described in this cohort provide 
valuable additional information on the management, treatment and clinical factors observed 
in horses with PPID as well as the long-term practices undertaken by owners. This will be 
useful for veterinary surgeons when advising on the long-term management and prognosis 
of horses with PPID. 
Introduction 
Diseases that are prevalent in older horses are becoming important in equine practice 
(Ireland et al., 2012c; McGowan et al., 2013a), since the equine population is living longer 
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(Welsh et al., 2016). Pituitary pars intermedia dysfunction (PPID) is a progressive endocrine 
disease caused dopaminergic neurodegeneration that is frequently diagnosed in older horses 
(aged ≥15 years) (Brosnahan and Paradis, 2003b; McGowan et al., 2013a). It is 
characterised by a wide variety of clinical signs including hypertrichosis, epaxial muscle 
wastage and lethargy (McFarlane, 2014; Ireland and McGowan, 2018), and its progressive 
nature means long-term management is required.  
Expected disease progression, both with and without treatment, has been identified as the 
most important research priority for owners and veterinary surgeons with experience of 
PPID (Chapter 2).  In human medicine, patient and public involvement (PPI) is regularly 
used to prioritise and direct research for chronic diseases, helping to improve patient care 
for conditions such as diabetes and heart disease (Crowe, 2009; Cowan, 2013; Finer et al., 
2017). This methodology was adapted into an equine veterinary setting to prioritise research 
questions for the diagnosis, treatment and prognosis of PPID (Chapter 2). Numerus studies 
have investigated the diagnosis and treatment of PPID (Donaldson et al., 2002; Pongratz et 
al., 2010; Anon, 2011a; McGowan et al., 2013b; Rendle et al., 2013; Gehlen et al., 2014), 
however information regarding disease progression, management and prognosis is currently 
limited to retrospective data (Welsh et al., 2016), small samples sizes (Rohrbach et al., 
2012; Schott et al., 2020b), case series (Spelta and Axon, 2012) or with a referral hospital 
bias (Horn et al., 2019). PPID has been reported to have a considerable negative effect on 
survival (Welsh et al., 2016), and associated with an increased risk of mortality (Ireland et 
al., 2011d; Welsh et al., 2016; Pollard et al., 2020). Rates and causes of mortality have been 
described for the general geriatric population (Ireland et al., 2011d), with an overall 
mortality rate of 11.1 per 100 horse-years at risk (HYAR) reported, while lameness (24%) 
and colic (21%) were the most frequent reasons for euthanasia. However, information 
regarding incidence of concurrent diseases as well as the incidence and causes of mortality 
in horses diagnosed with PPID is limited.  
Poor owner-reported QoL has also been associated with an increased risk of mortality in 
geriatric horses (Ireland et al., 2011c). However, despite the impact PPID has on equine 
health, horses with the disease are perceived by their owners to have a good QoL, as 
indicated by high ratings of overall QoL and general demeanour, together with low ratings 
for negative impacts on health-related QoL such as discomfort (Chapter 5). One small study 
reported that the vast majority of owners would choose to treat another horse with PPID, 
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and used this to infer that owners were satisfied with long-term QoL (Rohrbach et al., 
2012). Other studies have followed PPID cases prospectively and reported good clinical 
improvement (Schott et al., 2014; Horn et al., 2019) however, individual clinical signs were 
not investigated.  
There is a need for further information regarding owner disease management and clinical 
changes over time in horses with PPID. This could be utilised to help inform and improve 
management and treatment decisions, which in turn may improve prognosis. This 
observational, retrospective and prospective cohort study aimed to describe the changes in 
treatment, management, clinical factors and QoL observed overtime in horses with PPID as 
well as incidence of disease and mortality.  
Materials and methods  
Selection of the study population and retrospective data collection  
A review of the University of Liverpool Equine Practice (UoLEP) database was undertaken to 
identify all PPID cases diagnosed between 1st January 2014 and 31st August 2018 (Figure 1).  
Cases were diagnosed using basal plasma ACTH concentration above the upper limit of 
seasonally adjusted reference intervals (>29.7 pg/ml November-July or >47 pg/ml August-
October) or a positive response to the administration of thyrotropin-releasing hormone 
(TRH) (>110 pg/ml at 10 minutes). Horses diagnosed prior to 1st January 2014 were 
excluded to reduce the risk of owner recall bias. All owners of eligible cases were invited to 
participate in the study, therefore a sample size calculation was not performed. All owners 
were initially contacted by telephone and asked if they would like to opt in to the cohort 
study.  Owners opting in at this stage were subsequently sent an enrolment letter and 
participant information sheet (Appendix 1), which contained details about the study and a 
further option to opt out if they no longer wished to participate. This study was awarded 
institutional ethical approval on the 18 th May 2018, reference number VREC667. 
Owners verbally agreeing to participate during the initial telephone call were also asked 
whether they would consent to their horse’s clinical records being used for the purposes of 
the research study.  Where owners provided consent, data collected from clinical records, 
included signalment, date of PPID diagnosis, method of diagnosis, ACTH concentration, 
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owner-reported clinical signs, history of laminitis, clinical examination findings and details of 
any treatment(s) administered, prescribed or recommended.  
Cohort study design and prospective data collection 
Prior to commencement of the study >100 cases of PPID diagnosed within the previous four 
years had been identified on the UoLEP database (Figure 1). In order to optimise 
recruitment and retention, participating owners were contacted by the doctoral student via 
telephone to complete the baseline questionnaire, at least two weeks after receipt of the 
enrolment letter to allow ample time to opt out.  Design of the baseline questionnaire is 
described in full in Chapter 5.  In brief, the baseline questionnaire gathered data on 
stabling/turnout routine, feed, exercise, general health, medical treatment, alternative 
treatments and owner-perceived QoL. Data were collected on previous clinical signs 
observed as well as any clinical signs which occurred during the follow-up period. 
Consecutive prospective follow-up questionnaires were completed over an 18-month period. 
Both the baseline (Chapter 5 Appendix 4) and follow-up questionnaires (Appendix 2) were 
designed using online data capture software (KwikSurveys). Where owners were not 
contactable by telephone within five separate attempts, a link to the baseline questionnaire 
was sent via email and owners were requested to complete the questionnaire online. 
Owners who were not contactable by telephone and did not respond to the email requesting 
online completion of the baseline questionnaire were excluded from the prospective phase 
of the cohort study.  
Owners were then contacted by telephone within 3 – 4 months of the initial baseline 
questionnaire to complete the first follow-up questionnaire, with three subsequent follow-
ups conducted at 3 – 4 month intervals. Again, where owners were not contactable by 
telephone within five separate attempts, a link to the follow-up questionnaire was sent via 
email. Owners who were not contactable to complete a minimum of one follow-up 
questionnaire were excluded from the follow-up study. All telephone questionnaires were 
administered by the doctoral student.   
Data were collected on any changes to management, treatment and health since the 
previous questionnaire.  The Likert-style questions used to gather BCS ratings and the visual 
analogue scale (VAS) QoL questions were replicated from the baseline questionnaire (See 
Chapter 5 Appendix 4) and the comprehensive clinical signs list was also included to record 
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clinical signs observed at the time of follow-up questionnaire.  Additionally, episodes of 
disease or injury were recorded. Where applicable, respondents completed additional 
questions to gain information regarding the disease episode or injury reported and any 
treatment administered. The horse’s survival status was also confirmed, and where death 
was reported, owners completed a separate mortality questionnaire (Appendix 3).  
All owners who opted in to participate in the study gave consent to obtain their horse’s 
veterinary clinical history. Therefore, the data provided by respondents for ACTH levels at 
time of diagnosis, episodes of disease, injury or death were cross-referenced with clinical 
notes and dates of veterinary visits during the follow-up period.  
Data analysis   
All baseline and follow-up questionnaire data were exported into Microsoft Excel 
spreadsheets, using the KwikSurveys software, and each horse was allocated a unique 
identification number. Relevant clinical record data, including ACTH assay results, number of 
diagnostic and monitoring tests/visits, clinical signs and concurrent conditions, for all horses 
that entered the study were manually extracted from each individual horse’s UoLEP clinical 
history into a specifically designed Microsoft Excel spreadsheet. Results of all questionnaires 
and relevant clinical history for each individual horse were then merged into a single 
spreadsheet for comparison and analysis. Statistical analyses were performed using 
commercial statistical software (IBM SPSS Statistics Version 25). Analysis of baseline data 
was carried out using data for all horses for which a baseline questionnaire was completed. 
Data analyses of changes over the follow-up period included horses for which at least one 
follow-up questionnaire had been completed.  
Continuous data from the questionnaire responses were not normally distributed and are 
therefore described as medians with interquartile ranges (IQR), and categorical data are 
described as proportions. For BCS, the mean of three owner-reported scores (neck, ribs, and 
pelvis) was calculated to provide an overall BCS for each individual questionnaire (described 
in full in Chapter 5). Owner-reported overall QoL on a scale of 1 (could not be worse) – 10 
(could not be better) and ratings for individual QoL domains are reported as medians with 
IQR. An open-ended question was used to gather information on factors or changes that 
owners considered to influence their horse’s QoL during the follow-up period. Descriptive 
statistics were used to evaluate changes from baseline over the follow-up period. Pearson 
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Chi-squared or Fisher’s exact tests were used to assess associations between categorical 
variables. Incidence rates for binary outcomes of i) death/euthanasia, ii) laminitis and iii) 
infection were calculated and expressed as per 100 horse-years at risk (HYAR) with 95% 
confidence intervals (CI). Due to the difficulty in accurately defining the date of resolution of 
an episode of laminitis in recurrent cases, and therefore establishing when an affected horse 
could be defined as re-entering the population at risk, only the first new episode of laminitis 
during the follow-up period was included as an outcome of interest. For each of the three 
outcomes, time at risk was calculated from the date of baseline questionnaire completion, 
which signalled the date of entry of the horse into the study, until the date on which they 
were euthanased or died, reported to have a new episode of laminitis, or an infection (e.g. 
abscess, infected slow healing wound, eye infection).  For each analysis, horses that did not 
have the outcome of interest were censored on the date of the last completed follow-up 
questionnaire. A Kaplan-Meier estimate of overall survivor function was performed, and log 
rank (Mantel-Cox) tests were used to compare survival curves between pergolide-treated 
and non-treated PPID cases.  Statistical significance for all analyses was set at p<0.05. 
Results  
Database searches identified a total of 135 PPID cases, of which ten were excluded 
following review of clinical records as PPID diagnosis or commencement of PPID treatment 
was prior to 1st January 2014, and three further cases were excluded as results of endocrine 
assays did not meet inclusion criteria (Figure 1). A further seven cases were excluded as 
they had not been attended by UoLEP for over two years or owner contact details provided 
were not up-to-date (Figure 1). Five cases had been euthanased prior to the study start 
date, and two cases had been sold. Of the remaining 108 cases, 79 owners were 
contactable and all agreed to participate in the study at the opt-in phone call. As some 
owners cared for multiple horses (>1), this provided clinical record data for 83.3% of 
eligible PPID cases (n=90/108).  
Retrospective review of clinical records 
Clinical records of the 90 PPID cases for which owners gave consent were reviewed, and 
veterinary follow-up data were available for 88 of these cases during the prospective cohort 
study period, irrespective of owner questionnaire completion. The remaining two cases did 
not receive any veterinary visit after the start date for prospective data collection, and were 
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lost to veterinary follow-up during 2017. Information regarding PPID diagnosis was not 
available for four cases that had been diagnosed prior to registration with UoLEP. The vast 
majority of cases were diagnosed with PPID based on elevated basal ACTH (96.5%; 
n=83/86), with only 3 cases (3.5%) diagnosed based on results of a TRH stimulation test. 
Forty-four percent of cases (n=38/86) were diagnosed during autumn months (August-
October, inclusive, as per months included in laboratory seasonally adjusted reference 
intervals), with the remainder diagnosed during non-autumn months. Prior to the diagnosis 
of PPID, 26.7% of cases (n=23/86) had at least one measurement of basal ACTH that was 
within seasonally adjusted reference intervals (median of 1 previous test; IQR 1-2). The 
median time between the first normal/equivocal ACTH result and subsequent PPID diagnosis 
was 2.88 years (IQR 0.95-4.02 years), and laminitis was the most frequent reason for 
undertaking the initial ACTH measurement (21.7%; n=5/23).  Overall, 18.6% of cases 
(n=16/86) had a history of laminitis prior to any laboratory testing for PPID. An active 
episode of laminitis was the primary reason for ACTH measurement in 17.0% of cases 
(n=15/88), and eight of these animals also had a history of previous episodes of laminitis. A 
few cases (8%; n=7/90) were not treated for PPID following diagnosis, and for pergolide-
treated animals, the median recorded starting dose was 1mg/animal/day for both horses 
and ponies (IQR for ponies 0.5-1mg; range 0.25-1mg; IQR for horses 1-1mg; range 0.25-
2mg).  
Of the 18 cases that did not have a baseline questionnaire completed, four were euthanased 
during the prospective data collection period due to colic (n=2) or recurrent laminitis (n=2). 
There was no association between owner completion of the baseline questionnaire and 
mortality during the follow-up period (p=0.84) or cases receiving pergolide treatment at the 
time of diagnosis (p=0.69).  
Prospective cohort study population 
Subsequently, 84.8% of owners (n=67/79) then completed a baseline questionnaire, 
providing data for 72 PPID cases that were enrolled in the prospective cohort (Figure 1). 
Follow-up data were not available for 10 horses as owners were not contactable by 
telephone and did not respond to emails inviting them to complete follow-up questionnaires 
online.  Comparison between PPID cases that had at least one follow-up (n=62) and those 
cases with baseline data that did not have at least one completed follow-up questionnaire 
(n=10), and there were no differences in population medians for age (p=0.48) or height 
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(p=0.46).  Additionally, there were no significant differences in median time since diagnosis 
(p=0.71), daily pergolide dose (p=0.89) or QoL rating at baseline (p=0.17) between cases 
with follow-up data and those lost to follow-up at the start of prospective data collection. 
Additionally, administration of pergolide treatment at the time of baseline data collection 






Figure 1: Flowchart demonstrating the process of how cases were recruited to participate 
in the baseline questionnaire and prospective cohort study.  
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The remaining 62 horses in the cohort contributed a total of 53.4 HYAR, with a median 
duration of follow-up of 330.7 days (IQR 247.1-388.9 days). All losses to follow-up between 
the first and fourth follow-up questionnaires occurred due to unsuccessful telephone contact 
within five separate attempts (11.3%; n=7). Eleven cases of mortality were reported during 
the follow-up period, therefore, at the end of the follow-up period 44 horses were alive with 
complete owner-reported follow-up data.  
Demographics and diagnosis 
The median age of the population at baseline was 24.5 years (IQR 20.3-27.8 years) and the 
median duration of ownership was 14.0 years (IQR 7.1-19.0 years). The study population 
comprised 51.4% (n=37/72) geldings and the remaining 48.6% (n=35/72) were mares. 
Based solely on height, 58.3% of the cohort (n=42/72) were ponies (≤147.3 cm in height).  
The most numerous breeds were native/native-cross breeds (43.1%; n=31/72), followed 
Irish Draught/Irish Draught-cross (15.3%; n=11/72) and Thoroughbred/Thoroughbred-cross 
(13.9%; n=10/72). 
Based on clinical record data, horses had been diagnosed with PPID for a median of 2.1 
years (IQR 1.1-3.3 years) prior to baseline data collection. Where date of diagnosis was 
available, over half of horses (56.5%; n=39/69) were diagnosed during non-autumn months 
(Nov-Jul), while the remainder were diagnosed during autumn months (Aug-Oct). The 
median ACTH level reported in clinical records at the time of diagnosis was 93.0pg/ml (IQR 
66.6-151.0pg/ml). As expected, the median ACTH level of horses diagnosed in autumn 
(127.0 pg/ml) was significantly higher compared to those diagnosed during non-autumn 
months (72.8 pg/ml) (p<0.001). When owner-reported ACTH levels were compared to 
clinical record data, only 14.4% (n=12/69) of owners reported a broadly similar result 
(within ±20pg/ml).    
Treatment and veterinary visits  
At baseline, 81.9% (n=59/72) of cases received pergolide treatment, which was 
administered once daily by the majority of owners (93.2%; n=55/59) and the median dose 
was 1mg/animal/day (IQR 1-1mg/animal/day). Throughout the follow-up period, pergolide 
dose remained the same for 78.2% (n=43/55) of cases, decreased in 7.3% (n=4/55), 
increased in 10.9% (n=6/55) and treatment was stopped in two cases (3.6%). The reason 
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reported for stopping treatment in both cases was a lack of noticeable beneficial effect by 
the owner. One previously untreated case started pergolide treatment during the follow-up 
period. Throughout the follow-up period, 81.8% (n=45/55) of cases remained on once daily 
dosing. For 9.1% of cases (n=5/55), pergolide administration changed from being split twice 
daily to given once daily and for 7.3% (n=4/55) dosing changed from once daily to splitting 
the dose and administering twice daily. The owner of one further case reported changing 
from daily dosing to administering the same dose every other day (i.e. administered once 
every 48 hours).  Eleven percent of cases (n=8/72) received some form of alternative (n=5) 
or complementary (n=3 concurrently receiving pergolide) treatment at baseline, most 
frequently Vitex Agnus castus (5.6%; n=4/72) or another herbal supplement marketed for 
PPID cases (4.2%; n=3/72). During follow-up, one case was reported to receive a new 
complementary treatment during follow-up while alternative or complementary treatment 
discontinued in two cases due to lack of noticeable effect. 
Owners reported over half of horses (58.1%; n=36/62) to have received ≥1 veterinary visit 
for PPID monitoring, including an ACTH assay performed, while clinical data showed that 
69.4% (n=43/62) had ≥1 veterinary visit including an ACTH assay. A further two owners 
had monitoring visits but refused a blood test. The median number of ACTH monitoring 
assays carried out per horse over the follow-up period was 1 (IQR 0-2). Clinical record data 
showed that 40.3% (n=25/62) had a single ACTH assay performed, while 16.1% (n=10/62) 
had two. Of those that had one ACTH assay during follow-up, the majority (68.0% 
n=17/25) were performed during non-autumn months (Nov-July), and of those that had two 
ACTH assays, most (90.0%; n=9/10) tests were performed during both autumn (Aug-Oct) 
and non-autumn months.  
Based on the seasonally adjusted reference intervals (RI) detailed in the methods section 
above, 51.4% (n=18/35) of horses had ≥1 ACTH concentrations within seasonally adjusted 
RIs during the follow-up period. Of the horses that had a single ACTH test during the follow-
up period, 48.0% (n=12/25) had a concentration within seasonally adjusted RIs. Of those 
that had >1 test, 60.0% (n=6/10) had ACTH concentrations that were consistently within 
RIs, and the remaining four cases had high concentrations that decreased to within 
seasonally adjusted RI. Of the horses that had elevated or consistently elevated ACTH 
concentrations, 17.6% (n=3/17) had their pergolide dose increased during the follow-up 
period.    
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Owners reported that 44.4% (n=28/62) of horses were vaccinated for either tetanus of 
equine influenza during the follow-up period, while clinical records showed that 53.2% 
(n=33/62) were recorded as having been vaccinated. 
Description of changes over the follow-up period  
Management  
Less than half of horses (43.1%; n=31/72) were reportedly in regular ridden exercise at 
baseline, which consisted of low-level leisure activities such as hacking and schooling for all 
horses in work. Of those horses in regular ridden exercise at baseline for which follow-up 
data were available (43.5%; n=27/62), of these 22.2% (n=6/27) were retired during the 
follow-up period, the level/intensity of work increased for 14.8% (n=4/27) of cases and 
14.8% (n=4/27) resumed work after not being exercised for a period of time.  
Median turnout hours for each season at baseline and throughout the follow-up period are 
shown in Figure 2. Unsurprisingly, the amount of forage fed varied with season in over half 
of cases (54.8%; n=34/62) with owners reporting they decreased the amount during spring 
and summer months and increased it during autumn and winter months. The amount of 
forage fed changed for reasons other than season (such as weight management) in 24.2% 
(n=15/62) and did not change during follow-up in 21.0% (n=13/62) of cases. Half of horses 
had their bucket feed changed during the follow-up period (50.0%; n=31/62); the most 
common changes were increasing or decreasing the amount of current feed (58.1% 
n=18/31), the addition of another feed type (38.7% n=12/31) (additional feeds included 
concentrates/balancer [33.3% n=4/12] and sugar beet [25.0% n=3/12]) or the addition of 
a supplement (35.5%; n=11/31) (including pro/pre-biotics [41.7% n=5/12], linseed oil and 
joint supplements [both 25.0% n=3/12]). 
The median overall BCS (calculated as the mean of three owner-reported scores for neck [1-
5 scale], ribs and hindquarters regions based [0-5 scale] at baseline was 2.5/5 (IQR 2-3). 
Throughout the follow-up period, BCS remained constant in 25.8% (n=16/62) of horses, 





Figure 2: Median owner-reported turnout hours throughout the year at baseline and during 
the follow-up period with inter quartile ranges.  
Quality of life and clinical signs  
Median overall QoL rating at baseline was 9/10 (IQR 8-10). Quality of life rating remained 
unchanged during follow-up in 43.5% (n=27/62) of horses, decreased in 21.0% (n=13/62), 
increased in 8.1% (n=5/62) and fluctuated in 27.4% (n=17/62). Where QoL fluctuated it 
was reported to decrease for a period and then increase in 22.6% (n=14/17) and increase 
for a period and then decreased in 4.8% (n=3/17). The most frequently reported reason for 
a decrease in overall QoL rating during follow-up was development or worsening of 
osteoarthritis (14.5%; n=9/13) and all horses that were reported to suffer from laminitis 
had a decreased QoL during each episode (100%; n=8/8).  
Median ratings for appetite and demeanour were both 10/10 (IQR 9-10) at baseline. 
Demeanour rating remained unchanged during follow-up in 51.6% (n=32/62), decreased in 
16.1% (n=10/62), increased in 16.1% (n=10/62) and fluctuated in 16.1% (n=10/62). 
Appetite rating remained unchanged in 67.7% (n=42/62), decreased in 6.5% (n=4/62), 
increased in 12.9% (n=8/62) and fluctuated in 12.9% (n=8/62). Median discomfort rating 




















(n=30/62), decreased in 16.1% (n=10/62), increased in 17.7% (n=11/62) and fluctuated in 
17.7% (n=11/62). 
The most frequently reported clinical signs at baseline were abnormal coat shedding 
(26.4%; n=19/72), a history of laminitis (23.6%; n=17/72) and hypertrichosis (22.2%; 
n=16/72). Changes in clinical signs over the follow-up period are described in Table 1. None 
of the clinical signs observed were significantly associated with season. Unsurprisingly, 










Table 1: Clinical signs reported at baseline and throughout the follow-up period in a cohort of 62 horses diagnosed with PPID divided based 
on whether clinical signs were reported at baseline or not. 
Clinical sign PPID cases 





























% N % N % N % N % N 
None 50.0 8 - - - - - - 23.9 11 
Active laminitis 6.3 1 2.2 1 2.2 1 - 0 15.2 7 
Previous history of laminitis - 0 32.6 15 - 0 32.6 15 8.7 4 
Abnormal fat distribution  - 0 10.9 5 4.3 2 - 0 2.2 1 
Pot-bellied appearance 12.5 2 17.4 8 4.3 2 10.9 5 6.5 3 
Epaxial muscle wastage 6.3 1 10.9 5 2.2 1 8.7 4 10.9 5 
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Supraorbital or periorbital fat deposits  6.3 1 21.7 10 4.3 2 8.7 4 2.2 1 
Excessive/patchy sweating - 0 6.5 3 6.5 3 - 0 4.3 2 
Polydipsia and polyuria  - 0 6.5 3 2.2 1 - 0 2.2 1 
Lethargy/poor performance - 0 4.3 2 4.3 2 - 0 4.3 2 
Recurrent/persistent infection  12.5 2 10.9 5 2.2 1 - 0 21.7 10 
Abnormal coat shedding 12.5 2 37.0 17 15.2 7 17.4 8 17.4 8 
Curly coat - 0 4.3 2 2.2 1 2.2 1 6.5 3 
Hypertrichosis  18.8 3 28.3 13 13.0 6 8.7 4 8.7 4 
Changes to coat colour/texture 6.3 1 17.4 8 10.9 5 2.2 1 13.0 6 
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Mortality and disease incidence rates 
During the follow-up period, 17.7% (n=11/62) of horses died, representing an overall 
mortality rate of 20.6 deaths per 100 HYAR (95% CI 10.3-36.9). A Kaplan-Meier estimation 
of overall survival of the cohort is shown in Figure 3, and estimated mean survival time was 
428.0 days (95% CI 397.2-458.7 days). All cases of mortality were euthanased by a 
veterinary surgeon. The most common reason for euthanasia was colic (63.6%; n=7/11), 
and the remaining cases were euthanased due to recurrent laminitis, injury, severe infection 
and behavioural issues (each 9.0%; n=1). Owners of three cases reported that the fact their 
horse had PPID influenced their decision to have them euthanased, cause of death in these 
cases were acute illness, laminitis and behavioural issues. A further five horses were 
reported to have a decreased QoL prior to euthanasia, cause of death in these cases were 
colic (n=2), acute illness (n=1), laminitis (n=1) and neurological signs (n=1). There was no 
significant difference in the probability of survival between pergolide-treated cases (n=54) 
and those not receiving pergolide (n=8) (p=0.19). 
Figure 3: Kaplan-Meier estimate of overall survivor function for a cohort of diagnosed PPID 
cases registered with the University of Liverpool Equine Veterinary Practice (n=62).  
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New episodes of laminitis during the follow-up period were reported in 12.9% (n=8/62) of 
horses, of these; six were veterinary-diagnosed, and four horses had a previous history of 
laminitis. Two cases were reported to have had multiple episodes of laminitis during the 
follow-up period, with only time at risk to the date of the first episode included in incidence 
and survival analysis. Enrolled animals contributed a total of 51.0 HYAR for laminitis, and the 
incidence of laminitis was estimated to be 15.7 laminitis episodes per 100 HYAR (95% CI 
6.8-30.9 first new episodes per 100 HYAR). Six of the eight animals with at least one 
episode of laminitis during the follow-up period were receiving pergolide treatment, 
including the two cases with multiple laminitis episodes. The probability of not having an 
episode of laminitis was not significantly different between pergolide-treated cases (n=54) 
and those not receiving pergolide (n=8) (p=0.15). 
During follow-up, 19.4% (n=12/62) of horses were reported to have had an occurrence of 
infection, of which nine were veterinary-diagnosed and two had a previous history of 
recurrent infections. Types of infection reported were subsolar abscess (50.0%; n=6/12), 
ocular infection (41.7%; n=5/12) and skin infection (8.3%; n=1/12).  Enrolled animals 
contributed a total of 48.3 HYAR for infections, and the incidence of infection was estimated 
to be 24.9 events of infection per 100 HYAR (95% CI 12.8-43.4 episodes of infection per 
100 HYAR). Eleven of the 12 horses with at least one episode of infection during the follow-
up period were receiving pergolide treatment.  There was no difference in the probability of 
not having an episode of infection between pergolide-treated cases (n=54) and those not 
receiving pergolide (n=8) (p=0.58). 
Discussion 
The results presented here describe the changes in management, treatment, health and QoL 
in a field-based prospective cohort of horses with PPID, and provides useful information 
regarding rates of mortality and morbidity in a selected population of PPID cases. Many 
horses developed new morbidities during the follow-up period and overall mortality rate was 
20.6 deaths per 100 HYAR. QoL was excellent at baseline but decreased or fluctuated in half 
the horses, related to the development of comorbidities. 
Overall, the loss to follow-up was slightly higher than anticipated. A high level of loss to 
follow-up can lead to selection bias (Howe et al., 2016). Historically, a follow-up rate of 60% 
was considered good (Babbie, 1973), while a more recent study utilised simulated data sets 
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and reported that loss to follow-up can range for 5-60% without significant biases being 
observed (Kristman et al., 2004). The use of telephone recruitment and questionnaires 
resulted in good recruitment and retention rates, with a low loss to follow-up once 
participants were enrolled in the study, therefore the risk of selection bias is likely to be low. 
This methodology is also likely to have limited the risk of response bias and item omission, 
which can be a limitation of online or paper surveys (Paulhus, 1991; Fleming and Bowden, 
2009;). Moreover, the single veterinary practice, convenience sampling used to recruit 
participants and relatively small number of cases available at final follow-up means the 
population may not be entirely representative of the general population. However, the 
demographic characteristics of the study population were comparable to the larger cross-
section described in Chapter 5. Results derived from a wider population across multiple 
practices may be likely to differ. However, since pergolide is the only licensed medical 
therapy for PPID in the UK, it is probable that treatment recommendations would be broadly 
similar between different practices. Sampling cases from a single veterinary practice meant 
that diagnostic and treatment strategies undertaken are likely to have been similar among 
participants, and this similarity enabled the investigation of owner management changes, 
although it may reduce generalisability to other practice populations. Additionally, the use of 
both owner-reported data and clinical records allowed gaps to be filled where data was 
deficient or corrected where incorrectly reported.  
Follow-up questionnaires were conducted at regular intervals throughout the study, and the 
timing of each follow-up questionnaire would have been likely to influence owner responses. 
The QoL rating given would have been influenced by the clinical signs of PPID the horse was 
exhibiting at the time of follow-up. The degree to which owners consider clinical 
improvement synonymously with improvement in QoL has not been investigated to date and 
warrants further research. Owner ratings of QoL are also likely to be influenced by the 
presence or absence of other health problems. For example, during an episode of lameness, 
the owner QoL rating may be lower than several weeks prior to observation of lameness or 
after resolution. However, this study does uniquely demonstrate changes over time in 
horses with PPID, and highlights the important effect of comorbidities on overall QoL and 
owner perceptions of levels of discomfort.  
The mortality rate reported for the general geriatric population in the UK was 11.1 per 100 
HYAR (Ireland et al., 2011d), while a rate of 9.4 per 100 HYAR has been reported for the 
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geriatric population in Australia (McGowan, 2009). More recently, the incidence of 
euthanasia was 7.3 per 100 HYAR in a cohort of horses, with a median age of 15 years, 
recruited to a large laminitis study in Great Britain (Pollard et al., 2020). As PPID has been 
associated with an increased risk of mortality (Welsh et al., 2016) it is unsurprising that the 
incidence of mortality reported here is higher compared to these studies. The slightly older 
population reported here may also have influenced the incidence of mortality, as a previous 
study reported that the rate of mortality increased with increasing age, from 6.5 per 100 
HYAR for horses aged 15–19 years, to 35.2 per 100 HYAR aged >30 years (Ireland et al., 
2011d).  PPID was not reported as a cause of death in any cases and only three owners 
reported that the fact their horse had PPID influenced their decision to euthanase. The most 
frequently reported reason for mortality reported here was colic. Comparably, colic was also 
one of the most frequent reasons for euthanasia in a large field-based study (Pollard et al., 
2020) and in the general geriatric population (Ireland et al., 2011d).  
The majority of horses were reported by owners to have at least one clinical sign of PPID at 
baseline and also went on to develop at least one new clinical sign during the study. Of 
those horses reported to be exhibiting no clinical signs at the first follow-up, half remained 
free of clinical signs. Owners have been shown to underreport clinical signs of disease 
(Ireland et al., 2012a), however, in this study owners were aware their horse had PPID and 
therefore may monitor them more closely for clinical signs. The most frequently reported 
new clinical signs were; abnormal coat shedding and recurrent infections, while the clinical 
sign most frequently reported to resolve was also abnormal coat shedding. Coat changes 
were indicated in both groups and are well documented clinical signs of PPID (Schott, 2002; 
Innerå et al., 2013). These abnormalities are likely to be easiest for owners to notice and 
monitor, while also being most likely to resolve as they may not be observed during some 
seasons. It is therefore unsurprising they are most frequently reported. These data were 
predominantly based on owner-reported information as veterinary records often did not 
provide enough detail to enable the reporting of individual clinical signs. This highlights the 
importance of keeping correct and detailed clinical records that allow accurate data 
extraction for use in research.   
The incidence of laminitis reported in this cohort was higher than reported in previous 
studies. An Australian study of horses attending Pony Club events reported an incidence of 
laminitis within horse and pony groups separately: the pony group sampled was 6.5 cases 
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per 100 HYAR, while the incidence in horses was 0.55 cases per 100 HYAR (Potter et al., 
2017). A large prospective cohort reported an overall incidence of owner-reported laminitis 
of 9.6 per 100 HYAR for single episodes (Pollard et al., 2019). The higher incidence reported 
in this study may be due to the increased risk of laminitis in geriatric horses and horses 
diagnosed with PPID. Increasing age has been associated with an increased risk of laminitis 
(Alford et al., 2001) and laminitis is one of the most frequently reported clinical signs in  
PPID cases with an overall prevalence of 48.9% (Ireland and McGowan, 2018). The 
incidence of infections was higher than the overall incidence of owner-reported laminitis. 
Despite being a well-documented clinical sign of PPID, the prevalence of concurrent or 
recurrent infections is rarely documented (Ireland and McGowan 2018). To the authors 
knowledge this study is the first to report the incidence of infections in horses with PPID, 
which provides a valuable benchmark for comparison in future research. 
Despite the frequency of morbidities, both the general geriatric population (Ireland et al., 
2011c) and horses diagnosed with PPID have been reported to have a very good owner-
reported QoL (Chapter 5). In this study, cases were reported to have a very good owner-
reported QoL at baseline.  However, this rating changed in the majority of horses, with QoL 
reported to decrease over the follow-up period for over 20% of horses. Similarly discomfort 
ratings increased in nearly 18% of horses during the follow-up period. The main reason 
given by owners for a reduction in QoL was osteoarthritis and not related to PPID.  
Osteoarthritis is also age-associated and has been reported to be a common comorbidity in 
geriatric horses and PPID cases (Ireland et al., 2011d; Welsh et al., 2016). Owners may be 
more likely to notice the lameness and discomfort related to osteoarthritis, compared to 
some of the subtler clinical signs of PPID, and therefore associate it with a reduction in QoL. 
Unsurprisingly, all horses that were reported to suffer from laminitis had a decreased QoL 
during each episode. Decreased QoL has been reported to be associated with mortality in 
the general geriatric population (Ireland et al., 2011d), however it was out of the scope of 
this study to investigate factors associated with mortality. The occurrence of morbidities and 
risk of mortality were not affected by treatment status. The majority of cases were receiving 
pergolide treatment, with only a few owners choosing not to administer treatment or to use 
an alternative treatment. This is similar to the findings in Chapter 5 and a recent Australian 
study where 88.3% of cases were receiving pergolide treatment (Horn et al., 2019). For 
those cases which received pergolide treatment, the median dose was also comparable to 
other studies (Chapter 4; Chapter 5; Horn et al., 2019). Pergolide treatment was not 
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significantly associated with reduced incidence of mortality, laminitis or infection. This differs 
from the finding of Horn et al, (2019) which reported that pergolide treatment was positively 
associated with survival. However, both studies had relatively few horses that were not 
treated with pergolide, and the power of the current study is likely to be low for this reason, 
suggesting further work in this area is required.  
The majority of cases were maintained on the same dose of pergolide treatment throughout 
the follow-up period. However, nearly a third of horses did not receive a PPID veterinary 
assessment, including ACTH monitoring, during the follow-up period. Therefore, for many 
horses pergolide dose may have remained unchanged because of insufficient monitoring, 
rather than being due to satisfactory control of the disease. Additionally, owners of several 
cases reported decreasing or stopping treatment, suggesting non-compliance with veterinary 
recommended treatment (Steel et al., 2020; Hague et al., 2021). However, of those horses 
receiving pergolide treatment that had ≥1 ACTH assay performed during follow-up, just over 
half were within seasonally adjusted RIs. This is much higher than reported in a large 
retrospective study (28%; Rendle et al., 2013) and a recent cohort (34.7%; Horn et al., 
2020). Rendle et al., (2013) also reported that duration of treatment was positively 
associated with treatment response and that UK native breeds were more likely to return to 
within the reference interval. Therefore, the time since diagnosis and over-representation of 
native breeds in the population described here, may have contributed to the increased 
proportion of cases with ACTH levels within RIs. 
When owner-reported ACTH levels were compared with clinical records at diagnosis, there 
was a lack of accurate recall. This is unsurprising as horses were diagnosed a median of 2.1 
years previously, which may have increased the chance of recall bias. However, owners also 
under-reported monitoring veterinary visits and administration of routine vaccination. This 
demonstrates that recall bias can be an issue for owner-reported data even within a 
relatively short timeframe, and highlights the benefit of utilising clinical record data 
alongside owner-reported information. Clinical records demonstrated just under half of 
horses were not up-to-date with their vaccinations. This is in keeping with the fact that the 
frequency of vaccination reportedly reduces with increasing horse age and retirement 
(Mellor et al., 2001). However, the proportion reported to be vaccinated during follow-up in 
this study (53.2%) was lower than the reported in the general geriatric population (Ireland 
263 
 
et al., 2011b), where the majority of horses were regularly vaccinated for tetanus (82.8%) 
and equine influenza (66.3%). 
Retirement from exercise, turnout and BCS varied throughout the study based on routine 
seasonal changes as well as morbidities. Throughout follow-up, turnout hours during spring 
and autumn differed slightly from those reported by owners at baseline. Cases were 
reported to spend more time turned out during spring and more less turned out during the 
summer months. This may have been due to the phrasing of questions in the separate 
questionnaires. At baseline, owners were asked to report how long their horse was ‘usually 
turned out for’, compared to current hours during follow-up which is likely to have led to 
differences in response. Additionally, a small amount of variation may have be the result of 
specific weather conditions at the time of follow-up, which may have affected the amount of 
time horses spend turned out. During follow-up, owner-reported BCS changed in the 
majority of horses and was most frequently reported to decrease. Weight loss has been 
reported as a clinical sign of PPID (Ireland and McGowan, 2018) and has been associated 
with risk of mortality in geriatric horses (Ireland et al., 2011d) and horses with PPID (Horn 
et al., 2019). The overall BCS reported here was lower than for the general geriatric 
population, where the majority of horses (80.9%) were reported to be in good body 
condition (Ireland et al., 2011b). However, the change in BCS reported here may have been 
due to owner misinterpretation of clinical signs such as muscle loss and fat redistribution 
rather than true weight loss. A reasonable amount of horses were still in regular exercise 
despite their age. However, the number of horses in work was lower than reported in the 
geriatric population. Ireland et al (2011a) reported that 62% of horses were used for 
hacking/pleasure while over a quarter were still competing. The reduction in exercise 
reported here is perhaps unsurprisingly, as the amount of exercise was reported to decrease 
in intensity with increasing age (Ireland et al., 2011a). 
Conclusion  
In summary, the same treatment regime for most horses remained unchanged during the 
follow-up period, despite the majority of owners reporting the development of new clinical 
signs of PPID. Horses were perceived to have a very good QoL but this changed during 
follow-up in the majority of cases, with laminitis and osteoarthritis having the biggest 
detrimental impact on QoL rating. Many horses did not receive the recommended level of 
PPID monitoring, but of those that did, ACTH levels were predominantly well controlled. 
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Treatment regime did not significantly mortality rate or the incidence of laminitis or 
infection. Incidence of mortality was higher than in the general geriatric population, however 
none of the reasons for mortality were related to PPID. The prospective changes described 
in this cohort provide useful additional information on the management, treatment and 
clinical factors observed in horses with PPID as well as the long-term practices undertaken 
by owners. This will be useful for veterinary surgeons when advising on the long-term 
management and prognosis of horses with PPID, and for furthering owner education 




Appendices for Chapter 6 
Appendix 1 – Invitation letter and project information sent to participants 
by University of Liverpool Equine Practice 
 
Dear [client’s name], 
 
The University of Liverpool is conducting a survey of owners of horses and ponies diagnosed 
with Pituitary Pars Intermedia Dysfunction (PPID, also known as Cushing’s syndrome).  
In our previous research, consultation with vets and owners with experience of PPID has 
identified important research questions, which you as carers want answered. One of top ten 
most important research priorities was to investigate the most effective management and 
treatment strategies for horses and ponies with PPID. We are writing to invite you to 
participate in a research study we hope will go some way to addressing this important area 
of research.   
The purpose of this study is to improve our knowledge and understanding of current 
management and treatment approaches undertaken and to develop healthcare plans to 
improve the quality of life of horses and ponies with PPID. However, this research could not 
be done without your help.  The answers you provide about your horse or pony can help 
make a real difference to the health of horses and ponies with PPID. 
Before you decide whether to participate, it is important for you to understand why the 
research is being done and what it will involve.  Please take time to read the enclosed study 
information sheet carefully and feel free to ask us if you would like more information or if 
there is anything that you do not understand (using the contact details provided below).   
The initial survey will be conducted by telephone and consists of questions about your 
horse’s routine, feed, general health and, where applicable, treatment for PPID.  We will 
also ask you to complete three short follow-up questionnaires to document any changes 
over time. Your privacy is, of course, of the utmost importance to us and if you decide to 
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take part, all responses are completely confidential and will only be used for the purposes of 
this survey.   
We hope you will be able to participate, however your involvement is entirely voluntary, if 
you wish to opt out please email rebecca.tatum@liverpool.ac.uk or telephone Becky on 
01638 751000 extension 1241.  If we do not hear from you by xx 2018 (three weeks after 
the date the letters are sent), the University of Liverpool researcher, Becky Tatum, will 
contact you by telephone. 




Becky Tatum, PhD Student, University of Liverpool 
Dr Joanne Ireland, PhD Supervisor, University of Liverpool 








Optimising Care for Horses and Ponies with PPID 
You are being invited to participate in a research study. Before you decide whether to participate, it is 
important for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and feel free to ask us if you would like more 
information or if there is anything that you do not understand. Please also feel free to discuss this 
with your friends, relatives or veterinary surgeon if you wish. We would like to stress that are free to 
opt out of participation and should only agree to take part if you want to. 
What is the purpose of the study? 
The purpose of this study is to investigate what management and treatment factors are most l ikely to 
improve quality of life for horses and ponies with PPID. Quality of life is a way of measuring your 
horse/pony’s overall health, wellbeing and happiness.  
Why have I been chosen to take part? 
You have been chosen to take part in this study because your horse/pony has been diagnosed with 
PPID (based on a laboratory test result where the hormone ACTH was above the normal reference 
range for the time of year the sample was taken). If this information is no longer correct, please 
inform us of any change in circumstances using the contact details below.  All owners registered with 
the University of Liverpool Leahurst Equine Practice whose horse/pony has been diagnosed with PPID 
in the past three years are being invited to participate in this study. All horses/ponies diagnosed with 
PPID are eligible to be included in this study, whether or not they are currently receiving any medical 
treatment for the condition.  
About the study 
If you agree to take part in the study, we will ask you to take part in a telephone questionnaire, 
which will take around 20 minutes to complete. You will be asked questions about your horse/pony’s 
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routine, daily care, exercise, health, any medication or other treatments they receive and how you 
perceive their quality of life. This will be followed by three shorter follow-up questionnaires at three 
month intervals to document any changes over time. Your responsibility as a participant of this study 
will be to answer all questions honestly and with your own opinion. We will also use your 
horse/pony’s veterinary records from the Leahurst Equine Practice in order to help us understand the 
associations between PPID laboratory test results (measuring ACTH), as a potential indicator of 
disease severity, and health and quality of life of horses/ponies with PPID.  
Participating in this study will not interfere with your horse/pony’s management, routine preventive 
healthcare, treatment for PPID or treatment of any other conditions. However, if you chose to make 
any changes to your horse/pony’s management throughout the study, such as feeding, exercise 
regime, field turnout or stabling and any healthcare you provide such as worming or vaccinations, we 
would ask you to record these changes and let us know, either directly using the contact details  
provided, or during a follow-up telephone questionnaire. 
The data we collect will be anonymised with no information that could identify you or your horse. It 
will be kept confidential and stored securely on University password protected computers, it will  be 
used for this specific study only and only the study research team at the University of Liverpool will 
have access to the data. You or your horse/pony will not be identifiable from the results.  
Why is this study important? 
Pituitary pars intermedia dysfunction is the most common hormonal disorder of older horses/ponies. 
Previously we have engaged with vets and owners (with experience of PPID) to prioritise areas of 
research they consider to be important. Establishing which management (including aspects such as 
dietary and turnout) and treatment strategies are most effective were areas ranked in the top 10 
research priorities. The information provided in this study will help us to better understand current 
management and treatment approaches undertaken for horses/ponies with PPID. The aim is to have 
more information about management and treatment options for veterinary surgeons and owners in 
order to improve the quality of life of horses and ponies with PPID. 
Are there any risks to myself or my horse/pony? 
As we are only using telephone questionnaires to collect data we do not anticipate any disadvantages 




What happens if I want to stop taking part? 
We would like to stress that your participation is voluntary. As a participant if you wish to end your 
participation at any point during the phone call or duration of the study you are free to do so. If you 
decide to withdraw your responses during or at the end of the interview, and if you request it, we will 
destroy any data regarding yourself or your horse from the study.  
Contact details 
If you have any questions or for further information please contact: 
Becky Tatum  
Email: rebecca.tatum@liverpool.ac.uk 
Telephone: 01638 751000 Ext. 1241 
 
If you are unhappy, or if there is a problem, please feel free to let us know by contacting Becky 
Tatum or Jo Ireland and we will try to help. If you remain unhappy or have a complaint which you 
feel you cannot come to us with then you should contact the Research Governance Officer on 0151 
794 8290 (ethics@liv.ac.uk). When contacting the Research Governance Officer, please provide 
details of the name or description of the study (so that it can be identified), the researcher(s) 
involved, and the details of the complaint you wish to make. 
 
Thank you for taking the time to read this. 
 
Becky Tatum  
 
The contact details of lead Researcher (Principal Investigator) are: [Contact: Dr Joanne 
Ireland, Leahurst Equine Practice, Leahurst Campus, University of Liverpool, Neston, Wirral, 
CH64 7TE, email: joanne.ireland@liverpool.ac.uk]. If there are any problems, please let us 
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Factors influencing owner decision making regarding the management 
and treatment of pituitary pars intermedia dysfunction (PPID) 
Summary 
Pituitary pars intermedia dysfunction (PPID) is a chronic progressive disease that requires 
long-term treatment, predominantly administered by owners in their horse’s home 
environment. Pergolide has been shown to be effective at reducing clinical signs of PPID, 
however, studies have demonstrated that some owners choose not to follow veterinary 
recommended treatment protocols. The owner decision making process around how to treat 
their horse is complex and influenced by a multitude of factors. This study aimed to 
understanding the context in which owners think about PPID and make decisions in relation 
to the treatment and management of their horse. Semi-structured individual in-depth 
interviews were conducted with 10 purposely selected owners whose horses had be 
diagnosed with PPID by the University of Liverpool Leahurst Equine Practice. Data were 
analysed using thematic analysis to identify codes and themes within interview transcripts. 
At total of six overarching themes were identified; disease tangibility, balancing 
management and treatment complexities, owners being experts in their own horse, having a 
horse centred approach, the vet-owner relationship and how health and happiness go ‘hand 
in hand’. The themes demonstrated how treatment and management decisions were 
influenced by the impact of PPID on the horse’s daily life and the visible changes observed 
by the owner. This perception was then built on and framed by the owners understanding of 
the disease, their in-depth knowledge of what is normal for their own horse and the nature 
of the vet-owner relationship. Decisions were driven by what owners’ thought was best for 
their horse and enabling them to have the best QoL possible. However, this could be 
confounded by conflicting needs. The findings described here demonstrate how owner 
treatment and management decisions are influenced by a complex mixture of contextual 
factors and key drivers, providing a depth of understanding of owner’s experiences, beliefs 
and perceptions that is not available through quantitative surveys. 
Introduction 
Long-term adherence to treatment protocols has been reported to be problematical in both 
medical and veterinary practice. Despite demonstration of treatment efficiency, poor 
treatment compliance has been reported in various chronic diseases such as osteoporosis 
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(Huas, 2010), asthma (Dinwiddie and Müller, 2002) and type 2 diabetes (Cramer et al., 
2008). Compliance with recommended veterinary treatments such as dental procedures and 
surgery among companion animal owners has also been reported to be as low 30% (Kanji et 
al., 2012). Treatment choices in owners of small animals have been studied and are 
reportedly influenced by the vet-owner relationship and owner-pet relationship (Adams and 
Frankel, 2007; Lue et al., 2008; Kanji et al., 2012), as well as wider contextual factors such 
as perceptions of risk and trust (Maille and Hoffmann, 2013). However, understanding of the 
factors that influence treatment and management decisions among horse owners is limited.  
Pituitary pars intermedia dysfunction (PPID) is a chronic progressive disease, commonly 
diagnosed in older horses (van der Kolk, 1997; McFarlane and Cribb, 2005; McFarlane et al., 
2005b; McGowan et al., 2013a), requiring long-term management (Chapter 4). Pergolide 
has been shown to be effective at resolving clinical signs of PPID, but is reliant on regular 
administration by owners, in their horse’s home environment (Chapter 4; McFarlane et al., 
2017). There is evidence of poor owner compliance with veterinary prescribed treatment 
regimens for PPID (Hague et al., 2021). This is supported by the findings described in 
Chapters 5 and 6, which demonstrate that some horses may not be receiving veterinary 
recommended treatment, and that a small proportion of owners change or stop medical 
treatment without veterinary input. Pergolide administration has been associated with 
increased odds of survival (Horn et al., 2019), therefore unregulated changes to treatment 
may lead to increases in mortality and morbidity impacting on equine welfare.  
Understanding the context in which owners think about PPID and make decisions in relation 
to the treatment and management of their horse may assist veterinary surgeons in 
communicating with owners and supporting them to make the best decisions for equine 
welfare. This can be achieved using a qualitative approach in contrast to questionnaire-
based studies (Chapters 5 and 6). There is a growing awareness of the need for qualitative 
sociological studies in equine veterinary research, to investigate human-horse interactions 
and the impact they have on management decisions. The importance of human influence on 
horse care and the effect this has on equine health and welfare are increasingly being 
recognised. A range of human aspects have been investigated using surveys, providing 
useful insights into the prioritisation of health and quality of life (QoL) concerns among 
owners (Mellor et al., 2001; McGowan et al., 2010b; Ireland et al., 2011c), industry 
stakeholder attitudes towards and perceptions of equine welfare (Collins et al., 2010) and 
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factors influencing the uptake of biosecurity practices (Schemann et al., 2012, 2011, 2013; 
Crew, 2019). However, these questionnaire-based studies do not provide the depth of 
understanding around experiences, beliefs and perceptions which underpin how attitudes 
are formed or decisions made. Therefore, a variety of qualitative methods investigating the 
reasons behind owner and veterinary decision making for equine care are being slowing 
integrated into the veterinary literature. Thematic analysis and ethnographic studies have 
investigated management and training of race horses (Cassidy, 2002; Butler et al., 2019), 
narrative analysis was used to describe care of horses on livery yards (Birke et al., 2010), 
drivers influencing antibiotic prescription by veterinary surgeons where identified using 
thematic analysis (King et al., 2018) and grounded theory conceptualised owner perceptions 
of equine obesity (Furtado, 2019).  
This study aimed to improve understanding of the factors influencing management and 
health care choices made as well as how owners perceive QoL in horses with PPID. The 
objectives were to investigate owner understanding of the wider issues and questions 
around PPID and its treatment as well as how their attitudes or beliefs may have formed; an 
in-depth exploration of relevant issues relating to treating and managing PPID for horse 
owners and how these affect decisions made around caring for their horse. The qualitative 
research methodology was used to portray and develop an understanding of the relative 
meaning of PPID for horse owners within different contexts, and describe the reasons for 
decisions regarding treatment and management.  
Materials and Methods 
Semi-structured interviews were conducted with owners/carers of horses with PPID to elicit 
perceptions of their horse’s QoL and motivators for the management and health care 
choices made. Thematic analysis (Braun and Clarke, 2012) was used explore immediate and 
wider contextual influences shaping owner perceptions, decisions and behaviours. This 
qualitative approach was part of a mixed-methods study.  
Sample  
Owners were initially invited to complete a quantitative questionnaire the full details of 
which are described in Chapter 5. In brief, horse owners were recruited via the University of 
Liverpool Equine Practice (UoLEP) database. Using key word searches, owners of horses 
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diagnosed with PPID, based on elevated basal plasma adrenocorticotrophic hormone (ACTH) 
concentration, were identified and clinical records were reviewed to confirm that cases met 
study inclusion criteria. Information provided in the initial questionnaire was used to 
purposively select horse owners based on characteristics such as current PPID treatment 
used, premises type, PPID comorbidities reported and length of ownership. This ensured 
diverse experiences and a range of viewpoints. Owners were recruited to participate in the 
interview process by telephone where their PPID experience was confirmed and the 
interview process was explained. This was followed by a confirmation email or letter 
containing further details on the aims of the study and a consent form explaining 
confidentiality, anonymity and the right to withdraw (Appendix 1).  
Data collection  
Semi-structured one-to-one interviews were conducted using an interview topic guide 
(Appendix 2) that was developed and piloted with two fellow researchers and two horse 
owners. The topic guide used open questions to encourage meaningful discussion and was 
used to direct conversation between the researcher and interviewee. Each of the topics were 
included in all interviews and questions were carefully phased to encourage interviewees to 
express their views and recount their experiences. The focus was on gathering the 
information needed, however, the process was flexible and avenues of conversation were 
pursued for additional information on the interviewee’s thoughts or opinions as appropriate.  
Interviews were conducted at a time and place convenient for the interviewee. The majority 
were held at the premises where the horse was kept, with two taking place in a private 
consultation room at the UoL Equine Hospital. Interviews were recorded using a digital 
recording dictaphone and lasted between 43 and 80 minutes. For consistency, all interviews 
were conducted by the doctoral student, who is a knowledgeable horse owner with 
experience and knowledge of PPID, but not a veterinary surgeon. This meant owners were 
able to relate and open up to the interviewer without feeling they might give a ‘wrong’ 
answer. Not being a veterinary professional also meant the interviewer was likely to be less 
biased about the treatment decisions made by owners. However, the interviewer was 
associated with the UoLEP and this may have influenced any perspectives given by owners 
regarding vet-owner relationships. 
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Profiles of interviewees  
A total of 10 owners were recruited to participate in interviews with a variety of PPID 
experience. Based on their questionnaire responses, interviewees had cared for their horses 
for a median of 16 years (range 6 – 25 years), and their horses were diagnosed with PPID 
between 2 months and 4 years prior to interview. Four interviewees cared for a single horse, 
one interviewee cared for two horses, one of which had PPID, and another cared for two 
horses both of which had PPID. Four interviewees were responsible for caring for multiple 
horses (≥2), at least one of which had PPID. Baseline questionnaire data (Chapter 5), 
showed that seven interviewees currently administered pergolide treatment, two of which 
had also used alternative treatments. One interviewee had recently stopped administering 
pergolide treatment and another had stopped using pergolide for a period and then 
restarted treatment. One further interviewee had never used pergolide treatment and 
instead used an alternative treatment. Interviewees reported a variety of clinical signs of 
PPID in their horses, with three having observed the overgrown curly coat associated with 
advanced PPID, while four reported recurrent episodes of laminitis and seven also reported 
that their horse had concurrent conditions such as arthritis. All interviewees were female 
and amateur ‘hobbyist’ horse owners, however, two were also livery yard managers and one 
ran a horse sanctuary. Horses were kept at a variety of premises including livery yards 
(n=4), rented premises (n=1), family farm (n=1), private premises (n=1), a horse sanctuary 
(n=1) and the owner’s own livery yard (n=1). Quotes from each interviewee are presented 
with their individual identification code (e.g. P1).  
Data analysis 
Interview recordings were transcribed verbatim by the doctoral student and interviewees 
were allocated an identification code to ensure anonymity. Thematic analysis was 
undertaken following the iterative step-by-step approach described by Braun and Clarke 
(2006, 2012): 
• Familiarising yourself with the data 
• Generating initial codes  
• Searching for themes 
• Reviewing potential themes  
• Defining and naming themes  
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• Producing the report  
This approach is not specific to a theoretic framework and offers a flexible approach to 
examining issues and answering research questions. Thematic analysis offers an accessible 
form of analysis useful for examining different perspectives of research participants, 
highlighting similarities and differences and summarising key insights from the data (Cassell 
and Symon, 2004; Nowell et al., 2017). 
Familiarisation 
In this study the familiarisation process began during the transcription phase with initial 
observational notes being recorded throughout the process. Each interview was then 
actively re-read taking the time to think analytically about how the interviewee’s experiences 
influenced their decisions and what was revealed by their accounts. Further notes were 
taken at this stage highlighting data potentially relevant to the objectives and research 
question.  
Coding  
The data were systematically analysed using codes to identify diversity and patterns in the 
data. The purpose of this study was to ‘give a voice’ to all owners’ experiences of treating 
and caring for their horse with PPID. Therefore, a predominantly inductive approach to 
coding data was used. This meant codes were derived from, and closely reflected the 
content of the data. However, there was also a deductive ‘top down’ element to data 
interpretation as analysis was approached with specific research questions in mind to allow 
the aim of the project to be addressed. Everything potentially relevant to the research 
question was coded using a mixture of line-by-line and section coding depending on the 
richness of the content.  
Coding of the first three transcripts was conducted by hand on printed paper copies of the 
transcripts. The initial codes generated were used as a framework to build upon when 
coding subsequent transcripts. The remaining seven transcripts were imported into 
commercial qualitative data analysis software (NVivo version 12) and coded using its node 
function. The first three transcripts were then revisited in NVivo, as codes had evolved, 
developed or combined throughout the process and new codes had been identified. Initial 
codes were mainly descriptive and became more interpretive as the process progressed by 
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interpreting collective meanings and experiences. This enabled analysis to go beyond simple 
description of the data by taking a deliberative, reflective and thorough approach. For 
example, an initial code was ‘horses in discomfort can still be happy’, which became ‘setting 
acceptable QoL level’ as it became clear that owners had set thresholds for how much 
discomfort their horse could experience before it started to affect their ‘happiness’ and 
therefore QoL. Another example was the code ‘importance of field turnout’, which became 
‘freedom to live as naturally as possible’ to encompass the negativity owners felt about 
confinement to a stable, but that they also understood it was often a necessary part of 
management. Codes were reviewed a final time along with initial interview and coding 
notes, to ensure they appeared across more than one interview transcript and captured the 
salient features of the data.  
Searching for, reviewing and naming themes  
A theme “captures something important about the data in relation to the research question, 
and represents some level of patterned response or meaning within the data set” (Braun 
and Clarke, 2006, p. 82). Themes were actively searched for by reviewing the coded data 
and clustering similar codes together to identify unifying features and key differences. Codes 
were combined to form overarching themes that brought together and underpinned the 
data. Sub-themes were used initially to maintain context where several patterns within the 
data contributed to the theme in different ways. The relationships between themes were 
also explored to ensure they represented the story told by the data. To aid the process, 
codes were mapped onto an A0 pin board (Appendix 3). This was a fluid and iterative 
process, which involved grouping, reviewing and then re-grouping codes. The raw interview 
data and previous notes were referred to, in order to help guide which codes should be 
clustered to form themes and which themes were linked. This process also helped to add a 
level of analytical interpretation to the themes produced.  To ensure the themes generated 
were representative of the data set and had sufficient data to support them the transcripts 
were re-visited and themes were checked against data extracts. At this stage some themes 
were re-phased to ensure they meaningfully captured all the relevant data.  
Results  
Extracted themes are presented in Table 1. Treatment and management decisions were 
influenced by the impact of PPID on the horse’s daily life and the visible changes observed 
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by the owner. This perception was then built on and framed by the owners’ understanding 
of the disease, their in-depth knowledge of what is normal for their own horse and the vet-
owner relationship. Decisions were driven by what owners’ thought was best for their horse 
and enabling them to have the best QoL possible. Owners interpreted QoL on an almost 
daily basis and based it on a balance of signs of happiness and health. Contextual factors 
influenced the decisions made around achieving what was best for their horse. Figure 1 
outlines the overall goals that drove owner decision making and the contextual factors that 
influenced how these goals were achieved. Owner goals were distinct from other influencing 
factors as they represented the owner’s overarching ambitions, while contextual factors 
impacted or shaped the owner goals. The goal of owners was to ensure their horse was 
both happy and healthy, and that their daily life was, at least in some way, influenced by 
what the horse itself wanted (as perceived by the owner). However, various factors were 
taken into account when reaching these goals, such as the owner’s relationship with their 
vet, the impact of PPID on their horse’s daily life and complexities around treatment and 
comorbidities. This meant owner goals and contextual factors sat separately but were 
intrinsically linked as shown in Figure 1.  
Table 1: Themes representing influencers on health care choices for owners of horses with 
PPID and their perceptions of quality of life with representative interviewee quotations. 
Theme Representative quote(s) 
Disease tangibility ‘I don't know what you are supposed to see with it, because she 
has never looked any different to me [ok] and she has not got 
the waviness of her hair or anything like that, none of that is 
showing which is usually a visible sign’. P10 
‘I know he has got his Cushing’s and his feet but he's not an ill 
horse, you know what I mean, he's poorly but he is not ill 
…truthfully I don't really think it (PPID) does that much, because 
he can still go out on the grass and he's fine ’. P9 
‘I don't feel massively that the cushing's has a huge effect on 
him sort of outwardly, he's not had the laminitis, he's not sort of 






‘Well one thing I was worried about was keeping him in more 
than I was erm mainly because I knew you had to keep him 
stabled because of his weight but because the vet, the first test 
happened because he had, he was developing arthritis in his 
back end because he's had a serious injury 7 years ago…so it 
was a catch 22 do I put him out so he is walking around 
constantly or do I keep him in’. P2. 
‘We know how she reacts to the Prascend, if its increased erm I 
don't know quite, if she did need to have it increased I don't 
know quite how we'd go about doing it without her going into 
zombie mode’…P7. 
‘So I started him off on half a tablet and he had diarrhoea, and I 
thought well you know, you do with a paracetamol sometimes or 
whatever, with bute and stuff, so a few day and he got the runs 
erm, if I gave him a full tablet, because she said try and up it to 
a full tablet, you can up and down it, full tablet definitely 
diarrhoea, so it was like ok I'll just leave him on half for a while 
and he was half for about a week and a half, something like 
that, and he was still getting the runs with it and stuff and I 
thought that's got to be uncomfortable for him ’. P5 
‘He cannot control his temperature what so ever erm so 
obviously this summer's been really hard form him erm you 
know trying to keep the flies off him because if he gets a fly bite 
it's very, it's just a horrific reaction, and then on the other hand 
trying to keep him cool’. P4.  
 
Experts in their own 
horse 
‘I can judge, I have had him for 17 years so I can judge if it's the 
same or not…you just know that he's enjoying it and I can tell 
when he is miserable’. P2 
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‘It's always one leg and he will hold it up and that’s how he tells 
me, you know you just know don't you [yeah] you get to know 
your own horse’. P9 
‘I think you can tell erm just by being so close to them, if you 
were on full livery you probably wouldn't notice but because I'm 
here twice a day and I know him so well cos I've had him since 
he was 5 months old [yeah] you know I just know’. P4 
 ‘It’s all the normal things that she does, so I think you just know 
don't you, I think if you know your horse well enough you just 
know what she’s like’. P7  
Horse centred 
approach 
‘She hates being in, she is an outdoor horse she likes being out 
but she will stay in if the others stay in but she won’t stay in a 
long time, well I don't let her because it is not natural… being 
able to go out, she loves it in that little paddock believe it or not, 
she is used to it, she loves being with the horses’. P10. 
‘Monitoring her hay, she is a funny old so and so, she'll eat 
soaked hay for a few days and then she just won’t eat it at all, 
so sometimes I might do 2 or 3 days and if she keeps eating it 
we just keep going and then if she stops I give her a couple of 
nets of dry hay’. P7 
‘I mean when she wants to come in if it’s a horrible day stand 
she's going I know you are up there are you coming to get me, 
she has a watch on, and other days she will go no get lost I 




‘I think the majority of people should just go with what their vet 
has advised [yeah], I wouldn't take it any other way erm you 
know they are the ones who have done the research and are 
out in practice, I may know my horse but that's why we are a 
team so, and that’s the way that people should look at it, I think, 
294 
 
you are only trying to do the best for my horse the same as I am 
so yeah’. P4 
‘I know people come a long and say you need to try Laminase 
and you want to do this, no, I stick with what the vet said erm, 
and that’s what I like and want to do’. P9 
‘I think if the vets were a little bit more open to stuff and not so 
narrow minded and this is how much it costs, and it costs an 
absolute fortune and this and that, it puts a lot of people off ’. P5 
Health and happiness 
‘hand in hand’ 
‘If she had bad health then she wouldn't be happy would she, 
you know if she was in pain or not feeling herself then she 
wouldn't be happy so I think they go hand in hand really’. P8  
‘If you have got good health you are going to be happier, if you 
have got poor health you are bit down or whatever, so I don't 
know if we can have one more important than the other to be 
fair, not that we get it right all the time but we try anyway yeah… 
she has got to have her health to be happy if you know what I 
mean, if you don't have one you don't have the other’. P6 
‘You know if we had a really bad illness and it was very bad 
then we would get unhappy after a while, and it would bring up 
down wouldn't it and whatever, so if your healthy you have got 
every opportunity to be happy’. P5 
‘I would say, his happiness yeah because he has got to be 
happy but he needs to be in good health, if he was in really 
really bad health and unhappy then that is not good, but if he is 
in quite good health but happy I think that is ok as long as it is 





Figure 1: Contextual factors and owner goals influencing owner decisions around the 
treatment of PPID. 
Disease tangibility  
All owners had a daily ritual which they followed when caring for their horse, and how much 
PPID impacted on this influenced how they viewed the disease. If the disease was not 
perceived to be having a significant effect on their horse’s day to day life or if their horse 
was not exhibiting what were seen as the ‘typical signs’, PPID became something abstract 
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and difficult to comprehend. Many owners described their difficulty quantifying the disease 
as they did not see their horse as ‘ill’.  
…‘When he was first diagnosed he wasn’t a typical Cushing’s horse, he didn’t have any of fur 
you know curly fur, he was just a normal pony, he was a healthy fit horse and he still is, I 
know he has got his Cushing’s and his feet but he's not an ill horse, you know what I mean, 
he's poorly but he is not ill’…P9. 
…’I don't know what you are supposed to see with it, because she has never looked any 
different to me [ok] and she has not got the waviness of her hair or anything like that, none 
of that is showing which is usually a visible sign, it is the eyes, something to do with under 
the eyes or, that’s to do with laminitis isn't it’…P10. 
When it came to understanding the aetiology of PPID most owners described how they 
found it difficult to comprehend, despite lots of information being available.  
…’but it's in veterinary speak, the deeper you get into it and want to understand more about 
it there's a point at which even I couldn't understand what they were talking about and I 
still don't understand about the ACP the A whatever's *laughs*’…P2. 
Some owners were also aware how a lack of understanding could have a negative impact on 
the horse’s care. 
…‘I think that you could easily get lost if you weren't careful and I think that’s a shame 
because it's not the human that suffers it could be the horse’…P4. 
Owners of horses that had concurrent health issues such as equine metabolic syndrome 
(EMS) described how they found it particularly difficult to differentiate between diseases and 
apply this to what they observed in their horse. This lack of understanding added to the 
sense that PPID is an abstract concept that is difficult to define.  
…’you know to try and make sure that the insulin, no I may be getting the 2 things but the 
hormones and everything like that, I find it very difficult to, to, I find it personally, you 
probably don't but I find it very difficult to differentiate between what is causing what, so 
the EMS and the Cushing's I don't know which ones causing wh ich’…P4. 
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Disease tangibility was also influenced by whether they perceived their horse to have clinical 
signs of PPID. Whether observed in their own horse or not, coat abnormalities were by far 
the most talked about and recognisable sign of PPID. Some owners found it difficult to 
understand the diagnosis if their horse was not exhibiting this typical sign, while others 
referred to the fact their horse had a ‘hairy coat but that was it’. Even when owners 
observed ‘evidence’ of PPID, if it was not perceived to have an impact on daily life, the 
disease remained indefinable. Most owners also took their horse’s age into account when 
talking about PPID with many using the phrase ‘good for his/her age’. Owners did not 
expect their horse to have the same standard of health or to look the same as a younger 
horse. 
…‘difference between erm, apart from to look at tiffany you can tell with her coat she gets 
that ridiculous coat erm, but other than that to look at her, you know, she doesn't sink in 
round her eyes, her belly is nice and where, considering she's an old horse as well’…P3.  
…‘I am looking out for stuff more but not just because of the Cushing's because of his age 
as well, because you do keep an eye on them a bit more, with general things in 
themselves’…P5. 
This different expectation for older horses was an influential factor in the decisions made 
around treatment, as owners described how they made different treatment decisions 
compared to those they would for a younger horse. Most owners were happy to use 
analgesics, such as phenylbutazone (‘bute’), more readily and undertake less investigative 
procedures. 
…‘the quality of life for him is important now at his age so you know if I had to give him 
more bute I'd give him more bute even though it perhaps wouldn't be the best thing 
necessarily’… sometimes I think I'd quite like to have his erm, blood count done on him, in 
the sense of his kidney function and his liver just to see where he's at but, and if he was 10 
year's younger I probably would but I think at this stage being 31 I just, you know, to a 
certain extent I kind of want to leave him in peace because he's just so old erm, so for me 
it's keeping him comfortable and plenty of food that's important when they’re old boys’…P1. 
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Laminitis was also a major influencer on how owners perceived PPID. All owners, 
irrespective of their experience of laminitis, talked about an increased risk of laminitis 
associated with PPID and the impact it could have. 
…‘I think it's the laminitis more than anything that's the worry isn't  is with them’…P1. 
Owners find PPID difficult to fully comprehend and therefore do not always know what to 
expect, their perspective is also often influenced by a different expectation of health for 
older horses. While ACTH levels offer some clarity, this is not always enough for owners to 
base treatment decisions on.  
Balancing management and treatment complexities  
When making decisions regarding management and treatment most owners were influenced 
by conflicting needs and concerns. They weighed up multiple factors and then made 
decisions they felt were best suited to their horse’s situation. These conflicting concerns 
usually included other age-related conditions which required different management solutions 
to PPID.  
…‘well one thing I was worried about was keeping him in more than I was erm mainly 
because I knew you had to keep him stabled because of his weight but because the vet, the 
first test happened because he had, he was developing arthritis in his back end because he's 
had a serious injury 7 years ago…so it was a catch 22 do I put him out so he is walking 
around constantly or do I keep him in’…P2. 
This shows how owners considered and deliberated because different ailments require 
different approaches and how there may not necessarily be a correct answer. This tactic was 
also undertaken by some owners when it came to treatment. Ensuring correct treatment 
had to be balanced with factors such as side effects and cost.  
…‘I would possibly get it done in the autumn, which is what we decided, just to see, 
because we haven't got err to see whether it’s gone up or whether it’s come down or 
whether it’s just stayed the same [yep], we know how she reacts to the Prascend if its 
increased erm I don't know quite, if she did need to have it increased I don't know quite 
how we'd go about doing it without her going into zombie mode’…P7. 
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…‘I can't afford, you know, once the insurance run's out, it's another pound a day ’…P2 
However, cost was not a major influence in the majority of cases. 
…‘erm so yeah it has to come in to in but it's one of those, I just see it as you've got to eat, 
they've got to have the tablets, it’s the same thing, it's just a cost that I have to have, it's 
part of horses isn't it’…P3 
Treatment decisions were often influenced by perceived effectiveness of the treatment and 
severity of disease. One owner who currently used an alternative herbal treatment described 
how she would need to adapt if the clinical signs of PPID deteriorated.  
…‘but if I carry on giving him the chaste berry's and he goes downhill quite quickly they are 
obviously not doing the job their not preventing it enough, they’re not keeping that at bay 
so then I'd probably try getting him on the tablets something that is a bit more hard hitting, 
if his disease whatever he's got is hard hitting him I need to fight back with hard hitting and 
if they’re not enough then it will have to drugs to keep it at bay’…P5. 
Many owners viewed ACTH levels as a valuable and definitive measure of their horse’s 
health on which to base treatment decisions both initially and throughout monitoring. 
…‘she seems to be doing alright but as I say we will get her blood tested again in the 
autumn and see what that does and then we will go by what results we have got there and 
see whether we need to alter or change fiddle around with it or do something if we need to, 
and if we don't, if it still reasonably low we will leave it where it is’… P7 
However, occasionally when ACTH levels did not respond as expected, or did not seem to fit 
with what the owner was observing in terms of health, this led to confusion and resistance. 
Owners needed to weigh up what they observed in ‘the horse in front of them’ with the 
‘science’. 
 …‘ this time last year they were 1100 and something after 6 weeks of me trying all this 
herbal stuff and all the stuff that they recommend that are the alternatives to prascend 
[yeah] it didn't work so then he went on the prascend so it went down to a really reasonable 
level 21 or something [ok] then in the spring he had it done again and it was still really low 
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erm so then you come to this autumn and its gone back up to 150 or 170 but after speak 
with the vet erm cause its cost as well, he's 20 years old how much of this would of 
happened anyway, erm … but it’s just something to keep an eye on, so it has gone back up 
to 115 or so [ok] erm at the moment, but he’s never, he’s looking fine’…P2  
A specific objective change was not always required for owners to perceive a treatment as 
effective, many owners considered the bigger picture of their horse’s life overall when 
weighing up the difference before and after treatment.  
…‘It enables me to … erm I think for him to have more of a normal life as a horse’…  
In terms of management decisions, laminitis was one of the main concerns and 
considerations. The majority of owners explained how concerns around laminitis meant they 
restricted their horses grazing and constantly monitored for any changes, both in their horse 
and the grass. 
…‘yeah he's actually been, he goes up and down like anything, I have to to tally monitor him 
all the time because if he goes out on the grass he can only go out on crappy grass because 
if he goes out on anything good he will just come down with it [Laminitis]’…P9.  
…‘yeah because I am really aware of laminitis you know so, yeah, and I'd be careful you 
know with like spring grass and things like that, more than I would before previously’…P8  
Some owners described how their horse had already been on a strict management routine 
for other issues, such as weight management, prior to diagnosis with PPID. Therefore, they 
had not felt needed to make major changes post diagnosis. Subsequently they perceived 
PPID as ‘just something else to deal with’ which had minimal impact on their routine or their 
horse’s life.   
However, despite their experiences all owners stressed the importance of constantly 
monitoring everything about their horse’s behaviour and routine. This enabled owners to 
feel ‘on top things’ and in control of their horse’s health. 
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…‘I do keep an eye on him more erm, with his, just to make sure there's nothing going on 
with him as in he's looking depressed or looking unhappy or erm if he isn't sleeping because 
I can tell when he's sleeping obviously in his bed’…P5. 
Multiple and sometimes complex considerations had to be undertaken for owners to achieve 
the overall aim of doing the best for their horse. 
Experts on their horse  
Owners put a huge amount of value on their own experience: this often stemmed from the 
fact they had cared for their horse for a significant proportion of the horse’s life and 
therefore ‘knew their horse best’. Owners considered their horses to be individuals and the 
amount of time spent with them, both in years of ownership and daily routine, meant they 
knew what was normal for their horse in terms of their personality and behaviour traits, 
allowing them to recognise when changes in management are needed or identify changes in 
health.  
…’I can judge, I have had him for 17 years so I can judge if it's the same or not and if he's 
eaten every bit of it I know that I'm not giving him enough so I'll give him another couple of 
handfuls the next day’…P2. 
Owners described both objective and subjective signs of health in their horses. Subjective 
signs included looking ‘bright eyed and bushy tailed’ or other behavioural traits unique to 
their horse, as well as how they interacted with their companions. Objective signs described 
included the texture of their coat, their body condition and appetite.  
…’he's got a lovely coat [ok] yeah, he err, if his coat is a bit starry, if he's a bit tucked up 
err, he's really really very dramatic erm so you know when, you don't even, you can tell by 
his eye's erm yeah he's very easy to read [ok] he's so easy to read it untrue, so but his coat 
will be shinny erm his hair will she shinny and not breaking, you know his mane, erm his 
eyes will be bright erm yeah, but but when he's not well you know [ok], he's really really 
pathetic’…P4.  
…’I don't think he's had any major difference with not being on it, from the eye or in his 
demeanour, he's stayed pretty consistent’…P4.  
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…‘she's, you know bright eyed and bushy tailed’…P7. 
Many owners described how their horse communicated with them to show that they were in 
pain or discomfort.  
…’he just, he literally won’t walk he will just limp on one leg, it 's always one leg and he will 
hold it up and that’s how he tells me, you know you just know don't you [yeah] you get to 
know your own horse and will just start limping and as soon as I open the stable he is in so, 
because he has had it since he was 9 and he's 15 now, so he's quite clever’…P9.  
A deviation from the norm needed to be big enough to prompt the owner to question why 
the change occurred and therefore evoke a reaction. This appears to be key to owners 
recognising changing states of health. Owners described how they had the knowledge to be 
able to recognise what is normal for the animal, especially in terms of subjective behaviours. 
This was often the first thing owners noticed a change in.  
…‘just their mood and how they are looking in themselves, you know if Tiffany's very quiet 
and a bit subdued I would think oh that's not quite right, because she’s normally like there 
bossing about or getting all the attention if someone comes or whatever’…P3. 
Although the owner’s familiarity with their horse sometimes meant more gradual changes 
could go unnoticed until they had a big enough impact to provoke action.  
…’you don't realise do you how much it creeps up when you see them every day you’re not 
aware of it until you actually stand back and start assessing things’…P7. 
Many owners relied on past experiences and recounted stories referring back to past events 
to back up points they made. These past experiences, either positive or negative, were 
considered to be important and influenced management and treatment decisions currently 
being made.  
…’I'd had a little pony before him Dillan who had really bad laminitis so I knew the signs 
anyway, but Dillan had got put to sleep, I wish I had known then what I know now because 
I wouldn't have let him get PTS erm but he was just in a bad way, and I've thought I am 
not doing it with you and I have just tried everything’…P9. 
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…’hopefully the natural way will help him because it's helped his arthritis and he's only on 
devils claw with that’…P5. 
Another aspect which fed into the feeling that owners ‘know their horse best’ was the deep 
bond they felt with their horse. Most owners perceived their horse as a pet or members of 
the family. They owned their horse for pleasure and not to perform a job, meaning owners 
cared for them in the same way even if they could no longer be ridden. One owner 
described the difference between herself who owned horses for please and people who own 
their horse to compete. 
…‘because you look at competition horses they don't have them at an old age once their no 
good they are gone, they are sold on, erm children with their pony's when they grow out of 
them they're gone… your meeting people who are in it for the longevity, like me, Roxy is 
going to be with me for life whether I can ride him or not it doesn't made a difference 
[yeah] to me, he's my, you know he is part of my family’…P5 
The emotionally driven and long-term relationships formed meant ensuring the best QoL 
possible for their horse was extremely important and influenced the decisions made around 
treatment and management.  
…‘to me they’re just like pets I treat them like a treat my daughter to be honest yeah, they 
are like my babies…QoL is like massively important I would imagine for everyone, you know 
farmers with cattle and sheep and that might be a bit more kind of you know, but horsey 
people they’re like pets aren't they so it is the QoL yeah really very important’…P3 
Some owners described how they would make sacrifices to ensure their horse had the 
treatment they felt they needed.  
…‘for me it's important, their health is important and I've probably would not have a holiday 
if it meant having to treat my horse, you know what I mean, they are part of the family and 
it's important to keep them healthy’…P1 
A complex mixture of emotional attachment, experience and knowledge of their horse 
underpinned how owners perceived their horse’s health and therefore influenced the 
decisions made around treatment and management.  
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Horse centred approach  
Owners all wanted to ‘do their best’ for their horse by providing an environment in which 
they were comfortable, happy and had as much freedom to ‘be a horse’ as possible. The 
method of management was horse led, using approaches that were based on owners giving 
their horse the ability to choose for themselves. All owners gave examples of how their 
horse communicated needs and preferences. 
…‘it could be absolutely hammering down in the summer time I'd think oh my god I've got 
to go and see if he's alright, so I'd go to the field and I'd give him a shout and sometimes 
he's come running to me and I'd open the gate and get him in the stable, so he was out the 
rain, and there were times when I'd go… and I'd see him and he's be stood with the herd all 
nice and snuggles up like that, no rug on or anything just all nice and snuggles up, and I'd 
go 'Rox are you coming in, come on' and he'd be like no, [laughter] and I'd say alright and 
I'd go home, and I'm alright with that now because he's chose he doesn't want to come in 
and he knows what I am offering him’…P5.  
Owners also described reading the actions and behaviours of their horse to decide what 
management choices to make and when changes were needed. Their horse often dictated, 
to a certain degree, how much time they spent stabled/turned out and the type or quantity 
of food given. 
…‘she is a funny old so and so, she'll eat soaked hay for a few days and then she just won’t 
eat it at all, so sometimes I might do 2 or 3 days and if she keeps eating it we just keep 
going and then if she stops I give her a couple of nets of dry hay’…P7. 
…‘now I gave her one [hay net] about 1pm which is half a kilo, probably about 2pm she will 
start, excuse me she will whinny at me, I want another hay net now, she will let me 
know’..P6. 
Owners believed their horse was able to communicate with them through their behaviour 
and this helped to steer them towards making the right judgment regarding management 
depending on the behaviour displayed.  
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Freedom for their horse to have some form of turnout was perceived to be vitally important 
for happiness. Owners described how their horse needed time and freedom to exhibit the 
natural behaviours of a horse and interact with others, even if turnout or grazing was 
restricted. All owners talked about how their horse needed time to socialise and exercise.  
…‘so he can actually go out and have a bit of grass, ok he can't go out and have you know 
an acre or half an acre or a paddock you know he's got to be rigorously maintained, erm so 
he can have strip grazing, but he has, up until this point, been able to live a fairly normal 
EMS and Cushing’s horse type lifestyle…I mean you know they're not really horses that can 
go out in acres of grass erm so they should be able to have some kind of turn out whether 
its limited like he has in a paddock that's probably about the size of this (barn/feed room) 
maybe then strip graze it a bit bigger, so he can keep on top of it erm, but outside, they 
need to be outside he needs to be able to go in the arena and he needs to be able to run 
and have a good buck, he needs to be able to roll, he needs to be able to do all the things 
that horses do’…P4. 
….‘she hates being in, she is an outdoor horse she likes being out but she will stay in if the 
others stay in but she won’t stay in a long time, well I don't let her because it is not 
natural… being able to go out, she loves it in that little paddock believe it or not, she is used 
to it, she loves being with the horses’…P10. 
Owners described a kind of controlled freedom where the restriction of grass intake was 
considered an important management factor. One owner in particular described how she 
had never let her horse have …‘full rein to eat himself to death’…P1.  
Although stabling their horse was part of the day to day management for most owners, 
confinement to a stable for longer than was considered normal had negative connotations. 
…‘it is just like being in a prison really isn't it just in a square box no matter how good the 
scenery is’…P6. 
…‘he is in a little pen like that where he can see all his friends he's not stabled stuck away, 
stabled stuck away is not a good QoL not being able to eat, not being able to run with his 
friends, that’s not a good life that’s not fair, I think at that point it’s time to say enough is 
enough this is not a good QoL’…P9 
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Management practices were generally preventive with many owners describing how their 
horse had been on a strict management regime before being diagnosed with PPID, therefore 
they had not had to make any changes as a result.  
…‘I think his routine looks after him anyway [ok yeah] it would be different if he was left out 
more and left to his own devices’… P5 
How owners interpreted their horse’s behaviour was the main influencer in day to day 
decisions regarding management. Owners felt that this approach enabled them to determine 
what was best for their horse.  
The vet-owner relationship  
Most owners did basic research about PPID online or by reading articles, but mainly relied 
on their vet to provide them with information. Owners felt that vets played an important role 
in the care of their horse and were a great influence on the treatment decisions owners 
made. 
…‘I think I just googled cushings and you know then there were help site and things and I 
just read everything I could about it, as you do’…P8. 
…‘you know the vets they are up to date with most up to date information I just follow what 
they say, there would be nothing that I could suggest for mine anyway that you wouldn't 
already of suggested’…P3. 
Owners respected and put their faith in their vet, looking to them as the primary source of 
advice. However, owners also felt that they were able to have an input in their horse’s care 
and work in partnership with their vet towards a common goal. Owners described how they 
saw vets as experts in the disease but themselves as experts in their horse.  
…‘I think the majority of people should just go with what their vet has advised [yeah], I 
wouldn't take it any other way erm you know they are the ones who have done the research 
and are out in practice, I may know my horse but that's why we are a team so, and that’s 
the way that people should look at it, I think, you are only trying to do the best for my horse 
the same as I am so yeah’...P4. 
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Most owners valued the advice of their vet over other sources such as peers.  
…‘I just stay with my vets to be honest with you, I do, I know people come a long and say 
you need to try Laminase and you want to do this, no, I stick with what the vet said erm, 
and that’s what I like and want to do erm, and I have always stayed with my vet practice for 
20 years and I am happy with them and I am happy with the way everything is and I am 
not just saying it because your here, I really do, I am happy’…P9. 
However, there were factors which caused the vet-owner relationship to fluctuate. Some 
owners had feelings of resentment around the cost of treatment.  
…‘but then you think ok if more horses are healthy then vets would be out of a job and not 
earning the extortionate money that hospitals make’…P2. 
…‘so I think if the vets were a little bit more open to stuff and not so narrow minded and 
this is how much it costs, and it costs an absolute fortune and this and that, it puts a lot of 
people off, and that is not for the welfare of the horse, ultimately it is the horse that loses 
out’…P5. 
Although for most owners cost was not the main consideration it was a concern, especially 
when dose increases were required, it then became a potential influential factor in the level 
of treatment received.  
…‘I'd be quite happy to put him on 1 a day I could, you know I really would because 
obviously it cost me, I was so thrilled when I had my ACTH levels come back at 2 and he 
was fine, because in the summer he wasn't it went up to 2 and a half so it's come back 
down, that for me that extra half a tablet, I know it's only 50p but when it ’s in the grand 
scheme of things it all adds up’…P4. 
The vet-owner relationship is trust based and can be fragile: a single bad experience can 
have a long-term effect. One owner described how her experience of a misdiagnosis by a 
previous vet had affected her perception.  
…‘we got her on prascend but I think it was too late by then [I see] we tried to manage it 
but it got too bad, I think probably if we had caught it earlier, without me arguing with one 
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of the vets because I know my horse better, even though he's a vet, I know when my horse 
has laminitis and it was laminitis and I think possibly if it had been diagnosed earlier we 
wouldn't of had the rotation and whatever it is, I think if I saw him now I would punch 
him,’..P6 
Owners liked to feel they were in control of the treatment and management decisions being 
made. Many owners described how the vet put decisions back in their hands, so although 
they were following veterinary advice, they were ones in control and making the final 
decision.  
…‘this is what needs to be done how you do it is up to you but we are here for support if 
you need anything give us a ring’…P9. 
The vet-owner relationship plays an extremely important part in the decision making process 
of owners. Although owners are understandably heavily reliant on the advice from their vet, 
the relationship needs to be managed with care to enable owners to make the correct 
decisions, especially around treatment.  
Health and happiness ‘hand in hand’ 
To owners, the term QoL encompassed their horse being in good health both mentally and 
physically. Ensuring their horse had good physical health was a step towards ensuring good 
‘mental health’ and happiness for their horse. Owners descried how happiness and health 
were intrinsically linked and that you could not have one without the other. 
… ‘she has got to have her health to be happy if you know what I mean, if you don't have 
one you don't have the other’…P6 
… ‘I think it's hand in glove, I don't think you can have one without the other, if she hasn't 
got her health she probably wouldn't be very happy’... P7 
‘if she had bad health then she wouldn't be happy would she, you know if she was in pain or 
not feeling herself then she wouldn't be happy so I think they go hand in hand really’…P8 
When asked specifically about their perceptions of QoL, owners described key areas which 
underpinned how they constructed QoL. All owners expressed how freedom from pain and 
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the horse’s ability to do normally daily activities, such as turnout and socialise, without 
impingement were the most important considerations for a good QoL.  
‘she's happy when she is not in pain and she can go out in the field and not have to limp 
that’s her happiness I think’…P10 
…‘I said 7 years ago if my horse can't live in a field and run round with his friends then 
that's it, I will call it a day but he's doing that’…P2 
…’Interviewer: what do you think makes a good quality of life for your horses? 
Participant: I think they like their routine, they know their routine erm being with their 
mates and erm our stable are like an American barn type so they’re not high partitions, so 
when they are in, their always in each other’s space, you know, erm I think that's important 
for them, because they are all getting on now … errr, having their friends around them and 
having their  routine  and being pampered really I suppose, and keeping them, obviously 
keeping them healthy and pain free erm that’s priority for me’…P3   
Many owners visualised their horse’s health through their demeanour, making it an 
important symbol of health. Ensuring their horse was happy and engaged was considered to 
represent good ‘mental health’ and was just as important as physical health for a good QoL. 
…’She is perky, she is alert, she enjoys herself, so I think a stark coat or depression or 
things like that, I think would indicate … just need to check things’…P6 
…‘she was depressed definitely yeah, yeah and you know I couldn't have kept her like that 
because that it’s not fair really, she just had no interest in life just you know head down not 
interested in anything, not reacting to anything, like a zombie really ’…P8 
…’their health is obviously very important but if they were suffering, if their mental health 
was suffering because of what I was doing to keep them physically well they couldn't have 
quality, a good quality of life’…P3 
In some cases, discomfort was overlooked if owners deemed their horse’s demeanour to be 
happy. Two owners in particular talked about how discomfort can be misinterpreted or 
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missed all together by owners. Highlighting how owners may misunderstand what their 
horse is communicating to them and how they might come to overlook physical signs of pain 
if their horse seems ‘happy’. 
…‘it depends on the level of discomfort erm and I think you put low grade laminitis on the 
map, the reason that a lot of us probably miss it is because they are happy’…P4 
…‘he can be happy and still have something wrong with him and then you 'd measure up 
hang on how much is it hurting him, but if he's happy, I know when he snapped his 
suspensory he must have been in some sort of pain but he's eye's didn't tell me that he's 
really miserable’…P2 
Owners did recognise the need for ‘short term pain for long term gain’ with most owners 
describing how they would compromise happiness in the short-term if it meant a better QoL 
in the long-term. Owners generally set their own limit on what they felt was a reasonably 
amount of disruption to their horses QoL. Many owners put a time limit on disruption to QoL 
before it became unacceptable.  
…‘I've given him until err probably the end of March beginning of April, if he’s not better and 
can't go out then I've made the decision already that I'm going to call it a day, because his 
QoL needs to be that he can go out, he's a horse that needs to go out ’…P4. 
…‘I think if it's going to be a short term, you know, a couple of weeks erm obviously she 
had to come up here [Leahurst], she was up here a few times erm then for erm, it’s good 
for her in the long run but if it was going to be like err you know she is going to be on this 
medication for the rest of her life and that's how it's going to make her, I'd have to consider 
her happiness because she's be suffering, her mental health would be suffering’…P3 
Other owners put a limit on the amount of discomfort they would accept their horse being 
in. This could be in terms of the level of pain observed or how long the pain was observed 
for. Often what was seen as a small amount of discomfort was deemed acceptable in the 
longer term.  
 ‘if her stiffness goes in to her being very lame and very sore, or she get a really bad bout of 
laminitis then, no, I would have her put to sleep ’…P7. 
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…‘he will struggle on here but once he gets on there (the field) he is like a rocket so, your 
like when do you call time you know’…P9 
Some owners anthropomorphised their horse’s feelings and needs to make them more 
relatable and justify their decisions or actions for QoL management. 
‘I am thinking about my patients here, you just wouldn't do it would you, an old person 
stuck in the house on their own poorly, nobody to visit, nobody to see, there is no difference 
in a horse you know’…P9 
… ‘you know it's like old people isn't it you know they've usually got their aches and pains 
and stuff but they crack on and they do what they do and try and live their life as best as 
possible, and I think the horses do that obviously’…P3 
Although happiness and health were both considered important for QoL, owners were more 
in tune with their horse’s demeanour and ‘mental health’ than their physical health. When 
asked about the balance between health and happiness when it comes to QoL for their 
horse, owners more readily referred to their horse’s happiness, frequently considering 
demeanour before aspects of physical health in their response, considering how their horse 
looked in terms of manner and interactions. Owners generally found these aspects easier to 
read than more physical or clinical issues. 
…’just their mood and how they are looking in themselves, you know if tiffany's very quiet 
and a bit subdued I would think oh that's not quite right’…P3 
…’you can tell by his eye's erm yeah he's very easy to read’…P4  
…’she's nosy, she is in your pockets, she is all over the place, it’s not like she's you know 
how some of them get that depressed look, she is not like that, no she is not like that’…P6 
Owners perceived QoL to encapsulate both health and happiness. This was underpinned by 
key factors such as, their horse’s ability to do daily activities, reading their horses 
demeanour and perceived level of discomfort. Owners used their expertise in their own 
horse to develop their own pre-defined idea of what happiness and health meant for their 




This qualitative study provides insight into factors which influence owner decision making 
around the treatment and management of PPID as well as how QoL is perceived in the older 
horse. The overarching themes described here demonstrate how owner treatment and 
management decisions are influenced by a complex mixture of contextual factors and key 
drivers, providing a depth of understanding of owner’s experiences, beliefs and perceptions 
that is not available through quantitative surveys.  This study identified six themes which 
influenced and drove owner decision making around the treatment and management of their 
horses with PPID. Owners were driven by their want to do their best for their horse and 
ensure that they had a good QoL. Decisions to achieve these goals were influenced by their 
understanding of PPID and how it impacted their horse’s daily routine, the communication 
received from their veterinary surgeon, their in-depth knowledge of their horse as an 
individual as well as other issues and conditions they needed to consider. The reasons 
behind human behaviours and decision making are well established within human health 
care and areas such as medical psychology. In human medicine, qualitative research plays a 
vital role in understanding the patient’s behavioural response to disease. Qualitative insights 
have been used to describe and model areas such as; treatment and information seeking, 
attitudes and response to clinicians (Marshall et al., 2004; Walter et al., 2014). However, 
seeking to understand human behaviour in relation to the care of animals is still novel, 
especially in equine veterinary medicine.  
Qualitative thematic analysis, as described by Braun and Clarke (Braun and Clarke, 2012), 
provided a structured analysis method for exploring the relevant issues rather than a specific 
approach to conducing qualitative research. This meant it provided an accessible and flexible 
approach to data analysis. Thematic analysis has previously been queried as an analysis 
technique because it was perceived to lack interpretive depth, however, this was because 
until recently, the method was poorly defined (Nowell et al., 2017). Braun and Clarke set out 
a detailed framework which provided a robust and systematic approach to coding interview 
transcripts (Braun and Clarke, 2014). The level of interpretation of the patterns identified is 
down to the researcher (Braun and Clarke, 2012). This study attempted to go beyond simple 
description of the data to add a depth of understanding to the decisions made by owners, 
however it was beyond the scope of the methodology used to establish a theoretical model.  
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This study recruited owners based on their experiences of PPID reported in the quantitative 
baseline questionnaire (results of which are described in Chapter 5). A diverse range of 
experiences and situations was achieved. However, recruitment was restricted to owners 
registered with UoLEP meaning geographic location was limited and veterinary involvement 
and experiences may have been similar. All interviewees were female amateur hobbyist 
horse owners, which is likely to reflect the main demographic of people who care for horses 
into their old age. The type of horse ownership may have influenced some areas such as 
their relationship with the horse as a companion or pet, therefore, the results presented 
here may not be entirely relatable to other owner situations, such as competition yards or 
riding schools. Although many of the themes are likely to cross over, owner goals or 
perceptions may differ as the owner-horse relationship includes a spectrum of opinions and 
approaches to horse care which can vary depending on how the horse is kept and for what 
purpose. For example, ‘livery yard culture’ has been described as an important influence on 
people’s attitudes towards management and care (Birke et al., 2010) while amateurs and 
professionals have been reported to differ in their feeding practices (Harris, 1999) and 
decision making around treatment of conditions such as colic (Scantlebury et al., 2014). 
Competition and riding school horses have ‘a job to do’ therefore owner perceptions of QoL 
and priorities are likely to diverge from that of the leisure owner. Additionally, pergolide is 
not permitted under competition regulatory bodies. This means treatment decisions of 
competitive owners might significantly differ from leisure owners.   
The number of interviews undertaken was pre-determined by the doctoral student and 
supervisory team. It was agreed that due to the demographics of the target population, ten 
interviews would be sufficient to reach a level of saturation in the data. All interviewees 
were leisure owners registered with the same veterinary practice and in a small geographical 
area, meaning there were likely to undertake similar management practices. Although this is 
a relatively small number of interviews there was some evidence of data saturation. During 
the iterative process of coding transcripts, codes were developed using the first three 
transcripts and then reviewed and re-visited once all transcripts were coded. During this 
process few new or additional codes were identified, suggesting a level of saturation had 
been reached despite the relatively small number of interviews. A larger sample 
incorporating multiple geographic areas and owner disciplines would require a larger sample 
and, as discussed above, may identify themes that differ from those described here.   
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All interviews were undertaken by the doctoral student, who is a knowledgeable horse 
owner with experience and knowledge of PPID, but not a veterinary surgeon. The intention 
was that owners would feel comfortable discussing treatment decisions openly. However, 
the project’s veterinary supervisors, one of whom was practising at UoL Equine Practice, 
were named on the information sheet and consent form (as required for ethical approval). 
This association could potentially have influenced owner answers especially around the vet-
owner relationship. However, this did not appear to be the case with owners openly 
discussing negative aspects of the vet-owner relationship, such as the cost of treatment and 
lack of options. Some owners did assume the interviewer had a certain level of knowledge 
or status, and this perception may have caused a level of social desirability bias.  
PPID is a progressive disease with a wide variety of clinical signs (McGowan et al., 2013a). 
This made it difficult for owners to comprehend, especially when it was coupled with 
comorbidities that caused similar issues. Owners described their familiarity with the more 
advanced or obvious signs associated with PPID, such as a curly overgrown coat and 
laminitis. However, there was a clear lack of recognition of other more subtle or progressive 
clinical signs. This was coupled with the fact that owners expected their horse to look 
different as they got older and meant owners were likely to dismiss some signs as related to 
age rather than PPID. ACTH levels provide an objective measure for the disease, however, 
as discussed in Chapter 4, they do not always relate to clinical signs observed and pergolide 
treatment does not necessarily result in a return to within seasonally adjusted reference 
intervals (Rendle et al., 2013). This lack of correlation added another level of complexity, as 
owners were observing visible changes but no change in ACTH levels or vice versa. Owners 
have been shown to be effective at subjective evaluation of treatment efficacy (Gerber et 
al., 2011), however this is likely to be more challenging if owners are unsure what indictors 
to look for.  
Disease (in)tangibility or complexities may be reasons owners looked at their horse’s overall 
health when it came decisions around treatment. Medical studies into patient perceptions of 
new treatments have also shown the overall effect on QoL is as important as specific 
improvements in symptoms (Marshall et al., 2004). Equine studies have also demonstrated 
that evidence of efficacy is not a requirement for compliance (Goyen et al., 2017; 
Manyweathers et al., 2017), however this might be because owners have a different 
perception of what proves effectiveness for treatments. A study investigating owner decision 
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making around colic described how owners were influenced by contextual factors such as 
their previous experience, second hand experience, sources of information used and 
perception of the severity of the clinical signs demonstrated (Scantlebury et al., 2014). Lue 
et al, (2008) reported that one of the main reasons for owners not complying with 
veterinary care in companion animals is that treatment seems unnecessary. If owners are 
unable to understand PPID or accurately recognise its signs, then owners may be more likely 
to think treatment is unnecessary and therefore not to comply with treatment 
recommendations. 
The lack of lay friendly information available to help owners understanding was also 
highlighted as affecting disease tangibility. This means owners are likely to use their own lay 
beliefs (experts in their own horse) to develop management and treatment strategies. The 
impact of lay beliefs on health behaviours, such as management of osteoarthritis (OA), have 
been investigated in human sociology (Morden et al., 2011). Patients put chronic conditions 
such as OA into context by describing how much it affects their life, for example whether it 
stops them doing normal daily activities such as working or hobbies (Donovan, 1991). 
Similarly, owners put PPID into context by assessing how much it impacted on their horse’s 
normal daily routine, rationalising changes into their frame of reference and experience. In 
human medicine, findings have led to the recognition that clinicians need to build upon self-
management approaches, supporting the existing beliefs and strategies of chronic illness 
sufferers (Kennedy et al., 2007). However, this is hindered when self-care is deemed outside 
of the clinician’s perspective and boundaries are placed on patient participation. Veterinary 
surgeons need ensure they look at the wider context of the situation, not just clinical signs 
and ACTH levels, and fully engage with the aspects of care owners are already undertaking 
when setting out management and treatment plans (Rogers et al., 2005).  
Older horses are more likely to have multiple comorbidities (Ireland et al., 2011b; Ireland et 
al., 2012b; Ireland, 2016; Welsh et al., 2016). This meant owners were often dealing with 
multiple conditions which needed consideration when it came to treatment and management 
approaches. Consequently, many owners were not considering PPID as a single entity, but 
weighing it up with various other conditions and other treatments. Faircloth et al. (2004) 
described a theory of ‘biographical flow’ where other comorbidities, such as diabetes, 
influenced the impact of a stroke of a person’s life. Whether the stoke was major or minor, 
the part it played in the person’s life was dependent on other illnesses. This is echoed in 
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how owners described the impact of PPID. Another study investigated non-adherence to 
Type 2 diabetes, and found that treatment complexity, such as number of medications being 
taken, route of administration and frequency of administration as well as additional 
directions, increased the likelihood of non-adherence (de Vries et al., 2014). This is likely to 
translate to owners who have more than one treatment or management decision to consider 
alongside pergolide administration. Another factor which added to the complexity of decision 
making was experience of side effects. It has been reported that concerns about, or 
experiences with, adverse events are the most common reason for the discontinuation of 
certain diabetes treatments (de Vries et al., 2014). Similarly, for owners who had experience 
of side effects this became an important consideration when starting pergolide treatment or 
changes to dose were recommended.  
Among the many factors being considered by owners when it came to balancing 
management and treatment, perceived risk of laminitis was central. All owners talked about 
an increased risk of laminitis associated with PPID and this caused concern. Previous studies 
which have investigated motivators and barriers to undertaking preventive measures such as 
vaccination (Schemann et al., 2013; Goyen et al., 2017), identified perceived physical risk of 
illness as a key factor. Maille and Hoffmann, (2013) described how physical risk needs be 
high enough to induce fear, but if too high, may cause denial which inhibits its effect. In this 
study, laminitis did invoke a level of fear and owners described undertaking interventions if 
they thought the risk to their horse was high. Unlike other clinical signs of PPID, laminitis 
caused disruption to the normal daily routine in a similar way to that described by owners 
who had experienced colic (Scantlebury et al., 2014). Owners drew upon their own personal 
experience and knowledge of laminitis to inform changes in their management strategies 
which enabled them to ‘keep on top of things’ and constantly monitor their horses which 
reduced the fear factor. Nevertheless, it is still probable that owners who think their horse is 
at a higher risk of getting laminitis are more likely to comply with management and 
treatment recommendations. Some owners described how they had a strict management 
regime in place prior PPID diagnosis for managing other conditions, such as obesity or EMS, 
and therefore had not needed to make further adjustments to manage PPID. It has been 
described how stroke patients believed that changes to everyday life for management of 
diabetes, such as diet and exercise, may also help reduce the risk of stroke reoccurrence 
(Faircloth et al., 2004). Similarly, it is likely that some owners think their current 
management approach is sufficient to manage PPID in addition to concurrent conditions. 
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Owners felt that good management included aspects which implicitly reduced the risk of 
laminitis, their biggest PPID related concern. These aspects mainly related to controlled 
access to grass and were more active depending on individual experience of laminitis. 
Owners felt they knew their horse best, putting huge value on their own experience, basing 
most of their decisions on their expert knowledge of their horse as an individual. Studies 
have described the emotional bond between owner and horse, with Keaveney (2008) 
describing it as ‘unlike any other bond with companion animals’, demonstrating the depth of 
connection felt, especially among amateur riders. This connection is likely to be magnified in 
owners of older horses who have cared for them from large proportion of the horse’s 
lifetime. The same study described how owners were able to interpret their horse’s facial 
expressions and gestures (Keaveney, 2008). If these subtle indicators deviate from what is 
considered normal for that individual horse, owners used that as an indication something is 
wrong (Scantlebury, 2012). This supports the findings of this study, where owners described 
how they are able to read their horse’s body language and interpret behavioural indicators 
to assess their health and act accordingly. Studies have also highlighted that the way 
owners view their horse is an important influence on the way they manage and care for 
their horse (Hausberger et al., 2008). It was apparent that owners of horses with PPID had 
a very close bond with their horse, often describing them as part of the family, and this was 
reflected in how they cared for and managed their horse as an individual.  
Turnout and access to grazing was a vitally important aspect of management. The main 
horse-centred focus was ensuring their horse had turnout as this was associated with 
positive natural behaviours, even when it sometimes conflicted with restricting grazing and 
added balancing management and treatment complexity. Butler et al., (2019) reported that 
‘keeping the horses’ lives as natural as possible’ by providing grazing was identified by 
stakeholders as an important factor in the QoL of racehorses. Studies investigating 
perceptions of equine behaviour have stressed the importance of natural grazing and 
socialising behaviours (Butler et al., 2019) and here owners wanted to try and recreate 
these natural behaviours as much as possible. As a result, stabling their horse for long 
periods was perceived negatively. This view may also be influenced by the link between 
stabling and negative behaviours such as weaving and crib biting (McGreevy et al., 
1995a,b). When it came to daily decision making around routine, owners felt their horse was 
able to communicate with them regarding management decisions, in a similar way to how 
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they interpreted body language and behaviours to assess health. By letting their horse have 
input into their routine daily routine owners felt they were able to give their horse enough 
freedom to exhibit natural behaviours while maintaining overall control. Studies have 
reported that management practices change as horses age and that management and 
health care decline, especially if horses are retired (Ireland et al., 2011a, 2011b). However, 
this study shows that owners were putting careful consideration into the management of 
their aged horse.  
The vet relationship was important, primarily as a source of advice and information but, 
could also be negative with some bad experiences relayed, demonstrating its fragility. The 
importance of the vet-owner relationship described here is likely to derive from a lack of lay 
information sources in the owner’s social context, for example a lack of other owners in a 
similar situation on their livery yard. This meant owners turned to their veterinary surgeon 
more readily for advice. Consequently, veterinary surgeons became the main social 
influence, making the vet-owner relationship extremely influential. Social risk has also been 
shown to effect health behaviours (Hausenblas et al., 1997; Hausberger et al., 2008). 
Buckley et al. (2004) described how different owner groups access different information 
sources in different situations, demonstrating how complex information seeking behaviours 
are. Different social contexts, such as livery yard culture, have been shown to be influential 
in decision making (Birke et al., 2010; Scantlebury, 2012). This means lay sources of 
information are often reported to be the first point of reference for owners regarding their 
horse’s health, rather than their veterinary surgeon. However, this kind of social context was 
not found to be a key influencer in this study. Studies in small animal medicine show that 
owners often have a strong relationship with their veterinary surgeon and that this makes 
them more likely to comply with recommendations (Brown, 2018). However, this 
relationship is dependent on the communication skills of individual veterinary surgeons, for 
example, how well they explain the reason for treatment recommendations and ability to 
educate the owner about the animal’s needs. Owners who do not comply with treatment are 
likely to not have enough information to make the best decision (Lue et al., 2008). The 
strong influence of the vet-owner relationship means behaviour change strategies may be 
relatively simple to implement.  Cost was an important consideration which could influence 
the vet-owner relationship as some owners felt resentment around the price of treatment. 
The upkeep of a horse has significant cost impactions such as livery, feed and insurance, 
though the amount will differ with different owner management systems. One owner stated 
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that pergolide treatment costs around £1 per day. Adding this to the cost of upkeep, likely 
for the rest of a horse’s lifetime, means cost is a consideration in many cases. One study 
including 25 owners reported that many would be willing to pay up to $1000 per year 
(approximately £730) to medicate their horse with PPID (Schott et al., 2020b). Similarly, in 
this study many owners described how they would make sacrifices to ensure their horse got 
the correct treatment, highlighting the lengths owners would go to, to ensure their horses 
QoL.  
QoL has been defined as encompassing feelings as well as physical health (Wojciechowska 
and Hewson, 2005). In this study, when owners were asked about their perceptions of 
health and happiness, they identified an inherent link between mental (‘happiness’) and 
physical health, describing how you cannot have one without the other. This underpinned 
the development of the theme ‘health and happiness hand in hand’. In small animal 
medicine, QoL scores such as FETCH (Freeman et al., 2012), have been developed to assess 
and track QoL. This measures some of the indicator’s owners described in the current study, 
such as eating and exercising. However, horse owners also relied on more subtle changes in 
demeanour to indicate QoL, which are difficult to account for or define in a questionnaire. 
QoL has previously been reported as an important consideration for owners of geriatric 
horses (Ireland, et al., 2011c). In this study, owners visualised what a good QoL meant for 
their horse and this was a key driver behind decisions and behaviours. This may influence 
treatment and management decisions in a similar way to how parents are involved in the 
decisions surrounding treatment in paediatric care. Parents are involved in the decision 
making process and are motivated by what they perceive as best for their child (Whitney et 
al., 2006; Brown et al., 2008). However, owners perceived the QoL of geriatric horses to be 
different to that of younger horses, with many suggesting that a low level of discomfort was 
acceptable, as long as it did not affect the horse’s demeanour. Studies investigating the QoL 
of older patients describe how may perceive conditions such as OA as an accepted part of 
aging (Marshall et al., 2004). As owners anthropomorphised the feelings and actions of their 
horses, it is likely that this attitude seen in human patients is reflected in owners’ attitudes 
towards the QoL of their horse. This may be one of the reasons why studies report an 
association between increasing age and a reduced QoL in horses (Ireland et al., 2011c), the 
same trend is also seen in dog owners, despite the fact that a strong emotional bond is also 
associated with an increased QoL (Marinelli et al., 2007). It has been reported that cat 
owners perceive QoL to be more important than quantity of life (Reynolds et al., 2010). This 
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also seems to be the case here: owners were confident they knew what a good QoL meant 
for their horse and would only let it be compromised to certain extent. Similar to other 
studies, the extent was dependent on expected QoL post-treatment (Ireland et al., 2011c) 
and the owner’s individual experiences of the condition (Schemann et al., 2012; Scantlebury 
et al., 2014). 
Conclusion  
In summary, this study described owners’ approaches to managing and treating PPID. 
Although limited to clients of a single veterinary practice, the themes identified here provide 
novel insight into owner decision making in relation to PPID. Owners were mainly driven by 
the want to do the best for their horse and ensure a good QoL, considering themselves to 
be experts in their own horse. However, this is often hindered by a lack of understanding of 
the disease and what indicators to look out for. Owners were influenced by comorbidities of 
geriatric horses as well as complexities in balancing management and treatment. The 
relationship with their veterinary surgeon was influential. To improve compliance with 
treatment and management recommendations, it is important that veterinary surgeons 
communicate clearly while considering the wider context of the owner’s situation, including 
current management strategies, how they perceive QoL for their aged horse and other 
conditions they may be dealing with. Veterinary surgeons need to ensure that owners have 
a clear understanding of the complexities of diagnosis of PPID, including explaining seasonal 
variations in ACTH, and the difference between EMS and PPID and how these are 
diagnosed, as well as visible changes to look out for. The strong reliance on veterinary 
advice reported here means small improvements in communication by veterinary surgeons 









Appendices for Chapter 7 
Appendix 1: The invitation letter/email and consent form sent to and 
signed by all interviewees. 
Dear *name of owner*, 
 
Thank you for your participation so far in our research study. Further to our  telephone conversation on Friday I 
am writing to confirm the time and date of our interview which will take place at *address* on 23/10/2018 at 
2pm. Please can you just confirm the address we have on record is correct?  
 
The purpose of these interviews is to further understand the choices owners make when caring for a horse or 
pony with PPID (Cushing's), how owners understand their horse’s health and wellbeing, and the different 
challenges that owners face. The information gathered will be used to help develop effective healthcare plans 
to improve the quality of life of horses and ponies with PPID.  
During the interview I will ask questions about your experience of caring for Flynn and follow-up on topics 
touched on in the baseline questionnaire you completed.  
The interview will take approximately 1.5 hours. However, this will be very much led by yourself and it may 
take more or less time depending on the extent of our discussion. The interview will be audio recorded on a 
Dictaphone to ensure I do not miss anything you say.  
Prior to this visit, please could you complete the attached consent form which you can return at the time of 
the interview. If you have any questions or would like to change the date or time of your appointment, please 





Becky Tatum, PhD Student, University of Liverpool 
Dr Joanne Ireland, PhD Supervisor, University of Liverpool 




Committee on Research Ethics 
 
INTERVIEW PARTICIPANT CONSENT FORM 
Title of Research 
Project: 
Optimising Care for Cushing’s (PPID) Horses and Ponies - 
Interview Phase Please 
initial in the 
box Researcher(s): Becky Tatum (PhD Student), Dr Joanne Ireland, Prof Cathy 
McGowan and Dr Rachel Dean 
• I confirm that I have understood the information provided by the interviewer and 
in the appointment confirmation letter for this interview. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily.   
 
 
• I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my rights being affected.  In 
addition, should I not wish to answer any particular question or questions, I am 
free to decline.   
 
 
• I understand that, under the Data Protection Act,  I can at any time ask for 
access to the information I provide and I can also request the destruction of that 
information if I wish. 
 
• I understand that confidentiality and anonymity will be maintained and it will not 
be possible to identify me in any publications. 
 
 
• I understand and agree that my participation will be audio recorded and I am 
aware of and consent to your use of these recordings for the purposes.  
 
 
• I understand that my responses will be kept strictly confidential. I give 
permission for members of the research team to have access to my anonymised 




                     
 
          
               Participant Name                           Date                    Signature 
  
                
      Name of Person taking consent                                Date                   Signature 
 
       
       Researcher                                                     Date                               Signature 
Student Researcher: 
Becky Tatum 





Dr Joanne Ireland 
University of Liverpool, Institute of Veterinary Science, Leahurst Campus, Neston, CH64 7TE 
Joanne.Ireland@liverpool.ac.uk 
materials, and I will not be identified or identifiable in the report or reports that 
result from the research. 
 
• The information you have submitted will be published as a report; please 
indicate whether you would like to receive a copy.  
 
 





Appendix 2: The interview topic guide used during all interviews 
Interview Guide 
Introduction  
• Thank you 
• About 1.5 hour 
• Taking notes and digitally recording 
• Please speak clearly 
• Confidential 
• Information anonymised 
• Do not have to talk about anything they don’t want to  
• Can take a break or stop at any time 
• Any questions? 
 
Background information 
1. How has *name* been doing since we last spoke (to go through the baseline questionnaire)? 
• Health? 
• Any changes? 
Management  
2. Tell me about looking after your horse with Cushing’s?  
• Routine - Stabling/turnout/diet/feeding?  
• Are there particular reasons for the routine you have chosen? 
• How do you decide on changes to your horse’s routine? Can you give me a recent 
example? 
• Is exercise a part in your horse’s routine? If so, how often/doing what? 
• Do you feel that your horse is happy with his/her current set-up?  
 
3. How has being diagnosed with PPID affected his/her routine? 
• Changes to diet/turnout/exercise compared to before diagnosis? 
Treatment  
4. Can you tell me about your experience of treating your horse with Cushing’s? 
• Treatment given? 
• Treatment duration? 
• Did treatment make a difference to your horse?  
- Improved? Worsened?  
• How did you decide on the treatment your horse received?  
- Influencing factors? 
- Barriers? 
• Did you stop treatment at any time? If so were there any particular reasons for deciding 




5. If he/she wasn’t treated, were there any particular reasons for deciding not to use treatment? 
• Not recommended? 
• Possible side effects?  
• Investigating alternative options? 
 
6. What is your opinion on pergolide/Prascend/prescribed tablets? (If not covered above) 
• (if applicable) Can you tell me about your personal experience of using them? 
 
7. How do you feel about alternative treatments/therapies e.g. herbal supplements, 
homeopathy etc for the treatment of Cushing’s? 
• Why do/don’t you use them? 
 
8. What do you think about the advice available to you regarding treating your horse with PPID? 
• What made it clear/unclear? 
• Was it consistent?  
• What made you feel it was tailored to your horse/or not? 
• When were follow-up visits made/if at all? 
• Did you look online for advice? Was it helpful? 
 
9. Do you think anything could be done to improve the treatment of horses with Cushing’s? 
• Anything that could be done differently? 
 
Quality of life  
10. What does the term quality of life mean to you? 
• Familiar term? 
• What images does it conjure up? 
 
11. What do you think makes a good quality of life for your horse with Cushing’s? 
• What factors affect your horse’s happiness and comfort? 
• What factors do you think are most important to ensure your horse has a good quality of 
life? 
• Does your horse have any other health problems? If so, how do these affect his/her 
quality of life?  
• What signs tell you your horse is in good health? 
 
12. What is more important, your horse’s happiness or his/her health? 
• Do you make changes to improve your horse’s health which may affect his/her happiness 





Anything further they wish to add?  
Reiterate the confidential nature of the study and confirm they have contact details in case they have 














































The studies presented in this thesis represent a novel mixed methods investigation into the 
health and QoL of horses with PPID in the UK, as well as the priorities of those that care for 
them and lay beliefs surrounding their management. The combination of qualitative and 
quantitative research methodologies used enabled a more rounded picture of the 
management and treatment of PPID to be presented. The initial JLA priority setting study is 
the first to introduce patient and public involvement (PPI) into equine veterinary medicine, 
identifying and prioritising uncertainties regarding the diagnosis, treatment and prognosis of 
PPID. The subsequent studies help to build on the evidence base and begin to fill some of 
the most important research gaps. The review chapters represent the first systematic 
knowledge synthesis to evaluate primary research regarding the most commonly used 
diagnosis and treatment protocols, providing a comprehensive assessment of current 
available evidence. Further to this, the two epidemiological studies are novel investigation 
into owner treatment and management of the disease, providing important information 
regarding owner management and treatment practices as well as the perceived QoL of their 
horses with PPID. Finally, the study around horse owner decision making is the first to use 
qualitative sociological methods to try and understand how lay beliefs affect the 
management and treatment of horses with a long-term disease.     
The JLA priority setting partnership (Chapter 2) highlighted the many uncertainties which 
remain regarding the diagnosis, treatment and management of PPID and the lack of robust 
evidence regarding the disease. The JLA study also demonstrated the successful adaptation 
of PPI methodology into equine veterinary medicine. The views of end users are often 
overlooked in research fields (Whitney et al., 2006; Cowan, 2013). This process gave a voice 
to the veterinary surgeons who treat the animal and the owners who manage the disease on 
a daily basis, demonstrating the value they can add when identifying research priorities. 
However, there was a lack of engagement from veterinary surgeons in the rounds of online 
surveys. This may have been for a number of reasons, such as how the survey was 
disseminated, the open style of questions or the unfamiliar style of research. Veterinary 
surgeons in practice are time deficient: a survey of veterinary students described how time 
constraints were seen as the biggest barrier to being involved in research after graduation 
(Allan and Dunning, 2020). However, if the evidence base is to be improved effectively, they 
need to be encouraged to engage in PPI research. More widespread use of methodologies 
330 
 
such as the JLA framework could help to ensure that future research is more clinically 
relevant. Conversely, there was a good level of veterinary representation and input in the 
PSP workshop. This allowed owners and vets to share experiences and understand differing 
points of view. The kind of open discussion encouraged by PPI helps to bridge the gap 
between owners and veterinary surgeons and widen perspectives (Chalmers, 1995; Oliver, 
1995; Entwistle et al., 1998), aiding the development of effectual relationships. The 
importance of the experiences and beliefs of end users such as veterinary surgeons and 
owners is being increasingly recognised in veterinary medicine with studies investigating 
both owner and veterinary decision making (Scantlebury et al., 2014; Bambra et al., 2017; 
Goyen et al., 2017; Belshaw et al., 2018; King et al., 2018). However, recognition of PPI 
methodology and the integration of this into the research process, such as seen in the NHS 
(NHS Executive, 2000; NHS Executive, 2004; Department of Health, 2013), needs to occur 
in order to see a switch from purely researcher led fields of investigation.  
The cross-sectional study (Chapter 5) and prospective cohort study (Chapter 6) build on the 
evidence base available, filling some of the gaps prioritised in the JLA PSP. It is likely that 
the field-based sample recruited in Chapter 5 is more representative of the general 
veterinary diagnosed population of horses with PPID than previous small, predominantly 
hospital-based, populations studied. However, the method of dissemination meant it was not 
possible to calculate a response rate or to compare non-responders and limited the sample 
to owners who used the internet or social media. A subset of this sample registered with the 
UoLEP was then followed throughout the prospective cohort study (Chapter 6) and used to 
purposely select interview participants for Chapter 7. This meant the study population for 
both studies was limited to a single first opinion equine practice in the North West of 
England. Although telephone recruitment was used to maximise the sample in Chapter 6, 
non-response at the initial recruitment stage meant the number of horses included was 
smaller than anticipated. It was an accepted limitation of the study design that by using a 
convenience sample from a single veterinary practice means the study population may not 
be representative of the general population. However, inviting all eligible owners registered 
with a single veterinary practice reduces the potential variability of diagnostic and treatment 
recommendations, as may be seen between multiple veterinary practices. This aided the 
investigation of owner choices regarding daily management. Chapter 6 also used a 
combination of clinical records and owner questionnaires to obtain data, which provided a 
more comprehensive dataset than either route alone. However, this form of data collection 
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highlighted shortfalls in both approaches individually. There was some degree of recall bias 
or under-reporting by owners despite the short timeframe, which highlights the potential for 
inaccuracies in studies that use owner-reported data alone, such as Chapter 5. However, 
there were also deficiencies in clinical record keeping, which has possible implications for 
PPID research that relies solely on analysis of clinical record data, especially in retrospective 
studies.  
The question prioritised as most important during the JLA process showed that end users 
want further certainty around the long-term prognosis of horses with PPID, and whether 
treatment influences how the disease ultimately progresses. A retrospective study analysed 
survival of chronic diseases and reported that although horses with PPID had a median life 
expectancy of nearly 10 years following diagnosis, the disease was negatively associated 
with survival (p<0.01) (Welsh et al., 2016). However, the influence of treatment was not 
investigated. It has been suggested that early intervention with pergolide treatment could 
help slow the progression of neurodegeneration (McFarlane, 2007), however the evidence 
around this is lacking. Two recent studies, conducted since the JLA priority setting 
partnership (PSP), have made some attempt to investigate the effect of treatment on 
survival of PPID.  In a cohort of 137 cases, both treatment with pergolide and veterinary-
reported clinical improvement were associated with increased likelihood of survival (both 
p=0.01) (Horn et al., 2019).  However, this retrospective study was based in the southern 
hemisphere and had a high level of loss to follow-up. A further study followed cases for up 
to ten years and reported the majority of owners strongly agreed that treatment with 
pergolide improved their horses QoL (71%) (Schott et al., 2020b), however, this was based 
on smaller numbers.  Chapter 6 prospectively followed PPID cases over a period of 
approximately 12 months and did not find any association between pergolide treatment and 
survival. This is likely to be due to the relatively small sample size and small number of 
untreated cases. PPID was not reported as the reason for mortality in any of the cases 
euthanased during the follow-up period (n=11), but was stated as a contributing factor to 
their decision by three owners. The most robust way of investigating any associations 
between treatment with pergolide and survival would be a randomised controlled trial, 
however, this has various ethical considerations, such as withholding a treatment which is 
known to be beneficial. Therefore, the findings of Chapters 5 and 6 could be built on in 
several ways, more in-depth analysis of both prospective and retrospective data would 
increase time at risk and allow further comparison of owner-reported information with 
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clinical records to assess disease progression. Furthermore, a large multi-centre cohort study 
could provide further insight into treatment efficacy and factors affecting long-term survival.   
Chapter 5 demonstrated that the majority of owners (86.9%) administered pergolide, the 
treatment of choice for PPID. This corresponds with the 88.3% of horses receiving 
treatment in a recent Australian study (Horn et al., 2019). At the start of the study, the 
majority of owners (65.8%) reported that the pergolide dose administered had not changed 
in the preceding 12 months (Chapter 5). Similarly, the dose of pergolide remained largely 
unchanged in the prospective cohort study, with 78.2% of cases having no dose alterations 
throughout the follow-up period (Chapter 6). This suggests owners did not alter dose with 
season and that sustained clinical improvement was observed on the same dose for a 
prolonged period of time. Pergolide treatment was rated as highly effective by owners, with 
a median efficacy rating of 8/10 (IQR 7-10) and has been shown to be effective at resolving 
≥1 clinical sign in the majority of cases (≥76%) (Chapter 4). Chapter 5 built on this by 
demonstrating that pergolide treatment was associated with improved QoL (p=0.008). This 
is in line with the various studies that demonstrate clinical improvement following pergolide 
treatment (Chapter 4). However, despite this high efficacy rating, just over half of owners 
who treated their horse with pergolide reported observing side effects during the first two 
weeks of treatment (56.5%) and side effects were the predominant reason for stopping 
treatment (Chapter 5). It is therefore unsurprising that veterinary surgeons and owners 
ranked the question around side effects sixth during the JLA PSP. The most frequently 
reported side effects in Chapter 5 were loss of appetite (31.5%), lethargy/poor performance 
(21.0%) and diarrhoea/loose faeces (6.0%). A few studies in the systematic review of 
pergolide efficacy (Chapter 4) also reported prevalence of side effects, the most robust of 
which reported 33% of horses developed transient inappetence (Anon, 2011a). This was 
reported resolve following to a short-term dose reduction (Anon, 2011a). The higher 
prevalence of side effects reported by owners in Chapter 5 may be as a result of how well 
owners know their horse and the level day to day interaction they have with them (Chapter 
7) or a failure to reduce the dose of pergolide promptly at the onset of side effects.  
Veterinary surgeons need to ensure they clearly communicate with owners when 
commencing treatment to ensure they are aware of how to deal with common side effects 
which can be easily resolved if addressed quickly. The communication approach of 
veterinary surgeons can have huge influence on owner response and compliance, 
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consequently impacting the success of treatment (Lue et al., 2008). Therefore, effective 
communication is likely to help to reduce the number of cases where treatment is stopped.  
Pergolide’s effect on the occurrence of laminitis was of particular interest to end users 
(Chapter 2). Chapter 6 investigated the incidence of laminitis among both treated and 
untreated cases and found a lack of treatment effect, with six of the eight animals having at 
least one episode of laminitis during the follow-up period reported to be receiving pergolide 
treatment. This is similar to the finding of another recent study which found no association 
between treatment and a diagnosis of laminitis (Horn et al., 2019). This is likely to be 
because the underlying cause of laminitis in PPID cases is concurrent insulin dysregulation 
rather than PPID itself (Karikoski et al., 2016; de Laat et al., 2019a,b), therefore effectively 
treating PPID alone without addressing insulin dysregulation may not be sufficient to lead to 
an improvement in laminitis. It was beyond the scope of the studies presented here to 
undertake further investigate into the effect of pergolide on individual clinical signs. 
Therefore, additional investigation is required into this area as well as what other options 
could be considered in the ≤24% of cases (Chapter 4) where clinical signs do not 
satisfactorily resolve.  
Owners perceived the majority of horses to be enjoying a very good QoL (median rating = 
9/10; IQR 8-10) (Chapter 5), similar to that described for the general geriatric population 
(Ireland et al., 2011c). This QoL rating was based on owner rated overall QoL. Although 
various individual QoL domains were also assessed, such as activities of daily living and 
demeanour, direct associations between these domains and overall QoL was not assessed. 
This is an area which warrants further investigation to establish effective QoL ratings for use 
in horses. Pergolide treatment was also associated with an improvement in QoL rating since 
the time of diagnosis (p=0.002), with 75.9% (n=203/303) of owners reporting an 
improvement in their horse’s QoL following treatment. This is in keeping with the overall 
improvement in clinical signs observed in the majority of cases (≥76%) across treatment 
studies (Chapter 4, Figure 2) as well as the proportion of horses deemed to be treatment 
successes in a large field trial (76%) (Anon, 2011a).  This high QoL appeared to be 
maintained over time during the follow-up period (Chapter 6), however, during follow-up a 
number of clinical signs were reported to persist and some owners reported that their 
horses exhibited new ones. This indicates that owners still perceive their horse to have a 
good QoL when they are demonstrating signs of PPID, suggesting that clinical presentation 
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is not necessarily seen by owners as directly linked to QoL. This has also been observed in 
human medicine with the association between clinical variables and QoL domains varying 
from 12-40% (González-Blanch et al., 2018). The link between various clinical signs and QoL 
is an area which would benefit from further exploration, however the studies presented here 
go some way to demonstrating that specific clinical signs were negatively associated with 
QoL. In Chapter 7, owners described how health and happiness go ‘hand in hand’ when it 
comes to QoL. Seeing their horse as pain free was an important factor in this and was 
mainly visualised through their horse’s demeanour. Clinical signs such as coat changes are 
unlikely to be associated with pain and therefore may not be perceived to affect QoL, 
resulting in the high rating reported. However, several clinical signs, such as current active 
laminitis, muscle wastage and lethargy/poor performance, were negatively associated with 
QoL (Chapter 5).  This is because these signs are more likely to be linked with pain and a 
change in demeanour, as well as affecting the horse’s day to day life, and therefore are 
recognised as a deviation from the norm by owners (Chapter 7). Conversely, QoL from a 
veterinary perspective is likely to be much more objective and focussed on health-related 
QoL, therefore more closely linked to the clinical signs demonstrated. Further research is 
required to investigate veterinary perceptions of QoL and how this differs from owner 
perceptions.  
Two questions in the JLA top 10 (Chapter 2) centred around diagnostic accuracy, 
demonstrating that further clarity is needed regarding diagnostic protocols. Protocol 
recommendations have been made for the commonly used basal ACTH test (EEG, 2019). 
However, Chapter 3 is the first to systematically review the current available evidence 
regarding the diagnostic accuracy of this primary test using standardised criteria. The basal 
ACTH test was found to be relatively accurate with a median reported sensitivity of 75.5% 
(range 36.0-100%) and specificity of 95.2% (range 63.3%-100%) (Chapter 3). However, 
this systematic review also highlighted that evidence is predominantly based on small 
studies with poor or inconsistent methodology and a high risk of bias. This meant meta-
analysis was not undertaken, as it would likely have compounded or exaggerated the biases 
highlighted. Therefore, although the data synthesis presented in Chapter 3 builds on the 
evidence available regarding the accurate diagnosis of PPID, the primary evidence base 
needs to be improved before meta-analysis can be undertaken and stronger conclusions 
drawn about the diagnostic accuracy of basal ACTH.  
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The question ranked second pertained to the various in vivo and in vitro factors that are 
reported to effect ACTH levels and therefore diagnostic test accuracy. Studies have 
described how factors such as stress caused by travel (Fazio et al., 2008) and treadmill 
exercise (Nagata et al., 1999) can increase ACTH levels. It has also been reported that pain 
can lead to an increase in the release of ACTH and cortisol from the pars distalis (Molony 
and Kent, 1997; Beech et al., 2007; Gehlen et al., 2020). Pain is of particular interest in the 
diagnosis of PPID due to comorbidities such as laminitis. Laminitis was the most frequently 
reported reason that owners suspected PPID (28.6%) (Chapter 5) and the overall 
prevalence of laminitis in PPID cases has been reported to be 48.9% (Ireland and McGowan, 
2018). Therefore, there is some potential that pain may influence test results at diagnosis 
and throughout monitoring in a considerable proportion of cases. It was beyond the scope 
of the review in Chapter 3 to investigate individual factors which affect the reliability and 
accuracy of the basal ACTH test. A further scoping review is needed to provide clarification 
regarding the extent to which these factors may affect diagnosis of PPID.  
Further uncertainty was around inconclusive or conflicting test results and/or clinical signs 
(question ranked eighth; Chapter 2). The lack of a consistent association between clinical 
signs and ACTH levels was highlighted in Chapter 4, meaning ACTH levels may not 
necessarily reflect the clinical picture. The theme ‘disease tangibility’ in Chapter 7 
demonstrated how this can cause confusion and resistance among owners. ACTH test 
results were a way of quantifying the disease and a factor on which treatment decisions are 
based. Therefore, when they did not match the horse they were seeing in front of them, 
owners found the diagnosis difficult to understand. Their horse needed to be exhibiting what 
were seen as the ‘typical signs’. Owners were looking for these ‘typical signs’ and the effect 
on their horse’s day to day life to realise the disease and ultimately base management and 
treatment decisions around. Therefore, owners are unlikely to recognise the disease unless 
there is an obvious change in how their horse looks or acts. This finding has been reflected 
in other studies where owners under-recognise clinical signs or do not attribute them to 
disease (McGowan et al., 2010b; Ireland et al., 2012a). This shows the challenge of 
recognising PPID, even before the stage of laboratory testing is reached. Two of the main 
reasons for owners suspecting PPID were veterinary suggestion and an overgrown coat 
(25.7% and 23.3%, respectively) (Chapter 5). This suggests that diagnoses in the earlier 
stages of disease may be coincidental when the veterinary surgeon is attending for another 
reason. Therefore, although further research is undoubtedly needed to understand the 
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relationship between the increased circulation of POMC-derived peptides and the clinical 
signs of PPID, just as important is the education of owners regarding the progressive and 
varied nature of the disease.  Increasing owners’ awareness and ability to recognise and 
monitor more subtle clinical changes could improve management and treatment decisions, 
as well as the chances of early diagnosis.  
The prioritised questions ranked third and fourth related to additional treatment and 
management options for horses with PPID (Chapter 2). This suggests that although 
pergolide is considered to be an effective treatment, there is still a need for further 
management strategies to be investigated. The reported management of horses with PPID 
in Chapter 5 was not dissimilar to that described for the general geriatric population 
(Brosnahan and Paradis 2003a; Ireland et al., 2011a), with the exception of access to 
grazing. History of laminitis was significantly associated with a reduction in hours turned out 
throughout the year (p=0.003) and restricted grazing was associated with decreased QoL 
rating (p=0.006). Conversely, horses turned out at grass were perceived to have a 
significantly better QoL (p=0.007). Laminitis was a major influencer on how owners 
perceived PPID, irrespective of their experience of it. It was one of the main concerns and 
considerations when it came to making management decisions (Chapter 7). This is 
unsurprising considering the painful nature of laminitis and the risk of recurrence (Potter et 
al., 2017; de Laat et al., 2019a). When owners described balancing management 
complexities, perceived risk of laminitis was the main consideration and a key factor in 
practices such as restricting grazing. However, when access to grazing was restricted, it 
diminishes the amount of freedom horses have to exhibit natural behaviours while turned 
out, which was an important part of the horse centred approach described in Chapter 7. 
Similarly, a study investigating stakeholder perceptions of racehorse welfare identified 
opportunities for the horse to socialise and be as ‘natural as possible’ as part of a ‘best life’ 
model (Butler et al., 2019). The other key influencer on management was personal 
experience, with 67.2% of owners basing decisions regarding diet predominantly on their 
own personal experience (Chapter 5). This was also reflected in Chapter 7, where owners 
considered themselves experts in their own horse and were therefore able to determine 
what was best for them on a day-to-day basis. 
The effectiveness of non-prescription or alternative treatments was encompassed in the 
question raked forth during the JLA. This was a controversial topic which created much 
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debate during PSP workshop (Chapter 2). Only a small proportion of horses were receiving 
alternative treatments (8%) and these were mainly given as complementary therapy 
alongside pergolide treatment (Chapter 5). These treatments had a lower efficacy rating 
(median = 5/10; IQR 2.5-7) and were associated with a lower QoL rating (p=0.003) 
compared to pergolide treatment alone. Despite this lack of efficacy, their use could be for a 
multitude of reasons. In human medicine it has been reported that a poorer health status is 
associated with the use of alternative medicine (odds ratio 1.3) (Astin, 1998), while another 
study reported that worries about the cost of treatment were associated with individuals 
being more likely to use complementary or alternative medicines (Barnes et al., 2008).  
Owners may use complementary or alternative treatments when sufficient improvement had 
not been observed with pergolide alone.  Their use could be seen as a way of reducing 
pergolide dose and therefore cost or as a low-cost alternative in horses that are showing 
early or mild clinical signs. Cost of treatment was a consideration highlighted in Chapter 7, 
particularly because of the need to administer it long term. However, this tended to be 
overridden by the strong relationship that owners have with their horse and their want to do 
the best for their horse described in Chapter 7. This perhaps accounts for the small 
proportion of cases who did not receive pergolide treatment in Chapters 5 and 6. 
The vet-owner relationship has been shown to be an important influencer when it comes to 
owner’s treatment decisions. Studies investigating barriers to the uptake of Hendra virus 
vaccination in Australia found that a negative perception of veterinary surgeons hindered the 
uptake of vaccination (Goyen et al., 2017; Manyweathers et al., 2017). In small animal 
medicine, trust and communication have been shown to be important factors in building 
relationships with owners (Brown, 2018). Similarly, trust was an important factor in the vet-
owner relationship theme described in Chapter 7. When it comes to the treatment of PPID, 
owners generally described having a good relationship with their veterinary surgeon 
(Chapter 7), and this was also reflected in Chapter 5 where 81.4% of owners stated that 
advice from their veterinary surgeon influenced their treatment decisions. However, 
decisions are also influenced by a complex mixture of other factors such as the owner’s 
individual experiences and knowledge of their horse as well as wanting to feel in control of 
the treatment and management strategies being undertaken (Chapter 7). This novel insight 
into owner decision making and perceptions of equine veterinary surgeons can be used to 
advise veterinary surgeons when communicating with owners. A more diverse sample 
selected from a variety of practices is needed to provide a fuller picture of the vet-owner 
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relationship. However, the findings of Chapter 7 demonstrate that veterinary surgeons need 
to remember the owner behind the horse and that communicating effectively with them is 
just as important as treating the animal.  
Conclusion  
Overall, the work presented here has helped to begin filling the evidence gaps highlighted in 
the JLA PSP. It builds on the evidence base in a way which is relevant and useful to end 
users by addressing the areas most important to them. The systematic reviews offer 
evidence about diagnosis and treatment of PPID which is much higher on the hierarchy of 
evidence than any of the individual studies reviewed. These will help facilitate an evidence 
based veterinary medicine approach by improving the evidence available and providing a 
‘one stop’ source that busy clinicians can incorporate with clinical judgement. Chapter 3 will 
contribute to a better understanding of the use of basal ACTH for diagnosing PPID while 
Chapter 4 will enable veterinary surgeons to be confident in recommending pergolide 
treatment. Chapters 5 and 6 build on the primary evidence base, giving insight into the 
management practices and perceptions of owners. Providing useful information for 
veterinary surgeons when advising owners regarding ongoing management outside of 
veterinary visits. Finally, Chapter 7 emphasises the importance of understanding owner 
perspectives and the need for veterinary surgeons to communicate effectively with owners 
regarding treatment approaches. In order to be most effective, treatments should be 
administered as prescribed, and this chapter demonstrates how veterinary surgeons need to 
remember that building an effective relationship with the owner behind the horse, 
communicating with them successfully regarding management and treatment approaches is 
just as important treating the animal itself.   
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